Filter by species, tissue, cell type, disease, or experiment to explore our curated enhancer collection
| Enhancer ID | Genome Location | Tissue | Cell Source | Disease | Experiment Type |
|---|---|---|---|---|---|
| E_00001 | chr2:178806313~178806949 | heart | human induced pluripotent stem cell-derived cardiomyocytes | dilated cardiomyopathy | Enhancer activity assay; endogenous enhancer perturbation assay; disease variant analysis |
| E_00002 | chr2:178806313~178806949 | heart | human induced pluripotent stem cell-derived cardiomyocytes | dilated cardiomyopathy | Enhancer activity assay; endogenous enhancer perturbation assay; disease variant analysis |
| E_00003 | chr2:127082600~127082962 | brain | hPSC-derived microglia | Alzheimer disease | CRISPR-Cas9 loss-of-function deletion, PLAC-seq chromatin interaction, ChIP-qPCR |
| E_00004 | chr13:73958961~73960160 | colon | HCT 116 | colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00005 | chr13:73958961~73960160 | colon | SW480 | colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00006 | chr13:73958961~73960160 | colon | HCT 116 | colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00007 | chr13:73958961~73960160 | colon | SW480 | colorectal adenocarcinoma | Dual-luciferase reporter assay, CRISPR-Cas9 base editing, CRISPRi silencing, 3C chromatin capture, ChIP-qPCR |
| E_00008 | chr5:28395077~28395877 | limb | mouse embryonic limb bud | -- | Endogenous enhancer deletion; transgenic reporter; in vivo developmental phenotyping |
| E_00009 | chr8:128889122~128889450 | kidney | 786-O | renal cell carcinoma | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00010 | chrX:92344753~92346405 | forebrain | mouse embryonic forebrain | -- | Endogenous enhancer knockout; single and combinatorial enhancer deletion; neurodevelopmental phenotyping |
| E_00011 | chr7:128573081~128573816 | blood | Primary CD14+ monocytes | autoimmune disease | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Disease-variant functional analysis |
| E_00012 | chr7:128573081~128574098 | blood | Primary CD14+ monocytes | autoimmune disease | Allele-specific enhancer activity; TF binding; chromatin looping; causal-variant perturbation |
| E_00013 | chr7:128573081~128574098 | blood | Primary CD14+ monocytes/macrophages | autoimmune disease | Disease-risk variant functional enhancer validation; allele-specific TF binding; chromatin looping; endogenous perturbation |
| E_00014 | chr8:128889122~128889450 | kidney | primary renal tumors and renal-cell validation | Clear cell renal cell carcinoma | Causal renal-cancer risk enhancer; allele-specific HIF binding; enhancer-promoter interaction; endogenous HRE editing |
| E_00015 | chr8:128889122~128889450 | kidney | primary renal tumors and renal-cell validation | Clear cell renal cell carcinoma | Causal renal-cancer risk enhancer; allele-specific HIF binding; enhancer-promoter interaction; endogenous HRE editing |
| E_00016 | chr8:128889122~128889450 | kidney | primary renal tumors and renal-cell validation | clear cell renal cell carcinoma | Causal disease-risk enhancer validation; allele-specific HIF binding; chromatin interaction; endogenous HRE editing |
| E_00017 | chr10:46073046~46074046 | prostate gland | C4-2 | prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00018 | chr10:46073046~46074046 | prostate gland | DU145 | prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00019 | chr10:46073046~46074046 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00020 | chr20:63680793~63682109 | brain | U-251MG | malignant glioma | Enhancer activity assay; TF binding assay; chromatin interaction assay; functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00021 | chr13:12371881~12373182 | heart | hPSC-derived cardiomyocytes plus endogenous Actn2 enhancer-deletion mouse models | heart failure susceptibility | Actn2 enh/Rr593 endogenous enhancer deletion; human ortholog CRISPRi/enCRISPRa; direct MEF2C occupancy; maturation and mitochondrial phenotyping |
| E_00022 | chr13:12371881~12373182 | heart | hPSC-derived cardiomyocytes plus endogenous Actn2 enhancer-deletion mouse models | heart failure susceptibility | Actn2 enh/Rr593 endogenous enhancer deletion; human ortholog CRISPRi/enCRISPRa; direct GATA4 occupancy; maturation and mitochondrial phenotyping |
| E_00023 | chr7:128573081~128573816 | blood | SC monocyte-derived cells | autoimmune disease | Allele-specific enhancer activity; TF binding; chromatin looping; causal-variant perturbation; Disease-variant functional analysis |
| E_00024 | chr7:128573081~128574098 | blood | SC monocyte-derived cells | autoimmune disease | Allele-specific enhancer activity; TF binding; chromatin looping; causal-variant perturbation; Disease-variant functional analysis |
| E_00025 | chr7:128573817~128574098 | blood | SC monocyte-derived cells | autoimmune disease | Allele-specific enhancer activity; TF binding; chromatin looping; causal-variant perturbation; Disease-variant functional analysis |
| E_00026 | chr7:128573036~128573717 | prostate gland | Human prostate carcinoma cell | autoimmune disease | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay; Disease-variant functional analysis |
| E_00027 | chr7:128573081~128574098 | blood | 293T and SC cells for reporter/mechanistic assays | autoimmune disease | Disease-risk variant functional enhancer validation; allele-specific TF binding; chromatin looping; endogenous perturbation |
| E_00028 | chr14:23906940~23908253 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | dilated cardiomyopathy | Enhancer activity assay; endogenous enhancer perturbation assay; regulatory variant functional assay; genotype-phenotype association |
| E_00029 | chr14:23906940~23908253 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | dilated cardiomyopathy | Enhancer activity assay; endogenous enhancer perturbation assay; regulatory variant functional assay; genotype-phenotype association |
| E_00030 | chr14:23906940~23908253 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | dilated cardiomyopathy | Enhancer activity assay; endogenous enhancer perturbation assay; regulatory variant functional assay; genotype-phenotype association |
| E_00031 | chr14:23906940~23908253 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | dilated cardiomyopathy | Enhancer activity assay; endogenous enhancer perturbation assay; regulatory variant functional assay; genotype-phenotype association |
| E_00032 | chr14:23912000~23912961 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay; Functional perturbation assay; Regulatory variant functional assay; Engineered heart tissue functional assay |
| E_00033 | chr14:23912000~23912961 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay; Functional perturbation assay; Regulatory variant functional assay; Engineered heart tissue functional assay |
| E_00034 | chr7:117075400~117076000 | bronchus | 16HBE14o- | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00035 | chr7:117075400~117076000 | pleural effusion | Calu-3 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00036 | chr7:117075400~117076000 | bronchus | 16HBE14o- | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00037 | chr7:117075400~117076000 | pleural effusion | Calu-3 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00038 | chr7:117075400~117076000 | bronchus | 16HBE14o- | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00039 | chr7:117075400~117076000 | pleural effusion | Calu-3 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00040 | chr7:117084000~117086500 | bronchus | 16HBE14o- | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00041 | chr21:36179867~36180107 | breast | BT-549 | breast cancer | Enhancer activity assay; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_00042 | chr21:36179867~36180107 | breast | MDA-MB-231 | breast cancer | Enhancer activity assay; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_00043 | chr11:8289240~8289522 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_00044 | chr11:8289240~8289522 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_00045 | chr11:8289240~8289522 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_00046 | chr6:151953109~151955347 | Mammary gland / breast | T-47D | Breast cancer | Variant-to-enhancer functional validation; endogenous enhancer deletion; enhancer-target linkage |
| E_00047 | chr8:128889122~128889450 | kidney | 786-O | clear cell renal cell carcinoma | Causal disease-risk enhancer validation; allele-specific HIF binding; chromatin interaction; endogenous HRE editing |
| E_00048 | chr16:53800454~53801454 | subcutaneous adipose tissue | SGBS | obesity | Enhancer activity assay; endogenous allele editing; TF-binding assay; target-gene perturbation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00049 | chr16:53800454~53801454 | subcutaneous adipose tissue | SGBS | obesity | Enhancer activity assay; endogenous allele editing; TF-binding assay; target-gene perturbation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00050 | chr8:128889122~128889450 | kidney | 786-O | Clear cell renal cell carcinoma | Causal renal-cancer risk enhancer; allele-specific HIF binding; enhancer-promoter interaction; endogenous HRE editing |
| E_00051 | chr8:128889122~128889450 | kidney | 786-O | Clear cell renal cell carcinoma | Causal renal-cancer risk enhancer; allele-specific HIF binding; enhancer-promoter interaction; endogenous HRE editing |
| E_00052 | chr2:178806313~178806949 | heart | Cardiomyocytes | -- | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; Disease-variant functional analysis; In vivo functional validation |
| E_00053 | chr17:38065500~38067500 | blood | HuT 78 | asthma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_00054 | chr10:21054606~21054974 | bone marrow | primary mouse hematopoietic stem cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay, Chromatin interaction assay; Endogenous enhancer perturbation |
| E_00055 | chr14:23913940~23915344 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay; Functional perturbation assay; Regulatory variant functional assay |
| E_00056 | chr14:23915187~23917391 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay; Functional perturbation assay; Regulatory variant functional assay |
| E_00057 | chr8:129582024~129582425 | bone marrow | Primary t(3 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00058 | chr8:129582024~129582425 | bone marrow | Primary t(3 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00059 | chr8:129582024~129582425 | bone marrow | Primary t(3 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00060 | chr8:129582024~129582425 | bone marrow | Primary t(3 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00061 | chr8:129582024~129582425 | bone marrow | Primary t(3 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00062 | chr8:129582024~129582425 | bone marrow | Primary t(3 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00063 | chr8:128821774~128822358 | breast | MDA-MB-231 | breast cancer | Enhancer activity assay; Functional perturbation assay; Chromatin interaction assay; Promoter-enhancer competition assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_00064 | chr12:85463935~85468299 | brain | primary mouse cortical neurons | -- | Stimulus-responsive enhancer assay; enhancer-promoter interaction; endogenous enhancer perturbation |
| E_00065 | chr12:85463935~85468299 | brain | primary mouse cortical neurons | -- | Stimulus-responsive enhancer assay; enhancer-promoter interaction; endogenous enhancer perturbation |
| E_00066 | chr12:85490344~85493924 | brain | primary mouse cortical neurons | -- | Stimulus-responsive enhancer assay; enhancer-promoter interaction; endogenous enhancer perturbation |
| E_00067 | chr12:85490344~85493924 | brain | primary mouse cortical neurons | -- | Stimulus-responsive enhancer assay; enhancer-promoter interaction; endogenous enhancer perturbation |
| E_00068 | chr11:32145028~32146147 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00069 | chr11:32145028~32146147 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00070 | chr11:32145028~32146147 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00071 | chr11:32145028~32146147 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00072 | chr11:32145028~32146147 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00073 | chr11:32145028~32146147 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00074 | chr11:32145028~32146147 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00075 | chr11:32145028~32146147 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00076 | chr11:32150550~32151858 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00077 | chr11:32150550~32151858 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00078 | chr11:32150550~32151858 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00079 | chr11:32150550~32151858 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00080 | chr11:32150550~32151858 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00081 | chr11:32150550~32151858 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00082 | chr11:32150550~32151858 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00083 | chr11:32150550~32151858 | liver | primary E12.5 fetal-liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer deletion assay; Chromatin interaction assay; Chromatin accessibility assay; In vivo functional validation |
| E_00084 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00085 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00086 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00087 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00088 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00089 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00090 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00091 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00092 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00093 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00094 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00095 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00096 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00097 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00098 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00099 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00100 | chr11:32156048~32157191 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00101 | chr11:32156048~32157191 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00102 | chr11:32156048~32157191 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00103 | chr11:32156048~32157191 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00104 | chr11:32156048~32157191 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00105 | chr11:32156048~32157191 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00106 | chr11:32156048~32157191 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00107 | chr11:32156048~32157191 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00108 | chr11:32156048~32157191 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00109 | chr11:32156048~32157191 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00110 | chr11:32156048~32157191 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00111 | chr11:32156048~32157191 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00112 | chr11:32165011~32165922 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00113 | chr11:32165011~32165922 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00114 | chr11:32165011~32165922 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00115 | chr11:32165011~32165922 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00116 | chr11:32165011~32165922 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00117 | chr11:32165011~32165922 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00118 | chr11:32165011~32165922 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00119 | chr11:32165011~32165922 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00120 | chr11:32168783~32169689 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00121 | chr11:32168783~32169689 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00122 | chr11:32168783~32169689 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00123 | chr11:32168783~32169689 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00124 | chr11:32168783~32169689 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00125 | chr11:32168783~32169689 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00126 | chr11:32168783~32169689 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00127 | chr11:32168783~32169689 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00128 | chr11:32168783~32169689 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00129 | chr11:32168783~32169689 | liver | Primary mouse fetal liver erythroid cells | -- | Super-enhancer constituent functional dissection; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_00130 | chr11:32168783~32169689 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00131 | chr11:32168783~32169689 | liver | primary E12.5 fetal-liver erythroid cells | -- | Super-enhancer constituent functional assay; TF binding assay; Endogenous cis-element deletion assay; In vivo functional validation |
| E_00132 | chr2:60718042~60718186 | bone marrow | Primary human erythroid precursors/erythroblasts | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Disease-variant functional analysis; In vivo functional validation |
| E_00133 | chr2:60722238~60722466 | bone marrow | Primary human erythroid precursors/erythroblasts | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Disease-variant functional analysis; In vivo functional validation |
| E_00134 | chr2:60722238~60722466 | bone marrow | Primary human erythroid precursors/erythroblasts | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Disease-variant functional analysis; In vivo functional validation |
| E_00135 | chr2:60725424~60725688 | bone marrow | Primary human erythroid precursors/erythroblasts | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Disease-variant functional analysis; In vivo functional validation |
| E_00136 | chr2:60718042~60718186 | bone marrow | Primary human erythroid precursors/erythroblasts | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional variant assay; Genetic association analysis; Disease-variant functional analysis; In vivo functional validation |
| E_00137 | chr2:60725424~60725688 | bone marrow | Primary human erythroid precursors/erythroblasts | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Genetic association analysis; Disease-variant functional analysis; In vivo functional validation |
| E_00138 | chr2:60722238~60722466 | blood | primary human CD34-positive erythroid progenitors | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00139 | chr2:60722238~60722466 | blood | Primary human erythroblasts | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00140 | chr2:60722238~60722466 | blood | primary human CD34-positive erythroid progenitors | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00141 | chr2:60722238~60722466 | blood | Primary human erythroblasts | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00142 | chr2:60718042~60718186 | blood | primary human CD34-positive erythroid progenitors | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00143 | chr2:60718042~60718186 | blood | Primary human erythroblasts | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00144 | chr2:60718042~60718186 | blood | primary human CD34-positive erythroid progenitors | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00145 | chr2:60718042~60718186 | blood | Primary human erythroblasts | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00146 | chr2:60725424~60725688 | blood | primary human CD34-positive erythroid progenitors | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00147 | chr2:60725424~60725688 | blood | Primary human erythroblasts | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00148 | chr2:60725424~60725688 | blood | primary human CD34-positive erythroid progenitors | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00149 | chr2:60725424~60725688 | blood | Primary human erythroblasts | -- | Lineage-specific enhancer characterization; endogenous functional validation |
| E_00150 | chr12:25538591~25539583 | bone marrow | MKPL-1 | hematopoietic malignancy | Enhancer activity assay; functional perturbation assay; TF binding assay; Disease-variant functional analysis |
| E_00151 | chr22:42411693~42414130 | liver | Hep-G2 | -- | Enhancer activity assay; Chromatin interaction assay; Chromatin accessibility assay; Functional perturbation assay; Functional variant assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00152 | chr22:42411693~42414130 | liver | Hep-G2 | -- | Enhancer activity assay; Cofactor occupancy assay; Chromatin accessibility assay; Functional perturbation assay; Gene expression assay; Endogenous enhancer perturbation; Chromatin interaction assay; Disease-variant functional analysis |
| E_00153 | chr20:63680793~63682109 | brain | U-251MG | malignant glioma | Enhancer activity assay; TF binding assay; chromatin interaction assay; functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00154 | chr2:178806313~178806949 | heart | human induced pluripotent stem cell-derived cardiomyocytes | dilated cardiomyopathy | Enhancer activity assay; endogenous enhancer perturbation assay; disease variant analysis; Endogenous enhancer perturbation; TF binding assay; Disease-variant functional analysis; In vivo functional validation |
| E_00155 | chr14:23912000~23912961 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | -- | Enhancer activity assay; endogenous enhancer perturbation assay; engineered heart tissue functional assay |
| E_00156 | chr14:23912000~23912961 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | -- | Enhancer activity assay; endogenous enhancer perturbation assay; engineered heart tissue functional assay |
| E_00157 | chr14:23912000~23912961 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | -- | Enhancer activity assay; endogenous enhancer perturbation assay; engineered heart tissue functional assay |
| E_00158 | chr14:23912000~23912961 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | -- | Enhancer activity assay; endogenous enhancer perturbation assay; engineered heart tissue functional assay |
| E_00159 | chr14:23913940~23915344 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | -- | Enhancer activity assay; regulatory variant functional assay; endogenous perturbation control |
| E_00160 | chr14:23913940~23915344 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | -- | Enhancer activity assay; regulatory variant functional assay; endogenous perturbation control |
| E_00161 | chr8:129582024~129582425 | bone marrow | K-562 | acute myeloid leukemia with t(3; 8)(q26; q24) MECOM rearrangement | Enhancer activity assay; Enhancer hijacking assay; Functional perturbation assay; TF binding assay; Chromatin interaction assay; Structural variant analysis |
| E_00162 | chr8:129582024~129582425 | blood | K-562 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00163 | chr8:129582024~129582425 | bone marrow | 8)(q26 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00164 | chr8:129582024~129582425 | bone marrow | q24) AML blasts (AML-17) | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00165 | chr8:129582024~129582425 | bone marrow | K-562 | acute myeloid leukemia with t(3; 8)(q26; q24) MECOM rearrangement | Enhancer activity assay; Enhancer hijacking assay; Functional perturbation assay; TF binding assay; Chromatin interaction assay; Structural variant analysis |
| E_00166 | chr8:129582024~129582425 | blood | K-562 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00167 | chr8:129582024~129582425 | bone marrow | 8)(q26 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00168 | chr8:129582024~129582425 | bone marrow | q24) AML blasts (AML-17) | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00169 | chr8:129582024~129582425 | bone marrow | K-562 | acute myeloid leukemia with t(3; 8)(q26; q24) MECOM rearrangement | Enhancer activity assay; Enhancer hijacking assay; Functional perturbation assay; TF binding assay; Chromatin interaction assay; Structural variant analysis |
| E_00170 | chr8:129582024~129582425 | blood | K-562 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00171 | chr8:129582024~129582425 | bone marrow | 8)(q26 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00172 | chr8:129582024~129582425 | bone marrow | q24) AML blasts (AML-17) | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00173 | chr8:129582024~129582425 | bone marrow | K-562 | acute myeloid leukemia with t(3; 8)(q26; q24) MECOM rearrangement | Enhancer activity assay; Enhancer hijacking assay; Functional perturbation assay; TF binding assay; Chromatin interaction assay; Structural variant analysis |
| E_00174 | chr8:129582024~129582425 | blood | K-562 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00175 | chr8:129582024~129582425 | bone marrow | 8)(q26 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00176 | chr8:129582024~129582425 | bone marrow | q24) AML blasts (AML-17) | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00177 | chr8:129582024~129582425 | bone marrow | K-562 | acute myeloid leukemia with t(3; 8)(q26; q24) MECOM rearrangement | Enhancer activity assay; Enhancer hijacking assay; Functional perturbation assay; TF binding assay; Chromatin interaction assay; Structural variant analysis |
| E_00178 | chr8:129582024~129582425 | blood | K-562 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00179 | chr8:129582024~129582425 | bone marrow | 8)(q26 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00180 | chr8:129582024~129582425 | bone marrow | q24) AML blasts (AML-17) | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00181 | chr8:129582024~129582425 | bone marrow | K-562 | acute myeloid leukemia with t(3; 8)(q26; q24) MECOM rearrangement | Enhancer activity assay; Enhancer hijacking assay; Functional perturbation assay; TF binding assay; Chromatin interaction assay; Structural variant analysis |
| E_00182 | chr8:129582024~129582425 | blood | K-562 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00183 | chr8:129582024~129582425 | bone marrow | 8)(q26 | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00184 | chr8:129582024~129582425 | bone marrow | q24) AML blasts (AML-17) | acute myeloid leukemia | Enhancer hijacking; TF binding assay; chromatin interaction assay; functional enhancer deletion |
| E_00185 | chr2:126521490~126522490 | brain | H1-derived microglia | Alzheimer disease | Regulatory element functional validation, 3D chromatin interaction mapping; Disease-variant functional analysis |
| E_00186 | chr2:127892600~127892962 | brain | primary human microglia | Alzheimer disease | Disease-risk enhancer annotation; enhancer-promoter interaction mapping |
| E_00187 | chr2:127082600~127082962 | brain | human brain microglia / iPSC-derived brain-cell models | Alzheimer disease | Cell-type-specific enhancer-promoter mapping; disease-risk integration; endogenous enhancer deletion; Disease-variant functional analysis |
| E_00188 | chr2:127892629~127892991 | cerebral cortex | human cortical PU.1-positive microglial nuclei | Alzheimer disease | cell-type-specific enhancer-promoter mapping plus endogenous causal enhancer deletion |
| E_00189 | chr2:127892629~127892991 | cerebral cortex | EC11 iPSC- | Alzheimer disease | cell-type-specific enhancer-promoter mapping plus endogenous causal enhancer deletion |
| E_00190 | chr2:127892629~127892991 | cerebral cortex | H1 hESC-derived microglia | Alzheimer disease | cell-type-specific enhancer-promoter mapping plus endogenous causal enhancer deletion |
| E_00191 | chr6:135323327~135323580 | blood | THP-6 T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_00192 | chr17:5958900~5960100 | brain | U-251MG | malignant glioma | Functional enhancer validation; chromatin interaction assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00193 | chr2:18910338~18911438 | brain | U-251MG | malignant glioma | Enhancer activity assay; chromatin interaction assay; functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00194 | chr2:18910338~18911438 | brain | U-251MG | malignant glioma | Enhancer activity assay; chromatin interaction assay; functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00195 | chr2:18910338~18911438 | brain | U-251MG | malignant glioma | Enhancer activity assay; chromatin interaction assay; functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00196 | chr2:18910338~18911438 | brain | U-251MG | malignant glioma | Enhancer activity assay; chromatin interaction assay; functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00197 | chr17:5958900~5960100 | brain | U-251MG | malignant glioma | Chromatin interaction assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00198 | chr8:12738300~12744200 | brain | U-251MG | malignant glioma | Functional enhancer validation; chromatin interaction assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00199 | chr8:12738300~12744200 | brain | U-251MG | malignant glioma | Functional enhancer validation; Endogenous enhancer perturbation; Chromatin interaction assay; Chromatin-state profiling; Disease-variant functional analysis |
| E_00200 | chr2:178806313~178806949 | heart | human induced pluripotent stem cell-derived cardiomyocytes | dilated cardiomyopathy | Enhancer activity assay; endogenous enhancer perturbation; TF motif functional assay; target-gene expression assay; phenotypic assay; TF binding assay; Disease-variant functional analysis; In vivo functional validation |
| E_00201 | chr12:85490344~85493924 | cerebral cortex | Primary mouse cortical neurons | -- | Enhancer activity assay; TF binding assay; Enhancer RNA assay; Chromatin interaction assay; Functional perturbation assay |
| E_00202 | chr12:85509692~85513444 | cerebral cortex | Primary mouse cortical neurons | -- | Enhancer activity assay; TF binding assay; Enhancer RNA assay; Chromatin interaction assay; Functional perturbation assay |
| E_00203 | chr12:85509692~85513444 | brain | primary mouse cortical neurons | -- | Stimulus-responsive enhancer activity; enhancer-promoter interaction; endogenous CRISPRi test |
| E_00204 | chr12:85509692~85513444 | brain | primary mouse cortical neurons | -- | Stimulus-responsive enhancer activity; enhancer-promoter interaction; endogenous CRISPRi test |
| E_00205 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00206 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00207 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00208 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00209 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00210 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00211 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00212 | chr11:32145028~32146147 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00213 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00214 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00215 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00216 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00217 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00218 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00219 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00220 | chr11:32150550~32151858 | liver | Primary mouse fetal liver erythroid cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00221 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +58 enhancer〞GATA1 occupancy; corrected from non-minimal composite interval |
| E_00222 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +58 enhancer〞GATA1 occupancy; corrected from non-minimal composite interval |
| E_00223 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +58 enhancer〞TF occupancy and genetic-variant evidence |
| E_00224 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +58 enhancer〞TF occupancy and genetic-variant evidence |
| E_00225 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +58 enhancer〞TF occupancy and enhancer-promoter looping evidence |
| E_00226 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +58 enhancer〞TF occupancy and enhancer-promoter looping evidence |
| E_00227 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +58 enhancer〞GWAS fine-mapping evidence record |
| E_00228 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +58 enhancer〞GWAS fine-mapping evidence record |
| E_00229 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +58 enhancer〞developmental transgenic-reporter evidence record |
| E_00230 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +58 enhancer〞developmental transgenic-reporter evidence record |
| E_00231 | chr2:60725424~60725688 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +62 enhancer〞TF occupancy and genetic-variant evidence |
| E_00232 | chr2:60725424~60725688 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +62 enhancer〞TF occupancy and genetic-variant evidence |
| E_00233 | chr2:60725424~60725688 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +62 enhancer〞GWAS fine-mapping evidence record |
| E_00234 | chr2:60725424~60725688 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +62 enhancer〞GWAS fine-mapping evidence record |
| E_00235 | chr2:60725424~60725688 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +62 enhancer〞3C looping evidence record |
| E_00236 | chr2:60725424~60725688 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +62 enhancer〞3C looping evidence record |
| E_00237 | chr2:60725424~60725688 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +62 enhancer〞developmental transgenic-reporter evidence record |
| E_00238 | chr2:60725424~60725688 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +62 enhancer〞developmental transgenic-reporter evidence record |
| E_00239 | chr2:60718042~60718186 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +55 enhancer〞TF occupancy and chromatin-state evidence |
| E_00240 | chr2:60718042~60718186 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +55 enhancer〞TF occupancy and chromatin-state evidence |
| E_00241 | chr2:60718042~60718186 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +55 enhancer〞GWAS fine-mapping evidence record |
| E_00242 | chr2:60718042~60718186 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +55 enhancer〞GWAS fine-mapping evidence record |
| E_00243 | chr2:60718042~60718186 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +55 enhancer〞3C looping evidence record |
| E_00244 | chr2:60718042~60718186 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +55 enhancer〞3C looping evidence record |
| E_00245 | chr2:60718042~60718186 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | sickle cell disease | Constituent +55 enhancer〞developmental transgenic-reporter evidence record |
| E_00246 | chr2:60718042~60718186 | bone marrow / erythroid compartment | Primary human erythroid precursors/erythroblasts | beta-thalassemia | Constituent +55 enhancer〞developmental transgenic-reporter evidence record |
| E_00247 | chr8:129582024~129582425 | blood | Primary human CD34+ hematopoietic stem/progenitor cells | -- | Native enhancer chromatin-state/TF binding validation; cross-context enhancer-hijacking comparison |
| E_00248 | chr8:129582024~129582425 | blood | Primary human CD34+ hematopoietic stem/progenitor cells | -- | Native enhancer chromatin-state/TF binding validation; cross-context enhancer-hijacking comparison |
| E_00249 | chr8:129582024~129582425 | blood | Primary human CD34+ hematopoietic stem/progenitor cells | -- | Native enhancer chromatin-state/TF binding validation; cross-context enhancer-hijacking comparison |
| E_00250 | chr8:129582024~129582425 | blood | Primary human CD34+ hematopoietic stem/progenitor cells | -- | Native enhancer chromatin-state/TF binding validation; cross-context enhancer-hijacking comparison |
| E_00251 | chr8:129582024~129582425 | blood | Primary human CD34+ hematopoietic stem/progenitor cells | -- | Native enhancer chromatin-state/TF binding validation; cross-context enhancer-hijacking comparison |
| E_00252 | chr8:129582024~129582425 | blood | Primary human CD34+ hematopoietic stem/progenitor cells | -- | Native enhancer chromatin-state/TF binding validation; cross-context enhancer-hijacking comparison |
| E_00253 | chr21:36179867~36180107 | breast | BT-549 | breast carcinoma | Enhancer activity assay; TF binding assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_00254 | chr21:36179867~36180107 | breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay; TF binding assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_00255 | chr2:127892710~127893072 | brain | Resected cerebral cortex NEUN+ nuclei | Alzheimer disease | Enhancer activity assay; Chromatin interaction assay; Functional perturbation negative-control assay |
| E_00256 | chr2:127892710~127893072 | brain | H1 (WA01) hESC | Alzheimer disease | Enhancer activity assay; Chromatin interaction assay; Functional perturbation negative-control assay |
| E_00257 | chr2:127892710~127893072 | brain | EC11 iPSC-derived neurons | Alzheimer disease | Enhancer activity assay; Chromatin interaction assay; Functional perturbation negative-control assay |
| E_00258 | chr2:127892710~127893072 | brain | Resected cerebral cortex PU.1+ nuclei | Alzheimer disease | Enhancer activity assay; Chromatin interaction assay; TF binding assay; Functional perturbation assay |
| E_00259 | chr2:127892710~127893072 | brain | H1 (WA01) hESC | Alzheimer disease | Enhancer activity assay; Chromatin interaction assay; TF binding assay; Functional perturbation assay |
| E_00260 | chr2:127892710~127893072 | brain | EC11 iPSC-derived microglia | Alzheimer disease | Enhancer activity assay; Chromatin interaction assay; TF binding assay; Functional perturbation assay |
| E_00261 | chr2:127892710~127893072 | brain | Human cerebral cortex NEUN+ nuclei | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00262 | chr2:127892710~127893072 | brain | H1 (WA01) hESC | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00263 | chr2:127892710~127893072 | brain | EC11 iPSC-derived neurons | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00264 | chr2:127892710~127893072 | brain | Human cerebral cortex PU.1+ nuclei | Alzheimer disease | Epigenomic enhancer mapping; enhancer-promoter interaction mapping; TF binding support; endogenous enhancer deletion; cell-type-specific functional validation |
| E_00265 | chr2:127892710~127893072 | brain | H1 (WA01) hESC | Alzheimer disease | Epigenomic enhancer mapping; enhancer-promoter interaction mapping; TF binding support; endogenous enhancer deletion; cell-type-specific functional validation |
| E_00266 | chr2:127892710~127893072 | brain | EC11 iPSC-derived microglia | Alzheimer disease | Epigenomic enhancer mapping; enhancer-promoter interaction mapping; TF binding support; endogenous enhancer deletion; cell-type-specific functional validation |
| E_00267 | chr2:127892710~127893072 | brain | Human cerebral-cortex NEUN+ nuclei | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00268 | chr2:127892710~127893072 | brain | H1 (WA01) hESC | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00269 | chr2:127892710~127893072 | brain | EC11 iPSC-derived neurons | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00270 | chr2:127892710~127893072 | brain | Human cerebral-cortex PU.1+ nuclei | Alzheimer disease | Epigenomic enhancer mapping; enhancer-promoter interaction; TF-binding support; endogenous enhancer deletion; cell-type-specific functional validation |
| E_00271 | chr2:127892710~127893072 | brain | H1 (WA01) hESC | Alzheimer disease | Epigenomic enhancer mapping; enhancer-promoter interaction; TF-binding support; endogenous enhancer deletion; cell-type-specific functional validation |
| E_00272 | chr2:127892710~127893072 | brain | EC11 iPSC-derived microglia | Alzheimer disease | Epigenomic enhancer mapping; enhancer-promoter interaction; TF-binding support; endogenous enhancer deletion; cell-type-specific functional validation |
| E_00273 | chr8:128889122~128889450 | kidney | renal cell carcinoma model (paper-derived RCC cells) | renal cell carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay; Endogenous enhancer perturbation; TF binding assay; Disease-variant functional analysis |
| E_00274 | chr22:42411693~42414130 | liver | Primary human hepatocytes | -- | Chromatin interaction assay; Chromatin accessibility assay; Enhancer-associated cofactor binding assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00275 | chr22:42411333~42413643 | liver | Human Primary Hepatocytes | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00276 | chr1:236660389~236660646 | heart | H9 human pluripotent stem cells differentiated into hPSC-CMs | -- | causal enhancer deletion/CRISPRi/enCRISPRa plus direct TF-binding validation |
| E_00277 | chr1:236660389~236660646 | heart | mouse cardiomyocyte and in-vivo heart validation | -- | causal enhancer deletion/CRISPRi/enCRISPRa plus direct TF-binding validation |
| E_00278 | chr1:236660389~236660646 | heart | H9 human pluripotent stem cells differentiated into hPSC-CMs | -- | causal enhancer validation plus direct TF-binding validation |
| E_00279 | chr1:236660389~236660646 | heart | mouse cardiomyocyte and in-vivo heart validation | -- | causal enhancer validation plus direct TF-binding validation |
| E_00280 | chr1:236660389~236660646 | heart | H9 human pluripotent stem cells differentiated into hPSC-CMs | -- | causal enhancer validation plus TF-responsive reporter/in-vivo temporal occupancy support |
| E_00281 | chr1:236660389~236660646 | heart | mouse cardiomyocyte and in-vivo heart validation | -- | causal enhancer validation plus TF-responsive reporter/in-vivo temporal occupancy support |
| E_00282 | chr2:127892600~127892962 | brain | hPSC-derived microglia | -- | Enhancer activity assay; chromatin interaction assay; functional perturbation assay |
| E_00283 | chr2:60718042~60718186 | bone marrow | Primary human erythroid precursors/erythroblasts | -- | Erythroid enhancer mapping; TF occupancy; enhancer-promoter looping; genetic and genome-editing validation; Disease-variant functional analysis; In vivo functional validation |
| E_00284 | chr2:60718042~60718186 | bone marrow | Primary human erythroid precursors/erythroblasts | -- | Genetic fine-mapping; erythroid enhancer mapping; TF occupancy; chromatin interaction; Disease-variant functional analysis; In vivo functional validation |
| E_00285 | chr2:60722238~60722466 | bone marrow | Primary human erythroid precursors/erythroblasts | -- | Erythroid enhancer mapping; TF occupancy; enhancer-promoter looping; genetic and genome-editing validation; Disease-variant functional analysis; In vivo functional validation |
| E_00286 | chr2:60722238~60722466 | bone marrow | Primary human erythroid precursors/erythroblasts | -- | Genetic fine-mapping; erythroid enhancer mapping; TF occupancy; chromatin interaction; Disease-variant functional analysis; In vivo functional validation |
| E_00287 | chr2:60722238~60722466 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +58 enhancer〞GATA1 occupancy; corrected from non-minimal composite interval |
| E_00288 | chr2:60722238~60722466 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +58 enhancer〞GATA1 occupancy; corrected from non-minimal composite interval |
| E_00289 | chr2:60722238~60722466 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +58 enhancer〞GATA1 occupancy; corrected from non-minimal composite interval |
| E_00290 | chr2:60722238~60722466 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +58 enhancer〞GATA1 occupancy; corrected from non-minimal composite interval |
| E_00291 | chr2:60722238~60722466 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +58 enhancer〞TF occupancy and genetic-variant evidence |
| E_00292 | chr2:60722238~60722466 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +58 enhancer〞TF occupancy and genetic-variant evidence |
| E_00293 | chr2:60722238~60722466 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +58 enhancer〞TF occupancy and genetic-variant evidence |
| E_00294 | chr2:60722238~60722466 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +58 enhancer〞TF occupancy and genetic-variant evidence |
| E_00295 | chr2:60722238~60722466 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +58 enhancer〞TF occupancy and enhancer-promoter looping evidence |
| E_00296 | chr2:60722238~60722466 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +58 enhancer〞TF occupancy and enhancer-promoter looping evidence |
| E_00297 | chr2:60722238~60722466 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +58 enhancer〞TF occupancy and enhancer-promoter looping evidence |
| E_00298 | chr2:60722238~60722466 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +58 enhancer〞TF occupancy and enhancer-promoter looping evidence |
| E_00299 | chr2:60722238~60722466 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +58 enhancer〞GWAS fine-mapping evidence record |
| E_00300 | chr2:60722238~60722466 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +58 enhancer〞GWAS fine-mapping evidence record |
| E_00301 | chr2:60722238~60722466 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +58 enhancer〞GWAS fine-mapping evidence record |
| E_00302 | chr2:60722238~60722466 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +58 enhancer〞GWAS fine-mapping evidence record |
| E_00303 | chr2:60722238~60722466 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +58 enhancer〞developmental transgenic-reporter evidence record |
| E_00304 | chr2:60722238~60722466 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +58 enhancer〞developmental transgenic-reporter evidence record |
| E_00305 | chr2:60722238~60722466 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +58 enhancer〞developmental transgenic-reporter evidence record |
| E_00306 | chr2:60722238~60722466 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +58 enhancer〞developmental transgenic-reporter evidence record |
| E_00307 | chr2:60725424~60725688 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +62 enhancer〞TF occupancy and genetic-variant evidence |
| E_00308 | chr2:60725424~60725688 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +62 enhancer〞TF occupancy and genetic-variant evidence |
| E_00309 | chr2:60725424~60725688 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +62 enhancer〞TF occupancy and genetic-variant evidence |
| E_00310 | chr2:60725424~60725688 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +62 enhancer〞TF occupancy and genetic-variant evidence |
| E_00311 | chr2:60725424~60725688 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +62 enhancer〞GWAS fine-mapping evidence record |
| E_00312 | chr2:60725424~60725688 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +62 enhancer〞GWAS fine-mapping evidence record |
| E_00313 | chr2:60725424~60725688 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +62 enhancer〞GWAS fine-mapping evidence record |
| E_00314 | chr2:60725424~60725688 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +62 enhancer〞GWAS fine-mapping evidence record |
| E_00315 | chr2:60725424~60725688 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +62 enhancer〞3C looping evidence record |
| E_00316 | chr2:60725424~60725688 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +62 enhancer〞3C looping evidence record |
| E_00317 | chr2:60725424~60725688 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +62 enhancer〞3C looping evidence record |
| E_00318 | chr2:60725424~60725688 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +62 enhancer〞3C looping evidence record |
| E_00319 | chr2:60725424~60725688 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +62 enhancer〞developmental transgenic-reporter evidence record |
| E_00320 | chr2:60725424~60725688 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +62 enhancer〞developmental transgenic-reporter evidence record |
| E_00321 | chr2:60725424~60725688 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +62 enhancer〞developmental transgenic-reporter evidence record |
| E_00322 | chr2:60725424~60725688 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +62 enhancer〞developmental transgenic-reporter evidence record |
| E_00323 | chr2:60718042~60718186 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +55 enhancer〞TF occupancy and chromatin-state evidence |
| E_00324 | chr2:60718042~60718186 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +55 enhancer〞TF occupancy and chromatin-state evidence |
| E_00325 | chr2:60718042~60718186 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +55 enhancer〞TF occupancy and chromatin-state evidence |
| E_00326 | chr2:60718042~60718186 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +55 enhancer〞TF occupancy and chromatin-state evidence |
| E_00327 | chr2:60718042~60718186 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +55 enhancer〞GWAS fine-mapping evidence record |
| E_00328 | chr2:60718042~60718186 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +55 enhancer〞GWAS fine-mapping evidence record |
| E_00329 | chr2:60718042~60718186 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +55 enhancer〞GWAS fine-mapping evidence record |
| E_00330 | chr2:60718042~60718186 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +55 enhancer〞GWAS fine-mapping evidence record |
| E_00331 | chr2:60718042~60718186 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +55 enhancer〞3C looping evidence record |
| E_00332 | chr2:60718042~60718186 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +55 enhancer〞3C looping evidence record |
| E_00333 | chr2:60718042~60718186 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +55 enhancer〞3C looping evidence record |
| E_00334 | chr2:60718042~60718186 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +55 enhancer〞3C looping evidence record |
| E_00335 | chr2:60718042~60718186 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | sickle cell disease | Constituent +55 enhancer〞developmental transgenic-reporter evidence record |
| E_00336 | chr2:60718042~60718186 | bone marrow / erythroid compartment | transgenic mice | sickle cell disease | Constituent +55 enhancer〞developmental transgenic-reporter evidence record |
| E_00337 | chr2:60718042~60718186 | bone marrow / erythroid compartment | MEL and pre-B cells for orthologous enhancer deletion | beta-thalassemia | Constituent +55 enhancer〞developmental transgenic-reporter evidence record |
| E_00338 | chr2:60718042~60718186 | bone marrow / erythroid compartment | transgenic mice | beta-thalassemia | Constituent +55 enhancer〞developmental transgenic-reporter evidence record |
| E_00339 | chr2:42949150~42949551 | bone marrow | Primary t(2 | acute myeloid leukemia | Candidate enhancer hijacking; TF binding; chromatin-state validation |
| E_00340 | chr3:128603426~128604425 | bone marrow | primary inv(3)/t(3 | acute myeloid leukemia | Enhancer hijacking; TF binding; chromatin-state and structural-variant validation |
| E_00341 | chr7:92755125~92755526 | bone marrow | Primary t(3 | acute myeloid leukemia | Candidate enhancer hijacking; TF binding; chromatin-state validation |
| E_00342 | chr12:85475057~85477322 | brain | primary mouse cortical neurons | -- | Stimulus-responsive enhancer assay; endogenous enhancer perturbation |
| E_00343 | chr12:85475057~85477322 | brain | primary mouse cortical neurons | -- | Stimulus-responsive enhancer assay; endogenous enhancer perturbation |
| E_00344 | chr12:85433906~85439068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00345 | chr12:85433906~85439068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00346 | chr12:85433906~85439068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00347 | chr12:85433906~85439068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00348 | chr12:85433906~85439068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00349 | chr12:85433906~85439068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00350 | chr12:85452549~85458571 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00351 | chr12:85452549~85458571 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00352 | chr12:85452549~85458571 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00353 | chr12:85452549~85458571 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00354 | chr12:85452549~85458571 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00355 | chr12:85452549~85458571 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00356 | chr12:85466416~85469570 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00357 | chr12:85466416~85469570 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00358 | chr12:85466416~85469570 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00359 | chr12:85466416~85469570 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00360 | chr12:85466416~85469570 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00361 | chr12:85466416~85469570 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00362 | chr12:85470646~85474086 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00363 | chr12:85470646~85474086 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00364 | chr12:85470646~85474086 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00365 | chr12:85470646~85474086 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00366 | chr12:85470646~85474086 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00367 | chr12:85470646~85474086 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00368 | chr12:85482048~85490068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00369 | chr12:85482048~85490068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00370 | chr12:85482048~85490068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00371 | chr12:85482048~85490068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00372 | chr12:85482048~85490068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00373 | chr12:85482048~85490068 | brain | Mouse Cortical Neurons | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis |
| E_00374 | chr8:128889122~128889450 | kidney | RCC4 | renal cell carcinoma | TF binding assay; Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00375 | chr8:128821500~128822500 | breast | MDA-MB-231 | breast carcinoma | Enhancer activity; enhancer-promoter competition; endogenous perturbation |
| E_00376 | chr8:128866000~128867000 | breast | MDA-MB-231 | breast carcinoma | Enhancer activity; enhancer-promoter competition; endogenous perturbation |
| E_00377 | chr8:128912000~128913000 | breast | MCF-7 | breast carcinoma | Enhancer activity; enhancer-promoter competition; endogenous perturbation |
| E_00378 | chr8:128919000~128920000 | breast | MDA-MB-231 | breast carcinoma | Enhancer activity; enhancer-promoter competition; endogenous perturbation |
| E_00379 | chr12:85463935~85468299 | cerebral cortex | Primary mouse cortical neurons | -- | Enhancer activity assay; TF binding assay; Enhancer RNA assay; Chromatin interaction assay; Functional perturbation assay |
| E_00380 | chr12:85490344~85493924 | cerebral cortex | Primary mouse cortical neurons | -- | Enhancer activity assay; TF binding assay; Enhancer RNA assay; Chromatin interaction assay; Functional perturbation assay |
| E_00381 | chr12:85509692~85513444 | cerebral cortex | Primary mouse cortical neurons | -- | Enhancer activity assay; TF binding assay; Enhancer RNA assay; Chromatin interaction assay; Functional perturbation assay |
| E_00382 | chr22:42411693~42414130 | liver | Primary human hepatocytes (Hep4 | -- | Chromatin interaction assay; Cofactor occupancy assay; Chromatin accessibility assay; Epigenomic enhancer characterization; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00383 | chr2:18910338~18911438 | brain | U-251MG | malignant glioma | Functional enhancer validation; chromatin interaction assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00384 | chr2:18910338~18911438 | brain | U-251MG | malignant glioma | Functional enhancer validation; chromatin interaction assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00385 | chr2:18910338~18911438 | brain | U-251MG | malignant glioma | Functional enhancer validation; chromatin interaction assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00386 | chr2:18910338~18911438 | brain | U-251MG | malignant glioma | Functional enhancer validation; chromatin interaction assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_00387 | chr2:178806313~178806949 | heart | human induced pluripotent stem cell-derived cardiomyocytes | dilated cardiomyopathy | Enhancer activity assay; endogenous enhancer perturbation assay; disease variant analysis; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_00388 | chr14:98664280~98665247 | bone marrow | THP-6 | T-cell acute lymphoblastic leukemia | Enhancer essentiality screen; Enhancer hijacking analysis; TF binding assay; Endogenous enhancer perturbation |
| E_00389 | chr1:154150000~154150500 | heart | hPSC-CMs | -- | Enhancer activity assay, TF binding assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00390 | chr1:154151000~154151500 | heart | hPSC-CMs | -- | Enhancer activity assay, TF binding assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00391 | chr2:42949150~42949551 | bone marrow | 3) AML blasts | acute myeloid leukemia | Candidate enhancer hijacking; TF binding; chromatin-state validation |
| E_00392 | chr3:128603426~128604425 | bone marrow | 3) AML blasts | acute myeloid leukemia | Enhancer hijacking; TF binding; chromatin-state and structural-variant validation |
| E_00393 | chr7:92755125~92755526 | bone marrow | 7) AML blasts | acute myeloid leukemia | Candidate enhancer hijacking; TF binding; chromatin-state validation |
| E_00394 | chr6:156425000~156525000 | bone marrow | Primary t(3 | acute myeloid leukemia | Chromatin architectural element / enhancer-docking analysis |
| E_00395 | chr6:156425000~156525000 | bone marrow | Primary t(3 | acute myeloid leukemia | Enhancer-hijacking donor-locus mapping; TF binding; structural-variant validation |
| E_00396 | chr7:128573817~128574098 | blood | Primary CD14+ monocytes | autoimmune disease | Enhancer activity assay, TF binding assay, Chromatin interaction assay; Disease-variant functional analysis |
| E_00397 | chr14:23437399~23439399 | heart | human induced pluripotent stem cell-derived cardiomyocytes | cardiomyopathy | Enhancer variant functional assay; endogenous enhancer deletion; target-gene expression; cardiac phenotype; Chromatin interaction assay; Disease-variant functional analysis |
| E_00398 | chr8:129582024~129582425 | bone marrow | Primary t(3 | acute myeloid leukemia | Patient-like translocation engineering; constituent enhancer requirement; 3D-loop mechanism |
| E_00399 | chr8:129582024~129582425 | blood | Primary t(3 | acute myeloid leukemia | Patient-like translocation engineering; constituent enhancer requirement; 3D-loop mechanism |
| E_00400 | chr12:14409708~14410606 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00401 | chr8:128889122~128889450 | kidney | renal tubular cells | clear cell renal carcinoma | Disease-risk enhancer; enhancer-promoter interaction; allele-specific TF binding; endogenous genome editing |
| E_00402 | chr8:128889122~128889450 | kidney | RCC4 | clear cell renal carcinoma | Disease-risk enhancer; enhancer-promoter interaction; allele-specific TF binding; endogenous genome editing |
| E_00403 | chr8:128889122~128889450 | kidney | 786-O | clear cell renal carcinoma | Disease-risk enhancer; enhancer-promoter interaction; allele-specific TF binding; endogenous genome editing |
| E_00404 | chr8:128889122~128889450 | kidney | renal tubular cells | clear cell renal carcinoma | Disease-risk enhancer; allele-specific HIF binding; chromatin interaction; endogenous HRE editing |
| E_00405 | chr8:128889122~128889450 | kidney | RCC4 | clear cell renal carcinoma | Disease-risk enhancer; allele-specific HIF binding; chromatin interaction; endogenous HRE editing |
| E_00406 | chr8:128889122~128889450 | kidney | 786-O | clear cell renal carcinoma | Disease-risk enhancer; allele-specific HIF binding; chromatin interaction; endogenous HRE editing |
| E_00407 | chr8:128889122~128889450 | kidney | renal tubular cells | clear cell renal carcinoma | Disease-risk enhancer; allele-specific HIF binding; chromatin interaction; endogenous HRE editing |
| E_00408 | chr8:128889122~128889450 | kidney | RCC4 | clear cell renal carcinoma | Disease-risk enhancer; allele-specific HIF binding; chromatin interaction; endogenous HRE editing |
| E_00409 | chr8:128889122~128889450 | kidney | 786-O | clear cell renal carcinoma | Disease-risk enhancer; allele-specific HIF binding; chromatin interaction; endogenous HRE editing |
| E_00410 | chr14:23912000~23912961 | -- | human iPSC-derived cardiomyocytes | -- | Enhancer activity assay; Functional perturbation assay; Regulatory variant functional assay; Engineered heart tissue functional assay |
| E_00411 | chr14:23912000~23912961 | -- | human iPSC-derived cardiomyocytes | -- | Enhancer activity assay; Functional perturbation assay; Regulatory variant functional assay; Engineered heart tissue functional assay |
| E_00412 | chr22:42411693~42414130 | liver | Hep8 | -- | Chromatin interaction assay; Cofactor occupancy assay; Chromatin accessibility assay; Epigenomic enhancer characterization; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00413 | chr22:42411693~42414130 | liver | Hep10 | -- | Chromatin interaction assay; Cofactor occupancy assay; Chromatin accessibility assay; Epigenomic enhancer characterization; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00414 | chr22:42411693~42414130 | liver | Hep11) | -- | Chromatin interaction assay; Cofactor occupancy assay; Chromatin accessibility assay; Epigenomic enhancer characterization; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00415 | chr12:85428000~85428500 | cerebral cortex | Cortical neurons | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_00416 | chr12:85429000~85429500 | cerebral cortex | Cortical neurons | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_00417 | chr2:60718043~60725451 | bone marrow | Primary human erythroid precursors/erythroblasts | -- | Enhancer activity assay, Functional perturbation assay, TF binding assay; Disease-variant functional analysis; In vivo functional validation |
| E_00418 | chr3:128603426~128604425 | blood | Primary human CD34+ hematopoietic stem/progenitor cells | -- | Native enhancer TF-binding/chromatin-state validation |
| E_00419 | chr2:42949150~42949551 | blood | Primary human CD34+ hematopoietic stem/progenitor cells | -- | Native enhancer chromatin-state/TF-binding validation |
| E_00420 | chr7:92755125~92755526 | blood | Primary human CD34+ hematopoietic stem/progenitor cells | -- | Native enhancer chromatin-state/TF-binding validation |
| E_00421 | chr12:25538591~25539583 | bone marrow | MKPL-1 | hematopoietic malignancy | Enhancer activity assay; functional perturbation assay; TF binding assay; Disease-variant functional analysis |
| E_00422 | chr6:156425000~156525000 | bone marrow | 6) AML blasts | acute myeloid leukemia | Chromatin architectural element / enhancer-docking analysis |
| E_00423 | chr6:156425000~156525000 | bone marrow | 6) AML blasts | acute myeloid leukemia | Enhancer-hijacking donor-locus mapping; TF binding; structural-variant validation |
| E_00424 | chr17:38065000~38068000 | blood | Primary CD4+ T cells | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00425 | chr16:53800454~53801454 | subcutaneous adipose tissue | primary human subcutaneous adipose progenitors | obesity | Endogenous enhancer-variant validation; target-gene perturbation; cellular phenotype assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00426 | chr16:53800454~53801454 | subcutaneous adipose tissue | primary human subcutaneous adipose progenitors | obesity | Endogenous enhancer-variant validation; target-gene perturbation; cellular phenotype assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00427 | chr8:129582024~129582425 | bone marrow | CRISPR-engineered t(3 | acute myeloid leukemia | Patient-like translocation engineering; constituent enhancer requirement; 3D-loop mechanism |
| E_00428 | chr8:129582024~129582425 | bone marrow | 8) AML model | acute myeloid leukemia | Patient-like translocation engineering; constituent enhancer requirement; 3D-loop mechanism |
| E_00429 | chr8:129582024~129582425 | bone marrow | 8) AML | acute myeloid leukemia | Patient-like translocation engineering; constituent enhancer requirement; 3D-loop mechanism |
| E_00430 | chr8:129582024~129582425 | blood | CRISPR-engineered t(3 | acute myeloid leukemia | Patient-like translocation engineering; constituent enhancer requirement; 3D-loop mechanism |
| E_00431 | chr8:129582024~129582425 | blood | 8) AML model | acute myeloid leukemia | Patient-like translocation engineering; constituent enhancer requirement; 3D-loop mechanism |
| E_00432 | chr8:129582024~129582425 | blood | 8) AML | acute myeloid leukemia | Patient-like translocation engineering; constituent enhancer requirement; 3D-loop mechanism |
| E_00433 | chr2:127892710~127893072 | brain | Human cerebral cortex NEUN-negative/LHX2+ nuclei | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00434 | chr2:127892710~127893072 | brain | H1 (WA01) hESC | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00435 | chr2:127892710~127893072 | brain | EC11 iPSC-derived astrocytes | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00436 | chr2:127892710~127893072 | brain | Human cerebral-cortex NEUN-negative/LHX2+ nuclei | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00437 | chr2:127892710~127893072 | brain | H1 (WA01) hESC | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00438 | chr2:127892710~127893072 | brain | EC11 iPSC-derived astrocytes | Alzheimer disease | Cell-type specificity negative-control validation of the same enhancer; endogenous enhancer deletion |
| E_00439 | chr2:127892710~127893072 | brain | Resected cerebral cortex NEUN-negative/LHX2+ nuclei | Alzheimer disease | Enhancer activity assay; Functional perturbation negative-control assay |
| E_00440 | chr2:127892710~127893072 | brain | H1 (WA01) hESC | Alzheimer disease | Enhancer activity assay; Functional perturbation negative-control assay |
| E_00441 | chr2:127892710~127893072 | brain | EC11 iPSC-derived astrocytes | Alzheimer disease | Enhancer activity assay; Functional perturbation negative-control assay |
| E_00442 | chr11:32145028~32146147 | blood | primary mouse erythroid cells / enhancer-deletion mice | -- | Endogenous constituent-enhancer knockout; chromatin and 3D-conformation dissection |
| E_00443 | chr11:32145028~32146147 | blood | primary mouse erythroid cells / enhancer-deletion mice | -- | Endogenous constituent-enhancer knockout; chromatin and 3D-conformation dissection |
| E_00444 | chr11:32145028~32146147 | blood | primary mouse erythroid cells / enhancer-deletion mice | -- | Endogenous constituent-enhancer knockout; chromatin and 3D-conformation dissection |
| E_00445 | chr11:32145028~32146147 | blood | primary mouse erythroid cells / enhancer-deletion mice | -- | Endogenous constituent-enhancer knockout; chromatin and 3D-conformation dissection |
| E_00446 | chr11:32150550~32151858 | blood | primary mouse erythroid cells / enhancer-deletion mice | -- | Endogenous constituent-enhancer knockout; chromatin and 3D-conformation dissection |
| E_00447 | chr11:32150550~32151858 | blood | primary mouse erythroid cells / enhancer-deletion mice | -- | Endogenous constituent-enhancer knockout; chromatin and 3D-conformation dissection |
| E_00448 | chr11:32150550~32151858 | blood | primary mouse erythroid cells / enhancer-deletion mice | -- | Endogenous constituent-enhancer knockout; chromatin and 3D-conformation dissection |
| E_00449 | chr11:32150550~32151858 | blood | primary mouse erythroid cells / enhancer-deletion mice | -- | Endogenous constituent-enhancer knockout; chromatin and 3D-conformation dissection |
| E_00450 | chr6:156425000~156525000 | blood | Primary human CD34+ hematopoietic stem/progenitor cells | -- | Native donor-locus chromatin-state/TF-binding validation |
| E_00451 | chr6:151953109~151955347 | pleural effusion | T-47D | breast carcinoma | Functional perturbation assay; Enhancer activity assay |
| E_00452 | chr1:16160379~16162282 | bone marrow | MKPL-1 | hematopoietic malignancy | Enhancer activity assay; Functional perturbation assay; Disease-variant functional analysis |
| E_00453 | chr1:16160379~16162282 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00454 | chr1:24717819~24718917 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00455 | chr8:130180012~130180748 | bone marrow | THP-6 | T-cell acute lymphoblastic leukemia | Enhancer essentiality screen; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_00456 | chr14:23876121~23878188 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay; Regulatory variant functional assay |
| E_00457 | chr14:23876121~23878188 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay; Regulatory variant functional assay |
| E_00458 | chr12:85475057~85477322 | cerebral cortex | Primary mouse cortical neurons | -- | Enhancer activity assay; TF binding assay; Enhancer RNA assay; Functional perturbation assay |
| E_00459 | chr8:128821500~128822500 | breast | MCF-7 and breast cancer models | breast carcinoma | Enhancer-promoter competition/boundary perturbation and chromatin-contact assay |
| E_00460 | chr8:128866000~128867000 | breast | MCF-7 and breast cancer models | breast carcinoma | Enhancer-promoter competition/boundary perturbation and chromatin-contact assay |
| E_00461 | chr8:128912000~128913000 | breast | MCF-7 and breast cancer models | breast carcinoma | Enhancer-promoter competition/boundary perturbation and chromatin-contact assay |
| E_00462 | chr8:128919000~128920000 | breast | MCF-7 and breast cancer models | breast carcinoma | Enhancer-promoter competition/boundary perturbation and chromatin-contact assay |
| E_00463 | chr1:155936009~155937220 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00464 | chr1:155937201~155938359 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00465 | chr1:156073216~156074415 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00466 | chr1:156074366~156075480 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00467 | chr1:156092084~156093294 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00468 | chr1:156093103~156094494 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00469 | chr1:156095724~156096574 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00470 | chr1:156099538~156100640 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00471 | chr14:23870150~23870823 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00472 | chr14:23870150~23870823 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00473 | chr14:23870761~23871458 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00474 | chr14:23870761~23871458 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00475 | chr14:23871436~23872136 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00476 | chr14:23871436~23872136 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00477 | chr14:23876221~23877058 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00478 | chr14:23876221~23877058 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00479 | chr14:23876782~23877626 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00480 | chr14:23876782~23877626 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00481 | chr14:23877446~23878141 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00482 | chr14:23877446~23878141 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00483 | chr14:23922666~23924886 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00484 | chr14:23923381~23924171 | left cardiac ventricle | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer activity assay |
| E_00485 | chr11:128345996~128346496 | bone marrow | THP-6 | T-cell acute lymphoblastic leukemia | Enhancer essentiality screen; TF binding assay; Endogenous enhancer perturbation |
| E_00486 | chr11:128346532~128347032 | bone marrow | THP-6 | T-cell acute lymphoblastic leukemia | Enhancer essentiality screen; TF binding assay; Endogenous enhancer perturbation |
| E_00487 | chr17:8867991~8869544 | bone marrow | THP-6 | T-cell acute lymphoblastic leukemia | Enhancer essentiality screen; TF binding assay; Endogenous enhancer perturbation |
| E_00488 | chr17:56409696~56410196 | bone marrow | THP-6 | T-cell acute lymphoblastic leukemia | Enhancer essentiality screen; TF binding assay; Endogenous enhancer perturbation |
| E_00489 | chr3:127316882~127317656 | bone marrow | THP-6 | T-cell acute lymphoblastic leukemia | Enhancer essentiality screen; TF binding assay; Endogenous enhancer perturbation |
| E_00490 | chr5:169063976~169065285 | bone marrow | THP-6 | T-cell acute lymphoblastic leukemia | Enhancer essentiality screen; TF binding assay; Endogenous enhancer perturbation |
| E_00491 | chr7:128573817~128574098 | kidney | HEK293 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_00492 | chr1:154149500~154150000 | heart | Mouse embryonic/Adult cardiomyocytes | -- | TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00493 | chr1:154150000~154150500 | heart | Mouse embryonic/Adult cardiomyocytes | -- | TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00494 | chr1:154151000~154151500 | heart | Mouse embryonic/Adult cardiomyocytes | -- | TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00495 | chr1:16160379~16162282 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00496 | chr1:24717819~24718917 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00497 | chr1:26827000~26828194 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00498 | chr1:26827000~26828194 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00499 | chr1:90223243~90223945 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00500 | chr1:90223243~90223945 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00501 | chr1:92269671~92270441 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00502 | chr1:92269671~92270441 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00503 | chr1:92970067~92970871 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00504 | chr1:92970067~92970871 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00505 | chr1:152432052~152433139 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00506 | chr1:152432052~152433139 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00507 | chr10:8287120~8287832 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00508 | chr10:8287120~8287832 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00509 | chr10:12490188~12491664 | bone marrow | MKPL-1 | hematopoietic malignancy | Enhancer activity assay; Functional perturbation assay; Disease-variant functional analysis |
| E_00510 | chr10:12490188~12491664 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00511 | chr10:12490188~12491664 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00512 | chr10:73648369~73649316 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00513 | chr10:73648369~73649316 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00514 | chr10:74090966~74091882 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00515 | chr10:74090966~74091882 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00516 | chr10:75625477~75626252 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00517 | chr10:75625477~75626252 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00518 | chr10:98459973~98460780 | bone marrow | MKPL-1 | hematopoietic malignancy | Enhancer activity assay; Functional perturbation assay; Disease-variant functional analysis |
| E_00519 | chr10:98459973~98460780 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00520 | chr10:98459973~98460780 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00521 | chr10:134401705~134403146 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00522 | chr10:134401705~134403146 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00523 | chr11:122614110~122615622 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00524 | chr11:122614110~122615622 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00525 | chr12:1905658~1906492 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00526 | chr12:1905658~1906492 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00527 | chr12:24967199~24968349 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00528 | chr12:24967199~24968349 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00529 | chr12:25429052~25430002 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00530 | chr12:25429052~25430002 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00531 | chr12:27702331~27703065 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00532 | chr12:27702331~27703065 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00533 | chr12:120729447~120730585 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00534 | chr12:120729447~120730585 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00535 | chr14:52487681~52488440 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00536 | chr14:52487681~52488440 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00537 | chr14:91254408~91255183 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00538 | chr14:91254408~91255183 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00539 | chr15:33493747~33494735 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00540 | chr15:33493747~33494735 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00541 | chr15:77196826~77197790 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00542 | chr15:77196826~77197790 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00543 | chr15:83517842~83518593 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00544 | chr15:83517842~83518593 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00545 | chr16:3208813~3209656 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00546 | chr16:3208813~3209656 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00547 | chr16:83972527~83973363 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00548 | chr16:83972527~83973363 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00549 | chr17:6656019~6656759 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00550 | chr17:6656019~6656759 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00551 | chr17:35447019~35447926 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00552 | chr17:35447019~35447926 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00553 | chr19:3434613~3435744 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00554 | chr19:3434613~3435744 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00555 | chr19:13278523~13279241 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00556 | chr19:13278523~13279241 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00557 | chr19:49389348~49390121 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00558 | chr19:49389348~49390121 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00559 | chr19:50860281~50861408 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00560 | chr19:50860281~50861408 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00561 | chr2:86262562~86264318 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00562 | chr2:86262562~86264318 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00563 | chr2:225795025~225795782 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00564 | chr2:225795025~225795782 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00565 | chr3:42705321~42706477 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00566 | chr3:42705321~42706477 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00567 | chr3:193859290~193860013 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00568 | chr3:193859290~193860013 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00569 | chr4:8169111~8170256 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00570 | chr4:8169111~8170256 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00571 | chr4:40552794~40553798 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00572 | chr4:40552794~40553798 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00573 | chr4:176867777~176868491 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00574 | chr4:176867777~176868491 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00575 | chr6:27470012~27470721 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00576 | chr6:27470012~27470721 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00577 | chr6:41673311~41674775 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00578 | chr6:41673311~41674775 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00579 | chr6:100795540~100797229 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00580 | chr6:100795540~100797229 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00581 | chr6:135504517~135505261 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00582 | chr6:135504517~135505261 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00583 | chr7:2933701~2934454 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00584 | chr7:2933701~2934454 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00585 | chr7:4764779~4765676 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00586 | chr7:4764779~4765676 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00587 | chr7:8215498~8216965 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00588 | chr7:8215498~8216965 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00589 | chr7:65958067~65959039 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00590 | chr7:65958067~65959039 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00591 | chr7:129649912~129650743 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00592 | chr7:129649912~129650743 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00593 | chr8:102120481~102121738 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00594 | chr8:102120481~102121738 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00595 | chr8:116660008~116661198 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00596 | chr8:116660008~116661198 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00597 | chr9:96928325~96929213 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00598 | chr9:96928325~96929213 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00599 | chr9:115625021~115625725 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00600 | chr9:115625021~115625725 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00601 | chr9:127882943~127884195 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00602 | chr9:127882943~127884195 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00603 | chr17:38022100~38022900 | blood | Primary CD4+ T cells | asthma | Chromatin interaction assay, Enhancer activity assay, Gene expression assay |
| E_00604 | chr14:23876121~23878188 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | -- | Enhancer activity assay; regulatory variant functional assay |
| E_00605 | chr14:23876121~23878188 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | -- | Enhancer activity assay; regulatory variant functional assay |
| E_00606 | chr1:155937201~155938359 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | -- | Enhancer activity assay |
| E_00607 | chr1:155937201~155938359 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | -- | Enhancer activity assay |
| E_00608 | chr1:156074366~156075480 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | -- | Enhancer activity assay |
| E_00609 | chr1:156074366~156075480 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | -- | Enhancer activity assay |
| E_00610 | chr1:156093103~156094494 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | -- | Enhancer activity assay |
| E_00611 | chr1:156093103~156094494 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | -- | Enhancer activity assay |
| E_00612 | chr1:156095724~156096574 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | -- | Enhancer activity assay |
| E_00613 | chr1:156095724~156096574 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | -- | Enhancer activity assay |
| E_00614 | chr1:156099538~156100640 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | -- | Enhancer activity assay |
| E_00615 | chr1:156099538~156100640 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | -- | Enhancer activity assay |
| E_00616 | chr14:23871436~23872136 | heart left ventricle | GM03348-derived human iPSC cardiomyocytes | -- | Enhancer activity assay |
| E_00617 | chr14:23871436~23872136 | heart left ventricle | HL-1 mouse atrial cardiomyocyte cell line | -- | Enhancer activity assay |
| E_00618 | chr12:25398284~25400000 | bone marrow | MKPL-1 | hematopoietic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00619 | chr11:39392559~39393437 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00620 | chr11:39392559~39393437 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00621 | chr12:14409708~14410606 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00622 | chr15:70820443~70821348 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00623 | chr15:70820443~70821348 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00624 | chr2:61990869~61991991 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00625 | chr2:61990869~61991991 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00626 | chr4:107629151~107629921 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00627 | chr4:107629151~107629921 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00628 | chr4:139409505~139410233 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00629 | chr4:139409505~139410233 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00630 | chr8:126517993~126518698 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00631 | chr8:126517993~126518698 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00632 | chr9:107877035~107877852 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00633 | chr9:107877035~107877852 | bone marrow | MKPL-1 | hematopoietic malignancy | High-throughput functional CRE perturbation screen; candidate enhancer annotation; Disease-variant functional analysis |
| E_00634 | chr12:85479010~85480701 | cerebral cortex | Primary mouse cortical neurons | -- | Enhancer chromatin-state assay; TF binding assay; Enhancer RNA assay |
| E_00635 | chr12:85479010~85480701 | brain | primary mouse cortical neurons | -- | Stimulus-responsive enhancer characterization |
| E_00636 | chr17:38080665~38081065 | blood | TH2-enriched primary memory CD4+ T cells | asthma | Enhancer chromatin-state assay |
| E_00637 | chr17:38080712~38081112 | blood | TH2-enriched primary memory CD4+ T cells | asthma | Enhancer chromatin-state assay |
| E_00638 | chr17:38082607~38083007 | blood | TH2-enriched primary memory CD4+ T cells | asthma | Enhancer chromatin-state assay |
| E_00639 | chr22:42411544~42415106 | liver | Human Primary Hepatocytes | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_00640 | chr22:42411769~42414470 | liver | Human Primary Hepatocytes | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_00641 | chr2:127892600~127892962 | brain | hPSC-derived astrocyte | -- | Negative cell-type-specificity control |
| E_00642 | chr2:127892600~127892962 | brain | hPSC-derived neuron | -- | Negative cell-type-specificity control |
| E_00643 | chr11:122614110~122615622 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00644 | chr11:8240851~8242851 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL),RPMI-8402 and Jurkat | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_00645 | chr11:8289240~8289522 | breast | MCF-10A | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_00646 | chr1:16160379~16162282 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00647 | chr1:24717819~24718917 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00648 | chr1:26827000~26828194 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00649 | chr1:90223243~90223945 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00650 | chr1:92269671~92270441 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00651 | chr1:92970067~92970871 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00652 | chr1:152432052~152433139 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00653 | chr10:8287120~8287832 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00654 | chr10:12490188~12491664 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00655 | chr10:73648369~73649316 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00656 | chr10:74090966~74091882 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00657 | chr10:75625477~75626252 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00658 | chr10:98459973~98460780 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00659 | chr10:134401705~134403146 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00660 | chr12:1905658~1906492 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00661 | chr12:24967199~24968349 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00662 | chr12:25429052~25430002 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00663 | chr12:27702331~27703065 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00664 | chr12:120729447~120730585 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00665 | chr14:52487681~52488440 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00666 | chr14:91254408~91255183 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00667 | chr15:33493747~33494735 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00668 | chr15:77196826~77197790 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00669 | chr15:83517842~83518593 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00670 | chr16:3208813~3209656 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00671 | chr16:83972527~83973363 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00672 | chr17:6656019~6656759 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00673 | chr17:35447019~35447926 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00674 | chr19:3434613~3435744 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00675 | chr19:13278523~13279241 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00676 | chr19:49389348~49390121 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00677 | chr19:50860281~50861408 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00678 | chr2:86262562~86264318 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00679 | chr2:225795025~225795782 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00680 | chr3:42705321~42706477 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00681 | chr3:193859290~193860013 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00682 | chr4:8169111~8170256 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00683 | chr4:40552794~40553798 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00684 | chr4:176867777~176868491 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00685 | chr6:27470012~27470721 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00686 | chr6:41673311~41674775 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00687 | chr6:100795540~100797229 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00688 | chr6:135504517~135505261 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00689 | chr7:2933701~2934454 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00690 | chr7:4764779~4765676 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00691 | chr7:8215498~8216965 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00692 | chr7:65958067~65959039 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00693 | chr7:129649912~129650743 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00694 | chr8:102120481~102121738 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00695 | chr8:116660008~116661198 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00696 | chr9:96928325~96929213 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00697 | chr9:115625021~115625725 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00698 | chr9:127882943~127884195 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00699 | chr6:151953109~151955347 | breast | HCC1419 | breast carcinoma | TF binding assay; Allele-specific regulatory assay |
| E_00700 | chr17:38022212~38022898 | blood | Primary naive CD4+ T cells | asthma | Chromatin interaction assay |
| E_00701 | chr11:39392559~39393437 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00702 | chr12:14409708~14410606 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00703 | chr12:25538591~25539583 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00704 | chr15:70820443~70821348 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00705 | chr2:61990869~61991991 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00706 | chr4:107629151~107629921 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00707 | chr4:139409505~139410233 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00708 | chr8:126517993~126518698 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00709 | chr9:107877035~107877852 | blood | K-562 | hematologic malignancy | Enhancer activity assay; Functional perturbation assay |
| E_00710 | chr3:186239308~186239606 | cerebral cortex | WA09-derived cortical organoid | -- | Enhancer activity assay; functional perturbation assay; chromatin interaction assay; TF binding assay; Disease-variant functional analysis |
| E_00711 | chr3:186239308~186239606 | cerebral cortex | WA09-derived cortical organoid | -- | Enhancer activity assay; functional perturbation assay; chromatin interaction assay; TF binding assay; Disease-variant functional analysis |
| E_00712 | chr3:46186503~46187707 | bone element | Primary human osteoblast | osteoporosis | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay; TF binding assay; Disease-variant functional analysis |
| E_00713 | chr1:47704954~47704983 | blood | primary T-ALL specimens | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00714 | chr3:46186503~46187707 | bone element | MG-63 | osteoporosis | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay; TF binding assay; Disease-variant functional analysis |
| E_00715 | chr1:47704954~47704983 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00716 | chr1:47704954~47704983 | blood | MOLT-3 | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00717 | chr1:47704954~47704983 | blood | primary T-ALL specimens | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00718 | chr1:47704954~47704983 | blood | primary T-ALL specimens | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00719 | chr1:47704954~47704983 | blood | primary T-ALL specimens | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00720 | chr1:47704954~47704983 | blood | primary T-ALL specimens | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00721 | chr1:47704954~47704983 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00722 | chr1:47704954~47704983 | blood | MOLT-3 | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00723 | chr1:47704954~47704983 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00724 | chr1:47704954~47704983 | blood | MOLT-3 | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00725 | chr1:47704954~47704983 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00726 | chr1:47704954~47704983 | blood | MOLT-3 | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00727 | chr1:47704954~47704983 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00728 | chr1:47704954~47704983 | blood | MOLT-3 | T-cell acute lymphoblastic leukemia | Mutation-created oncogenic enhancer; TF recruitment; endogenous allele dependency |
| E_00729 | chr3:186239308~186239606 | cerebral cortex | 8799-derived neural progenitor cells | -- | Enhancer activity assay; TF regulatory assay; chromatin interaction assay; Disease-variant functional analysis |
| E_00730 | chr3:186239308~186239606 | cerebral cortex | 8799-derived neural progenitor cells | -- | Enhancer activity assay; TF regulatory assay; chromatin interaction assay; Disease-variant functional analysis |
| E_00731 | chr1:47669000~47669500 | blood | Jurkat and TAL1-mutant primary T-ALL | T-cell acute lymphoblastic leukemia | Mutation-created neo-enhancer and TF recruitment |
| E_00732 | chr1:47669000~47669500 | blood | Jurkat and TAL1-mutant primary T-ALL | T-cell acute lymphoblastic leukemia | Neo-enhancer TF-complex occupancy |
| E_00733 | chr1:47669000~47669500 | blood | Jurkat and TAL1-mutant primary T-ALL | T-cell acute lymphoblastic leukemia | Autoregulatory oncogenic enhancer complex |
| E_00734 | chr1:47669000~47669500 | blood | Jurkat and TAL1-mutant primary T-ALL | T-cell acute lymphoblastic leukemia | Neo-enhancer TF-complex occupancy |
| E_00735 | chr3:46186503~46187707 | bone element | hFOB1.19 | osteoporosis | Enhancer activity assay; TF binding assay; Disease-variant functional analysis |
| E_00736 | chr1:129180000~129181000 | blood | T-ALL | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay |
| E_00737 | chr10:72782000~72783500 | brain | Primary mouse embryonic hindbrain cells | -- | Functional perturbation assay |
| E_00738 | chr2:11661224~11661284 | blood/lymphoid tissue | primary mouse T cells (activated CD4+ T cells for chromatin assays | -- | TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00739 | chr2:11664841~11664854 | blood/lymphoid tissue | primary mouse T cells (activated CD4+ T cells for chromatin assays | -- | TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00740 | chr2:11661224~11661284 | blood/lymphoid tissue | mutant T cells for functional assays) | -- | TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00741 | chr2:11664841~11664854 | blood/lymphoid tissue | mutant T cells for functional assays) | -- | TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00742 | chr8:11564419~11614821 | blood / hematopoietic system | T Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_00743 | chr8:11564419~11614821 | blood / hematopoietic system | T Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_00744 | chr10:77407210~77407740 | hindbrain | embryonic hindbrain tissue | -- | Enhancer activity assay; Cis-regulatory potentiator assay |
| E_00745 | chr10:66855267~66855768 | hindbrain | E8.5-E9.5 mouse embryonic hindbrain | -- | In vivo enhancer functional perturbation assay; cis-regulatory potentiator assay |
| E_00746 | chr10:67853705~67855705 | -- | Embryo | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_00747 | chr10:67926705~67928705 | -- | Embryo | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_00748 | chr10:112731665~112732664 | heart | engineered heart tissue cardiomyocytes | cardiomyopathy | Enhancer reporter assay; noncoding variant functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00749 | chr8:11941645~11942644 | heart | engineered heart tissue cardiomyocytes | dilated cardiomyopathy | Enhancer reporter assay; noncoding variant functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00750 | chr3:14229951~14235950 | heart | human iPSC-derived cardiomyocytes in engineered heart tissues | dilated cardiomyopathy | Haplotype-resolved enhancer reporter assay; endogenous CRISPR deletion assay; target-gene expression profiling; engineered heart tissue functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00751 | chr3:14229951~14235950 | heart | primary human cardiac fibroblasts present in EHTs | dilated cardiomyopathy | Haplotype-resolved enhancer reporter assay; endogenous CRISPR deletion assay; target-gene expression profiling; engineered heart tissue functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00752 | chr3:14229951~14235950 | heart | human iPSC-derived cardiomyocytes in engineered heart tissues | dilated cardiomyopathy | Haplotype-resolved enhancer reporter assay; endogenous CRISPR deletion assay; target-gene expression profiling; engineered heart tissue functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00753 | chr3:14229951~14235950 | heart | primary human cardiac fibroblasts present in EHTs | dilated cardiomyopathy | Haplotype-resolved enhancer reporter assay; endogenous CRISPR deletion assay; target-gene expression profiling; engineered heart tissue functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00754 | chr7:35156536~35156974 | liver | HPC-7 | -- | Enhancer activity assay; chromatin interaction assay |
| E_00755 | chrX:48782664~48783392 | blood | K-562 | -- | Enhancer activity assay; TF binding assay; functional perturbation assay; Endogenous enhancer perturbation |
| E_00756 | chrX:48782664~48783392 | blood | K-562 | -- | Enhancer activity assay; TF binding assay; functional perturbation assay; Endogenous enhancer perturbation |
| E_00757 | chr20:44420684~44421883 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay; Functional perturbation assay |
| E_00758 | chr20:44426134~44428433 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay; Functional perturbation assay |
| E_00759 | chr20:44442384~44444183 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay; Functional perturbation assay |
| E_00760 | chr8:127898362~127899967 | blood | K-562 | -- | Enhancer activity assay; functional perturbation assay; chromatin interaction assay; Endogenous enhancer perturbation |
| E_00761 | chr8:127960009~127960984 | blood | K-562 | -- | Enhancer activity assay; functional perturbation assay; chromatin interaction assay; Endogenous enhancer perturbation |
| E_00762 | chr8:128044721~128046192 | blood | K-562 | -- | Enhancer activity assay; functional perturbation assay; chromatin interaction assay; Endogenous enhancer perturbation |
| E_00763 | chr8:128048231~128050347 | blood | K-562 | -- | Enhancer activity assay; functional perturbation assay; chromatin interaction assay; Endogenous enhancer perturbation |
| E_00764 | chr8:129581780~129583797 | blood | K-562 | -- | Enhancer activity assay; functional perturbation assay; chromatin interaction assay; Endogenous enhancer perturbation |
| E_00765 | chr8:129688360~129690572 | blood | K-562 | -- | Enhancer activity assay; functional perturbation assay; chromatin interaction assay; Endogenous enhancer perturbation |
| E_00766 | chr8:129691425~129693640 | blood | K-562 | -- | Enhancer activity assay; functional perturbation assay; chromatin interaction assay; Endogenous enhancer perturbation |
| E_00767 | chrX:48800418~48801257 | blood | K-562 | -- | Enhancer activity assay; functional perturbation assay; chromatin interaction assay; Endogenous enhancer perturbation |
| E_00768 | chrX:48800418~48801257 | blood | K-562 | -- | Enhancer activity assay; functional perturbation assay; chromatin interaction assay; Endogenous enhancer perturbation |
| E_00769 | chr10:112731665~112732664 | heart | human iPSC-derived cardiomyocytes | cardiomyopathy | Enhancer reporter assay; noncoding variant functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00770 | chr8:11941645~11942644 | heart | human iPSC-derived cardiomyocytes | dilated cardiomyopathy | Enhancer reporter assay; noncoding variant functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00771 | chr17:66306034~66307033 | heart | engineered heart tissue cardiomyocytes | cardiomyopathy | Allele-specific enhancer reporter assay; noncoding variant functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00772 | chr17:66307175~66308174 | heart | engineered heart tissue cardiomyocytes | cardiomyopathy | Allele-specific enhancer reporter assay; noncoding variant functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00773 | chr17:66306034~66307033 | heart | human iPSC-derived cardiomyocytes | cardiomyopathy | Allele-specific enhancer reporter assay; noncoding variant functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00774 | chr17:66307175~66308174 | heart | human iPSC-derived cardiomyocytes | cardiomyopathy | Allele-specific enhancer reporter assay; noncoding variant functional assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00775 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00776 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00777 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00778 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00779 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00780 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00781 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00782 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00783 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00784 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00785 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00786 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00787 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00788 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00789 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00790 | chr4:115040426~115042426 | -- | HPC-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00791 | chr20:44420684~44421883 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay |
| E_00792 | chr20:44420684~44421883 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay |
| E_00793 | chr20:44420684~44421883 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay |
| E_00794 | chr20:44426134~44428433 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay |
| E_00795 | chr20:44426134~44428433 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay |
| E_00796 | chr20:44426134~44428433 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay |
| E_00797 | chr20:44442384~44444183 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay |
| E_00798 | chr20:44442384~44444183 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay |
| E_00799 | chr20:44442384~44444183 | bone tissue | PC-3 | castration-resistant prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Histone modification assay |
| E_00800 | chr8:127898362~127899967 | blood | K-562 | -- | Genome-scale enhancer-target functional perturbation assay; Endogenous enhancer perturbation |
| E_00801 | chr8:127960009~127960984 | blood | K-562 | -- | Genome-scale enhancer-target functional perturbation assay; Endogenous enhancer perturbation |
| E_00802 | chr8:128044721~128046192 | blood | K-562 | -- | Genome-scale enhancer-target functional perturbation assay; Endogenous enhancer perturbation |
| E_00803 | chr8:128048231~128050347 | blood | K-562 | -- | Genome-scale enhancer-target functional perturbation assay; Endogenous enhancer perturbation |
| E_00804 | chr8:129581780~129583797 | blood | K-562 | -- | Genome-scale enhancer-target functional perturbation assay; Endogenous enhancer perturbation |
| E_00805 | chr8:129688360~129690572 | blood | K-562 | -- | Genome-scale enhancer-target functional perturbation assay; Endogenous enhancer perturbation |
| E_00806 | chr8:129691425~129693640 | blood | K-562 | -- | Genome-scale enhancer-target functional perturbation assay; Endogenous enhancer perturbation |
| E_00807 | chr20:44430820~44433428 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00808 | chr20:44430820~44433428 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00809 | chr20:44430820~44433428 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00810 | chr20:44430820~44433428 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00811 | chr20:44430820~44433428 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00812 | chr20:44430820~44433428 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00813 | chr20:44430820~44433428 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00814 | chr20:44430820~44433428 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00815 | chr20:44441255~44444472 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00816 | chr20:44441255~44444472 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00817 | chr20:44441255~44444472 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00818 | chr20:44441255~44444472 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00819 | chr20:44441255~44444472 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00820 | chr20:44441255~44444472 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00821 | chr20:44441255~44444472 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00822 | chr20:44441255~44444472 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00823 | chr20:44478646~44484559 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00824 | chr20:44478646~44484559 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00825 | chr20:44478646~44484559 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00826 | chr20:44478646~44484559 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00827 | chr20:44478646~44484559 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00828 | chr20:44478646~44484559 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00829 | chr20:44478646~44484559 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00830 | chr20:44478646~44484559 | prostate gland | PC-3 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00831 | chr20:44413081~44426646 | prostate gland | PC-3,DU-145 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00832 | chr20:44413081~44426646 | prostate gland | PC-3,DU-145 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00833 | chr20:44413081~44426646 | prostate gland | PC-3,DU-145 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00834 | chr20:44413081~44426646 | prostate gland | PC-3,DU-145 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_00835 | chr19:45050000~45051000 | liver | HPC-7 | -- | Enhancer activity assay |
| E_00836 | chr8:128264000~128277000 | blood | ANBL-6 | plasma cell myeloma | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay |
| E_00837 | chr8:128264000~128277000 | blood | ANBL-6 | plasma cell myeloma | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay |
| E_00838 | chr17:41792666~41793322 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00839 | chr17:41792666~41793322 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00840 | chr8:127668529~127669329 | breast | MCF-7 and ER-positive breast cancer models | estrogen receptor-positive breast cancer | Oncogenic enhancer activity; ER-associated chromatin; endogenous core-enhancer deletion; MYC and cancer-phenotype validation |
| E_00841 | chr3:148898000~148901500 | kidney | Caki-1 | clear cell renal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00842 | chr3:148898000~148901500 | kidney | VMRC-RCW | clear cell renal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00843 | chr8:127668529~127669329 | breast | MCF-7 | Estrogen receptor-positive breast cancer | Oncogenic MYC enhancer (汐Emyc) activity; ER-associated chromatin; endogenous enhancer deletion/CRISPRi; cancer phenotype |
| E_00844 | chr15:45731612~45732080 | pancreas | Capan-1 | pancreatic ductal adenocarcinoma | Enhancer functional validation; chromatin interaction assay; Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00845 | chr15:45731612~45732080 | pancreas | PANC-1-IN (PANC-1-derived highly invasive cells) | pancreatic ductal adenocarcinoma | Enhancer functional validation; chromatin interaction assay; metastatic phenotype validation; Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00846 | chr15:45737631~45738460 | pancreas | Capan-1 | pancreatic ductal adenocarcinoma | Enhancer functional validation; chromatin interaction assay; Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00847 | chr15:45737631~45738460 | pancreas | PANC-1-IN (PANC-1-derived highly invasive cells) | pancreatic ductal adenocarcinoma | Enhancer functional validation; chromatin interaction assay; metastatic phenotype validation; Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00848 | chr15:45742113~45742770 | pancreas | Capan-1 | pancreatic ductal adenocarcinoma | Enhancer functional validation; chromatin interaction assay; Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00849 | chr15:45742113~45742770 | pancreas | PANC-1-IN (PANC-1-derived highly invasive cells) | pancreatic ductal adenocarcinoma | Enhancer functional validation; chromatin interaction assay; metastatic phenotype validation; Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00850 | chr15:45731612~45732080 | pancreas | CFPAC-1 | pancreatic ductal adenocarcinoma | Candidate enhancer state annotation within PDAC cell-line panel; Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; In vivo functional validation |
| E_00851 | chr15:45737631~45738460 | pancreas | CFPAC-1 | pancreatic ductal adenocarcinoma | Candidate enhancer state annotation within PDAC cell-line panel; Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; In vivo functional validation |
| E_00852 | chr15:45742113~45742770 | pancreas | CFPAC-1 | pancreatic ductal adenocarcinoma | Candidate enhancer state annotation within PDAC cell-line panel; Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; In vivo functional validation |
| E_00853 | chr13:42940000~42940969 | blood | GM12878 | osteoporosis | GWAS/eQTL integration; enhancer activity; chromatin interaction; endogenous perturbation |
| E_00854 | chr8:27456153~27456353 | lens of eye | HEK293 | Alzheimer disease | causal risk-enhancer validation with allele-specific TF mechanism |
| E_00855 | chr8:27456153~27456353 | lens of eye | human lens-capsule disease samples | Alzheimer disease | causal risk-enhancer validation with allele-specific TF mechanism |
| E_00856 | chr8:27456153~27456353 | lens of eye | HEK293 | exfoliation syndrome | causal risk-enhancer validation with allele-specific TF mechanism |
| E_00857 | chr8:27456153~27456353 | lens of eye | human lens-capsule disease samples | exfoliation syndrome | causal risk-enhancer validation with allele-specific TF mechanism |
| E_00858 | chr13:42940000~42940969 | bone | U2OS | osteoporosis | GWAS/eQTL integration; enhancer activity; chromatin interaction; endogenous perturbation |
| E_00859 | chr13:42955000~42955967 | bone marrow | CD34+ hematopoietic stem/progenitor cells | osteoporosis | Risk-variant regulatory analysis; super-enhancer annotation; enhancer-gene interaction |
| E_00860 | chr13:42955000~42955967 | blood | GM12878 | osteoporosis | Risk-variant regulatory analysis; super-enhancer annotation; enhancer-gene interaction |
| E_00861 | chr13:42956000~42956832 | bone marrow | CD34+ hematopoietic stem/progenitor cells | osteoporosis | Risk-variant regulatory analysis; super-enhancer annotation; enhancer-gene interaction |
| E_00862 | chr13:42956000~42956832 | blood | GM12878 | osteoporosis | Risk-variant regulatory analysis; super-enhancer annotation; enhancer-gene interaction |
| E_00863 | chr13:42965000~42965891 | bone marrow | CD34+ hematopoietic stem/progenitor cells | osteoporosis | Risk-variant regulatory analysis; super-enhancer annotation; enhancer-gene interaction |
| E_00864 | chr13:42965000~42965891 | blood | GM12878 | osteoporosis | Risk-variant regulatory analysis; super-enhancer annotation; enhancer-gene interaction |
| E_00865 | chr13:42955000~42955967 | bone | U2OS | osteoporosis | Risk-variant regulatory analysis; super-enhancer annotation; enhancer-gene interaction |
| E_00866 | chr13:42956000~42956832 | bone | U2OS | osteoporosis | Risk-variant regulatory analysis; super-enhancer annotation; enhancer-gene interaction |
| E_00867 | chr13:42965000~42965891 | bone | U2OS | osteoporosis | Risk-variant regulatory analysis; super-enhancer annotation; enhancer-gene interaction |
| E_00868 | chr3:148898000~148901500 | kidney | 769-P | clear cell renal carcinoma | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_00869 | chr3:148898000~148901500 | kidney | 786-O | clear cell renal carcinoma | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_00870 | chr8:12891950~12892610 | bone marrow | ANBL-6 | plasma cell myeloma | dCas9-KRAB CRISPRi, CRISPR-Cas9 binding site knockout, dual-luciferase reporter assay, Micro-C chromatin contact validation |
| E_00871 | chr13:42939000~42967000 | bone marrow | CD34+ hematopoietic stem/progenitor cells | osteoporosis | GWAS/eQTL integration; enhancer activity; chromatin interaction; endogenous perturbation |
| E_00872 | chr13:42939000~42967000 | blood | GM12878 | osteoporosis | GWAS/eQTL integration; enhancer activity; chromatin interaction; endogenous perturbation |
| E_00873 | chr13:42939000~42967000 | bone | U2OS | osteoporosis | GWAS/eQTL integration; enhancer activity; chromatin interaction; endogenous perturbation |
| E_00874 | chr19:29844909~29845562 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00875 | chr8:27455903~27456103 | -- | HEK-293 | Alzheimer's Disease | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_00876 | chr8:27455903~27456103 | -- | HEK-293 | Alzheimer's Disease | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_00877 | chr8:27455903~27456103 | -- | HEK-293 | Alzheimer's Disease | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_00878 | chr19:29844909~29845562 | esophagus | CP-A | -- | Enhancer activity; KLF5 binding; functional CRISPRi perturbation |
| E_00879 | chr8:27456150~27456350 | kidney | HEK293 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00880 | chr8:27456150~27456350 | kidney | HEK293 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00881 | chr8:27456150~27456350 | kidney | HEK293 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_00882 | chr20:43657287~43657942 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00883 | chr8:127668529~127669329 | breast | MCF-7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_00884 | chr8:27456153~27456353 | lens of eye | HEK293 | Alzheimer disease | distal enhancer-target validation; no target-specific TF mechanism separately demonstrated |
| E_00885 | chr8:27456153~27456353 | lens of eye | human lens-capsule disease samples | Alzheimer disease | distal enhancer-target validation; no target-specific TF mechanism separately demonstrated |
| E_00886 | chr8:27456153~27456353 | lens of eye | HEK293 | exfoliation syndrome | distal enhancer-target validation; no target-specific TF mechanism separately demonstrated |
| E_00887 | chr8:27456153~27456353 | lens of eye | human lens-capsule disease samples | exfoliation syndrome | distal enhancer-target validation; no target-specific TF mechanism separately demonstrated |
| E_00888 | chr8:27456153~27456353 | lens of eye | HEK293 | Alzheimer disease | distal enhancer-target validation; no target-specific TF mechanism separately demonstrated |
| E_00889 | chr8:27456153~27456353 | lens of eye | human lens-capsule disease samples | Alzheimer disease | distal enhancer-target validation; no target-specific TF mechanism separately demonstrated |
| E_00890 | chr8:27456153~27456353 | lens of eye | HEK293 | exfoliation syndrome | distal enhancer-target validation; no target-specific TF mechanism separately demonstrated |
| E_00891 | chr8:27456153~27456353 | lens of eye | human lens-capsule disease samples | exfoliation syndrome | distal enhancer-target validation; no target-specific TF mechanism separately demonstrated |
| E_00892 | chr2:65608668~65609150 | pericardium | MH7A | rheumatoid arthritis | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00893 | chr2:16619625~16621501 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00894 | chr2:16619625~16621501 | blood | RPMI-8402 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00895 | chr2:16619625~16621501 | blood | primary TAL1-positive T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_00896 | chr2:65609946~65610996 | pericardium | MH7A | rheumatoid arthritis | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00897 | chr2:65609946~65610996 | pericardium | MH7A | rheumatoid arthritis | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00898 | chr2:65633710~65634058 | pericardium | MH7A | rheumatoid arthritis | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_00899 | chr2:16619625~16621501 | blood | primary/PDX T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer-associated oncogene dependency assay; Functional perturbation assay; In vivo functional validation |
| E_00900 | chr5:29314881~29315667 | limb bud | Zone of polarizing activity cells | -- | Enhancer activity assay; Functional perturbation assay |
| E_00901 | chr5:29314881~29315667 | limb bud | Zone of polarizing activity cells | -- | Enhancer activity assay; Functional perturbation assay |
| E_00902 | chr5:29314881~29315667 | limb bud | Zone of polarizing activity cells | -- | Enhancer activity assay; Functional perturbation assay |
| E_00903 | chr8:128018000~128023000 | prostate gland | LNCaP clone FGC | prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Disease-variant functional analysis |
| E_00904 | chr8:128018000~128023000 | prostate gland | LNCaP clone FGC | prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Disease-variant functional analysis |
| E_00905 | chr8:128018000~128023000 | prostate gland | LNCaP clone FGC | prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Disease-variant functional analysis |
| E_00906 | chr4:55554102~55554596 | blood | Kasumi-1 | acute myeloid leukemia | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Chromatin-state profiling |
| E_00907 | chr1:75694480~75848058 | limb bud | E11.5 mouse distal limb tissue | congenital limb malformation | Enhancer activity assay; chromatin interaction assay; engineered structural-variant assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00908 | chr1:75694480~75848058 | limb bud | E11.5 mouse distal limb tissue | congenital limb malformation | Enhancer activity assay; chromatin interaction assay; engineered structural-variant assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00909 | chr1:75694480~75848058 | limb bud | E11.5 mouse distal limb tissue | congenital limb malformation | Enhancer activity assay; chromatin interaction assay; engineered structural-variant assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_00910 | chr1:190181400~190182400 | lymphatic vessel | primary mouse lymphatic endothelial cells | -- | Enhancer activity assay; TF binding assay; endogenous enhancer perturbation assay; chromatin interaction assay; developmental phenotype assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00911 | chr1:190181400~190182400 | lymphatic vessel | primary mouse lymphatic endothelial cells | -- | Enhancer activity assay; TF binding assay; endogenous enhancer perturbation assay; chromatin interaction assay; developmental phenotype assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00912 | chr1:190181400~190182400 | lymphatic vessel | primary mouse lymphatic endothelial cells | -- | Enhancer activity assay; TF binding assay; endogenous enhancer perturbation assay; chromatin interaction assay; developmental phenotype assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00913 | chr1:190181400~190182400 | lymphatic vessel | primary mouse lymphatic endothelial cells | -- | Enhancer activity assay; TF binding assay; endogenous enhancer perturbation assay; chromatin interaction assay; developmental phenotype assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_00914 | chr8:55251754~55251853 | pulmonary artery endothelium | primary human pulmonary artery endothelial cells (hPAECs) | pulmonary arterial hypertension | Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_00915 | chr8:55269891~55269990 | pulmonary artery endothelium | primary human pulmonary artery endothelial cells (hPAECs) | pulmonary arterial hypertension | Enhancer activity assay, Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_00916 | chr8:55251754~55251853 | pulmonary artery endothelium | primary human pulmonary artery endothelial cells (hPAECs) | pulmonary arterial hypertension | Allele-specific enhancer activity; TF-binding assay; endogenous enhancer perturbation; disease-mechanism validation; Disease-variant functional analysis; In vivo functional validation |
| E_00917 | chr8:55251754~55251853 | pulmonary artery endothelium | primary human pulmonary artery endothelial cells (hPAECs) | pulmonary arterial hypertension | Regulatory variant enhancer assay; endogenous enhancer perturbation assay; TF binding assay; endothelial functional assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_00918 | chr8:55251754~55251853 | pulmonary artery endothelium | primary human pulmonary artery endothelial cells (hPAECs) | pulmonary arterial hypertension | Regulatory variant enhancer assay; CRISPR interference assay; TF binding assay; endothelial functional assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_00919 | chr8:55269891~55269990 | pulmonary artery endothelium | primary human pulmonary artery endothelial cells (hPAECs) | pulmonary arterial hypertension | Allele-specific enhancer activity; TF-binding assay; endogenous enhancer perturbation; disease-mechanism validation; Disease-variant functional analysis; In vivo functional validation |
| E_00920 | chr8:55269891~55269990 | pulmonary artery endothelium | primary human pulmonary artery endothelial cells (hPAECs) | pulmonary arterial hypertension | Regulatory variant enhancer assay; endogenous enhancer perturbation assay; TF binding assay; endothelial functional assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_00921 | chr8:55269891~55269990 | pulmonary artery endothelium | primary human pulmonary artery endothelial cells (hPAECs) | pulmonary arterial hypertension | Regulatory variant enhancer assay; CRISPR interference assay; TF binding assay; endothelial functional assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_00922 | chr16:19007329~19008187 | bone marrow | primary pro-/pre-B cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00923 | chr16:19007329~19008187 | bone marrow | primary pro-/pre-B cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00924 | chr16:19026931~19027772 | bone marrow | primary pro-/pre-B cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00925 | chr16:19026931~19027772 | bone marrow | primary pro-/pre-B cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00926 | chr2:11656369~11660078 | spleen | primary CD8-positive T cells | -- | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_00927 | chr2:11661180~11664889 | spleen | primary splenic CD8-positive T cells | -- | Super-enhancer functional dissection; TF binding assay; chromatin interaction assay; endogenous functional perturbation assay |
| E_00928 | chr2:11661180~11664889 | spleen | primary splenic natural killer cells | -- | Super-enhancer functional dissection; TF binding assay; endogenous functional perturbation assay |
| E_00929 | chr2:11661224~11661284 | spleen | primary peripheral CD8-positive T cells | -- | Super-enhancer constituent validation; STAT5-binding-site functional perturbation assay; TF binding assay |
| E_00930 | chr2:11663068~11663249 | spleen | primary peripheral CD8-positive T cells | -- | Super-enhancer constituent validation; STAT5-binding-site functional perturbation assay; TF binding assay |
| E_00931 | chr17:34255285~34257203 | pancreas | FACS-sorted PDAC patient epithelial cells | pancreatic ductal adenocarcinoma | TF binding/epigenomic regulatory assay; Functional perturbation assay |
| E_00932 | chr17:34255285~34257203 | pancreas | primary PDAC epithelial cells | pancreatic ductal adenocarcinoma | TF binding/epigenomic regulatory assay; Functional perturbation assay |
| E_00933 | chr4:76213678~76224314 | colon | CCD-1108Sk | colon cancer susceptibility / colorectal carcinoma | GWAS-variant genome editing; super-enhancer looping; target-gene expression |
| E_00934 | chr4:76213678~76224314 | colon | CCD-1108Sk | colon cancer susceptibility / colorectal carcinoma | GWAS-variant genome editing; super-enhancer looping; target-gene expression |
| E_00935 | chr4:76213678~76224314 | colon | CCD-1108Sk | colon cancer susceptibility / colorectal carcinoma | GWAS-variant genome editing; super-enhancer looping; target-gene expression |
| E_00936 | chr4:76213678~76224314 | colon | CCD-1108Sk | colon cancer susceptibility / colorectal carcinoma | GWAS-variant genome editing; super-enhancer looping; target-gene expression |
| E_00937 | chr4:76213678~76224314 | colon | CCD-1108Sk | colon cancer susceptibility / colorectal carcinoma | GWAS-variant genome editing; super-enhancer looping; target-gene expression |
| E_00938 | chr4:76213678~76224314 | colon | CCD-1108Sk | colon cancer susceptibility / colorectal carcinoma | GWAS-variant genome editing; super-enhancer looping; target-gene expression |
| E_00939 | chr8:129543949~129554294 | uterus | Endometrial Carcinoma Cell Lines Ishikawa | endometrial carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_00940 | chr5:51773619~51857504 | pancreas | HEK-293,汕-Cell | Type 2 Diabetes Mellitus | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; In vivo functional validation; Disease-associated enhancer analysis |
| E_00941 | chr5:51773619~51857504 | pancreas | HEK-293,汕-Cell | Type 2 Diabetes Mellitus | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; In vivo functional validation; Disease-associated enhancer analysis |
| E_00942 | chr5:51773619~51857504 | pancreas | HEK-293,汕-Cell | Type 2 Diabetes Mellitus | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; In vivo functional validation; Disease-associated enhancer analysis |
| E_00943 | chr4:55859107~55860311 | -- | Kasumi-1,U937-AE | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_00944 | chr13:73880413~74042621 | lung | Esophageal Carcinoma | lung adenocarcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation; Disease-associated enhancer analysis |
| E_00945 | chr13:73880413~74042621 | lung | Esophageal Carcinoma | lung adenocarcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation; Disease-associated enhancer analysis |
| E_00946 | chr2:11664841~11664854 | spleen | primary peripheral CD8-positive T cells | -- | Super-enhancer constituent minimal functional core; STAT5-binding-site functional perturbation assay; TF binding assay |
| E_00947 | chr10:17228241~17237593 | pancreas | Capan-2 | pancreatic ductal adenocarcinoma | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_00948 | chr10:17228241~17237593 | pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_00949 | chr8:129188417~129189959 | lung | A-549 | lung adenocarcinoma | Enhancer activity assay; TF binding assay; TF motif functional assay; Endogenous enhancer perturbation |
| E_00950 | chr8:129188417~129189959 | lung | A-549 | lung adenocarcinoma | Enhancer activity assay; TF binding assay; TF motif functional assay; Endogenous enhancer perturbation |
| E_00951 | chr8:129166547~129190290 | lung | A549,NCI-H358,NCI-H2009 | lung adenocarcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_00952 | chr13:27523026~27544353 | blood / hematopoietic system | Colon Crypt Cell | colorectal carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_00953 | chr20:48997377~49019434 | liver | Hep G2 | hepatocellular carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_00954 | chr4:76192040~76237727 | colon | HCT 116 | colon cancer susceptibility / colorectal carcinoma | GWAS-variant genome editing; super-enhancer looping; target-gene expression |
| E_00955 | chr16:19007329~19008187 | bone marrow | PIPER-15 inducible pro-B-cell model | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00956 | chr16:19007329~19008187 | bone marrow | PIPER-15 inducible pro-B-cell model | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00957 | chr16:19026931~19027772 | bone marrow | PIPER-15 inducible pro-B-cell model | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00958 | chr16:19026931~19027772 | bone marrow | PIPER-15 inducible pro-B-cell model | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Endogenous functional perturbation assay |
| E_00959 | chr2:11621753~11635500 | thymus | DN thymocytes | -- | Regulatory element functional validation, 3D chromatin interaction mapping; Endogenous enhancer perturbation; In vivo functional validation |
| E_00960 | chr2:11621753~11635500 | thymus | DN thymocytes | -- | Regulatory element functional validation, 3D chromatin interaction mapping; Endogenous enhancer perturbation; In vivo functional validation |
| E_00961 | chr17:34255285~34257203 | pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | TF binding/epigenomic regulatory assay; Functional perturbation assay |
| E_00962 | chr17:34255285~34257203 | pancreas | Capan-1 | pancreatic ductal adenocarcinoma | TF binding/epigenomic regulatory assay; Functional perturbation assay |
| E_00963 | chr17:34255285~34257203 | pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | TF binding/epigenomic regulatory assay; Functional perturbation assay |
| E_00964 | chr17:34255285~34257203 | pancreas | PANC-1 | pancreatic ductal adenocarcinoma | TF binding/epigenomic regulatory assay; Functional perturbation assay |
| E_00965 | chr17:34255285~34257203 | pancreas | PDX-derived basal-like PDAC cells | pancreatic ductal adenocarcinoma | TF binding/epigenomic regulatory assay; Functional perturbation assay |
| E_00966 | chr4:75700000~76000000 | colon | FHC | colorectal cancer | rs6854845-containing ~300-kb super-enhancer domain; representative affected target from SE-regulated gene cluster (also including EPGN/CXCL genes); Endogenous enhancer perturbation; Chromatin interaction assay; Disease-variant functional analysis |
| E_00967 | chr4:55572140~55572780 | blood | Kasumi-1 | acute myeloid leukemia t(8; 21) | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_00968 | chr4:55575000~55577000 | blood | Kasumi-1 | acute myeloid leukemia with t(8; 21)(q22; q22.1) | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_00969 | chr1:190181703~190182534 | lymphatic vessel | Lymphatic endothelial cells (LECs) | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_00970 | chr1:58751000~58752500 | pancreas | primary/PDX PDAC epithelial cells | pancreatic ductal adenocarcinoma | Enhancer-reprogramming/TF occupancy assay; Functional perturbation assay |
| E_00971 | chr1:58765000~58766500 | pancreas | primary/PDX PDAC epithelial cells | pancreatic ductal adenocarcinoma | Enhancer-reprogramming/TF occupancy assay; Functional perturbation assay |
| E_00972 | chr1:58770000~58771500 | pancreas | primary/PDX PDAC epithelial cells | pancreatic ductal adenocarcinoma | Enhancer-reprogramming/TF occupancy assay; Functional perturbation assay |
| E_00973 | chr17:34255285~34257203 | pancreas | HEK293 | pancreatic ductal adenocarcinoma | TF binding/epigenomic regulatory assay; Functional perturbation assay |
| E_00974 | chr8:129166547~129190290 | lung | Human non-small cell lung carcinoma cell | lung adenocarcinoma | Epigenomic mapping, Enhancer functional validation, Genome editing; Endogenous enhancer perturbation |
| E_00975 | chr8:129166547~129190290 | lung | Human non-small cell lung carcinoma cell | lung adenocarcinoma | Epigenomic mapping, Enhancer functional validation, Genome editing; Endogenous enhancer perturbation |
| E_00976 | chr8:129543949~129554294 | endometrium | Ishikawa | endometrial carcinoma | Super-enhancer profiling; Chromatin interaction assay; Copy-number-expression association analysis; Endogenous enhancer perturbation |
| E_00977 | chr8:129543949~129554294 | endometrium | Ishikawa | endometrial carcinoma | Super-enhancer profiling; Chromatin interaction assay; Copy-number amplification analysis; Endogenous enhancer perturbation |
| E_00978 | chr13:73880690~73990596 | -- | BICR-31 | Esophageal Carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_00979 | chr4:76192040~76237727 | colon | CCD-1108Sk | colon cancer susceptibility / colorectal carcinoma | GWAS-variant genome editing; super-enhancer looping; target-gene expression |
| E_00980 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelium | -- | Enhancer activity assay; TF-binding assay; chromatin-interaction assay; endogenous functional perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_00981 | chr1:190181400~190182400 | lymphatic vessel | orthogonal TF occupancy in primary human dermal lymphatic endothelial cells | -- | Enhancer activity assay; TF-binding assay; chromatin-interaction assay; endogenous functional perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_00982 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelium | -- | Enhancer activity assay; TF-binding assay; chromatin-interaction assay; endogenous functional perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_00983 | chr1:190181400~190182400 | lymphatic vessel | orthogonal TF occupancy in primary human dermal lymphatic endothelial cells | -- | Enhancer activity assay; TF-binding assay; chromatin-interaction assay; endogenous functional perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_00984 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelium | -- | Enhancer activity assay; TF-binding assay; chromatin-interaction assay; endogenous functional perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_00985 | chr1:190181400~190182400 | lymphatic vessel | orthogonal TF occupancy in primary human dermal lymphatic endothelial cells | -- | Enhancer activity assay; TF-binding assay; chromatin-interaction assay; endogenous functional perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_00986 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelium | -- | Enhancer activity assay; TF-binding assay; chromatin-interaction assay; endogenous functional perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_00987 | chr1:190181400~190182400 | lymphatic vessel | orthogonal TF occupancy in primary human dermal lymphatic endothelial cells | -- | Enhancer activity assay; TF-binding assay; chromatin-interaction assay; endogenous functional perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_00988 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Developmental enhancer activity; TF binding; enhancer-promoter interaction; endogenous motif/enhancer perturbation; in vivo lineage phenotyping |
| E_00989 | chr1:190181400~190182400 | lymphatic vessel | primary human dermal lymphatic endothelial cells for orthogonal occupancy validation | -- | Developmental enhancer activity; TF binding; enhancer-promoter interaction; endogenous motif/enhancer perturbation; in vivo lineage phenotyping |
| E_00990 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Developmental enhancer activity; TF binding; enhancer-promoter interaction; endogenous motif/enhancer perturbation; in vivo lineage phenotyping |
| E_00991 | chr1:190181400~190182400 | lymphatic vessel | primary human dermal lymphatic endothelial cells for orthogonal occupancy validation | -- | Developmental enhancer activity; TF binding; enhancer-promoter interaction; endogenous motif/enhancer perturbation; in vivo lineage phenotyping |
| E_00992 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Developmental enhancer activity; TF binding; enhancer-promoter interaction; endogenous motif/enhancer perturbation; in vivo lineage phenotyping |
| E_00993 | chr1:190181400~190182400 | lymphatic vessel | primary human dermal lymphatic endothelial cells for orthogonal occupancy validation | -- | Developmental enhancer activity; TF binding; enhancer-promoter interaction; endogenous motif/enhancer perturbation; in vivo lineage phenotyping |
| E_00994 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Developmental enhancer activity; TF binding; enhancer-promoter interaction; endogenous motif/enhancer perturbation; in vivo lineage phenotyping |
| E_00995 | chr1:190181400~190182400 | lymphatic vessel | primary human dermal lymphatic endothelial cells for orthogonal occupancy validation | -- | Developmental enhancer activity; TF binding; enhancer-promoter interaction; endogenous motif/enhancer perturbation; in vivo lineage phenotyping |
| E_00996 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Prox1 ?11-kb developmental enhancer; direct TF occupancy; GATA2-site endogenous editing; enhancer-promoter interaction; in vivo lymphatic-endothelial identity validation |
| E_00997 | chr1:190181400~190182400 | lymphatic vessel | primary human dermal lymphatic endothelial cells for orthogonal occupancy validation | -- | Prox1 ?11-kb developmental enhancer; direct TF occupancy; GATA2-site endogenous editing; enhancer-promoter interaction; in vivo lymphatic-endothelial identity validation |
| E_00998 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Prox1 ?11-kb developmental enhancer; FOXC2 occupancy; enhancer-promoter interaction; endogenous enhancer/motif perturbation and in vivo lymphatic-lineage validation |
| E_00999 | chr1:190181400~190182400 | lymphatic vessel | primary human dermal lymphatic endothelial cells for orthogonal occupancy validation | -- | Prox1 ?11-kb developmental enhancer; FOXC2 occupancy; enhancer-promoter interaction; endogenous enhancer/motif perturbation and in vivo lymphatic-lineage validation |
| E_01000 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Prox1 ?11-kb developmental enhancer; NFATC1 occupancy; enhancer-promoter interaction; endogenous enhancer/motif perturbation and in vivo lymphatic-lineage validation |
| E_01001 | chr1:190181400~190182400 | lymphatic vessel | primary human dermal lymphatic endothelial cells for orthogonal occupancy validation | -- | Prox1 ?11-kb developmental enhancer; NFATC1 occupancy; enhancer-promoter interaction; endogenous enhancer/motif perturbation and in vivo lymphatic-lineage validation |
| E_01002 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Prox1 ?11-kb developmental enhancer; PROX1 occupancy/autoregulatory association; enhancer-promoter interaction; endogenous enhancer perturbation and in vivo lymphatic-lineage validation |
| E_01003 | chr1:190181400~190182400 | lymphatic vessel | primary human dermal lymphatic endothelial cells for orthogonal occupancy validation | -- | Prox1 ?11-kb developmental enhancer; PROX1 occupancy/autoregulatory association; enhancer-promoter interaction; endogenous enhancer perturbation and in vivo lymphatic-lineage validation |
| E_01004 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Prox1 ?11-kb enhancer; direct TF occupancy; enhancer-promoter interaction; endogenous GATA2-motif editing; in vivo lineage phenotyping |
| E_01005 | chr1:190181400~190182400 | lymphatic vessel | primary human dermal lymphatic endothelial cells for orthogonal occupancy validation | -- | Prox1 ?11-kb enhancer; direct TF occupancy; enhancer-promoter interaction; endogenous GATA2-motif editing; in vivo lineage phenotyping |
| E_01006 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Prox1 ?11-kb enhancer; FOXC2 occupancy; enhancer-promoter interaction; endogenous enhancer perturbation; in vivo lineage validation |
| E_01007 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Prox1 ?11-kb enhancer; NFATC1 occupancy; enhancer-promoter interaction; endogenous enhancer perturbation; in vivo lineage validation |
| E_01008 | chr1:190181400~190182400 | lymphatic vessel | Primary embryonic mouse lymphatic endothelial cells | -- | Prox1 ?11-kb enhancer; PROX1 occupancy/autoregulatory association; enhancer-promoter interaction; endogenous enhancer perturbation; in vivo lineage validation |
| E_01009 | chr4:76191350~76202240 | colon | Human normal colon epithelial cell | colorectal cancer | Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; Disease-variant functional analysis |
| E_01010 | chr4:76213678~76224314 | prostate gland | colon epithelial/carcinoma cell model from study (FHC, HCT-116 or SW-480) | colorectal cancer | Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; Disease-variant functional analysis |
| E_01011 | chr4:75700000~76000000 | colon | Human normal colon epithelial cell | colon cancer susceptibility / colorectal carcinoma | GWAS-variant genome editing; super-enhancer looping; target-gene expression |
| E_01012 | chr4:75746565~75746914 | colon | FHC / normal human colon epithelial cells | colorectal cancer | Regulatory variant functional assay; Chromatin interaction assay; Functional perturbation assay |
| E_01013 | chr4:75746565~75746914 | colon | FHC / normal human colon epithelial cells | colorectal cancer | Regulatory variant functional assay; Chromatin interaction assay; Functional perturbation assay |
| E_01014 | chr1:58751000~58752500 | pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer-reprogramming/TF occupancy assay; Functional perturbation assay |
| E_01015 | chr1:58751000~58752500 | pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer-reprogramming/TF occupancy assay; Functional perturbation assay |
| E_01016 | chr1:58765000~58766500 | pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer-reprogramming/TF occupancy assay; Functional perturbation assay |
| E_01017 | chr1:58765000~58766500 | pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer-reprogramming/TF occupancy assay; Functional perturbation assay |
| E_01018 | chr1:58770000~58771500 | pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer-reprogramming/TF occupancy assay; Functional perturbation assay |
| E_01019 | chr1:58770000~58771500 | pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer-reprogramming/TF occupancy assay; Functional perturbation assay |
| E_01020 | chr8:129188417~129189959 | lymph node | NCI-H2009 | lung adenocarcinoma | Functional perturbation assay; Enhancer activity assay; Chromatin profiling; Endogenous enhancer perturbation |
| E_01021 | chr1:190181400~190182400 | lymphatic vessel | human dermal lymphatic endothelial cells | -- | Prox1 ?11-kb enhancer; FOXC2 occupancy; enhancer-promoter interaction; endogenous enhancer perturbation; in vivo lineage validation |
| E_01022 | chr1:190181400~190182400 | lymphatic vessel | human dermal lymphatic endothelial cells | -- | Prox1 ?11-kb enhancer; NFATC1 occupancy; enhancer-promoter interaction; endogenous enhancer perturbation; in vivo lineage validation |
| E_01023 | chr1:190181400~190182400 | lymphatic vessel | human dermal lymphatic endothelial cells | -- | Prox1 ?11-kb enhancer; PROX1 occupancy/autoregulatory association; enhancer-promoter interaction; endogenous enhancer perturbation; in vivo lineage validation |
| E_01024 | chr4:75700000~76000000 | colon | FHC / normal human colon epithelial cells | colorectal cancer | Regulatory variant functional assay; Chromatin interaction assay; Functional perturbation assay |
| E_01025 | chr8:129188417~129189959 | lung | NCI-H358 | lung adenocarcinoma | Enhancer activity assay; Chromatin profiling; Endogenous enhancer perturbation |
| E_01026 | chr4:76192040~76237727 | lung | colon epithelial/carcinoma cell model from study (FHC, HCT-116 or SW-480) | colorectal cancer | Enhancer activity assay, Chromatin interaction assay; Endogenous enhancer perturbation; Chromatin interaction assay; Disease-variant functional analysis |
| E_01027 | chr4:75700000~76000000 | colon | Human normal colon epithelial cell | colorectal cancer | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; Disease-variant functional analysis |
| E_01028 | chr6:37772587~37778315 | pancreas | HEK-293,汕-Cell | Type 2 Diabetes Mellitus | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_01029 | chr6:37772587~37778315 | pancreas | HEK-293,汕-Cell | Type 2 Diabetes Mellitus | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_01030 | chr6:37772587~37778315 | pancreas | HEK-293,汕-Cell | Type 2 Diabetes Mellitus | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_01031 | chr4:75700000~76000000 | colon | Human normal colon epithelial cell | colorectal cancer | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; Disease-variant functional analysis |
| E_01032 | chr6:37883250~37883831 | islet of Langerhans | primary human pancreatic islets | type 2 diabetes mellitus | Enhancer activity assay; TF binding assay; Allele-specific functional assay; Genetic risk-variant analysis; Disease-variant functional analysis |
| E_01033 | chr6:37883250~37883831 | islet of Langerhans | primary human pancreatic islets | type 2 diabetes mellitus | Enhancer activity assay; TF binding assay; Allele-specific functional assay; Genetic risk-variant analysis; Disease-variant functional analysis |
| E_01034 | chr6:37883250~37883831 | islet of Langerhans | primary human pancreatic islets | type 2 diabetes mellitus | Enhancer activity assay; TF binding assay; Allele-specific functional assay; Genetic risk-variant analysis; Disease-variant functional analysis |
| E_01035 | chr6:37883250~37883831 | islet of Langerhans | primary human pancreatic islets | type 2 diabetes mellitus | Enhancer activity assay; TF binding assay; Allele-specific functional assay; Genetic risk-variant analysis; Disease-variant functional analysis |
| E_01036 | chr6:37883250~37883831 | islet of Langerhans | primary human pancreatic islets | type 2 diabetes mellitus | Enhancer activity assay; TF binding assay; Allele-specific functional assay; Genetic risk-variant analysis; Disease-variant functional analysis |
| E_01037 | chr6:170855462~170856787 | pancreas | HEK-293,汕-Cell | Type 2 Diabetes Mellitus | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_01038 | chr6:170855462~170856787 | pancreas | HEK-293,汕-Cell | Type 2 Diabetes Mellitus | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_01039 | chr6:170855462~170856787 | pancreas | HEK-293,汕-Cell | Type 2 Diabetes Mellitus | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_01040 | chr16:51623658~51623900 | forelimb bud | Limb bud mesenchymal cells | -- | Enhancer activity assay, Functional perturbation assay |
| E_01041 | chr10:114758249~114758449 | pancreas | primary human pancreatic islets | type 2 diabetes mellitus | Disease-risk enhancer mapping; TF binding; allele-specific enhancer activity |
| E_01042 | chr10:114758249~114758449 | pancreas | primary human pancreatic islets | type 2 diabetes mellitus | Disease-risk enhancer mapping; TF binding; allele-specific enhancer activity |
| E_01043 | chr10:114758249~114758449 | pancreas | primary human pancreatic islets | type 2 diabetes mellitus | Disease-risk enhancer mapping; TF binding; allele-specific enhancer activity |
| E_01044 | chr5:50400000~50401200 | islet of Langerhans | Human pancreatic islet | -- | Enhancer activity assay |
| E_01045 | chr4:8698911~8707711 | blood | SC monocyte-derived cells | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01046 | chr10:105668100~105669000 | -- | human neural crest cells | cutaneous melanoma | Regulatory variant functional assay; Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_01047 | chr2:74075311~74075843 | limb | E12.5 distal forelimb cells | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Chromatin interaction assay; Functional perturbation assay |
| E_01048 | chr2:74075311~74075843 | limb | E12.5 distal forelimb cells | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Chromatin interaction assay; Functional perturbation assay |
| E_01049 | chr2:74075311~74075843 | limb | E12.5 distal forelimb cells | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Chromatin interaction assay; Functional perturbation assay |
| E_01050 | chr2:74075311~74075843 | limb | E12.5 distal forelimb cells | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Chromatin interaction assay; Functional perturbation assay |
| E_01051 | chr2:74075311~74075843 | limb | E12.5 distal forelimb cells | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Chromatin interaction assay; Functional perturbation assay |
| E_01052 | chr2:74075311~74075843 | limb | E12.5 distal forelimb cells | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Chromatin interaction assay; Functional perturbation assay |
| E_01053 | chr17:79459000~79507000 | lung | A-549 | lung adenocarcinoma | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Chromatin-state profiling; In vivo functional validation |
| E_01054 | chr17:79780000~79828000 | lung | PC-9 | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay; TF binding assay; Chromatin interaction assay; Chromatin-state profiling; In vivo functional validation |
| E_01055 | chr17:79780000~79828000 | lung | PC-9 | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay; TF binding assay; Chromatin interaction assay; Chromatin-state profiling; In vivo functional validation |
| E_01056 | chr10:43581812~43582711 | intestine | SK-N-SH | Hirschsprung disease | Enhancer activity assay; Allele-specific TF binding assay; Regulatory-variant functional assay; In vivo developmental enhancer assay; Genetic association assay |
| E_01057 | chr10:105668100~105669000 | zone of skin | A-375 | cutaneous melanoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01058 | chr10:105668100~105669000 | zone of skin | CJM [Human OCSCC] | cutaneous melanoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01059 | chr10:105668100~105669000 | zone of skin | UACC1816 | cutaneous melanoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01060 | chr10:105668100~105669000 | neural crest | Human Neural Crest Cells | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay, TF binding assay |
| E_01061 | chr10:105664375~105670803 | skin | Primary melanoma tumor | cutaneous malignant melanoma | Functional association assay |
| E_01062 | chr4:8691119~8700974 | pulmonary lobule | hCNCC | -- | Enhancer activity assay, Functional perturbation assay |
| E_01063 | chr10:105664375~105670803 | skin | HEK293T | cutaneous malignant melanoma | Functional perturbation assay |
| E_01064 | chr5:35623357~35624110 | external ear | E14.5 mEC1dup/dup and mEC1del/del pinna | BCE-like auricular malformation model | Enhancer activity assay; Functional perturbation assay; Phenotypic validation assay |
| E_01065 | chr4:8712912~8728565 | blood | K-562 | -- | Enhancer activity assay, Chromatin interaction assay |
| E_01066 | chr10:43581812~43582888 | digestive tract | human fetal gut | Hirschsprung disease | Enhancer-variant association; TF binding; functional enhancer assay |
| E_01067 | chr10:43581812~43582888 | digestive tract | enteric neural crest reporter models | Hirschsprung disease | Enhancer-variant association; TF binding; functional enhancer assay |
| E_01068 | chr10:43447346~43448347 | adult organism | Neuroblastoma cell | neuroblastoma | Enhancer activity assay, TF binding assay |
| E_01069 | chr10:43552395~43553394 | adrenal gland | Neuroblastoma cell | neuroblastoma | Enhancer activity assay, TF binding assay |
| E_01070 | chr19:16439455~16439541 | blood | primary immune cells from healthy controls and patients with SLE | systemic lupus erythematosus | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01071 | chr10:89986509~89987396 | zone of skin | Melanoma cell line | cutaneous melanoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01072 | chr15:99982353~99983277 | zone of skin | Melanoma cell line | cutaneous melanoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01073 | chr21:43745000~43747000 | breast | MCF-7 | breast carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay, Chromatin interaction assay; Endogenous enhancer perturbation; TF binding assay |
| E_01074 | chr21:43795658~43798708 | breast | MCF-7 | breast carcinoma | Enhancer activity assay; Functional perturbation assay; TF binding assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01075 | chr21:36399106~36399322 | bone marrow | primary RUNX1-mutant AML | acute myeloid leukemia | Endogenous enhancer editing; enhancer dependency; leukemia survival analysis |
| E_01076 | chr13:73941969~73943506 | head and neck epithelium | BICR31 squamous carcinoma cells | head and neck squamous cell carcinoma | Cancer super-enhancer mapping; enhancer-promoter interaction; constituent CRISPRi |
| E_01077 | chr13:73995211~73996254 | head and neck epithelium | BICR31 squamous carcinoma cells | head and neck squamous cell carcinoma | Cancer super-enhancer mapping; enhancer-promoter interaction; constituent CRISPRi |
| E_01078 | chr13:74002153~74004429 | head and neck epithelium | BICR31 squamous carcinoma cells | head and neck squamous cell carcinoma | Cancer super-enhancer mapping; enhancer-promoter interaction; constituent CRISPRi |
| E_01079 | chr13:73941969~74004429 | head and neck epithelium | BICR31 squamous carcinoma cells | head and neck squamous cell carcinoma | Cancer super-enhancer mapping; enhancer-promoter interaction; constituent CRISPRi |
| E_01080 | chr21:36399106~36399322 | bone marrow | OCI-AML5 | acute myeloid leukemia | Endogenous enhancer editing; enhancer dependency; leukemia survival analysis |
| E_01081 | chr5:1320064~1320208 | -- | HEK293T | cancer | Enhancer retargeting assay; Functional promoter-tether perturbation assay; Chromatin interaction assay; Cancer mutation analysis |
| E_01082 | chr10:89875711~89876693 | breast | T-47D | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01083 | chr9:37104181~37105469 | -- | HEK293T | cancer | Enhancer retargeting assay; Functional promoter-tether perturbation assay; Chromatin interaction assay; Cancer mutation analysis |
| E_01084 | chr21:36399106~36399322 | bone marrow | primary RUNX1-mutant AML | acute myeloid leukemia | Endogenous enhancer editing; AML survival dependency |
| E_01085 | chr21:36399106~36399322 | blood | primary RUNX1-mutant AML | acute myeloid leukemia | Endogenous enhancer editing; AML survival dependency |
| E_01086 | chr21:36399106~36399322 | bone marrow | RUNX1-mutant AML cell lines | acute myeloid leukemia | Endogenous enhancer editing; AML survival dependency |
| E_01087 | chr21:36399106~36399322 | blood | RUNX1-mutant AML cell lines | acute myeloid leukemia | Endogenous enhancer editing; AML survival dependency |
| E_01088 | chr1:47680000~47681000 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01089 | chr3:66845656~66847450 | limb bud | FACS-sorted embryonic limb mesenchymal cells | -- | Enhancer activity assay; Functional enhancer validation; Chromatin interaction assay; Temporal enhancer profiling |
| E_01090 | chr3:66977632~66978927 | limb bud | FACS-sorted embryonic limb mesenchymal cells | -- | Enhancer activity assay; Functional enhancer validation; Chromatin interaction assay; Temporal enhancer profiling |
| E_01091 | chr4:122542425~122542887 | blood | Activated primary human CD4+ T cells | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Enhancer-promoter regulatory interaction analysis; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01092 | chr4:122542425~122542887 | blood | Activated primary human CD4+ T cells | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Enhancer-promoter regulatory interaction analysis; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01093 | chr9:120869062~120871341 | embryo | Mouse Embryonic Stem Cells (ESCs) | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01094 | chr17:38081807~38083807 | lung | A-549 | asthma | Enhancer activity assay; Functional perturbation assay; Gene expression assay; Endogenous enhancer perturbation; Chromatin interaction assay; Chromatin-state profiling; Disease-variant functional analysis |
| E_01095 | chr9:119377827~119389749 | heart | mouse heart/cardiomyocytes | -- | Canonical RE6-9 cluster; deletion reduces Scn5a and alters topology; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_01096 | chr9:119377827~119389749 | heart | mouse heart/cardiomyocytes | -- | Independent in vivo/topology evidence context for same canonical cluster; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_01097 | chr4:122458532~122459022 | blood | Primary human CD4+ memory T cells from healthy donors | -- | Enhancer activity assay; Functional perturbation assay; Enhancer-promoter regulatory interaction analysis; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01098 | chr20:48900221~48901229 | liver | Hep-G2 | hepatocellular carcinoma | Enhancer activity assay; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_01099 | chr8:128804720~128805310 | bone marrow | mantle cell lymphoma cell lines (REC-1 | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01100 | chr8:128804720~128805310 | bone marrow | SP-49 | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01101 | chr8:128804720~128805310 | bone marrow | Granta-519) | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01102 | chr8:128807460~128808040 | bone marrow | mantle cell lymphoma cell lines (REC-1 | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01103 | chr8:128807460~128808040 | bone marrow | SP-49 | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01104 | chr8:128807460~128808040 | bone marrow | Granta-519) | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01105 | chr20:48900221~48901229 | liver | Hep-G2 | hepatocellular carcinoma | Enhancer methylation mapping; endogenous enhancer deletion; enhancer-target and tumorigenic validation; Endogenous enhancer perturbation |
| E_01106 | chr20:48900221~48901229 | liver | Hep-G2 | hepatocellular carcinoma | Enhancer activity assay; TF binding assay; DNA methylation assay; Functional perturbation assay; eRNA/gene expression assay; Endogenous enhancer perturbation |
| E_01107 | chr20:48900221~48901229 | liver | Human hepatocellular carcinoma cell | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_01108 | chr20:48900221~48901229 | liver | Human normal liver cell | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_01109 | chr8:127117755~127202754 | blood | mantle cell lymphoma cell lines (REC-1 | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01110 | chr8:127117755~127202754 | blood | SP-49 | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01111 | chr8:127117755~127202754 | blood | Granta-519) | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01112 | chr8:127202755~127287755 | blood | mantle cell lymphoma cell lines (REC-1 | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01113 | chr8:127202755~127287755 | blood | SP-49 | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01114 | chr8:127202755~127287755 | blood | Granta-519) | mantle cell lymphoma | TF occupancy assay; Chromatin interaction assay; CRISPRi functional perturbation assay; In vivo functional validation |
| E_01115 | chr20:48900221~48901229 | liver | Hep-G2 | hepatocellular carcinoma | Enhancer methylation mapping; endogenous enhancer deletion; enhancer-target and tumorigenic validation; Endogenous enhancer perturbation |
| E_01116 | chr20:48900221~48901229 | liver | Huh-7 | hepatocellular carcinoma | Enhancer methylation mapping; endogenous enhancer deletion; enhancer-target and tumorigenic validation; Endogenous enhancer perturbation |
| E_01117 | chr4:122458532~122459022 | blood | Jurkat E6.1 | -- | Enhancer activity assay; Functional perturbation assay; Chromatin accessibility assay; Enhancer-promoter regulatory interaction analysis; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01118 | chr9:120869524~120870219 | brown adipose tissue | Brown adipocytes (SVF) | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01119 | chr19:41868242~41871230 | lung | A-549 | asthma | Enhancer activity assay; Functional perturbation assay; Gene expression assay |
| E_01120 | chr19:41868242~41871230 | lung | A-549 | chronic obstructive pulmonary disease | Enhancer activity assay; Functional perturbation assay; Gene expression assay |
| E_01121 | chr19:41868242~41871230 | lung | A-549 | asthma | Enhancer activity assay; Functional perturbation assay; Gene expression assay |
| E_01122 | chr19:41868242~41871230 | lung | A-549 | chronic obstructive pulmonary disease | Enhancer activity assay; Functional perturbation assay; Gene expression assay |
| E_01123 | chr19:41868242~41871230 | lung | A-549 | asthma | Enhancer activity assay; Functional perturbation assay; Gene expression assay |
| E_01124 | chr19:41868242~41871230 | lung | A-549 | chronic obstructive pulmonary disease | Enhancer activity assay; Functional perturbation assay; Gene expression assay |
| E_01125 | chr9:119377827~119379749 | heart | Mouse cardiomyocyte cell | -- | Enhancer activity assay, Functional perturbation assay, TF binding assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_01126 | chr8:98253530~98257713 | blood / hematopoietic system | Mantle Cell Lymphoma (MCL) | Small B Cell Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01127 | chr8:98253530~98257713 | blood / hematopoietic system | Mantle Cell Lymphoma (MCL) | Small B Cell Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01128 | chr8:98253530~98257713 | blood / hematopoietic system | Mantle Cell Lymphoma (MCL) | Small B Cell Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01129 | chr8:98253530~98257713 | blood / hematopoietic system | Mantle Cell Lymphoma (MCL) | Small B Cell Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01130 | chr8:98310330~98314427 | blood / hematopoietic system | Mantle Cell Lymphoma (MCL) | Small B Cell Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01131 | chr8:98310330~98314427 | blood / hematopoietic system | Mantle Cell Lymphoma (MCL) | Small B Cell Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01132 | chr8:98310330~98314427 | blood / hematopoietic system | Mantle Cell Lymphoma (MCL) | Small B Cell Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01133 | chr8:98310330~98314427 | blood / hematopoietic system | Mantle Cell Lymphoma (MCL) | Small B Cell Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01134 | chr4:122578161~122579217 | blood | Jurkat E6.1 | -- | Enhancer activity assay; Functional perturbation assay; Enhancer-enhancer regulatory interaction analysis; Enhancer-promoter regulatory interaction analysis; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01135 | chr3:41119924~41122071 | inner cell mass | HCC827 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01136 | chr8:128130000~128300000 | lymphoid tissue | REC-1 | mantle cell lymphoma | TF occupancy assay; chromatin interaction assay; CRISPRi functional perturbation assay |
| E_01137 | chr8:128130000~128300000 | lymphoid tissue | SP-49 | mantle cell lymphoma | TF occupancy assay; chromatin interaction assay; CRISPRi functional perturbation assay |
| E_01138 | chr8:128130000~128300000 | lymphoid tissue | Granta-519 mantle cell lymphoma models | mantle cell lymphoma | TF occupancy assay; chromatin interaction assay; CRISPRi functional perturbation assay |
| E_01139 | chr8:128130000~128300000 | lymphoid tissue | REC-1 | mantle cell lymphoma | TF occupancy assay; chromatin interaction assay; CRISPRi functional perturbation assay |
| E_01140 | chr8:128130000~128300000 | lymphoid tissue | SP-49 | mantle cell lymphoma | TF occupancy assay; chromatin interaction assay; CRISPRi functional perturbation assay |
| E_01141 | chr8:128130000~128300000 | lymphoid tissue | Granta-519 mantle cell lymphoma models | mantle cell lymphoma | TF occupancy assay; chromatin interaction assay; CRISPRi functional perturbation assay |
| E_01142 | chr9:119378700~119379271 | heart | Mouse cardiomyocyte cell | -- | Enhancer activity assay, Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_01143 | chr20:48900221~48901229 | uterine cervix | L-02 | hepatocellular carcinoma | Enhancer activity assay; DNA methylation assay; Functional perturbation assay; eRNA/gene expression assay; Endogenous enhancer perturbation |
| E_01144 | chr3:66740432~66749559 | limb bud | Embryonic proximal limb mesenchymal cells | -- | Enhancer activity assay; Chromatin interaction assay; Temporal enhancer profiling |
| E_01145 | chr20:48900221~48901229 | liver | Primary HCC tumor tissue | hepatocellular carcinoma | DNA methylation profiling; Clinical epigenomic validation; Enhancer-target association; Endogenous enhancer perturbation |
| E_01146 | chr12:56075734~56076734 | lung | BEAS-2B | asthma | Enhancer activity assay, TF binding assay, Functional perturbation assay, Chromatin interaction assay; Disease-variant functional analysis |
| E_01147 | chr3:98678906~98697335 | liver | Hep-G2 | head and neck squamous cell carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation; TF binding assay; Chromatin interaction assay; Chromatin-state profiling; In vivo functional validation |
| E_01148 | chr1:116506181~116506381 | blood | THP-1 | autoimmune disease | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Disease-variant functional analysis |
| E_01149 | chr4:145218235~145219235 | lung | Human bronchial epithelial cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay, Chromatin interaction assay; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; Chromatin interaction assay; Chromatin-state profiling; Disease-variant functional analysis |
| E_01150 | chr4:144579000~144586000 | bone marrow | Kasumi-1 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; Chromatin interaction assay; Chromatin-state profiling; Disease-variant functional analysis |
| E_01151 | chr6:135266000~135268000 | stomach | SNU-719 | gastric cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_01152 | chr6:135266000~135268000 | stomach | YCCEL1 | gastric cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_01153 | chr13:24149800~24150800 | colon | HCT 116 | non-small cell lung carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay; Disease-variant functional analysis; In vivo functional validation |
| E_01154 | chr2:217918268~217921910 | breast | Breast Cancer Cell | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; In vivo functional validation; Disease-associated enhancer analysis |
| E_01155 | chr20:52173000~52174500 | colon | LS180 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_01156 | chr8:121495079~121495626 | spleen | primary CD24+ cDC1 | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Functional perturbation assay; In vivo enhancer deletion assay |
| E_01157 | chr8:121495079~121495626 | spleen | primary CD24+ cDC1 | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Functional perturbation assay; In vivo enhancer deletion assay |
| E_01158 | chr11:118559857~118561857 | brain | U-87MG ATCC | malignant glioma | Enhancer activity assay; Allele-specific functional assay; Chromatin interaction assay; Functional perturbation assay |
| E_01159 | chr17:32565596~32566796 | -- | U-87MG ATCC | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Chromatin interaction assay; Functional perturbation assay |
| E_01160 | chr17:32565596~32566796 | -- | U-87MG ATCC | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Chromatin interaction assay; Functional perturbation assay |
| E_01161 | chr17:32565596~32566796 | -- | U-87MG | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01162 | chr17:32565596~32566796 | -- | U-87MG | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01163 | chr17:32565596~32566796 | -- | U-87MG | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01164 | chr8:120777048~120777744 | bone marrow | Primary mouse bone-marrow MDP/CDP/pre-cDC1 populations | -- | Chromatin-state mapping; TF-binding analysis; endogenous enhancer deletion; lineage differentiation assay; Endogenous enhancer perturbation |
| E_01165 | chr8:120777048~120777744 | bone marrow | Primary mouse MDP/CDP/pre-cDC1 populations | -- | Irf8 +41-kb enhancer chromatin opening; TF binding; endogenous enhancer deletion; cDC1-lineage specification |
| E_01166 | chr8:121503787~121504483 | bone marrow | common dendritic cell progenitors and pre-cDC1 | -- | Chromatin accessibility assay; Functional perturbation assay; In vivo enhancer deletion assay |
| E_01167 | chr8:120777048~120777744 | bone marrow | enhancer-deletion mice | -- | Irf8 +41-kb enhancer chromatin opening; TF binding; endogenous enhancer deletion; cDC1-lineage specification |
| E_01168 | chr11:118559857~118561857 | brain | hTERT-immortalized normal human astrocytes | malignant glioma | Enhancer activity assay; Allele-specific functional assay; Chromatin-state assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_01169 | chr20:52157000~52158500 | zone of skin | JOV675 | Kaposi's sarcoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_01170 | chr11:118540532~118575295 | brain | Normal Human Astrocyte | glioma | Enhancer activity assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_01171 | chr5:143200112~143200889 | liver | CHME-5 | asthma | Enhancer activity assay; Disease-variant functional analysis |
| E_01172 | chr2:217920100~217921400 | zone of skin | GA-10 clone 4 | cutaneous melanoma | Enhancer activity assay |
| E_01173 | chr3:111274001~111275000 | sigmoid colon | COLO320DM | colorectal adenocarcinoma | Enhancer activity assay; Functional perturbation assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01174 | chr17:43589381~43595263 | heart | human iPSC-derived cardiac fibroblast | Heart Failure | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_01175 | chr16:68362000~68362400 | liver | hepatocellular carcinoma cell model | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis; In vivo functional validation |
| E_01176 | chr8:128804981~128806980 | colon | COLO 320DM | colorectal carcinoma | Enhancer activity assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_01177 | chr9:126770367~126771183 | brain | -- | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01178 | chr17:68663972~68675613 | cranial neural crest | hCNCC | -- | Enhancer activity assay, Functional perturbation assay |
| E_01179 | chr11:111456657~111460228 | developing mandible / craniofacial mesenchyme | Human cranial neural crest cells plus endogenous orthologous mouse EC1.45 deletion models | isolated Pierre Robin sequence | EC1.45/Rr80 extreme long-range enhancer cluster; TWIST1 occupancy; Capture-C target assignment; endogenous orthologous enhancer deletion; craniofacial phenotyping |
| E_01180 | chr22:27493955~27497536 | pancreas | BxPC-3 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay; Disease-variant functional analysis; In vivo functional validation |
| E_01181 | chr6:12902957~12904957 | aorta | pluripotent stem cell-derived endothelial cells | vascular disease susceptibility | Disease-associated enhancer variant functional perturbation; Chromatin interaction assay |
| E_01182 | chr3:111274001~111275000 | sigmoid colon | COLO320DM | colorectal adenocarcinoma | Enhancer activity assay; endogenous epigenetic perturbation; ecDNA structural mapping; chromatin-interaction mapping; 3D spatial interaction analysis; chromatin-state profiling; transcriptional imaging; cancer-cell fitness assay; Endogenous enhancer perturbation |
| E_01183 | chr1:226215164~226215656 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01184 | chr1:226215164~226215656 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01185 | chr1:226215164~226215656 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01186 | chr1:226215164~226215656 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01187 | chr18:21933810~21935298 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01188 | chr18:21933810~21935298 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01189 | chr18:21933810~21935298 | definitive endoderm | HUES 8 | -- | Pooled CRISPRi enhancer screening; individual enhancer validation; TF binding; chromatin-state/3D integration; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01190 | chr18:21933810~21935298 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01191 | chr18:21933810~21935298 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01192 | chr18:22194123~22194455 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01193 | chr18:22194123~22194455 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01194 | chr18:22194123~22194455 | definitive endoderm | HUES 8 | -- | Pooled CRISPRi enhancer screening; individual enhancer validation; TF binding; chromatin-state/3D integration; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01195 | chr18:22194123~22194455 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01196 | chr18:22194123~22194455 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01197 | chr3:27712007~27712923 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01198 | chr3:27712007~27712923 | definitive endoderm | HUES 8 | -- | Pooled CRISPRi enhancer screening; individual enhancer validation; TF binding; chromatin-state/3D integration; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01199 | chr3:27712007~27712923 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01200 | chr3:27712007~27712923 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01201 | chr3:27712007~27712923 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01202 | chr3:27728339~27729090 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01203 | chr3:27728339~27729090 | definitive endoderm | HUES 8 | -- | Pooled CRISPRi enhancer screening; individual enhancer validation; TF binding; chromatin-state/3D integration; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01204 | chr3:27728339~27729090 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01205 | chr3:27728339~27729090 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01206 | chr3:27728339~27729090 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01207 | chr3:27730029~27730667 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01208 | chr3:27730029~27730667 | definitive endoderm | HUES 8 | -- | Pooled CRISPRi enhancer screening; individual enhancer validation; TF binding; chromatin-state/3D integration; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01209 | chr3:27730029~27730667 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01210 | chr3:27730029~27730667 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01211 | chr3:27730029~27730667 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01212 | chr8:54224560~54225711 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01213 | chr8:54224560~54225711 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01214 | chr8:54224560~54225711 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01215 | chr8:54224560~54225711 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01216 | chr8:54224560~54225711 | definitive endoderm | HUES 8 | -- | Pooled CRISPRi enhancer screening; individual enhancer validation; TF binding; chromatin-state/3D integration; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01217 | chr8:54259816~54260322 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01218 | chr8:54259816~54260322 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01219 | chr8:54259816~54260322 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01220 | chr8:54259816~54260322 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01221 | chr8:54259816~54260322 | definitive endoderm | HUES 8 | -- | Pooled CRISPRi enhancer screening; individual enhancer validation; TF binding; chromatin-state/3D integration; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01222 | chr8:54300591~54300987 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01223 | chr8:54300591~54300987 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01224 | chr8:54300591~54300987 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01225 | chr8:54300591~54300987 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01226 | chr8:54300591~54300987 | definitive endoderm | HUES 8 | -- | Pooled CRISPRi enhancer screening; individual enhancer validation; TF binding; chromatin-state/3D integration; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01227 | chr8:54301978~54302426 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01228 | chr8:54301978~54302426 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01229 | chr8:54301978~54302426 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01230 | chr8:54301978~54302426 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01231 | chr8:54301978~54302426 | definitive endoderm | HUES 8 | -- | Pooled CRISPRi enhancer screening; individual enhancer validation; TF binding; chromatin-state/3D integration; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01232 | chr8:54454106~54455036 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01233 | chr8:54454106~54455036 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01234 | chr8:54454106~54455036 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01235 | chr8:54454106~54455036 | inner cell mass | HCC827 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01236 | chr8:54454106~54455036 | definitive endoderm | HUES 8 | -- | Pooled CRISPRi enhancer screening; individual enhancer validation; TF binding; chromatin-state/3D integration; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_01237 | chr4:174249537~174250490 | connective tissue | WT hMPC | -- | Baseline HMGB2 enhancer / SOX5 comparison; Endogenous enhancer perturbation; In vivo functional validation |
| E_01238 | chr1:116544766~116545360 | bone marrow | primary B-ALL blasts | B-cell acute lymphoblastic leukemia | Endogenous enhancer perturbation; TF-motif causality; immunotherapy-response validation |
| E_01239 | chr1:116544766~116545360 | blood | primary B-ALL blasts | B-cell acute lymphoblastic leukemia | Endogenous enhancer perturbation; TF-motif causality; immunotherapy-response validation |
| E_01240 | chr1:63189000~63192000 | embryo | ES-R1 | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01241 | chr1:63189000~63192000 | embryo | Mouse embryonic stem cells (mESCs) | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01242 | chr1:63193000~63196000 | embryo | ES-R1 | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01243 | chr1:63193000~63196000 | embryo | Mouse embryonic stem cells (mESCs) | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_01244 | chr11:354514~356503 | lung | A-549 | -- | Enhancer activity; endogenous perturbation; chromatin interaction; TF binding; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; In vivo functional validation |
| E_01245 | chr11:354514~356503 | kidney | HEK293 | -- | Enhancer activity; endogenous perturbation; chromatin interaction; TF binding; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; In vivo functional validation |
| E_01246 | chr11:354514~356503 | lung | A-549 | -- | Enhancer activity; endogenous perturbation; chromatin interaction; TF binding; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; In vivo functional validation |
| E_01247 | chr11:355447~358949 | lung | A-549 | -- | Enhancer activity assay; Chromatin interaction assay; Endogenous enhancer perturbation; TF binding assay; In vivo functional validation |
| E_01248 | chr11:355447~358949 | lung | A-549 | -- | Enhancer activity assay; Chromatin interaction assay; Endogenous enhancer perturbation; TF binding assay; In vivo functional validation |
| E_01249 | chr11:355447~358949 | lung | A-549 | -- | Enhancer activity assay; Chromatin interaction assay; Endogenous enhancer perturbation; TF binding assay; In vivo functional validation |
| E_01250 | chr11:355447~358949 | lung / epithelial cell-line context | A-549 | -- | Interferon-responsive enhancer activity; STAT1 binding; long-range chromatin interaction; endogenous enhancer editing |
| E_01251 | chr11:355447~358949 | lung / epithelial cell-line context | HEK293 cells | -- | Interferon-responsive enhancer activity; STAT1 binding; long-range chromatin interaction; endogenous enhancer editing |
| E_01252 | chr11:355447~358949 | lung / epithelial cell-line context | A-549 | -- | Interferon-responsive enhancer activity; STAT1 binding; long-range chromatin interaction; endogenous enhancer editing |
| E_01253 | chr11:355447~358949 | lung / epithelial cell-line context | HEK293 cells | -- | Interferon-responsive enhancer activity; STAT1 binding; long-range chromatin interaction; endogenous enhancer editing |
| E_01254 | chr11:355447~358949 | lung / epithelial cell-line context | A-549 | -- | Interferon-responsive enhancer activity; STAT1 binding; long-range chromatin interaction; endogenous enhancer editing |
| E_01255 | chr11:355447~358949 | lung / epithelial cell-line context | HEK293 cells | -- | Interferon-responsive enhancer activity; STAT1 binding; long-range chromatin interaction; endogenous enhancer editing |
| E_01256 | chr12:3946672~3948652 | pituitary gland | AtT-20 | -- | Enhancer activity assay; TF binding assay; Enhancer-promoter looping assay; Functional perturbation assay; Nascent transcription assay |
| E_01257 | chr12:3946672~3948652 | pituitary gland | AtT-20 | -- | Enhancer activity assay; Enhancer-promoter looping assay; Functional perturbation assay; Transcriptional regulation assay |
| E_01258 | chr12:3946672~3948652 | pituitary gland | AtT-20 | -- | Enhancer activity assay; TF binding assay; Enhancer-promoter looping assay; Functional perturbation assay; Nascent transcription assay |
| E_01259 | chr12:3946672~3948652 | pituitary gland | AtT-20 | -- | Enhancer activity assay; TF binding assay; Enhancer-promoter looping assay; Functional perturbation assay; Nascent transcription assay |
| E_01260 | chr12:3946672~3948652 | pituitary gland | AtT-20 | -- | Enhancer occupancy assay; Enhancer-promoter looping assay; Functional perturbation assay; Transcriptional regulation assay |
| E_01261 | chr3:34755799~34762535 | embryo | F123 mouse embryonic stem cells | -- | Super-enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01262 | chr3:34755799~34762535 | embryo | F123 mouse embryonic stem cells | -- | Super-enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01263 | chr3:34755799~34762535 | embryo | F123 mouse embryonic stem cells | -- | Super-enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01264 | chr3:34652359~34665321 | blastocyst | F123 | -- | Super-enhancer functional validation; TF binding assay; Chromatin interaction analysis; Functional perturbation assay; Gene expression assay; Epigenomic profiling |
| E_01265 | chr3:34652359~34665321 | blastocyst | F123 | -- | Super-enhancer functional validation; TF binding assay; Chromatin interaction analysis; Functional perturbation assay; Gene expression assay; Epigenomic profiling |
| E_01266 | chr3:34652359~34665321 | blastocyst | F123 | -- | Super-enhancer functional validation; TF binding assay; Chromatin interaction analysis; Functional perturbation assay; Gene expression assay; Epigenomic profiling |
| E_01267 | chr18:22026135~22027396 | definitive endoderm | HUES 8 | -- | dCas9-KRAB CRISPRi loss-of-function, CRISPR-Cas9 clonal deletion, Hi-C chromatin contact validation |
| E_01268 | chr18:22061243~22062444 | definitive endoderm | HUES 8 | -- | dCas9-KRAB CRISPRi loss-of-function, CRISPR-Cas9 clonal deletion, Hi-C chromatin contact validation |
| E_01269 | chr3:27713393~27715978 | definitive endoderm | HUES 8 | -- | dCas9-KRAB CRISPRi loss-of-function, Hi-C chromatin contact validation |
| E_01270 | chr2:38203254~38204076 | brain | Neuro-2a | -- | Enhancer activity assay; In vivo functional perturbation assay; Evolutionary cis-regulatory analysis |
| E_01271 | chr1:63189000~63192000 | embryonic stem/epiblast cell state | J1 | -- | Dynamic enhancer partitioning; chromatin interaction; genetic perturbation |
| E_01272 | chr1:63193000~63196000 | embryonic stem/epiblast cell state | J1 | -- | Dynamic enhancer partitioning; chromatin interaction; genetic perturbation |
| E_01273 | chr11:355447~358949 | kidney | HEK293 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay |
| E_01274 | chr11:355447~358949 | kidney | HEK293 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay |
| E_01275 | chr11:355447~358949 | kidney | HEK293 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay |
| E_01276 | chr6:12852000~12853000 | lung | BEAS-2B | coronary artery disease | Enhancer perturbation assay; Disease-variant functional analysis |
| E_01277 | chr1:116544766~116545360 | blood | 697 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_01278 | chr11:72308500~72309000 | brainstem | Cranial motor neurons | -- | Enhancer activity assay, Chromatin interaction assay; Disease-variant functional analysis; In vivo functional validation |
| E_01279 | chr1:116544766~116545360 | bone marrow | 697 B-ALL | B-cell acute lymphoblastic leukemia | Endogenous enhancer perturbation; TF-motif causality; immunotherapy-response validation |
| E_01280 | chr1:116544766~116545360 | blood | 697 B-ALL | B-cell acute lymphoblastic leukemia | Endogenous enhancer perturbation; TF-motif causality; immunotherapy-response validation |
| E_01281 | chr11:355447~358949 | lung | A549 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01282 | chr11:355447~358949 | lung | A549 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01283 | chr11:355447~358949 | lung | A549 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01284 | chr11:355447~358949 | lung | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01285 | chr11:355447~358949 | lung | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01286 | chr11:355447~358949 | lung | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01287 | chr6:12902957~12904957 | blood vessel | iPSC-derived endothelial cells | vascular disease susceptibility | Functional enhancer variant assay; Chromatin interaction assay; Genome editing |
| E_01288 | chr4:174249537~174250490 | connective tissue | WS hMPC | Werner syndrome | HMGB2 enhancer activation and rejuvenation response; Endogenous enhancer perturbation; In vivo functional validation |
| E_01289 | chr1:226210519~226211619 | definitive endoderm | HUES 8 | -- | dCas9-KRAB CRISPRi loss-of-function, Hi-C chromatin contact validation |
| E_01290 | chr8:54268120~54269407 | definitive endoderm | HUES 8 | -- | dCas9-KRAB CRISPRi loss-of-function, Hi-C chromatin contact validation |
| E_01291 | chr4:174249537~174250490 | connective tissue | Primary human mesenchymal progenitor cells | -- | Functional perturbation and enhancer activity validation; Endogenous enhancer perturbation; In vivo functional validation |
| E_01292 | chr4:174249537~174250490 | connective tissue | WS hMPC | osteoarthritis | SOX5 binding / HMGB2 enhancer activation; Endogenous enhancer perturbation; In vivo functional validation |
| E_01293 | chr4:174249537~174250490 | connective tissue | WS hMPC | Werner syndrome | Senescence-associated enhancer remodeling; Endogenous enhancer perturbation; In vivo functional validation |
| E_01294 | chr12:3944001~3947078 | -- | AtT-20,Pituitary Corticotrope Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01295 | chr12:3956137~3961266 | -- | AtT-20,Pituitary Corticotrope Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01296 | chr12:3938522~3942093 | -- | Pituitary Corticotrope Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01297 | chr4:174249537~174250490 | connective tissue | WT hMPC | -- | SOX5-responsive HMGB2 enhancer in senescent hMPCs; Endogenous enhancer perturbation; In vivo functional validation |
| E_01298 | chr4:174249537~174250490 | connective tissue | WT hMPC | -- | Mechanistic validation linked to cartilage rejuvenation; Endogenous enhancer perturbation; In vivo functional validation |
| E_01299 | chr6:12903457~12904457 | red nucleus | HUVEC and CRISPR-edited endothelial models | pleiotropic vascular-disease susceptibility locus | Allele-specific distal regulatory-variant perturbation and target analysis |
| E_01300 | chr4:174249537~174250490 | connective tissue | WS hMPC | osteoarthritis | Genome-wide CRISPRa rejuvenation screen with HMGB2 mechanistic validation; Endogenous enhancer perturbation; In vivo functional validation |
| E_01301 | chr1:116544766~116545360 | bone marrow | primary B-ALL blasts | B-cell acute lymphoblastic leukemia | Endogenous TF-site perturbation; enhancer reporter validation; immunotherapy-response functional analysis |
| E_01302 | chr1:116544766~116545360 | blood | primary B-ALL blasts | B-cell acute lymphoblastic leukemia | Endogenous TF-site perturbation; enhancer reporter validation; immunotherapy-response functional analysis |
| E_01303 | chr2:129323600~129328600 | heart | Macrophage | atherosclerosis | Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01304 | chr13:115686619~115688040 | brainstem | Embryonic cranial motor neurons | -- | Enhancer activity assay; Single-cell chromatin accessibility profiling; Peak-to-gene linking; Histone modification profiling; Disease-variant functional analysis; In vivo functional validation |
| E_01305 | chr13:116087428~116088064 | brainstem | Embryonic cranial motor neurons (cMN3/4, cMN6 and cMN7) | -- | Enhancer activity assay; Single-cell chromatin accessibility profiling; Peak-to-gene linking; Histone modification profiling; Disease-variant functional analysis; In vivo functional validation |
| E_01306 | chr13:116514002~116515994 | brainstem | Embryonic cranial motor neurons | -- | Enhancer activity assay; Single-cell chromatin accessibility profiling; Peak-to-gene linking; Histone modification profiling; Disease-variant functional analysis; In vivo functional validation |
| E_01307 | chr13:116632748~116634332 | brainstem | Embryonic cranial motor neuron atlas | -- | Enhancer activity assay; Single-cell chromatin accessibility profiling; Peak-to-gene linking; Histone modification profiling; Disease-variant functional analysis; In vivo functional validation |
| E_01308 | chr4:174249537~174250490 | connective tissue / articular cartilage | Human mesenchymal precursor cells (WT and progeroid-syndrome model) | Werner syndrome | Genome-wide CRISPRa rejuvenation screen; SOX5-dependent HMGB2 enhancer activation; epigenomic remodeling; in vivo osteoarthritis validation |
| E_01309 | chr4:174249537~174250490 | connective tissue / articular cartilage | aged mouse articular cartilage for in vivo validation | Werner syndrome | Genome-wide CRISPRa rejuvenation screen; SOX5-dependent HMGB2 enhancer activation; epigenomic remodeling; in vivo osteoarthritis validation |
| E_01310 | chr4:174249537~174250490 | connective tissue / articular cartilage | Human mesenchymal precursor cells (WT and progeroid-syndrome model) | osteoarthritis | Genome-wide CRISPRa rejuvenation screen; SOX5-dependent HMGB2 enhancer activation; epigenomic remodeling; in vivo osteoarthritis validation |
| E_01311 | chr4:174249537~174250490 | connective tissue / articular cartilage | aged mouse articular cartilage for in vivo validation | osteoarthritis | Genome-wide CRISPRa rejuvenation screen; SOX5-dependent HMGB2 enhancer activation; epigenomic remodeling; in vivo osteoarthritis validation |
| E_01312 | chr1:116544766~116545360 | bone marrow | 697 B-ALL cells | B-cell acute lymphoblastic leukemia | Endogenous TF-site perturbation; enhancer reporter validation; immunotherapy-response functional analysis |
| E_01313 | chr1:116544766~116545360 | blood | 697 B-ALL cells | B-cell acute lymphoblastic leukemia | Endogenous TF-site perturbation; enhancer reporter validation; immunotherapy-response functional analysis |
| E_01314 | chr1:63189000~63192000 | embryo | mouse embryonic stem cells | -- | One of four Zdbf2 regulatory enhancers; duplicated supplied intervals retained as separate experimental-context records; Endogenous enhancer perturbation; In vivo functional validation |
| E_01315 | chr1:63193000~63196000 | embryo | mouse embryonic stem cells | -- | One of four Zdbf2 regulatory enhancers; duplicated supplied intervals retained as separate experimental-context records; Endogenous enhancer perturbation; In vivo functional validation |
| E_01316 | chr3:34743178~34776096 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01317 | chr3:34743178~34776096 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01318 | chr3:34743178~34776096 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01319 | chr6:12490000~12590000 | -- | HUVEC | Coronary Artery Disease,Migraine Headache,Cervical Artery Dissection,Fibromuscular Dysplasia,Hypertension | Enhancer activity assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_01320 | chr3:46453226~46459225 | prostate gland | 22Rv1 | prostate cancer | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay; TF binding assay; Chromatin-state profiling |
| E_01321 | chr3:46453226~46459225 | prostate gland | LNCaP | prostate cancer | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay; TF binding assay; Chromatin-state profiling |
| E_01322 | chr3:46453226~46459225 | prostate gland | 22Rv1 | prostate cancer | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay; TF binding assay; Chromatin-state profiling |
| E_01323 | chr3:46453226~46459225 | prostate gland | LNCaP | prostate cancer | Functional perturbation assay, Enhancer activity assay, Chromatin interaction assay, TF binding assay; TF binding assay; Chromatin-state profiling |
| E_01324 | chr20:50027744~50030383 | lung | A-549 | breast cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; In vivo functional validation |
| E_01325 | chr20:50027744~50030383 | breast | MDA-MB-231 | breast cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; In vivo functional validation |
| E_01326 | chr8:118183060~118260108 | islet of Langerhans | EndoC-betaH3 | type 2 diabetes mellitus | Super-enhancer characterization; Chromatin interaction assay; Functional perturbation assay |
| E_01327 | chr8:118183060~118260108 | islet of Langerhans | EndoC-betaH3 | type 2 diabetes mellitus | Super-enhancer characterization; Chromatin interaction assay; Functional perturbation assay |
| E_01328 | chr8:118183060~118260108 | islet of Langerhans | EndoC-betaH3 | type 2 diabetes mellitus | Super-enhancer characterization; Chromatin interaction assay; Functional perturbation assay |
| E_01329 | chr8:121495097~121496097 | blood / hematopoietic system | primary dendritic-cell lineage populations | -- | Enhancer essentiality assay; Functional perturbation assay; Chromatin interaction assay |
| E_01330 | chr8:121504097~121505097 | blood / hematopoietic system | primary dendritic-cell lineage populations | -- | Enhancer essentiality assay; Functional perturbation assay; Chromatin interaction assay |
| E_01331 | chr13:74003796~74004073 | colon | HT-29 | colorectal cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_01332 | chr13:74003796~74004073 | colon | HT-29 | colorectal cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay |
| E_01333 | chr13:74003796~74004073 | colon | HT-29 | colorectal cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay |
| E_01334 | chr1:3593076~3594185 | blood | TL-Om1 | adult T-cell leukemia/lymphoma | Super-enhancer constituent activity assay; TF binding assay; Enhancer-promoter interaction assay; Functional enhancer perturbation assay; In vivo functional validation |
| E_01335 | chr1:3593076~3594185 | blood | TL-Om1 | adult T-cell leukemia/lymphoma | Super-enhancer constituent activity assay; TF binding assay; Enhancer-promoter interaction assay; Functional enhancer perturbation assay; In vivo functional validation |
| E_01336 | chr2:217994794~217995294 | breast | MCF-7 | breast carcinoma | Enhancer activity assay; Regulatory variant functional assay; Functional perturbation assay; TF binding assay |
| E_01337 | chr2:217994794~217995294 | breast | T-47D | breast carcinoma | Enhancer activity assay; Regulatory variant functional assay; Functional perturbation assay; TF binding assay |
| E_01338 | chr12:114461575~114496377 | spleen | Primary activated mature B cells | -- | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_01339 | chr12:114461575~114496377 | spleen | Primary activated mature B cells | -- | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_01340 | chr19:51352371~51354471 | prostate gland | LNCaP | prostate cancer | Enhancer RNA assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_01341 | chr8:118183060~118185060 | islet of Langerhans | BRE | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01342 | chr8:118250000~118252000 | islet of Langerhans | BRE | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01343 | chr8:118183060~118185060 | islet of Langerhans | Human Pancreatic Islets | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01344 | chr8:121495079~121495626 | bone marrow | maturing cDC1 cells | -- | TF binding assay; Chromatin interaction assay; Endogenous enhancer perturbation assay |
| E_01345 | chr8:121495079~121495626 | bone marrow | maturing cDC1 cells | -- | Enhancer activity/occupancy assay; Chromatin interaction assay; Endogenous enhancer perturbation assay |
| E_01346 | chr8:121503787~121504483 | bone marrow | pre-cDC1 / dendritic progenitors | -- | Enhancer activity/occupancy assay; Chromatin interaction assay; Endogenous enhancer perturbation assay |
| E_01347 | chr8:121503787~121504483 | bone marrow | pre-cDC1 / dendritic progenitors | -- | Enhancer activity/occupancy assay; Chromatin interaction assay; Endogenous enhancer perturbation assay |
| E_01348 | chr2:45279107~45280206 | bone marrow | Primary mouse bone-marrow dendritic progenitors | -- | TF-binding assay; endogenous enhancer mutagenesis; lineage differentiation assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_01349 | chr2:45279107~45280206 | bone marrow | Primary mouse bone-marrow dendritic progenitors | -- | TF-binding assay; endogenous enhancer mutagenesis; lineage differentiation assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_01350 | chr2:45279107~45280206 | bone marrow | Primary mouse bone-marrow dendritic progenitors | -- | TF-binding assay; endogenous enhancer mutagenesis; lineage differentiation assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_01351 | chr3:128322411~128323124 | Bone marrow / hematopoietic system | MUTZ-3 EVI1-GFP AML model | Acute myeloid leukemia with MECOM rearrangement [inv(3)(q21;q26.2)/t(3;3)(q21;q26.2)] | Endogenous enhancer dependency; TF-motif causality; enhancer hijacking |
| E_01352 | chr7:3198900~3202780 | embryo | Epiblast-like Cells (EpiLCs) | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01353 | chr7:3198900~3202780 | embryo | Epiblast-like Cells (EpiLCs) | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01354 | chr1:136170800~136171203 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, Functional perturbation assay |
| E_01355 | chr1:136171700~136172103 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01356 | chr1:136177900~136178345 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01357 | chr1:136180500~136180903 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01358 | chr1:136184128~136184880 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01359 | chr8:120876144~120876856 | lung | Mouse Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01360 | chr8:120876144~120876856 | lung | Mouse Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01361 | chr8:120876144~120876856 | lung | Mouse Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01362 | chr8:120882734~120883410 | lung | Mouse Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01363 | chr8:120882734~120883410 | lung | Mouse Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01364 | chr8:120882734~120883410 | lung | Mouse Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01365 | chr8:121088830~121089174 | lung | Mouse Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01366 | chr8:121088830~121089174 | lung | Mouse Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01367 | chr8:121088830~121089174 | lung | Mouse Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01368 | chr8:130180217~130180629 | blood | Primary ATL cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01369 | chr8:130180217~130180629 | blood | Primary ATL cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_01370 | chr15:63087071~63087595 | -- | T6E murine T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_01371 | chr15:63087071~63087595 | -- | T6E murine T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_01372 | chr3:128322411~128323124 | bone marrow | primary inv(3)/t(3 | acute myeloid leukemia | Endogenous enhancer functional validation; TF-site causality; leukemia dependency |
| E_01373 | chr3:128322411~128323124 | blood | primary inv(3)/t(3 | acute myeloid leukemia | Endogenous enhancer functional validation; TF-site causality; leukemia dependency |
| E_01374 | chr12:114462800~114464200 | spleen | mature B | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_01375 | chr12:114465285~114467786 | spleen | mature B | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_01376 | chr6:122498000~122499500 | spleen | mature B | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_01377 | chr1:136170803~136192554 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay |
| E_01378 | chr2:45279107~45280206 | bone marrow | Hoxb8-immortalized DC precursor system used for mechanistic assays | -- | TF-binding assay; endogenous enhancer mutagenesis; lineage differentiation assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_01379 | chr2:45279107~45280206 | bone marrow | Hoxb8-immortalized DC precursor system used for mechanistic assays | -- | TF-binding assay; endogenous enhancer mutagenesis; lineage differentiation assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_01380 | chr2:45279107~45280206 | bone marrow | Hoxb8-immortalized DC precursor system used for mechanistic assays | -- | TF-binding assay; endogenous enhancer mutagenesis; lineage differentiation assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_01381 | chr1:3572730~3574116 | blood | T cell leukemia cell | adult T-cell leukemia/lymphoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; In vivo functional validation |
| E_01382 | chr3:128322411~128323124 | peripheral blood | primary inv(3)/t(3 | acute myeloid leukemia | Endogenous enhancer sequence-function mapping; TF-site causality; leukemia fitness and differentiation |
| E_01383 | chr3:128322411~128323124 | bone marrow | MUTZ-3 | acute myeloid leukemia | Enhancer essentiality assay; TF binding assay; Functional perturbation assay; Target-gene expression assay |
| E_01384 | chr12:114461575~114496377 | spleen | mature B | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_01385 | chr3:34752523~34766449 | embryo | 129℅CAST F1 mouse ESCs | -- | Super-enhancer methylation dynamics; TF/chromatin-state coupling; endogenous allele-specific reporter; Enhancer activity assay; In vivo functional validation |
| E_01386 | chr3:34752523~34766449 | embryo | v6.5 mouse ESCs | -- | Super-enhancer methylation dynamics; TF/chromatin-state coupling; endogenous allele-specific reporter; Enhancer activity assay; In vivo functional validation |
| E_01387 | chr3:34752523~34766449 | embryo | 129℅CAST F1 mouse ESCs | -- | Super-enhancer methylation dynamics; TF/chromatin-state coupling; endogenous allele-specific reporter; Enhancer activity assay; In vivo functional validation |
| E_01388 | chr3:34752523~34766449 | embryo | v6.5 mouse ESCs | -- | Super-enhancer methylation dynamics; TF/chromatin-state coupling; endogenous allele-specific reporter; Enhancer activity assay; In vivo functional validation |
| E_01389 | chr7:3198900~3202780 | embryo | mouse embryonic stem cells | -- | Super-enhancer methylation dynamics; TF/chromatin-state coupling; endogenous allele-specific reporter; Enhancer activity assay; In vivo functional validation |
| E_01390 | chr7:3198900~3202780 | embryo | mouse embryonic stem cells | -- | Super-enhancer methylation dynamics; TF/chromatin-state coupling; endogenous allele-specific reporter; Enhancer activity assay; In vivo functional validation |
| E_01391 | chr1:136179654~136180057 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, Functional perturbation assay, TF binding assay; TF binding assay; Chromatin-state profiling |
| E_01392 | chr1:136185854~136186299 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, Functional perturbation assay, TF binding assay; TF binding assay; Chromatin-state profiling |
| E_01393 | chr1:136188454~136188857 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, Functional perturbation assay, TF binding assay; TF binding assay; Chromatin-state profiling |
| E_01394 | chr3:128322411~128323124 | bone marrow | MUTZ-3/inv(3) AML models | acute myeloid leukemia | Endogenous enhancer functional validation; TF-site causality; leukemia dependency |
| E_01395 | chr3:128322411~128323124 | blood | MUTZ-3/inv(3) AML models | acute myeloid leukemia | Endogenous enhancer functional validation; TF-site causality; leukemia dependency |
| E_01396 | chr3:128322411~128323124 | bone marrow | 3) AML | acute myeloid leukemia | Endogenous enhancer functional validation; TF-site causality; leukemia dependency |
| E_01397 | chr3:128322411~128323124 | blood | 3) AML | acute myeloid leukemia | Endogenous enhancer functional validation; TF-site causality; leukemia dependency |
| E_01398 | chr15:61825000~62125000 | spleen | mature B | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_01399 | chr15:63254341~63256341 | thymus | primary murine T-ALL blasts and T-ALL cell models | T-cell acute lymphoblastic leukemia | TF occupancy; long-range enhancer-promoter interaction; drug-response functional assay |
| E_01400 | chr2:45279107~45280206 | bone marrow | Primary mouse bone-marrow dendritic progenitors | -- | TF competition at Zeb2 ?165-kb enhancer; endogenous triple-motif mutagenesis; lineage differentiation and in vivo functional validation |
| E_01401 | chr2:45279107~45280206 | bone marrow | Primary mouse bone-marrow dendritic progenitors | -- | TF competition at Zeb2 ?165-kb enhancer; endogenous triple-motif mutagenesis; lineage differentiation and in vivo functional validation |
| E_01402 | chr2:45279107~45280206 | bone marrow | Primary mouse bone-marrow dendritic progenitors | -- | TF competition at Zeb2 ?165-kb enhancer; endogenous triple-motif mutagenesis; lineage differentiation and in vivo functional validation |
| E_01403 | chr3:128322411~128323124 | peripheral blood | MUTZ-3 | acute myeloid leukemia | Endogenous enhancer sequence-function mapping; TF-site causality; leukemia fitness and differentiation |
| E_01404 | chr3:128322411~128323124 | peripheral blood | 3) AML | acute myeloid leukemia | Endogenous enhancer sequence-function mapping; TF-site causality; leukemia fitness and differentiation |
| E_01405 | chr1:136179600~136180045 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; TF binding assay; Chromatin-state profiling |
| E_01406 | chr1:136170878~136192613 | -- | C2C12 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01407 | chr1:136170878~136192613 | -- | C2C12 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01408 | chr13:74003796~74004073 | colon | SW48 | colorectal cancer | TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_01409 | chr1:136188400~136188845 | skeletal muscle tissue | C2C12 | -- | Functional perturbation assay; TF binding assay; Chromatin-state profiling |
| E_01410 | chr2:217955458~217957767 | breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01411 | chr2:45279107~45280206 | bone marrow | Hoxb8-immortalized dendritic-cell precursor system | -- | TF competition at Zeb2 ?165-kb enhancer; endogenous triple-motif mutagenesis; lineage differentiation and in vivo functional validation |
| E_01412 | chr2:45279107~45280206 | bone marrow | Hoxb8-immortalized dendritic-cell precursor system | -- | TF competition at Zeb2 ?165-kb enhancer; endogenous triple-motif mutagenesis; lineage differentiation and in vivo functional validation |
| E_01413 | chr2:45279107~45280206 | bone marrow | Hoxb8-immortalized dendritic-cell precursor system | -- | TF competition at Zeb2 ?165-kb enhancer; endogenous triple-motif mutagenesis; lineage differentiation and in vivo functional validation |
| E_01414 | chr8:130180217~130180629 | blood | HPB-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer-target validation; TF-dependent enhancer activity; signaling-dependent enhancer regulation |
| E_01415 | chr8:130180217~130180629 | lymph | HPB-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer-target validation; TF-dependent enhancer activity; signaling-dependent enhancer regulation |
| E_01416 | chr8:130180217~130180629 | blood | CUTLL1 | T-cell acute lymphoblastic leukemia | Long-range enhancer-target validation; TF-dependent enhancer activity; signaling-dependent enhancer regulation |
| E_01417 | chr8:130180217~130180629 | lymph | CUTLL1 | T-cell acute lymphoblastic leukemia | Long-range enhancer-target validation; TF-dependent enhancer activity; signaling-dependent enhancer regulation |
| E_01418 | chr8:130180217~130180629 | blood | HPB-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer-target validation; TF-site-dependent enhancer activity |
| E_01419 | chr8:130180217~130180629 | lymph | HPB-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer-target validation; TF-site-dependent enhancer activity |
| E_01420 | chr8:130180217~130180629 | blood | CUTLL1 | T-cell acute lymphoblastic leukemia | Long-range enhancer-target validation; TF-site-dependent enhancer activity |
| E_01421 | chr8:130180217~130180629 | lymph | CUTLL1 | T-cell acute lymphoblastic leukemia | Long-range enhancer-target validation; TF-site-dependent enhancer activity |
| E_01422 | chr8:130180065~130180972 | bone marrow | HPB-ALL | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-dependent enhancer activity |
| E_01423 | chr8:130180065~130180972 | blood | HPB-ALL | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-dependent enhancer activity |
| E_01424 | chr8:130180065~130180972 | bone marrow | CUTLL1 | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-dependent enhancer activity |
| E_01425 | chr8:130180065~130180972 | blood | CUTLL1 | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-dependent enhancer activity |
| E_01426 | chr8:130180065~130180972 | bone marrow | HPB-ALL | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-site-dependent enhancer activity |
| E_01427 | chr8:130180065~130180972 | blood | HPB-ALL | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-site-dependent enhancer activity |
| E_01428 | chr8:130180065~130180972 | bone marrow | CUTLL1 | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-site-dependent enhancer activity |
| E_01429 | chr8:130180065~130180972 | blood | CUTLL1 | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-site-dependent enhancer activity |
| E_01430 | chr19:51352419~51358208 | prostate gland | LNCaP | prostate cancer | Long-range enhancer-RNA-mediated regulation of KLK2; enhancer-promoter looping |
| E_01431 | chr19:51352419~51358208 | prostate gland | LNCaP | prostate cancer | Enhancer-RNA perturbation; enhancer-promoter looping; AR occupancy; long-range KLK3e-to-KLK2 promoter regulation |
| E_01432 | chr19:51358995~51369041 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_01433 | chr19:51358995~51369041 | prostate gland | VCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_01434 | chr15:63254341~63256341 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL) | acute lymphoblastic leukemia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_01435 | chr8:130180065~130180972 | bone marrow | additional T-ALL models | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-dependent enhancer activity |
| E_01436 | chr8:130180065~130180972 | blood | additional T-ALL models | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-dependent enhancer activity |
| E_01437 | chr8:130180065~130180972 | bone marrow | additional T-ALL models | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-site-dependent enhancer activity |
| E_01438 | chr8:130180065~130180972 | blood | additional T-ALL models | T-cell acute lymphoblastic leukemia | Enhancer-promoter interaction; TF-site-dependent enhancer activity |
| E_01439 | chr3:34752523~34766449 | embryo | mouse embryonic stem cells | -- | Sox2 super-enhancer; endogenous allele-specific methylation reporter study; Enhancer activity assay; In vivo functional validation |
| E_01440 | chr8:123406634~123407310 | lung | Embryonic lung cells | pulmonary vascular disease | Chromatin interaction assay |
| E_01441 | chr8:123400044~123400756 | lung | Embryonic lung cells | pulmonary vascular disease | Chromatin interaction assay |
| E_01442 | chr19:51347500~51349700 | prostate gland | Primary epithelial | prostate cancer | Enhancer activity assay |
| E_01443 | chr20:50030216~50034271 | breast epithelium | MCF10AT1k.cl2 and breast-cancer epithelial models | Breast cancer cell plasticity / epithelial-mesenchymal transition | Enhancer-RNA-producing SNAI1 regulatory locus; cis eRNA perturbation; cancer-cell plasticity validation |
| E_01444 | chr2:218305944~218306443 | breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay |
| E_01445 | chr15:53455006~53455051 | pancreas | Progenitor cells | type 2 diabetes mellitus | Enhancer activity assay, Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01446 | chr1:207584741~207589069 | maxilla | Raji | -- | Enhancer activity assay; Functional perturbation assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_01447 | chr9:22102683~22103683 | brain | U-118MG | glioblastoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01448 | chr3:36999364~37001216 | colon | SW620 | colorectal carcinoma | Functional perturbation assay, Chromatin interaction assay; Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; Disease-variant functional analysis |
| E_01449 | chr21:38576000~38577000 | bone marrow | primary MECOM-rearranged AML cells | acute myeloid leukemia | TF binding assay; Enhancer reporter assay; Functional perturbation assay; In vivo functional validation |
| E_01450 | chr6:32571777~32578269 | blood | Raji | Burkitt lymphoma | Enhancer functional perturbation; TF binding assay; chromatin interaction assay |
| E_01451 | chr6:32571777~32578269 | blood | Raji | Burkitt lymphoma | Enhancer functional perturbation; chromatin interaction assay |
| E_01452 | chr13:40800476~40817024 | -- | Rh4 | alveolar rhabdomyosarcoma | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Chromatin-state profiling |
| E_01453 | chr13:40800476~40817024 | -- | Rh4 | alveolar rhabdomyosarcoma | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Chromatin-state profiling |
| E_01454 | chr13:40800476~40817024 | -- | Rh4 | alveolar rhabdomyosarcoma | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Chromatin-state profiling |
| E_01455 | chr12:86257615~86258800 | eye | OCM-8 | uveal melanoma | Enhancer activity assay; Functional perturbation assay; Chromatin interaction assay |
| E_01456 | chr12:86257615~86258800 | eye | OM431 | uveal melanoma | Enhancer activity assay; Functional perturbation assay; Chromatin interaction assay |
| E_01457 | chr12:86257615~86258800 | eye | OMM-1 | uveal melanoma | Enhancer activity assay; Functional perturbation assay; Chromatin interaction assay |
| E_01458 | chr17:39725049~39725326 | breast | primary HER2-positive breast tumors | breast carcinoma | functional gene-body enhancer-core mapping plus TF and epigenetic validation |
| E_01459 | chr3:36999364~37001216 | colon | SW620,RKO | Lynch Syndrome | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01460 | chr17:35499359~35507923 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01461 | chr5:119654061~119663588 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01462 | chr8:124321890~124323890 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_01463 | chr8:124321890~124323890 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_01464 | chr8:124323890~124325890 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_01465 | chr8:124323890~124325890 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_01466 | chr8:124319890~124321890 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_01467 | chr8:124319890~124321890 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_01468 | chr1:47677544~47677944 | blood | primary T-ALL UPNT-802 | T-cell acute lymphoblastic leukemia | Somatic neo-enhancer discovery and functional engineering |
| E_01469 | chr11:112217398~112217642 | testis | primary embryonic mouse XY gonadal somatic cells | -- | In vivo developmental enhancer validation; TF-binding assay; endogenous enhancer deletion |
| E_01470 | chr11:112217398~112217642 | testis | primary embryonic mouse XY gonadal somatic cells | -- | In vivo developmental enhancer validation; TF-binding assay; endogenous enhancer deletion |
| E_01471 | chr7:117227200~117229503 | intestinal epithelium | Caco-2 | -- | Endogenous enhancer deletion; chromatin interaction; TF occupancy |
| E_01472 | chr7:117227200~117229503 | intestinal epithelium | human epithelial comparison models | -- | Endogenous enhancer deletion; chromatin interaction; TF occupancy |
| E_01473 | chr17:39725049~39725326 | breast | SK-BR-3 | breast carcinoma | functional gene-body enhancer-core mapping plus TF and epigenetic validation |
| E_01474 | chr17:39725049~39725326 | breast | BT-474 | breast carcinoma | functional gene-body enhancer-core mapping plus TF and epigenetic validation |
| E_01475 | chr17:39725049~39725326 | breast | HCC1954 | breast carcinoma | functional gene-body enhancer-core mapping plus TF and epigenetic validation |
| E_01476 | chr21:38376000~38377000 | bone marrow | HNT-34 | acute myeloid leukemia | Functional validation, TF binding; In vivo functional validation |
| E_01477 | chr21:38576000~38577000 | bone marrow | EVI1-high human AML cell models | acute myeloid leukemia | TF binding assay; Enhancer reporter assay; Functional perturbation assay; In vivo functional validation |
| E_01478 | chr6:32595564~32596093 | blood | Raji | Burkitt lymphoma | TF binding assay; chromatin interaction assay |
| E_01479 | chr17:39725049~39725326 | breast | HEK293T reporter cells | breast carcinoma | functional gene-body enhancer-core mapping plus TF and epigenetic validation |
| E_01480 | chr1:47677466~47678021 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Neo-enhancer activity; TF binding; endogenous genetic perturbation |
| E_01481 | chr1:47677466~47678021 | blood | PDX UPNT-613 | T-cell acute lymphoblastic leukemia | Neo-enhancer activity; TF binding; endogenous genetic perturbation |
| E_01482 | chr1:47677466~47678021 | blood | PDX UPNT-802 | T-cell acute lymphoblastic leukemia | Neo-enhancer activity; TF binding; endogenous genetic perturbation |
| E_01483 | chr1:47677466~47678021 | blood | Peer | T-cell acute lymphoblastic leukemia | Neo-enhancer activity; TF binding; endogenous genetic perturbation |
| E_01484 | chr11:10941473~10942029 | gonadal ridge | Bipotential gonadal somatic cells | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo transgenic reporter assay, In vivo functional assay |
| E_01485 | chr11:10941473~10942029 | gonadal ridge | Bipotential gonadal somatic cells | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo transgenic reporter assay, In vivo functional assay |
| E_01486 | chr11:10941473~10942029 | gonadal ridge | Bipotential gonadal somatic cells | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo transgenic reporter assay, In vivo functional assay |
| E_01487 | chr1:47677544~47677944 | blood | engineered Jurkat models | T-cell acute lymphoblastic leukemia | Somatic neo-enhancer discovery and functional engineering |
| E_01488 | chr11:10954273~10955559 | testis | Sertoli cells | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo transgenic reporter assay |
| E_01489 | chr6:32543534~32553534 | lymphoid tissue | Raji | -- | Functional perturbation assay; Chromatin interaction assay; Enhancer activity assay |
| E_01490 | chr6:32543534~32553534 | lymphoid tissue | Raji | -- | Functional perturbation assay; Chromatin interaction assay; Enhancer activity assay |
| E_01491 | chr6:32543534~32553534 | lymphoid tissue | -- | -- | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01492 | chr6:32543534~32553534 | lymphoid tissue | Not available | -- | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay |
| E_01493 | chr7:117099048~117099450 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01494 | chr7:117099048~117099450 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01495 | chr7:117099048~117099450 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01496 | chr7:117099048~117099450 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01497 | chr7:117228051~117229440 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01498 | chr7:117228051~117229440 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01499 | chr7:117228051~117229440 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01500 | chr7:117228051~117229440 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01501 | chr7:117038917~117040917 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01502 | chr7:117038917~117040917 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01503 | chr7:117038917~117040917 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01504 | chr7:117038917~117040917 | -- | Caco-2 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01505 | chr1:47677466~47678021 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01506 | chr1:47677466~47678021 | blood | Peer | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01507 | chr11:10996600~10999794 | testis | Sertoli cell precursors | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_01508 | chr11:10996600~10999794 | testis | Sertoli cell precursors | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_01509 | chr11:10996600~10999794 | testis | Sertoli cell precursors | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_01510 | chr7:117125000~117126200 | colon | Human normal colon epithelial cell | -- | Enhancer activity assay, TF binding assay; Endogenous enhancer perturbation |
| E_01511 | chr17:37900000~37900500 | breast | SK-BR-3 | breast cancer | Enhancer functional assay, TF binding assay |
| E_01512 | chr11:112078592~112079149 | testis | embryonic gonad | -- | 557-bp Sox9 Enh13 (original paper coordinate); essential endogenous sex-determining enhancer |
| E_01513 | chr17:37879571~37880263 | blood / hematopoietic system | K-562 | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01514 | chr1:207411000~207424000 | blood | Reh | -- | Functional perturbation assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_01515 | chr11:112217210~112217767 | gonad | Testis | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01516 | chr8:124417000~124427000 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay; TF binding assay |
| E_01517 | chr17:35503912~35504118 | embryo | mouse embryonic stem cells | -- | Enhancer activity assay; Epigenome-editing assay; Functional perturbation assay |
| E_01518 | chr11:10999900~11000869 | testis | Sertoli cells | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay, In vivo transgenic reporter assay |
| E_01519 | chr11:10999900~11000869 | testis | Sertoli cells | sex reversal | Developmental biology assay, Functional genomics assay, Epigenomic profiling assay, Transcriptional regulation assay, In vivo transgenic reporter assay |
| E_01520 | chr11:10997900~10999300 | testis | Sertoli cell precursors | sex reversal | Developmental biology assay, Functional genomics assay, Transcriptional regulation assay |
| E_01521 | chr11:10997900~10999300 | testis | Sertoli cell precursors | sex reversal | Developmental biology assay, Functional genomics assay, Transcriptional regulation assay |
| E_01522 | chr11:10997900~10999300 | testis | Sertoli cell precursors | sex reversal | Developmental biology assay, Functional genomics assay, Transcriptional regulation assay |
| E_01523 | chr17:35504981~35505186 | embryo | mouse embryonic stem cells | -- | Epigenome-editing assay; Functional enhancer-state assay |
| E_01524 | chr4:139771035~139771985 | bone marrow | Mouse hematopoietic stem cells (HSCs) | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01525 | chr12:8570500~8571000 | cerebral cortex | Primary mouse cortical neurons | -- | Activity-induced enhancer assay; Chromatin remodeling/looping assay; In vivo phosphosite knock-in functional assay |
| E_01526 | chr16:25574210~25575090 | prostate gland | LCD prostate organoids | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay |
| E_01527 | chr14:54705845~54707084 | bone marrow | Primary Mouse Bone Marrow Cells | -- | TF binding assay, Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay |
| E_01528 | chr14:57395000~57400000 | skeletal muscle tissue | C2C12 | -- | Chromatin interaction assay; TF binding assay; Chromatin accessibility assay; Functional perturbation assay |
| E_01529 | chr14:57395000~57400000 | skeletal muscle tissue | C2C12 | -- | Chromatin interaction assay; TF binding assay; Chromatin accessibility assay; Functional perturbation assay |
| E_01530 | chr14:57520000~57525000 | skeletal muscle tissue | C2C12 | -- | Chromatin interaction assay; TF binding assay; Chromatin accessibility assay; Functional perturbation assay |
| E_01531 | chr14:57520000~57525000 | skeletal muscle tissue | C2C12 | -- | Chromatin interaction assay; TF binding assay; Chromatin accessibility assay; Functional perturbation assay |
| E_01532 | chr14:57665000~57670000 | skeletal muscle tissue | C2C12 | -- | Chromatin interaction assay; TF binding assay; Chromatin accessibility assay; Functional perturbation assay |
| E_01533 | chr14:57665000~57670000 | skeletal muscle tissue | C2C12 | -- | Chromatin interaction assay; TF binding assay; Chromatin accessibility assay; Functional perturbation assay |
| E_01534 | chr4:46410632~46411247 | bone marrow | Erythroblasts | -- | Functional perturbation assay, Chromatin interaction assay, TF binding assay; Endogenous enhancer perturbation; TF binding assay; Chromatin interaction assay |
| E_01535 | chr4:46410632~46411247 | liver | MB-1 [Human thyroid carcinoma] | -- | Functional perturbation assay, Chromatin interaction assay, TF binding assay |
| E_01536 | chr7:150360481~150366493 | blood | Jurkat and primary T-ALL models | T-cell acute lymphoblastic leukemia | Oncogenic TF occupancy; enhancer activity; endogenous enhancer deletion |
| E_01537 | chr9:89630000~89631000 | breast | MCF-7 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01538 | chr12:111517811~111518523 | blood | E13.5 fetal liver derived erythroblasts | -- | Enhancer activity assay; Functional perturbation assay; Chromatin interaction assay |
| E_01539 | chr12:111517811~111518523 | blood | MEL cells | -- | Enhancer activity assay; Functional perturbation assay; Chromatin interaction assay |
| E_01540 | chr1:13084831~13085465 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01541 | chr1:13093655~13096290 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01542 | chr14:99338943~99341862 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01543 | chr12:86497006~86503356 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01544 | chr7:35156536~35156974 | bone marrow | primary mouse hematopoietic stem/progenitor-cell context | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01545 | chr7:35156536~35156974 | bone marrow | primary mouse hematopoietic stem/progenitor-cell context | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01546 | chr7:35156536~35156974 | bone marrow | primary mouse hematopoietic stem/progenitor-cell context | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01547 | chr7:35156536~35156974 | bone marrow | primary mouse hematopoietic stem/progenitor-cell context | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01548 | chr7:35156536~35156974 | bone marrow | primary mouse hematopoietic stem/progenitor-cell context | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01549 | chr7:35156536~35156974 | bone marrow | primary mouse hematopoietic stem/progenitor-cell context | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01550 | chr7:35156536~35156974 | bone marrow | primary mouse hematopoietic stem/progenitor-cell context | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01551 | chr7:35156536~35156974 | bone marrow | primary mouse hematopoietic stem/progenitor-cell context | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01552 | chr7:35156536~35156974 | bone marrow | primary mouse hematopoietic stem/progenitor-cell context | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01553 | chr12:48368875~48369590 | cartilage tissue | primary differentiated human articular chondrocytes | -- | Hormone-responsive enhancer/TF-complex activity assay; TF binding assay; In vivo functional validation |
| E_01554 | chr12:48368875~48369590 | cartilage tissue | primary differentiated human articular chondrocytes | -- | Hormone-responsive enhancer/TF-complex activity assay; TF binding assay; In vivo functional validation |
| E_01555 | chr12:48368875~48369590 | cartilage tissue | primary differentiated human articular chondrocytes | -- | Hormone-responsive enhancer/TF-complex activity assay; TF binding assay; In vivo functional validation |
| E_01556 | chr12:48368875~48369590 | cartilage tissue | primary differentiated human articular chondrocytes | -- | Hormone-responsive enhancer/TF-complex activity assay; TF binding assay; In vivo functional validation |
| E_01557 | chr1:13072129~13076981 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01558 | chr1:13072129~13076981 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01559 | chr1:13084831~13085465 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01560 | chr1:13093655~13096290 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01561 | chr1:13093655~13096290 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01562 | chr14:99338943~99341862 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01563 | chr14:99338943~99341862 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01564 | chr12:86497006~86503356 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01565 | chr12:86497006~86503356 | embryo | ES-R1 | -- | Enhancer chromatin-state profiling; functional enhancer deletion; germline-competence assay |
| E_01566 | chr12:48368875~48369590 | cartilage tissue | dedifferentiated OA-phenotype human articular chondrocytes | osteoarthritis | Hormone-responsive enhancer/TF-complex activity assay; TF binding assay; In vivo functional validation |
| E_01567 | chr12:48368875~48369590 | cartilage tissue | dedifferentiated OA-phenotype human articular chondrocytes | osteoarthritis | Hormone-responsive enhancer/TF-complex activity assay; TF binding assay; In vivo functional validation |
| E_01568 | chr12:48368875~48369590 | cartilage tissue | dedifferentiated OA-phenotype human articular chondrocytes | osteoarthritis | Hormone-responsive enhancer/TF-complex activity assay; TF binding assay; In vivo functional validation |
| E_01569 | chr12:48368875~48369590 | cartilage tissue | dedifferentiated OA-phenotype human articular chondrocytes | osteoarthritis | Hormone-responsive enhancer/TF-complex activity assay; TF binding assay; In vivo functional validation |
| E_01570 | chr15:8079500~8080000 | cerebral cortex | Primary mouse cortical neurons | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01571 | chr12:111517811~111518523 | -- | Erythroblasts | -- | Functional perturbation assay; Chromatin interaction assay; TF binding assay |
| E_01572 | chr7:35156536~35156974 | bone marrow | 32Dcl3 myeloid progenitor cells | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01573 | chr7:35156536~35156974 | bone marrow | 32Dcl3 myeloid progenitor cells | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01574 | chr7:35156536~35156974 | bone marrow | 32Dcl3 myeloid progenitor cells | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01575 | chr7:35156536~35156974 | bone marrow | 32Dcl3 myeloid progenitor cells | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01576 | chr7:35156536~35156974 | bone marrow | 32Dcl3 myeloid progenitor cells | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01577 | chr7:35156536~35156974 | bone marrow | 32Dcl3 myeloid progenitor cells | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01578 | chr7:35156536~35156974 | bone marrow | 32Dcl3 myeloid progenitor cells | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01579 | chr7:35156536~35156974 | bone marrow | 32Dcl3 myeloid progenitor cells | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01580 | chr7:35156536~35156974 | bone marrow | 32Dcl3 myeloid progenitor cells | -- | Cebpa +37-kb enhancer TF-site dissection; endogenous Ets-site replacement; target-gene expression validation |
| E_01581 | chr16:25400000~25900000 | prostate gland | Mouse Prostate Epithelial Organoids | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01582 | chr12:48395262~48395977 | articular cartilage | Primary articular chondrocytes | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_01583 | chr12:48395262~48395977 | articular cartilage | Primary articular chondrocytes | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_01584 | chr12:48395262~48395977 | articular cartilage | Primary articular chondrocytes | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_01585 | chr12:48368875~48369590 | breast | 10T1/2,MC615 Cells,MCF-7 | osteoarthritis | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_01586 | chr12:48368875~48369590 | breast | 10T1/2,MC615 Cells,MCF-7 | osteoarthritis | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_01587 | chr12:48368875~48369590 | breast | 10T1/2,MC615 Cells,MCF-7 | osteoarthritis | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_01588 | chr12:48368875~48369590 | breast | 10T1/2,MC615 Cells,MCF-7 | osteoarthritis | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_01589 | chr7:150360500~150366500 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL) | T-cell acute lymphoblastic leukemia | TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01590 | chr7:150360500~150366500 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL) | T-cell acute lymphoblastic leukemia | TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01591 | chr9:91737604~92057238 | -- | Primary Human BJ Fibroblasts | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_01592 | chr9:91737604~92057238 | -- | Primary Human BJ Fibroblasts | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_01593 | chr10:6094588~6094934 | blood | Jurkat E6.1 | autoimmune disease | Functional enhancer discovery; enhancer activity assay; disease-variant perturbation; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_01594 | chr10:6094588~6094934 | blood | primary human CD4-positive T cells | autoimmune disease | Disease-variant functional validation; endogenous response-eQTL assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_01595 | chr11:1986889~1991809 | liver | HCCLM3 | hepatocellular carcinoma | Enhancer activity assay; epigenetic activation assay; chromatin interaction assay; functional perturbation assay; disease phenotype assay; In vivo functional validation |
| E_01596 | chr11:1986889~1991809 | liver | HCCLM3 | hepatocellular carcinoma | Enhancer activity assay; epigenetic activation assay; chromatin interaction assay; functional perturbation assay; disease phenotype assay; In vivo functional validation |
| E_01597 | chr11:1986889~1991809 | liver | Huh-7 | hepatocellular carcinoma | Enhancer activity assay; epigenetic activation assay; chromatin interaction assay; functional perturbation assay; disease phenotype assay; In vivo functional validation |
| E_01598 | chr11:1986889~1991809 | liver | Huh-7 | hepatocellular carcinoma | Enhancer activity assay; epigenetic activation assay; chromatin interaction assay; functional perturbation assay; disease phenotype assay; In vivo functional validation |
| E_01599 | chr10:118242449~118243449 | spleen | CD4+ Th1 cells | -- | Enhancer activity assay; chromatin interaction assay; functional perturbation assay |
| E_01600 | chr10:118254449~118255449 | spleen | CD4+ Th1 cells | -- | Enhancer activity assay; chromatin interaction assay; functional perturbation assay |
| E_01601 | chr10:118295449~118296449 | spleen | CD4+ Th1 cells | -- | Enhancer activity assay; chromatin interaction assay; functional perturbation assay |
| E_01602 | chr10:118305449~118306449 | spleen | CD4+ Th1 cells | -- | Enhancer activity assay; chromatin interaction assay; functional perturbation assay |
| E_01603 | chr11:112334364~112335294 | cartilage tissue | Primary rib chondrocytes from newborn mice | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01604 | chr11:112482190~112483273 | cartilage tissue | Primary rib chondrocytes from newborn mice | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01605 | chr2:106412871~106423516 | mammary gland | MDA-MB-436 | triple-negative breast carcinoma | CRISPR-Cas9 knockout loss-of-function, dCas9-KRAB CRISPRi repression, Hi-C chromatin looping validation, CasRx eRNA knockdown |
| E_01606 | chr2:106412871~106423516 | mammary gland | MDA-MB-436 | triple-negative breast carcinoma | CRISPR-Cas9 knockout loss-of-function, dCas9-KRAB CRISPRi repression, Hi-C chromatin looping validation, CasRx eRNA knockdown |
| E_01607 | chr7:131323622~131334609 | mammary gland | MDA-MB-231 | triple-negative breast carcinoma | CRISPR-Cas9 knockout loss-of-function, dCas9-KRAB CRISPRi repression, Hi-C chromatin looping validation, CasRx eRNA knockdown |
| E_01608 | chr7:131323622~131334609 | mammary gland | MDA-MB-436 | triple-negative breast carcinoma | CRISPR-Cas9 knockout loss-of-function, dCas9-KRAB CRISPRi repression, Hi-C chromatin looping validation, CasRx eRNA knockdown |
| E_01609 | chr7:131323622~131334609 | mammary gland | MDA-MB-468 | triple-negative breast carcinoma | CRISPR-Cas9 knockout loss-of-function, dCas9-KRAB CRISPRi repression, Hi-C chromatin looping validation, CasRx eRNA knockdown |
| E_01610 | chr19:12995236~12998015 | blood | primary human CD34+-derived erythroid cells | -- | Enhancer chromatin-accessibility assay; TF binding assay; Endogenous enhancer editing assay; In vivo functional validation |
| E_01611 | chr19:12995236~12998015 | blood | primary human CD34+-derived erythroid cells | -- | Enhancer chromatin-accessibility assay; TF binding assay; Endogenous enhancer editing assay; In vivo functional validation |
| E_01612 | chr15:99948331~99948831 | mesenchyme of umbilical cord | Primary human umbilical cord-derived hMSCs after osteogenic differentiation | obesity | Super-enhancer constituent activity assay; TF binding assay; Functional enhancer perturbation assay; Lineage-specific differentiation assay; Disease-variant functional analysis |
| E_01613 | chr15:99948331~99948831 | mesenchyme of umbilical cord | Primary human umbilical cord-derived hMSCs after osteogenic differentiation | obesity | Super-enhancer constituent activity assay; TF binding assay; Functional enhancer perturbation assay; Lineage-specific differentiation assay; Disease-variant functional analysis |
| E_01614 | chr5:115553982~115555842 | heart primordium | E11.5 mouse embryo | -- | Enhancer capture Hi-C assay; In vivo enhancer validation |
| E_01615 | chr5:115553982~115555842 | heart primordium | E11.5 mouse embryo | -- | Enhancer capture Hi-C assay; In vivo enhancer validation |
| E_01616 | chr12:121799763~121803094 | liver | Hep-G2 | hepatocellular carcinoma | SE activity / TF-binding validation; In vivo functional validation |
| E_01617 | chr12:121799763~121803094 | liver | SK-HEP-1 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; In vivo functional validation |
| E_01618 | chr11:2233643~2234213 | colon | colorectal adenocarcinoma/adenoma/normal colon tissues | colorectal adenocarcinoma | Tumor-specific enhancer mapping; chromatin interaction assay; CRISPR epigenomic perturbation |
| E_01619 | chr12:130610556~130610854 | colon | colorectal adenocarcinoma/adenoma/normal colon tissues | colorectal adenocarcinoma | Tumor-specific enhancer mapping; chromatin interaction assay; CRISPR epigenomic perturbation |
| E_01620 | chr6:1335829~1335870 | cerebral microvasculature / vascular wall | HEK293 enhancer/CRISPR assays | stroke susceptibility | Experimentally defined ETS1/SNP functional core within the 750-bp FOXF2 construct-E enhancer; endogenous enhancer perturbation and disease-variant analysis |
| E_01621 | chr6:1335829~1335870 | cerebral microvasculature / vascular wall | zebrafish vascular mural-cell models | stroke susceptibility | Experimentally defined ETS1/SNP functional core within the 750-bp FOXF2 construct-E enhancer; endogenous enhancer perturbation and disease-variant analysis |
| E_01622 | chr6:1335829~1335870 | cerebral microvasculature / vascular wall | human GWAS cohorts | stroke susceptibility | Experimentally defined ETS1/SNP functional core within the 750-bp FOXF2 construct-E enhancer; endogenous enhancer perturbation and disease-variant analysis |
| E_01623 | chr6:1335829~1335870 | cerebral microvasculature / vascular wall | HEK293 enhancer/CRISPR assays | stroke susceptibility | Functional core within the 750-bp construct-E enhancer; RBPJ occupancy/site mutagenesis; endogenous enhancer perturbation and FOXF2 target validation |
| E_01624 | chr6:1335829~1335870 | cerebral microvasculature / vascular wall | zebrafish vascular mural-cell models | stroke susceptibility | Functional core within the 750-bp construct-E enhancer; RBPJ occupancy/site mutagenesis; endogenous enhancer perturbation and FOXF2 target validation |
| E_01625 | chr6:1335829~1335870 | cerebral microvasculature / vascular wall | human GWAS cohorts | stroke susceptibility | Functional core within the 750-bp construct-E enhancer; RBPJ occupancy/site mutagenesis; endogenous enhancer perturbation and FOXF2 target validation |
| E_01626 | chr9:94190762~94191795 | mesenchyme of umbilical cord | Primary human umbilical cord-derived hMSCs after adipogenic differentiation | obesity | Super-enhancer constituent activity assay; Functional enhancer perturbation assay; Lineage-specific differentiation assay; Disease-variant functional analysis |
| E_01627 | chr7:54888020~54890020 | brain | GBM3565 patient-derived glioblastoma model | glioblastoma | Enhancer activity assay; chromatin interaction assay; CRISPRi functional screen |
| E_01628 | chr7:54932020~54934020 | brain | GBM3565 patient-derived glioblastoma model | glioblastoma | Enhancer activity assay; chromatin interaction assay; CRISPRi functional screen |
| E_01629 | chr7:54888020~54890020 | brain | GSC23 patient-derived glioblastoma model | glioblastoma | Enhancer-promoter chromatin interaction assay |
| E_01630 | chr7:54932020~54934020 | brain | GSC23 patient-derived glioblastoma model | glioblastoma | Enhancer-promoter chromatin interaction assay |
| E_01631 | chr2:24942670~24943220 | bone marrow | bone marrow-derived mast cells | anaphylaxis | Enhancer activity assay; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_01632 | chr2:24942670~24943220 | bone marrow | bone marrow-derived mast cells | anaphylaxis | Enhancer activity assay; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_01633 | chr2:126627537~126628771 | bone marrow | bone marrow-derived mast cells | anaphylaxis | Enhancer activity assay; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_01634 | chr2:126631900~126633000 | bone marrow | bone marrow-derived mast cells | anaphylaxis | Enhancer activity assay; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_01635 | chr19:12995236~12998015 | blood | KU812/JK1 assay models | -- | Enhancer chromatin-accessibility assay; TF binding assay; Endogenous enhancer editing assay; In vivo functional validation |
| E_01636 | chr19:12995236~12998015 | blood | KU812/JK1 assay models | -- | Enhancer chromatin-accessibility assay; TF binding assay; Endogenous enhancer editing assay; In vivo functional validation |
| E_01637 | chr12:121799763~121803094 | liver | Huh-7 | hepatocellular carcinoma | SE activity / TF-binding validation; In vivo functional validation |
| E_01638 | chr12:121799763~121803094 | liver | SNU-387 | hepatocellular carcinoma | SE activity / TF-binding validation; In vivo functional validation |
| E_01639 | chr12:121803095~121805690 | liver | Hep-G2 | hepatocellular carcinoma | SE activity validation; In vivo functional validation |
| E_01640 | chr12:121803095~121805690 | liver | SK-HEP-1 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay; In vivo functional validation |
| E_01641 | chr12:121803095~121805690 | liver | Huh-7 | hepatocellular carcinoma | SE activity validation; In vivo functional validation |
| E_01642 | chr12:121803095~121805690 | liver | SNU-387 | hepatocellular carcinoma | SE activity validation; In vivo functional validation |
| E_01643 | chr7:54888020~54890020 | brain | G361 | glioblastoma | Functional perturbation assay |
| E_01644 | chr7:54932020~54934020 | brain | G361 | glioblastoma | Functional perturbation assay |
| E_01645 | chr11:2233643~2234213 | colon | SW480 functional validation | colorectal adenocarcinoma | Tumor-specific enhancer mapping; chromatin interaction assay; CRISPR epigenomic perturbation |
| E_01646 | chr11:2233643~2234213 | colon | HCT116/LS513/SW620 HiChIP context | colorectal adenocarcinoma | Tumor-specific enhancer mapping; chromatin interaction assay; CRISPR epigenomic perturbation |
| E_01647 | chr12:130610556~130610854 | colon | SW480 functional validation | colorectal adenocarcinoma | Tumor-specific enhancer mapping; chromatin interaction assay; CRISPR epigenomic perturbation |
| E_01648 | chr12:130610556~130610854 | colon | HCT116/LS513/SW620 HiChIP context | colorectal adenocarcinoma | Tumor-specific enhancer mapping; chromatin interaction assay; CRISPR epigenomic perturbation |
| E_01649 | chr11:2223156~2236495 | colon | SW480 | colorectal adenocarcinoma | Enhancer functional validation; Functional perturbation assay; Chromatin interaction assay |
| E_01650 | chr11:2201926~2215265 | colon | SW480 | colorectal adenocarcinoma | Enhancer functional validation; Functional perturbation assay; Chromatin interaction assay |
| E_01651 | chr6:1335829~1335870 | cerebral microvasculature / vascular wall | HEK293 enhancer/CRISPR assays | stroke susceptibility | Functional FOXF2 enhancer core with CTCF occupancy; endogenous enhancer perturbation and target-gene validation |
| E_01652 | chr6:1335829~1335870 | cerebral microvasculature / vascular wall | zebrafish vascular mural-cell models | stroke susceptibility | Functional FOXF2 enhancer core with CTCF occupancy; endogenous enhancer perturbation and target-gene validation |
| E_01653 | chr6:1335829~1335870 | cerebral microvasculature / vascular wall | human GWAS cohorts | stroke susceptibility | Functional FOXF2 enhancer core with CTCF occupancy; endogenous enhancer perturbation and target-gene validation |
| E_01654 | chr7:55085000~55090000 | brain | GSC23 | glioblastoma | Enhancer perturbation assay |
| E_01655 | chr13:73425662~73427510 | forebrain | E11.5 mouse embryo | -- | Enhancer capture Hi-C assay; In vivo enhancer validation |
| E_01656 | chr13:73511172~73512191 | forebrain | E11.5 mouse embryo | -- | Enhancer capture Hi-C assay; In vivo enhancer validation |
| E_01657 | chr13:73578542~73580243 | forebrain | E11.5 mouse embryo | -- | Enhancer capture Hi-C assay; In vivo enhancer validation |
| E_01658 | chr2:166631000~166633000 | forebrain | E11.5 mouse embryo | -- | Enhancer capture Hi-C assay; In vivo enhancer validation |
| E_01659 | chr2:166634000~166636000 | forebrain | E11.5 mouse embryo | -- | Enhancer capture Hi-C assay; In vivo enhancer validation |
| E_01660 | chr5:87787087~87788935 | forebrain | E11.5 mouse embryo | -- | Enhancer capture Hi-C assay; In vivo enhancer validation |
| E_01661 | chr5:87872597~87873616 | forebrain | E11.5 mouse embryo | -- | Enhancer capture Hi-C assay; In vivo enhancer validation |
| E_01662 | chr5:87944125~87945828 | forebrain | E11.5 mouse embryo | -- | Enhancer capture Hi-C assay; In vivo enhancer validation |
| E_01663 | chr5:87787087~87788935 | forebrain | E11.5 mouse embryo | -- | Enhancer-promoter interaction assay; In vivo enhancer validation |
| E_01664 | chr5:87872597~87873616 | forebrain | E11.5 mouse embryo | -- | Enhancer-promoter interaction assay; In vivo enhancer validation |
| E_01665 | chr5:87944125~87945828 | forebrain | E11.5 mouse embryo | -- | Enhancer-promoter interaction assay; In vivo enhancer validation |
| E_01666 | chr12:121799763~121803094 | liver | Hep-G2 | hepatocellular carcinoma | SE functional perturbation; EMT / metastasis validation; In vivo functional validation |
| E_01667 | chr7:54956710~55086709 | brain | GBM3565 | glioblastoma | Enhancer functional perturbation; chromatin-interaction assay; ecDNA regulatory analysis |
| E_01668 | chr7:54956710~55086709 | brain | GSC23 | glioblastoma | Enhancer functional perturbation; chromatin-interaction assay; ecDNA regulatory analysis |
| E_01669 | chr12:121799763~121803094 | liver | Huh-7 | hepatocellular carcinoma | SE functional perturbation; EMT / metastasis validation; In vivo functional validation |
| E_01670 | chr12:121799763~121803094 | liver | SNU-387 | hepatocellular carcinoma | SE functional perturbation; EMT / metastasis validation; In vivo functional validation |
| E_01671 | chr12:121803095~121805690 | liver | Hep-G2 | hepatocellular carcinoma | SE functional perturbation; LINC01089-dependent metastatic phenotype; In vivo functional validation |
| E_01672 | chr12:121803095~121805690 | liver | Huh-7 | hepatocellular carcinoma | SE functional perturbation; LINC01089-dependent metastatic phenotype; In vivo functional validation |
| E_01673 | chr12:121803095~121805690 | liver | SNU-387 | hepatocellular carcinoma | SE functional perturbation; LINC01089-dependent metastatic phenotype; In vivo functional validation |
| E_01674 | chr7:54915000~54917000 | brain | MDCK-P-gp | glioblastoma | Functional perturbation assay |
| E_01675 | chr7:54925000~54927000 | brain | MDCK-P-gp | glioblastoma | Functional perturbation assay |
| E_01676 | chr11:62864230~62864780 | colon | colorectal cancer tissues and cell lines | colorectal adenocarcinoma | Tumor-specific enhancer functional perturbation |
| E_01677 | chr12:97432140~97432710 | colon | colorectal cancer tissues and cell lines | colorectal adenocarcinoma | Tumor-specific enhancer functional perturbation |
| E_01678 | chr7:54888020~54890020 | brain | G361 glioblastoma patient-derived model | glioblastoma | Enhancer functional perturbation assay |
| E_01679 | chr7:54932020~54934020 | brain | G361 glioblastoma patient-derived model | glioblastoma | Enhancer functional perturbation assay |
| E_01680 | chr9:90690384~90694866 | midbrain | transgenic mouse embryo | -- | CRISPR deletion, Transgenic reporter assay |
| E_01681 | chr11:112334364~112335294 | embryo | C3H/10T1/2 clone 8 | -- | Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01682 | chr11:112482190~112483273 | embryo | C3H/10T1/2 clone 8 | -- | Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01683 | chr9:89500000~92500000 | midbrain | E11.5 mouse embryo | -- | Enhancer capture Hi-C assay; In vivo enhancer validation |
| E_01684 | chr2:126593905~126595430 | blood / hematopoietic system | Connective Tissue Mast Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_01685 | chr2:126593905~126595430 | blood / hematopoietic system | Connective Tissue Mast Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_01686 | chr2:126601468~126603468 | blood / hematopoietic system | Connective Tissue Mast Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_01687 | chr2:126601468~126603468 | blood / hematopoietic system | Connective Tissue Mast Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_01688 | chr11:112334364~112335294 | -- | ATDC-5 | -- | Enhancer activity assay; Differentiation-associated enhancer activity assay |
| E_01689 | chr11:112482190~112483273 | -- | ATDC-5 | -- | Enhancer activity assay; Differentiation-associated enhancer activity assay |
| E_01690 | chrX:153492724~153500546 | thyroid gland | Thyroid carcinoma cell | thyroid gland carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation |
| E_01691 | chr1:155100545~155103815 | thyroid gland | TPC-1 | cervical cancer | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay; In vivo functional validation |
| E_01692 | chr5:53031762~53032075 | vasculature | Primary human vascular smooth muscle cells | coronary artery disease | Enhancer activity assay; Chromatin interaction assay; Enhancer-associated lncRNA functional perturbation assay; RNA-chromatin interaction assay; RNA-protein interaction assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_01693 | chr2:188184262~188184791 | blood vessel | Human aortic endothelial cells (HAECs) | coronary artery disorder | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_01694 | chr17:39611085~39689899 | liver | Hep-G2 | lung adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation; Chromatin interaction assay; Chromatin-state profiling; Disease-variant functional analysis |
| E_01695 | chr7:108960000~108961000 | breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01696 | chr3:134460112~134466940 | coronary artery | Human coronary artery tissue smooth muscle cell compartment | coronary artery disorder | Variant-to-enhancer-to-gene mapping; Chromatin accessibility assay; Chromatin interaction assay; Enhancer activity profiling |
| E_01697 | chr22:39666991~39667170 | pancreas | Paclitaxel-resistant PDAC derivative (PacR) | pancreatic ductal adenocarcinoma | Functional enhancer perturbation; TF binding; enhancer-hub chromatin interaction; In vivo functional validation |
| E_01698 | chr22:39666991~39667170 | pancreas | L3.6pl | pancreatic ductal adenocarcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; In vivo functional validation |
| E_01699 | chr20:31595392~31597085 | colon | HCT 116 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01700 | chr10:61960755~61962481 | blood | NALM-6 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay; TF binding assay; Disease-variant functional analysis |
| E_01701 | chr11:69916000~70050000 | small intestine | Primary GIST tumor samples | SDH-deficient gastrointestinal stromal tumor | Enhancer activity assay; Chromatin interaction assay |
| E_01702 | chr9:133401000~133404500 | breast | ZR-75-1 | ovarian carcinoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay; In vivo functional validation |
| E_01703 | chr2:188184700~188185000 | artery | Endothelial cells | -- | Enhancer activity assay, Functional perturbation assay |
| E_01704 | chr11:111838889~111839334 | -- | Cartilage | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_01705 | chr6:31140556~31141204 | -- | Human Primordial Germ Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01706 | chr4:55449628~55461828 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01707 | chr4:55449628~55461828 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01708 | chr4:55449628~55461828 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01709 | chr4:55453628~55465828 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01710 | chr4:55453628~55465828 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01711 | chr4:55453628~55465828 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01712 | chr8:109134068~109136068 | -- | NMuMG | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01713 | chr11:111838889~111839334 | cartilage tissue | primary chondrocytes | -- | Promoter-enhancer complex capture; TF identification; epigenetic silencing; enhancer-deletion mouse validation |
| E_01714 | chr1:92390990~92393985 | forebrain | Mouse embryonic GE progenitor | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_01715 | chr1:92390990~92393985 | forebrain | Mouse embryonic GE progenitor | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_01716 | chr1:92390990~92393985 | forebrain | Mouse embryonic GE progenitor | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_01717 | chr12:39300010~39302995 | forebrain | Mouse embryonic GE progenitor | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_01718 | chr12:39300010~39302995 | forebrain | Mouse embryonic GE progenitor | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_01719 | chr12:39300010~39302995 | forebrain | Mouse embryonic GE progenitor | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_01720 | chr12:47732000~47733500 | zone of skin | SK-MEL-147 | cutaneous melanoma | Enhancer activity assay, Functional perturbation assay |
| E_01721 | chr5:28476034~28479024 | lung | Colon Adenocarcinoma Cell Lines | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01722 | chr5:28476034~28479024 | lung | Colon Adenocarcinoma Cell Lines | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01723 | chr5:28495262~28497421 | lung | Colon Adenocarcinoma Cell Lines | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01724 | chr5:28495262~28497421 | lung | Colon Adenocarcinoma Cell Lines | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01725 | chr5:28500370~28502363 | lung | Colon Adenocarcinoma Cell Lines | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01726 | chr5:28500370~28502363 | lung | Colon Adenocarcinoma Cell Lines | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01727 | chr5:28561915~28564905 | lung | Colon Adenocarcinoma Cell Lines | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01728 | chr5:28561915~28564905 | lung | Colon Adenocarcinoma Cell Lines | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01729 | chr17:39611085~39689899 | bronchus | HSAEC1-KT | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation; Chromatin interaction assay; Chromatin-state profiling; Disease-variant functional analysis |
| E_01730 | chr6:31132200~31132800 | embryo | human ESC-derived primordial germ cell-like cells and fetal hPGCs | -- | Enhancer activity; TF occupancy; endogenous enhancer perturbation |
| E_01731 | chr11:111838889~111839334 | cartilage tissue | ATDC5 | -- | Promoter-enhancer complex capture; TF identification; epigenetic silencing; enhancer-deletion mouse validation |
| E_01732 | chr12:47483742~47503742 | skin | SK-MEL-147 | metastatic melanoma | super-enhancer constituent validation and endogenous constituent deletion |
| E_01733 | chr12:47483742~47503742 | skin | additional melanoma cell lines | metastatic melanoma | super-enhancer constituent validation and endogenous constituent deletion |
| E_01734 | chr12:47483742~47503742 | skin | short-term melanoma cultures | metastatic melanoma | super-enhancer constituent validation and endogenous constituent deletion |
| E_01735 | chr12:47483742~47503742 | skin | normal human melanocyte controls | metastatic melanoma | super-enhancer constituent validation and endogenous constituent deletion |
| E_01736 | chr12:47483742~47503742 | skin | SK-MEL-147 | metastatic melanoma | super-enhancer constituent validation and endogenous constituent deletion |
| E_01737 | chr12:47483742~47503742 | skin | additional melanoma cell lines | metastatic melanoma | super-enhancer constituent validation and endogenous constituent deletion |
| E_01738 | chr12:47483742~47503742 | skin | short-term melanoma cultures | metastatic melanoma | super-enhancer constituent validation and endogenous constituent deletion |
| E_01739 | chr12:47483742~47503742 | skin | normal human melanocyte controls | metastatic melanoma | super-enhancer constituent validation and endogenous constituent deletion |
| E_01740 | chr3:134460112~134466940 | coronary artery | Primary human coronary artery smooth muscle cells (HCASMC) | coronary artery disorder | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay; Cell-type-specific enhancer validation |
| E_01741 | chr11:111838889~111839334 | cartilage tissue | primary mouse costal chondrocytes | -- | Endogenous enhancer deletion; combinatorial enhancer perturbation; TF-binding/functional assay; Endogenous enhancer perturbation |
| E_01742 | chr12:47471429~47487762 | skin | SKmel147 | melanoma | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01743 | chr12:47471429~47487762 | skin | SKmel147 | melanoma | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01744 | chr6:31132200~31132800 | gonad | human naive pluripotent stem cells / hESC | -- | Enhancer activity; TF binding; endogenous enhancer deletion; germline differentiation assay; Endogenous enhancer perturbation; Chromatin-state profiling |
| E_01745 | chr6:31132200~31132800 | gonad | human primordial germ cells (hPGCs) | -- | Enhancer activity; TF binding; endogenous enhancer deletion; germline differentiation assay; Endogenous enhancer perturbation; Chromatin-state profiling |
| E_01746 | chr6:31132200~31132800 | gonad | human primordial germ cell-like cells (hPGCLCs) | -- | Enhancer activity; TF binding; endogenous enhancer deletion; germline differentiation assay |
| E_01747 | chr6:31139519~31140167 | -- | Human Primordial Germ Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_01748 | chr6:31137056~31138028 | -- | Human Primordial Germ Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_01749 | chr4:55559000~55560500 | embryo | P3/NS1/1-Ag4.1 | -- | Functional perturbation assay |
| E_01750 | chr13:53802995~53810985 | forebrain | Mouse neuroblastoma cell | -- | Enhancer activity assay, TF binding assay |
| E_01751 | chr13:53802995~53810985 | forebrain | Mouse neuroblastoma cell | -- | Enhancer activity assay, TF binding assay |
| E_01752 | chr14:23090994~23098987 | forebrain | Mouse neuroblastoma cell | -- | Enhancer activity assay, TF binding assay |
| E_01753 | chr14:23090994~23098987 | forebrain | Mouse neuroblastoma cell | -- | Enhancer activity assay, TF binding assay |
| E_01754 | chr14:23090994~23098987 | forebrain | Mouse neuroblastoma cell | -- | Enhancer activity assay, TF binding assay |
| E_01755 | chr8:106613868~106615868 | -- | NMuMG | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_01756 | chr8:106610150~106612150 | -- | Non-tumorigenic Mouse Mammary Gland Cells | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_01757 | chr8:106610150~106612150 | -- | Non-tumorigenic Mouse Mammary Gland Cells | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_01758 | chr11:111838889~111839334 | cartilage tissue | chondrocytes/cartilage | -- | Critical far-upstream Sox9 cartilage cis-element; STAT3 identified as trans-acting factor; Endogenous enhancer perturbation |
| E_01759 | chr4:135548688~135550688 | -- | NMuMG | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_01760 | chr11:111838889~111839334 | cartilage tissue | enhancer-deletion mouse | -- | Same defined cartilage enhancer retained as independent deletion-model evidence row; Endogenous enhancer perturbation |
| E_01761 | chr5:28820000~28821700 | lung | Embryonic endodermal epithelial cells | -- | Enhancer activity assay, Chromatin interaction assay |
| E_01762 | chr8:125454150~125454370 | mammary gland | SNU-398 | -- | TF binding assay |
| E_01763 | chr8:125450780~125451000 | mammary gland | NMuMG | -- | Enhancer activity assay |
| E_01764 | chr17:59785798~59787315 | zone of skin | A-375 | cutaneous melanoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01765 | chr14:77808992~77809573 | brain | SH-SY5Y | neuroblastoma | Chromatin interaction assay, Enhancer activity assay, Functional perturbation assay |
| E_01766 | chr14:77635927~77639784 | -- | SH-SY5Y | Alzheimer's Disease | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_01767 | chr8:102449260~102449687 | embryo | Human embryonic stem cells | -- | Functional perturbation assay, TF binding assay, Chromatin interaction assay |
| E_01768 | chr8:102467180~102467504 | embryo | Human embryonic stem cells | -- | Functional perturbation assay, TF binding assay, Chromatin interaction assay |
| E_01769 | chr8:102486442~102486801 | embryo | Human embryonic stem cells | -- | Functional perturbation assay, TF binding assay, Chromatin interaction assay |
| E_01770 | chr12:11718965~11902194 | bone marrow | Primary ETV6::ACSL6 B-ALL cells (RJ-9) | B-cell acute lymphoblastic leukemia | Super-enhancer activity assay; Enhancer hijacking assay; Chromatin interaction assay; In vivo functional validation |
| E_01771 | chr12:11718965~11902194 | bone marrow | Primary ETV6::ACSL6 B-ALL cells (RJ-9) | B-cell acute lymphoblastic leukemia | Super-enhancer activity assay; Enhancer hijacking assay; Chromatin interaction assay; Functional perturbation assay; In vivo functional validation |
| E_01772 | chr12:11718965~11902194 | bone marrow | Primary ETV6::ACSL6 B-ALL cells (RJ-9) | B-cell acute lymphoblastic leukemia | Super-enhancer activity assay; Enhancer hijacking assay; Chromatin interaction assay; In vivo functional validation |
| E_01773 | chr1:185660000~185710000 | plantar part of pes | C666-1 | nasopharyngeal carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; TF binding assay; Chromatin interaction assay; Chromatin-state profiling |
| E_01774 | chr1:185660000~185710000 | plantar part of pes | C666-1 | nasopharyngeal carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; TF binding assay; Chromatin interaction assay; Chromatin-state profiling |
| E_01775 | chr1:191100000~191150000 | plantar part of pes | C666-1 | nasopharyngeal carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; TF binding assay; Chromatin interaction assay; Chromatin-state profiling |
| E_01776 | chr1:191100000~191150000 | plantar part of pes | C666-1 | nasopharyngeal carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; TF binding assay; Chromatin interaction assay; Chromatin-state profiling |
| E_01777 | chr6:134350000~134400000 | plantar part of pes | C666-1 | nasopharyngeal carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; TF binding assay; Chromatin interaction assay; Chromatin-state profiling |
| E_01778 | chr6:134350000~134400000 | plantar part of pes | C666-1 | nasopharyngeal carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; TF binding assay; Chromatin interaction assay; Chromatin-state profiling |
| E_01779 | chr7:79042226~79044226 | intervertebral disk | primary mouse annulus fibrosus cells / chondrocytes | -- | Enhancer activity assay; TF-site functional dissection; endogenous enhancer deletion; In vivo functional validation |
| E_01780 | chr7:79042226~79044226 | intervertebral disk | primary mouse annulus fibrosus cells / chondrocytes | -- | Enhancer activity assay; TF-site functional dissection; endogenous enhancer deletion; In vivo functional validation |
| E_01781 | chr7:79042226~79044226 | intervertebral disk | primary mouse annulus fibrosus cells / chondrocytes | -- | Enhancer activity assay; TF-site functional dissection; endogenous enhancer deletion; In vivo functional validation |
| E_01782 | chr11:3650000~3652019 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; In vivo functional validation |
| E_01783 | chr13:10543000~10544508 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; In vivo functional validation |
| E_01784 | chr17:29065000~29066050 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; In vivo functional validation |
| E_01785 | chr10:30091300~30093300 | blood | Primary CD14+ monocytes | -- | Enhancer activity assay, Chromatin interaction assay |
| E_01786 | chr14:90559777~90561777 | blood | Primary CD14+ monocytes | -- | Enhancer activity assay, Chromatin interaction assay |
| E_01787 | chr19:54550115~54552115 | blood | Primary CD14+ monocytes | -- | Enhancer activity assay, Chromatin interaction assay |
| E_01788 | chr4:76816412~76818412 | blood | Primary CD14+ monocytes | -- | Enhancer activity assay, Chromatin interaction assay |
| E_01789 | chr7:26134404~26136404 | blood | Primary CD14+ monocytes | -- | Enhancer activity assay, Chromatin interaction assay |
| E_01790 | chr10:3773382~3787964 | thyroid gland | MDA-T41 | thyroid gland carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; In vivo functional validation |
| E_01791 | chr11:69419632~69420080 | kidney | 786-O | renal cell carcinoma | Enhancer activity assay, Functional perturbation assay; Disease-variant functional analysis |
| E_01792 | chr8:11446898~11447336 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_01793 | chr8:11446898~11447336 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_01794 | chr8:11446898~11447336 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_01795 | chr8:11446898~11447336 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_01796 | chr8:11446898~11447336 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_01797 | chr8:11446898~11447336 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_01798 | chr8:11446898~11447336 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_01799 | chr8:11446898~11447336 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_01800 | chr8:11446898~11447336 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_01801 | chr16:23819225~23820225 | brain | U-87MG ATCC | glioblastoma | Functional perturbation assay |
| E_01802 | chr17:31939569~31956756 | embryo | mouse embryonic stem cells | -- | Super-enhancer profiling; Enhancer activity assay; Functional constituent perturbation assay |
| E_01803 | chr17:31939569~31956756 | embryo | mouse embryonic stem cells | -- | Super-enhancer profiling; Enhancer activity assay; Functional constituent perturbation assay |
| E_01804 | chr17:31939569~31956756 | embryo | mouse embryonic stem cells | -- | Super-enhancer profiling; Enhancer activity assay; Functional constituent perturbation assay |
| E_01805 | chr2:60722300~60722700 | hematopoietic system | HUDEP-2 | -- | Functional perturbation assay, Enhancer activity assay; Endogenous enhancer perturbation |
| E_01806 | chr8:128320000~128322000 | colon | HCT 116 | colorectal cancer | Chromatin interaction assay, Functional perturbation assay |
| E_01807 | chr8:128320000~128322000 | colon | HCT 116 | colorectal cancer | Chromatin interaction assay, Functional perturbation assay |
| E_01808 | chr8:128320000~128322000 | colon | HCT 116 | colorectal cancer | Chromatin interaction assay, Functional perturbation assay |
| E_01809 | chr6:45407433~45444666 | thyroid gland | MDA-T41 | thyroid gland carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; In vivo functional validation |
| E_01810 | chr7:13905623~13926156 | thyroid gland | MDA-T41 | thyroid gland carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; In vivo functional validation |
| E_01811 | chr1:218337520~218379240 | thyroid gland | MDA-T41 | thyroid gland carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay; In vivo functional validation |
| E_01812 | chr5:151674321~151709808 | thyroid gland | MDA-T41 | thyroid gland carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay; In vivo functional validation |
| E_01813 | chr3:34765000~34767361 | embryo | mouse embryonic stem cells | -- | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_01814 | chr3:34765000~34767361 | embryonic stem-cell culture / multiple mouse tissues | mouse embryonic stem cells | -- | MPRA enhancer discovery; endogenous deletion; long-range target validation |
| E_01815 | chr11:69419632~69420080 | bone element | OS-LM1 | osteosarcoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01816 | chr8:128132902~128133724 | kidney | Human renal cell carcinoma cell | renal cell carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; Disease-variant functional analysis |
| E_01817 | chr8:128526339~128526710 | kidney | Human renal cell carcinoma cell | renal cell carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; Disease-variant functional analysis |
| E_01818 | chr11:69419632~69420080 | kidney | 786-M1A | renal cell carcinoma | Enhancer activity assay; TF binding assay; Functional perturbation assay; Disease-variant functional analysis |
| E_01819 | chr11:69419632~69420080 | kidney | 786-M1A | renal cell carcinoma | Enhancer activity assay; TF binding assay; Functional perturbation assay; Disease-variant functional analysis |
| E_01820 | chr1:218337520~218379240 | thyroid gland | TPC-1 | thyroid gland carcinoma | TF binding assay; RNA-chromatin association assay; Functional perturbation assay; In vivo functional validation |
| E_01821 | chr5:151674321~151709808 | thyroid gland | TPC-1 | thyroid gland carcinoma | TF binding assay; RNA-chromatin association assay; Functional perturbation assay; In vivo functional validation |
| E_01822 | chr10:3773382~3787964 | thyroid gland | TPC-1 | thyroid gland carcinoma | RNA-chromatin association assay; Functional perturbation assay; In vivo functional validation |
| E_01823 | chr7:94261534~94261892 | intervertebral disk | Annulus fibrosus | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01824 | chr7:94290200~94290707 | intervertebral disk | Annulus fibrosus | -- | Enhancer activity assay, TF binding assay |
| E_01825 | chr15:39315234~39315720 | blood | Primary CD14+ monocytes | -- | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_01826 | chr15:89000000~89002500 | blood | Primary monocytes | -- | Enhancer activity assay, Chromatin interaction assay |
| E_01827 | chr4:76815143~76817143 | blood | Primary CD14+ monocytes | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_01828 | chr7:1209755~1211755 | blood | Primary CD14+ monocytes | -- | Chromatin interaction assay; Enhancer activity assay |
| E_01829 | chr11:3650000~3652019 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; MPRA functional screening; Endogenous enhancer perturbation; Chromatin interaction assay; In vivo functional validation |
| E_01830 | chr17:35600000~35630000 | embryo | mouse ESCs | -- | Enhancer activity assay, Functional perturbation assay |
| E_01831 | chr17:35600000~35630000 | embryo | mouse ESCs | -- | Enhancer activity assay, Functional perturbation assay |
| E_01832 | chr17:35600000~35630000 | embryo | mouse ESCs | -- | Enhancer activity assay, Functional perturbation assay |
| E_01833 | chr8:45600000~45640000 | embryo | mouse ESCs | -- | Enhancer activity assay, Functional perturbation assay |
| E_01834 | chr8:45600000~45640000 | embryo | mouse ESCs | -- | Enhancer activity assay, Functional perturbation assay |
| E_01835 | chr8:45600000~45640000 | embryo | mouse ESCs | -- | Enhancer activity assay, Functional perturbation assay |
| E_01836 | chr6:45407433~45444666 | thyroid gland | TPC-1 | thyroid gland carcinoma | RNA-chromatin association assay; Functional perturbation assay; In vivo functional validation |
| E_01837 | chr8:11446898~11447336 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay; Functional perturbation assay; Disease-variant functional analysis |
| E_01838 | chr8:11446898~11447336 | esophagus | OE33 | esophageal adenocarcinoma | Enhancer activity assay; Functional perturbation assay; Disease-variant functional analysis |
| E_01839 | chr8:11446898~11447336 | esophagus | OE19 | esophageal adenocarcinoma | Enhancer activity assay; Functional perturbation assay; Disease-variant functional analysis |
| E_01840 | chr8:11446898~11447336 | esophagus | OE33 | esophageal adenocarcinoma | Enhancer activity assay; Functional perturbation assay; Disease-variant functional analysis |
| E_01841 | chr6:139766548~139767000 | blood | K-562 | -- | Functional validation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01842 | chr2:60722238~60722466 | bone marrow / erythroid compartment | primary CD34+ hematopoietic progenitors differentiated toward erythroblasts | sickle cell disease | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01843 | chr2:60722238~60722466 | bone marrow / erythroid compartment | primary CD34+ hematopoietic progenitors differentiated toward erythroblasts | beta-thalassemia | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01844 | chr2:60725424~60725688 | bone marrow / erythroid compartment | primary CD34+ hematopoietic progenitors differentiated toward erythroblasts | sickle cell disease | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01845 | chr2:60725424~60725688 | bone marrow / erythroid compartment | primary CD34+ hematopoietic progenitors differentiated toward erythroblasts | beta-thalassemia | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01846 | chr2:60725424~60725688 | bone marrow / erythroid compartment | primary CD34+ hematopoietic progenitors differentiated toward erythroblasts | sickle cell disease | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01847 | chr2:60725424~60725688 | bone marrow / erythroid compartment | primary CD34+ hematopoietic progenitors differentiated toward erythroblasts | beta-thalassemia | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01848 | chr2:60722238~60722466 | bone marrow / erythroid compartment | primary CD34+ hematopoietic progenitors differentiated toward erythroblasts | sickle cell disease | Endogenous Cas9 saturating mutagenesis; enhancer functional mapping; TF-site mapping; therapeutic HbF validation |
| E_01849 | chr2:60722238~60722466 | bone marrow / erythroid compartment | primary CD34+ hematopoietic progenitors differentiated toward erythroblasts | beta-thalassemia | Endogenous Cas9 saturating mutagenesis; enhancer functional mapping; TF-site mapping; therapeutic HbF validation |
| E_01850 | chr8:128132902~128133724 | kidney | Kidney proximal tubule epithelial cell | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01851 | chr8:128526339~128526710 | kidney | Kidney proximal tubule epithelial cell | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01852 | chr1:13041306~13127367 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_01853 | chr1:13041306~13127367 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_01854 | chr1:13041306~13127367 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_01855 | chr8:128230503~128232194 | colon | HT-29 | colorectal carcinoma | Chromatin interaction assay; lncRNA-mediated enhancer regulation assay; Functional perturbation assay |
| E_01856 | chr18:9876906~9877723 | blood | T cell leukemia cell | -- | Functional validation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01857 | chr2:60722238~60722466 | bone marrow / erythroid compartment | HUDEP-2/human erythroid cells | sickle cell disease | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01858 | chr2:60722238~60722466 | bone marrow / erythroid compartment | HUDEP-2/human erythroid cells | beta-thalassemia | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01859 | chr2:60725424~60725688 | bone marrow / erythroid compartment | HUDEP-2/human erythroid cells | sickle cell disease | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01860 | chr2:60725424~60725688 | bone marrow / erythroid compartment | HUDEP-2/human erythroid cells | beta-thalassemia | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01861 | chr2:60725424~60725688 | bone marrow / erythroid compartment | HUDEP-2/human erythroid cells | sickle cell disease | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01862 | chr2:60725424~60725688 | bone marrow / erythroid compartment | HUDEP-2/human erythroid cells | beta-thalassemia | Endogenous Cas9 saturating mutagenesis of BCL11A erythroid enhancer; TF-site functional mapping; therapeutic HbF validation |
| E_01863 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Human erythroid cells | sickle cell disease | Endogenous Cas9 saturating mutagenesis; enhancer functional mapping; TF-site mapping; therapeutic HbF validation |
| E_01864 | chr2:60722238~60722466 | bone marrow / erythroid compartment | Human erythroid cells | beta-thalassemia | Endogenous Cas9 saturating mutagenesis; enhancer functional mapping; TF-site mapping; therapeutic HbF validation |
| E_01865 | chr2:60722238~60722466 | bone marrow | Human erythroid cells and primary CD34+ haematopoietic progenitors differentiated toward erythroblasts | sickle cell disease | Endogenous saturation mutagenesis; enhancer functional mapping; therapeutic perturbation validation; Endogenous enhancer perturbation |
| E_01866 | chr2:60722238~60722466 | bone marrow | Human erythroid cells and primary CD34+ haematopoietic progenitors differentiated toward erythroblasts | beta-thalassemia | Endogenous saturation mutagenesis; enhancer functional mapping; therapeutic perturbation validation; Endogenous enhancer perturbation |
| E_01867 | chr2:60725424~60725688 | bone marrow | Human erythroid cells and primary CD34+ haematopoietic progenitors differentiated toward erythroblasts | sickle cell disease | Endogenous saturation mutagenesis; enhancer functional mapping; therapeutic perturbation validation; Endogenous enhancer perturbation |
| E_01868 | chr2:60725424~60725688 | bone marrow | Human erythroid cells and primary CD34+ haematopoietic progenitors differentiated toward erythroblasts | beta-thalassemia | Endogenous saturation mutagenesis; enhancer functional mapping; therapeutic perturbation validation; Endogenous enhancer perturbation |
| E_01869 | chr2:60725424~60725688 | bone marrow | Human erythroid cells and primary CD34+ haematopoietic progenitors differentiated toward erythroblasts | sickle cell disease | Endogenous saturation mutagenesis; enhancer functional mapping; therapeutic perturbation validation; Endogenous enhancer perturbation |
| E_01870 | chr2:60725424~60725688 | bone marrow | Human erythroid cells and primary CD34+ haematopoietic progenitors differentiated toward erythroblasts | beta-thalassemia | Endogenous saturation mutagenesis; enhancer functional mapping; therapeutic perturbation validation; Endogenous enhancer perturbation |
| E_01871 | chr17:35501272~35506872 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; Endogenous enhancer perturbation |
| E_01872 | chr8:119677099~119681977 | colon | HT-29 | colorectal cancer | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_01873 | chr8:119677099~119681977 | colon | HCT 116 | colorectal cancer | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_01874 | chr8:119677099~119681977 | colon | HT-29 | colorectal cancer | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_01875 | chr8:119677099~119681977 | colon | HCT 116 | colorectal cancer | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_01876 | chr19:12994425~12994945 | blood | K-562 | -- | High-throughput enhancer-gene mapping; endogenous CRISPRi validation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01877 | chr4:56595855~56596581 | blood | K-562 | -- | Functional validation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01878 | chr4:56596632~56597095 | blood | K-562 | -- | Functional validation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01879 | chr4:56600029~56600394 | blood | K-562 | -- | Functional validation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01880 | chr1:71140581~71141097 | blood | K-562 | -- | Functional validation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01881 | chr1:182308166~182308458 | blood | K-562 | -- | Functional validation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01882 | chr11:85862307~85862817 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; singleton replication; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01883 | chr16:23833191~23833694 | blood | K-562 | -- | Functional validation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01884 | chr2:8665160~8666881 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01885 | chr2:10437938~10438550 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01886 | chr2:39369017~39369469 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01887 | chr2:127402697~127403360 | blood | K-562 | -- | Functional validation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01888 | chr2:220526749~220526916 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01889 | chr2:236369078~236369902 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01890 | chr3:20064352~20064799 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01891 | chr3:138594478~138595211 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01892 | chr4:1786615~1787989 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01893 | chr4:48483630~48484025 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01894 | chr4:56589677~56589836 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; cis-regulatory element-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01895 | chr4:75196204~75196503 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01896 | chr4:79612721~79612827 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01897 | chr4:79612993~79613671 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01898 | chr4:79642177~79642661 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01899 | chr4:79653654~79654287 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01900 | chr4:81100680~81101328 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01901 | chr4:99603807~99604262 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01902 | chr4:99607997~99608423 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01903 | chr4:123670867~123671008 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01904 | chr4:140099709~140099833 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01905 | chr4:164414180~164414451 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01906 | chr6:3162748~3163640 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01907 | chr6:27156121~27157007 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01908 | chr6:27636220~27636738 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01909 | chr6:32099282~32099729 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01910 | chr7:2439538~2440225 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01911 | chr7:5613818~5614929 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01912 | chr7:7144678~7144795 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01913 | chr7:7188420~7188897 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01914 | chr7:12762340~12762740 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01915 | chr7:22721481~22722093 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01916 | chr7:43796195~43796962 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01917 | chr7:64309754~64310337 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01918 | chr7:92634200~92634655 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01919 | chr7:100130956~100131300 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01920 | chr7:100290947~100292440 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01921 | chr7:103636422~103637017 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01922 | chr7:106618759~106619430 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01923 | chr7:106619602~106619915 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01924 | chr7:106620127~106620526 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01925 | chr7:106647453~106648219 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01926 | chr7:106650504~106650972 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01927 | chr7:106666076~106666272 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01928 | chr7:106675810~106676245 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01929 | chr7:155082665~155083264 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01930 | chr8:11736787~11737581 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01931 | chr8:23366136~23366992 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; singleton replication; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01932 | chr8:30769348~30770834 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01933 | chr8:56760398~56760957 | pleural effusion | K-562 | -- | Endogenous CRISPRi cis-regulatory perturbation; enhancer-gene mapping; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01934 | chr1:182307087~182307634 | cerebellum | Mouse Embryonic Cerebellum | -- | Functional validation |
| E_01935 | chr17:31794375~31829875 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; Endogenous enhancer perturbation |
| E_01936 | chr7:3183157~3229407 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; Endogenous enhancer perturbation |
| E_01937 | chr17:35501113~35507015 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_01938 | chr16:28930687~28931032 | prostate gland | LNCaP | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation; TF binding assay; Disease-variant functional analysis |
| E_01939 | chr10:21241829~21242175 | liver | Erythroid progenitor | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_01940 | chr12:6612734~6614634 | blood | K-562 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_01941 | chr14:99739099~99739310 | embryo | ES-R1 | -- | Functional perturbation assay, Chromatin topology assay |
| E_01942 | chr8:120792731~120793053 | bone marrow | Primary mouse bone marrow hematopoietic progenitors (LMPP/MDP/CDP) | -- | Enhancer activity assay; TF binding assay; Enhancer epigenetic-state assay; In vivo functional validation |
| E_01943 | chr14:23379863~23380961 | heart | human iPSC-derived cardiomyocytes | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_01944 | chr3:142940163~142943066 | liver | Hep-G2 | metabolic dysfunction-associated steatotic liver disease | Enhancer activity assay; TF binding assay; Allele-specific functional assay; Functional perturbation assay; Disease-variant functional analysis |
| E_01945 | chr12:12874700~12875275 | blood | Primary T cells | systemic lupus erythematosus | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_01946 | chr3:181624870~181626200 | breast | MDA-MB-231 | squamous cell carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_01947 | chrX:55054584~55054678 | blood / hematopoietic system | K-562 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01948 | chrX:55041578~55041679 | blood / hematopoietic system | K-562 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_01949 | chr1:133308997~133319722 | hypothalamus | primary arcuate nucleus kisspeptin neurons | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; In vivo reporter assay; In vivo functional validation |
| E_01950 | chr1:133303739~133325138 | -- | Kisspeptin-Immunoreactive Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_01951 | chr10:52442551~52444237 | pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; In vivo functional validation |
| E_01952 | chr10:52442551~52444237 | pancreas | HPAC | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; In vivo functional validation |
| E_01953 | chr10:52442551~52444237 | pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; In vivo functional validation |
| E_01954 | chr10:52442551~52444237 | pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; In vivo functional validation |
| E_01955 | chr10:52442551~52444237 | pancreas | HPAC | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; In vivo functional validation |
| E_01956 | chr10:52442551~52444237 | pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; In vivo functional validation |
| E_01957 | chr12:114182511~114183025 | bone marrow | Primary Rag2-/- pro-B cells | -- | Enhancer activity; TF occupancy; chromatin-conformation and V(D)J functional perturbation |
| E_01958 | chr12:114182511~114183025 | bone marrow | Primary Rag1-/- pro-B cells | -- | Enhancer activity; TF occupancy; chromatin-conformation and V(D)J functional perturbation |
| E_01959 | chr12:114182511~114183025 | bone marrow | Primary pro-B cells / EVH1-mutant mouse | -- | Enhancer activity; TF occupancy; chromatin-conformation and V(D)J functional perturbation |
| E_01960 | chr6:50789172~50828639 | pharyngeal arch | Cranial neural crest cells | -- | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay, TF binding assay |
| E_01961 | chr5:149631000~149636000 | breast | Human breast cancer cell | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01962 | chr5:149631000~149636000 | breast | Human breast cancer cell | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01963 | chr5:149631000~149636000 | breast | Human breast cancer cell | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01964 | chr5:149631000~149636000 | breast | Human breast cancer cell | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_01965 | chr2:75147318~75148561 | limb | E9-E12.5 mouse forelimb bud | -- | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_01966 | chr2:75439366~75440449 | limb | E9-E12.5 mouse forelimb bud | -- | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_01967 | chr7:103852766~103877545 | blood | MEL mouse erythroleukemia cells | -- | Chromatin interaction assay; Enhancer-promoter looping perturbation assay |
| E_01968 | chr6:50913170~51087888 | pharyngeal arch | E10.5 second pharyngeal arch cranial neural crest cells | -- | Enhancer activity assay; Chromatin interaction assay; Endogenous functional perturbation assay; TF occupancy analysis; Endogenous enhancer perturbation; In vivo functional validation |
| E_01969 | chr6:50913170~51087888 | pharyngeal arch | E10.5 PA3/PA4 cranial neural crest cells | -- | Chromatin interaction assay; Endogenous functional perturbation assay; TF occupancy analysis; Endogenous enhancer perturbation; In vivo functional validation |
| E_01970 | chr6:50913170~51087888 | pharyngeal arch | E10.5 second pharyngeal arch cranial neural crest cells | -- | Enhancer activity assay; Chromatin interaction assay; Endogenous functional perturbation assay; TF occupancy analysis; Endogenous enhancer perturbation; In vivo functional validation |
| E_01971 | chr6:50913170~51087888 | pharyngeal arch | E10.5 second pharyngeal arch cranial neural crest cells | -- | Enhancer activity assay; Chromatin interaction assay; Endogenous functional perturbation assay; TF occupancy analysis; Endogenous enhancer perturbation; In vivo functional validation |
| E_01972 | chr6:50913170~51087888 | pharyngeal arch | E10.5 PA3/PA4 cranial neural crest cells | -- | Chromatin interaction assay; Endogenous functional perturbation assay; TF occupancy analysis; Endogenous enhancer perturbation; In vivo functional validation |
| E_01973 | chr12:6607234~6609134 | blood | K-562 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_01974 | chr1:52662800~52663070 | brain | iPSC-derived excitatory neurons | -- | Enhancer activity assay, TF binding assay |
| E_01975 | chr5:88396400~88396670 | brain | iPSC-derived excitatory neurons | -- | Enhancer activity assay, TF binding assay |
| E_01976 | chr6:97306500~97306770 | brain | iPSC-derived excitatory neurons | -- | Enhancer activity assay, TF binding assay |
| E_01977 | chr6:97306500~97306770 | brain | iPSC-derived excitatory neurons | -- | Enhancer activity assay, TF binding assay |
| E_01978 | chr6:162856700~162856970 | brain | iPSC-derived excitatory neurons | -- | Enhancer activity assay, TF binding assay |
| E_01979 | chr6:162856700~162856970 | brain | iPSC-derived excitatory neurons | -- | Enhancer activity assay, TF binding assay |
| E_01980 | chr8:130180065~130180972 | thymus | primary T-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer functional validation and knockout |
| E_01981 | chr8:130180065~130180972 | thymus | primary T-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer TF-binding and genetic validation |
| E_01982 | chr8:130180065~130180972 | thymus | primary T-ALL samples | T-cell acute lymphoblastic leukemia | Long-range enhancer characterization; enhancer-promoter interaction; genetic loss-of-function |
| E_01983 | chr8:130180065~130180972 | thymus | primary T-ALL samples | T-cell acute lymphoblastic leukemia | Long-range enhancer characterization; enhancer-promoter interaction; genetic loss-of-function |
| E_01984 | chr16:92950000~92951000 | liver | MB-1 [Human thyroid carcinoma] | -- | Chromatin interaction assay |
| E_01985 | chr2:12870000~12871000 | liver | MB-1 [Human thyroid carcinoma] | -- | Chromatin interaction assay |
| E_01986 | chr12:114182511~114183025 | bone marrow | Abl-transformed Rag1-/- pro-B cells | -- | Enhancer activity; TF occupancy; chromatin-conformation and V(D)J functional perturbation |
| E_01987 | chr13:80276300~80276570 | brain | iPSC-derived excitatory neurons | -- | Enhancer activity assay, TF binding assay |
| E_01988 | chr8:130180065~130180972 | thymus | HPB-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer functional validation and knockout |
| E_01989 | chr8:130180065~130180972 | thymus | CUTLL1 | T-cell acute lymphoblastic leukemia | Long-range enhancer functional validation and knockout |
| E_01990 | chr8:130180065~130180972 | thymus | HPB-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer TF-binding and genetic validation |
| E_01991 | chr8:130180065~130180972 | thymus | CUTLL1 | T-cell acute lymphoblastic leukemia | Long-range enhancer TF-binding and genetic validation |
| E_01992 | chr8:130180065~130180972 | thymus | CUTLL1 | T-cell acute lymphoblastic leukemia | Long-range enhancer characterization; enhancer-promoter interaction; genetic loss-of-function |
| E_01993 | chr8:130180065~130180972 | thymus | Jurkat | T-cell acute lymphoblastic leukemia | Long-range enhancer characterization; enhancer-promoter interaction; genetic loss-of-function |
| E_01994 | chr8:130180065~130180972 | thymus | CUTLL1 | T-cell acute lymphoblastic leukemia | Long-range enhancer characterization; enhancer-promoter interaction; genetic loss-of-function |
| E_01995 | chr8:130180065~130180972 | thymus | Jurkat | T-cell acute lymphoblastic leukemia | Long-range enhancer characterization; enhancer-promoter interaction; genetic loss-of-function |
| E_01996 | chr8:130180065~130180972 | bone marrow | primary T-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer functional validation; genetic enhancer requirement |
| E_01997 | chr8:130180065~130180972 | blood | primary T-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer functional validation; genetic enhancer requirement |
| E_01998 | chr8:130180065~130180972 | bone marrow | HPB-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer functional validation; genetic enhancer requirement |
| E_01999 | chr8:130180065~130180972 | blood | HPB-ALL | T-cell acute lymphoblastic leukemia | Long-range enhancer functional validation; genetic enhancer requirement |
| E_02000 | chr8:130180065~130180972 | bone marrow | CUTLL1 | T-cell acute lymphoblastic leukemia | Long-range enhancer functional validation; genetic enhancer requirement |
| E_02001 | chr8:130180065~130180972 | blood | CUTLL1 | T-cell acute lymphoblastic leukemia | Long-range enhancer functional validation; genetic enhancer requirement |
| E_02002 | chr8:130180065~130180972 | bone marrow | N-Me knockout leukemia model | T-cell acute lymphoblastic leukemia | Long-range enhancer functional validation; genetic enhancer requirement |
| E_02003 | chr8:130180065~130180972 | blood | N-Me knockout leukemia model | T-cell acute lymphoblastic leukemia | Long-range enhancer functional validation; genetic enhancer requirement |
| E_02004 | chr6:97306690~97307260 | brain | Neurons | -- | Enhancer activity assay; Chromatin-state profiling; Disease-variant functional analysis; In vivo functional validation |
| E_02005 | chr11:101234567~101235689 | bone marrow | Myeloid cells | -- | Functional perturbation assay; In vivo functional validation |
| E_02006 | chr2:74925621~74939634 | forelimb bud | E9.5/E12.5 mouse forelimb buds | -- | Chromatin interaction assay; Functional perturbation assay; Gene expression assay |
| E_02007 | chr8:130180065~130180972 | blood | Human T-ALL cell | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_02008 | chr8:130180065~130180972 | blood | Human T-ALL cell | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_02009 | chr2:75208104~75210328 | limb | E9-E12.5 mouse forelimb bud | -- | Enhancer activity assay; Chromatin interaction assay |
| E_02010 | chr8:130179643~130181490 | blood / hematopoietic system | HPB-ALL,JURKAT,T-acute lymphoblastic leukemia (T-ALL) | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_02011 | chr2:75081283~75094718 | limb | E9 mouse forelimb bud | -- | Enhancer activity assay |
| E_02012 | chr11:68155000~68173900 | kidney | HEK293T | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02013 | chrX:16824570~16829407 | breast | MCF-7 | breast carcinoma | Super-enhancer activity assay; Histone modification assay; Functional perturbation assay |
| E_02014 | chrX:16824570~16829407 | breast | T-47D | breast carcinoma | Super-enhancer activity assay; Histone modification assay; Functional perturbation assay |
| E_02015 | chr7:142599494~142601493 | skeletal muscle tissue | Skeletal muscle myocytes | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_02016 | chr3:169000000~169001000 | umbilical vein | HUVEC-C | -- | Enhancer activity assay, Chromatin interaction assay |
| E_02017 | chr7:55249000~55251000 | brain | U-251MG | glioblastoma | Enhancer activity assay; endogenous enhancer perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02018 | chr8:128554145~128555945 | liver | Huh-7 | hepatocellular carcinoma | Enhancer activity assay; enhancer RNA Functional perturbation assay; Endogenous enhancer perturbation |
| E_02019 | chr13:28268000~28270000 | bone marrow | NALM-16 | B-cell acute lymphoblastic leukemia | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_02020 | chr1:16162175~16195191 | ovary | OVCAR-3 | ovarian carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Chromatin interaction assay |
| E_02021 | chr20:53730511~53757381 | ovary | OVCAR-3 | ovarian carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Chromatin interaction assay |
| E_02022 | chr9:119540801~119544032 | heart | primary mouse atrial cardiomyocytes and ventricular conduction-system cardiomyocytes | atrial fibrillation | Endogenous enhancer perturbation assay; regulatory variant analysis; cardiac electrophysiological assay |
| E_02023 | chr9:119540801~119544032 | heart | primary mouse atrial cardiomyocytes and ventricular conduction-system cardiomyocytes | Brugada syndrome | Endogenous enhancer perturbation assay; regulatory variant analysis; cardiac electrophysiological assay |
| E_02024 | chr1:47677539~47677958 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Chromatin interaction assay; Functional chromatin-architecture perturbation assay |
| E_02025 | chr7:105711382~105713753 | colon | Primary Treg cells | colitis | Functional perturbation assay, Enhancer activity assay, TF binding assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02026 | chr8:120733232~120735226 | kidney | HEK293 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02027 | chr11:76586431~76600121 | colon | Primary Treg cells | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02028 | chr14:99260419~99393893 | embryonic tissue | ES-R1 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02029 | chr15:40809500~40810500 | inner cell mass | WA13 | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation |
| E_02030 | chr17:44542500~44543500 | zone of skin | Human neonatal foreskin fibroblasts | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation |
| E_02031 | chr22:36656500~36657500 | zone of skin | Human neonatal foreskin fibroblasts | -- | CRISPR interference-based functional screen; Endogenous enhancer perturbation |
| E_02032 | chr6:396104~396604 | zone of skin | Human melanoma cell | cutaneous melanoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02033 | chr8:28094779~28095609 | pharyngeal arch | NIH 3T3 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_02034 | chr8:28094779~28095609 | pharyngeal arch | NIH 3T3 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_02035 | chr5:131406243~131406930 | blood | Jurkat | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin accessibility assay; Chromatin remodeling assay; In vivo functional validation |
| E_02036 | chr5:131406243~131406930 | blood | Jurkat | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin accessibility assay; Chromatin remodeling assay; In vivo functional validation |
| E_02037 | chr5:131406243~131406930 | blood | Jurkat | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin accessibility assay; Chromatin remodeling assay; In vivo functional validation |
| E_02038 | chr5:131406243~131406930 | blood | Jurkat | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin accessibility assay; Chromatin remodeling assay; In vivo functional validation |
| E_02039 | chrX:49264210~49265210 | blood | Primary regulatory T cells | -- | Promoter functional perturbation assay; TF binding assay |
| E_02040 | chr15:61958143~62188886 | embryo | mESC | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_02041 | chr1:180887014~180889994 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02042 | chr1:180887014~180889994 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02043 | chr1:180887014~180889994 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02044 | chr1:180887014~180889994 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02045 | chr1:180887014~180889994 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02046 | chr1:180887014~180889994 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02047 | chr1:180887014~180889994 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02048 | chr1:180924460~180925486 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02049 | chr1:180924460~180925486 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02050 | chr1:180924460~180925486 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02051 | chr1:180924460~180925486 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02052 | chr1:180924460~180925486 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02053 | chr1:180924460~180925486 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02054 | chr1:180924460~180925486 | embryo | Mouse embryonic stem | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02055 | chr12:54295641~54296181 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02056 | chr12:54303561~54304061 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02057 | chr12:54303561~54304061 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02058 | chr12:54306981~54307501 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02059 | chr12:54306981~54307501 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02060 | chr19:12681111~12681611 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02061 | chr19:12775155~12776011 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02062 | chr19:12775155~12776011 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02063 | chr19:12782291~12783171 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02064 | chr19:12782291~12783171 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02065 | chr19:12805831~12806863 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02066 | chr19:12880980~12881831 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02067 | chr19:12883611~12884131 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02068 | chr19:12884935~12885511 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02069 | chr19:12884935~12885511 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02070 | chr19:12886091~12888153 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02071 | chr19:12886091~12888153 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02072 | chr19:12886091~12888153 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02073 | chr19:12886091~12888153 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02074 | chr19:12886091~12888153 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02075 | chr19:12886091~12888153 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02076 | chr19:12886091~12888153 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02077 | chr19:12888891~12889391 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02078 | chr19:48740463~48741888 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02079 | chr19:48745108~48745628 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02080 | chr19:48898139~48899488 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02081 | chr19:48962199~48962768 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02082 | chr19:48970828~48971348 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02083 | chrX:47232664~47233947 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02084 | chrX:48761499~48762241 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02085 | chrX:48800418~48801257 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02086 | chrX:48800418~48801257 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02087 | chrX:48800418~48801257 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02088 | chrX:48941369~48942569 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02089 | chrX:48941369~48942569 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02090 | chrX:49047157~49047736 | blood | K-562 | -- | Genome-scale enhancer-gene perturbation and activity-by-contact modeling; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02091 | chr14:69196226~69202226 | blood / hematopoietic system | G1ER Erythroid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02092 | chr14:69196226~69202226 | blood / hematopoietic system | G1ER Erythroid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02093 | chr14:119710660~119714758 | blood / hematopoietic system | G1ER Erythroid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02094 | chr14:119710660~119714758 | blood / hematopoietic system | G1ER Erythroid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02095 | chr8:28094779~28095609 | pharyngeal arch | NIH 3T3 | -- | Enhancer activity assay; TF binding assay; In vivo functional validation |
| E_02096 | chr15:62009732~62013089 | embryo | MycGFP/GFP mESCs (SR+LIF+2i | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02097 | chr15:62009732~62013089 | embryo | naive pluripotency) and E3.5 blastocyst epiblast | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02098 | chr15:62009732~62013089 | embryo | MycGFP/GFP mESCs (SR+LIF+2i | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02099 | chr15:62009732~62013089 | embryo | naive pluripotency) and E3.5 blastocyst epiblast | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02100 | chr15:62009732~62013089 | embryo | MycGFP/GFP mESCs (SR+LIF+2i | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02101 | chr15:62009732~62013089 | embryo | naive pluripotency) and E3.5 blastocyst epiblast | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02102 | chr15:62092610~62093180 | embryo | MycGFP/GFP mESC-derived EpiLCs (2 days N2B27+FGF2/Activin A) and E6.0-E6.5 post-implantation epiblast | -- | Enhancer activity assay; TF binding evidence; Chromatin interaction assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02103 | chr16:18164900~18165100 | pharyngeal arch | NIH 3T3 | -- | Enhancer activity assay, TF binding assay; In vivo functional validation |
| E_02104 | chr2:73389900~73390100 | pharyngeal arch | NIH 3T3 | -- | Enhancer activity assay, TF binding assay; In vivo functional validation |
| E_02105 | chr8:23422136~23432636 | bone marrow | Adult bone marrow CD34+-derived proerythroblasts (A5 ProE) | -- | Super-enhancer profiling; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_02106 | chr8:23422136~23432636 | bone marrow | Adult bone marrow CD34+-derived proerythroblasts (A5 ProE) | -- | Super-enhancer profiling; TF binding assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_02107 | chr8:23448386~23454886 | blood / hematopoietic system | Human CD34+ Hematopoietic Stem/Progenitor Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02108 | chr8:23448386~23454886 | blood / hematopoietic system | Human CD34+ Hematopoietic Stem/Progenitor Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02109 | chr8:23433011~23439511 | blood / hematopoietic system | Human CD34+ Hematopoietic Stem/Progenitor Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02110 | chr8:23433011~23439511 | blood / hematopoietic system | Human CD34+ Hematopoietic Stem/Progenitor Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02111 | chr8:23422136~23432636 | blood / hematopoietic system | Human CD34+ Hematopoietic Stem/Progenitor Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02112 | chr8:23422136~23432636 | blood / hematopoietic system | Human CD34+ Hematopoietic Stem/Progenitor Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02113 | chr8:128556059~128557653 | liver | Hep-G2 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation |
| E_02114 | chrX:49268807~49270673 | blood | Primary conventional CD4+ T cells | -- | Silencer activity assay; Functional perturbation assay; TF binding assay |
| E_02115 | chrX:7573447~7575334 | spleen | Primary murine conventional CD4+ T cells | -- | Silencer activity assay; TF binding assay; Functional perturbation assay |
| E_02116 | chrX:7573447~7575334 | lymph node | Primary murine conventional CD4+ T cells | -- | Silencer activity assay; TF binding assay; Functional perturbation assay |
| E_02117 | chrX:49273000~49274000 | blood | Primary conventional CD4+ T cells | -- | Enhancer activity assay; Functional perturbation assay; TF binding assay |
| E_02118 | chrX:49276500~49278500 | blood | Primary conventional CD4+ T cells | -- | Enhancer activity assay; Functional perturbation assay; TF binding assay |
| E_02119 | chr14:69221635~69222851 | blood / hematopoietic system | G1ER Erythroid Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_02120 | chr14:69221635~69222851 | blood / hematopoietic system | G1ER Erythroid Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_02121 | chrX:49265618~49268300 | blood | Primary regulatory T cells | -- | Repressive cis-regulatory element validation; Functional perturbation assay |
| E_02122 | chrX:49260470~49261090 | blood | Primary regulatory T cells | -- | Enhancer activity assay; Functional perturbation assay |
| E_02123 | chrX:49260470~49261090 | -- | Conventional T cells | -- | Functional perturbation assay; Enhancer activity assay |
| E_02124 | chrX:49264210~49265210 | -- | Conventional T cells | -- | Functional perturbation assay; Enhancer activity assay |
| E_02125 | chrX:49265618~49268300 | -- | Conventional T cells | -- | Functional perturbation assay; Enhancer activity assay |
| E_02126 | chrX:49268807~49270673 | -- | Conventional T cells | -- | Functional perturbation assay; Enhancer activity assay |
| E_02127 | chrX:49273000~49274000 | -- | Conventional T cells | -- | Functional perturbation assay; Enhancer activity assay |
| E_02128 | chrX:49276500~49278500 | -- | Conventional T cells | -- | Functional perturbation assay; Enhancer activity assay |
| E_02129 | chrX:7566060~7568152 | -- | Conventional T cells | -- | Functional perturbation assay; Enhancer activity assay |
| E_02130 | chrX:7570463~7571424 | -- | Conventional T cells | -- | Functional perturbation assay; Enhancer activity assay |
| E_02131 | chrX:7573447~7575334 | -- | Conventional T cells | -- | Functional perturbation assay; Enhancer activity assay |
| E_02132 | chrX:7579185~7580141 | -- | Conventional T cells | -- | Functional perturbation assay; Enhancer activity assay |
| E_02133 | chrX:7583853~7584485 | blood / immune system | conventional CD4-positive T cells | -- | Cis-regulatory element screen; Functional perturbation assay; TF-circuitry assay |
| E_02134 | chrX:7570463~7571424 | spleen | Primary murine conventional CD4+ T cells | -- | Enhancer-associated chromatin profiling; TF binding assay |
| E_02135 | chrX:7570463~7571424 | lymph node | Primary murine conventional CD4+ T cells | -- | Enhancer-associated chromatin profiling; TF binding assay |
| E_02136 | chr22:36328713~36329931 | lung | primary lung fibroblasts from idiopathic pulmonary fibrosis donors | idiopathic pulmonary fibrosis | Disease-context functional perturbation assay; Endogenous enhancer perturbation |
| E_02137 | chrX:7566060~7568152 | spleen | Primary murine conventional CD4+ T cells | -- | Enhancer-associated chromatin profiling; TF binding assay |
| E_02138 | chrX:7566060~7568152 | lymph node | Primary murine conventional CD4+ T cells | -- | Enhancer-associated chromatin profiling; TF binding assay |
| E_02139 | chrX:7579185~7580141 | spleen | Primary murine conventional CD4+ T cells | -- | Promoter-associated regulatory profiling |
| E_02140 | chrX:7579185~7580141 | lymph node | Primary murine conventional CD4+ T cells | -- | Promoter-associated regulatory profiling |
| E_02141 | chrX:7583853~7584485 | spleen | Primary murine regulatory T cells | -- | Enhancer-associated chromatin profiling |
| E_02142 | chrX:7583853~7584485 | lymph node | Primary murine regulatory T cells | -- | Enhancer-associated chromatin profiling |
| E_02143 | chr14:99319699~99358748 | embryonic stem cell | mouse embryonic stem cells | -- | Chromatin interaction assay |
| E_02144 | chr14:99319699~99358748 | embryonic stem cell | mouse embryonic stem cells | -- | Chromatin interaction assay |
| E_02145 | chr14:99319699~99358748 | embryonic stem cell | mouse embryonic stem cells | -- | Chromatin interaction assay |
| E_02146 | chr14:99319699~99358748 | embryonic stem cell | mouse embryonic stem cells | -- | Chromatin interaction assay |
| E_02147 | chr3L:8670850~8671350 | brain | Kenyon cell | -- | Enhancer activity assay |
| E_02148 | chrX:4010500~4011000 | brain | Kenyon cell | -- | Enhancer activity assay |
| E_02149 | chrX:9786300~9786800 | brain | Kenyon cell | -- | Enhancer activity assay |
| E_02150 | chrX:15547650~15548150 | brain | Kenyon cell | -- | Enhancer activity assay |
| E_02151 | chr16:54926631~54929466 | blood | ALL-SIL | T-cell acute lymphoblastic leukemia | Enhancer activity assay; Functional perturbation assay; Chromatin interaction assay; Chromatin accessibility assay; Histone modification profiling |
| E_02152 | chr1:58780000~58785000 | lung | Primary human lung fibroblasts | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02153 | chr10:78046488~78046636 | -- | Thymic Medullary Epithelial Cells (mTECs) | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_02154 | chr16:11075000~11075280 | lymph node | Namalwa (B-lymphocyte) | Burkitt lymphoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02155 | chr16:11075000~11075280 | lymph node | Namalwa (B-lymphocyte) | Burkitt lymphoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02156 | chr16:11075000~11075280 | lymph node | Namalwa (B-lymphocyte) | Burkitt lymphoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02157 | chr6:31350000~31355000 | lung | Human Pulmonary Artery Endothelial Cells | -- | Functional perturbation assay, TF binding assay; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling |
| E_02158 | chr6:31356000~31361000 | lung | Human Pulmonary Artery Endothelial Cells | -- | TF binding assay, Enhancer activity assay; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling |
| E_02159 | chr14:36973254~36976254 | prostate gland | LuCaP93 PDX | prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_02160 | chr14:36980000~36983000 | prostate gland | LuCaP93 PDX | prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_02161 | chr14:36508249~36509448 | left supraclavicular lymph node | LNCaP | neuroendocrine prostate cancer | TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_02162 | chr14:36514552~36515387 | left supraclavicular lymph node | LNCaP | neuroendocrine prostate cancer | TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_02163 | chr14:36990000~36996211 | prostate gland | LuCaP93 PDX | prostate cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_02164 | chr20:46000017~46000761 | placenta | HTR-8/SVneo | -- | Enhancer activity assay; Functional perturbation assay; TF-binding/motif analysis |
| E_02165 | chr20:46000017~46000761 | placenta | HTR-8/SVneo | -- | Enhancer activity assay; Functional perturbation assay; TF-binding/motif analysis |
| E_02166 | chr20:46000017~46000761 | placenta | HTR-8/SVneo | -- | Enhancer activity assay; Functional perturbation assay; TF-binding/motif analysis |
| E_02167 | chr5:75699926~75706926 | zone of skin | Primary Melanocytes (Kit ?30k) | -- | Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02168 | chr5:75825926~75832926 | zone of skin | Primary Melanocytes (Kit ?30k) | -- | Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02169 | chr5:75699926~75706926 | bone marrow | Primary Mast cells | -- | Functional perturbation assay, Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02170 | chr5:75825926~75832926 | zone of skin | Primary Melanocytes | -- | Functional perturbation assay, Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02171 | chr21:40149729~40317726 | colon | Ulcerative-colitis-derived colon organoids | inflammatory bowel disease | Disease-associated super-enhancer activity; TF binding; chromatin interaction |
| E_02172 | chr14:98602411~98675204 | blood | DND-41 | T-cell acute lymphoblastic leukemia | Enhancer-hijacking assay; Chromatin interaction assay; Chromatin-state assay; CRISPRi functional perturbation assay; Disease-variant functional analysis |
| E_02173 | chr17:26850487~26851000 | outflow tract | embryonic mouse anterior second heart field, outflow tract and right ventricular myocardium | conotruncal heart malformations | Endogenous enhancer deletion assay; TF-enhancer interaction assay; developmental phenotyping; cardiac electrophysiology; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02174 | chr17:26850487~26851000 | outflow tract | human iPSC-derived cardiomyocytes for GATA6 chromatin assays | conotruncal heart malformations | Endogenous enhancer deletion assay; TF-enhancer interaction assay; developmental phenotyping; cardiac electrophysiology; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02175 | chrX:103578000~103588000 | embryo | GATA6-inducible mouse embryonic stem cells | -- | RE79 long-range enhancer functional validation; TF binding assay; Functional perturbation assay; database working interval; Endogenous enhancer perturbation; In vivo functional validation |
| E_02176 | chr1:172411511~172413110 | heart | -- | -- | Enhancer activity assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_02177 | chr12:4704343~4706142 | heart | -- | -- | Enhancer activity assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_02178 | chr15:103026344~103028143 | heart | -- | -- | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_02179 | chr7:84833410~84834080 | cartilage tissue | RCS rat chondrosarcoma cells | -- | Enhancer activity assay; TF binding assay; Endogenous enhancer perturbation; Chromatin-state profiling |
| E_02180 | chr7:84833410~84834080 | cartilage tissue | RCS rat chondrosarcoma cells | -- | Enhancer activity assay; TF binding assay; Endogenous functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling |
| E_02181 | chr6:135418600~135418700 | bone marrow | KG-1a | acute myeloid leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_02182 | chr4:111553098~111553222 | heart | hESC-derived cardiomyocytes | atrial fibrillation | Disease-associated enhancer assay; TF binding assay; endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_02183 | chr5:115358083~115360083 | brain | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_02184 | chr5:115358083~115360083 | brain | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_02185 | chr8:127737737~127738437 | colon | HCT 116 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Chromatin interaction assay |
| E_02186 | chr8:127744001~127744701 | colon | HCT 116 | colorectal carcinoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Chromatin interaction assay |
| E_02187 | chr8:128754000~128755000 | colon | HCT 116 | colorectal carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay; Chromatin interaction assay |
| E_02188 | chr7:156268357~156269154 | hypothalamus | Transient transgenic mouse embryos | holoprosencephaly | Enhancer activity assay; Functional perturbation assay; Disease-variant assay; TF binding assay |
| E_02189 | chr21:40149729~40317726 | colon | Primary normal colon epithelial cells | -- | Super-enhancer activity; TF binding; chromatin interaction; functional perturbation |
| E_02190 | chr5:173245543~173245843 | heart | hiPSC-derived cardiomyocytes | -- | TF binding assay; chromatin accessibility assay; cross-species enhancer validation; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_02191 | chr17:26853910~26854423 | heart | Embryonic mouse heart / anterior second heart field | -- | In vivo enhancer deletion; TF binding; developmental functional validation; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02192 | chr4:111553081~111553310 | heart | WA07 | atrial fibrillation | Enhancer activity assay; TF binding assay; Functional perturbation assay; Gene expression assay; eRNA assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_02193 | chr17:34520000~34525000 | lung | Mouse Pulmonary Artery Endothelial Cells | -- | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation; Chromatin-state profiling |
| E_02194 | chr18:60811244~60811580 | brain | Mouse primary macrophages | -- | Functional perturbation assay, Enhancer activity assay, TF binding assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02195 | chr11:5279732~5280272 | blood | Primary human erythroblasts | -- | Enhancer activity; TF binding; endogenous functional perturbation; chromatin-opening assay |
| E_02196 | chr11:5279732~5280272 | blood | Primary human erythroblasts | -- | Enhancer activity; TF binding; endogenous functional perturbation; chromatin-opening assay |
| E_02197 | chr11:5279732~5280272 | blood | Primary human erythroblasts | -- | Enhancer activity; TF binding; endogenous functional perturbation; chromatin-opening assay |
| E_02198 | chr11:5279732~5280272 | blood | Primary human erythroblasts | -- | Enhancer activity; TF binding; endogenous functional perturbation; chromatin-opening assay |
| E_02199 | chr11:5279732~5280272 | blood | Primary human erythroblasts | -- | Enhancer activity; TF binding; endogenous functional perturbation; chromatin-opening assay |
| E_02200 | chr1:214150511~214151337 | dermis | Primary adult human dermal lymphatic endothelial cells (hLECs) | lymphedema | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02201 | chr5:44385696~44386743 | outflow tract | human embryonic cardiac outflow tract tissue | -- | Enhancer activity assay; TF binding assay; transgenic functional validation |
| E_02202 | chr12:8112145~8113645 | umbilical vein | Primary human umbilical vein endothelial cells (HUVECs) | -- | SLC2A3 distal enhancer 2 (~24 kb upstream); HIF1/H3K27ac enrichment; enhancer activity and promoter interaction under hypoxia |
| E_02203 | chr12:8122645~8123945 | umbilical vein | Primary human umbilical vein endothelial cells (HUVECs) | -- | SLC2A3 distal enhancer 1 (~35 kb upstream); strong HIF1 reporter/3C evidence in 2012; later work shows overlap with the HIF-responsive NICI promoter and supports an additional lncRNA-mediated mechanism |
| E_02204 | chr14:98602411~98675204 | bone marrow | UT242 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_02205 | chr14:98602411~98675204 | bone marrow | UT308 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_02206 | chr7:155754267~155755366 | forebrain | Primary embryonic cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02207 | chr21:40149729~40317726 | colon | HCT 116 | colorectal carcinoma | Super-enhancer activity; TF binding; chromatin interaction; CRISPRi functional perturbation |
| E_02208 | chr12:8112145~8113645 | vascular endothelium / kidney-derived cell-line context | Primary human endothelial cells for HIF1 chromatin profiling | -- | Hypoxia-responsive distal enhancer activity; HIF1 binding; chromatin-conformation remodeling; KDM3A cooperation |
| E_02209 | chr12:8122645~8123945 | vascular endothelium / kidney-derived cell-line context | Primary human endothelial cells for HIF1 chromatin profiling | -- | Hypoxia-responsive distal enhancer activity; HIF1 binding; chromatin-conformation remodeling; KDM3A cooperation |
| E_02210 | chr3:108045000~108135000 | lung | Primary human lung fibroblasts | -- | TF binding assay, Functional perturbation assay |
| E_02211 | chr11:5279732~5280272 | blood | K-562 | -- | Enhancer activity; TF binding; endogenous functional perturbation; chromatin-opening assay |
| E_02212 | chr11:5279732~5280272 | blood | K-562 | -- | Enhancer activity; TF binding; endogenous functional perturbation; chromatin-opening assay |
| E_02213 | chr11:5279732~5280272 | blood | K-562 | -- | Enhancer activity; TF binding; endogenous functional perturbation; chromatin-opening assay |
| E_02214 | chr11:5279732~5280272 | blood | K-562 | -- | Enhancer activity; TF binding; endogenous functional perturbation; chromatin-opening assay |
| E_02215 | chr11:5279732~5280272 | blood | K-562 | -- | Enhancer activity; TF binding; endogenous functional perturbation; chromatin-opening assay |
| E_02216 | chr12:8112145~8113645 | umbilical vein | HEK293 for HIF1 overexpression reporter assays | -- | SLC2A3 distal enhancer 2 (~24 kb upstream); HIF1/H3K27ac enrichment; enhancer activity and promoter interaction under hypoxia |
| E_02217 | chr12:8122645~8123945 | umbilical vein | HEK293 for HIF1 overexpression reporter assays | -- | SLC2A3 distal enhancer 1 (~35 kb upstream); strong HIF1 reporter/3C evidence in 2012; later work shows overlap with the HIF-responsive NICI promoter and supports an additional lncRNA-mediated mechanism |
| E_02218 | chr5:44385696~44386743 | outflow tract | human embryonic cardiac outflow tract tissue | -- | Enhancer activity assay; cooperative TF regulation assay; transgenic functional validation |
| E_02219 | chr5:44385696~44386743 | outflow tract | human embryonic cardiac outflow tract tissue | -- | Enhancer activity assay; cooperative TF regulation assay; transgenic functional validation |
| E_02220 | chr7:155595558~155596658 | kidney | COS-1 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02221 | chr7:129554284~129564284 | -- | Rat Chondrosarcoma Cells (RCS cells) | Skeletal Diseases | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_02222 | chr12:8112145~8113645 | vascular endothelium / kidney-derived cell-line context | HEK293 for mechanistic reporter/3C assays | -- | Hypoxia-responsive distal enhancer activity; HIF1 binding; chromatin-conformation remodeling; KDM3A cooperation |
| E_02223 | chr12:8122645~8123945 | vascular endothelium / kidney-derived cell-line context | HEK293 for mechanistic reporter/3C assays | -- | Hypoxia-responsive distal enhancer activity; HIF1 binding; chromatin-conformation remodeling; KDM3A cooperation |
| E_02224 | chr8:128745000~128745100 | colon | HCT 116 | colorectal cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Chromatin interaction assay |
| E_02225 | chr8:128750000~128750100 | colon | HCT 116 | colorectal cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Chromatin interaction assay |
| E_02226 | chrX:103578000~103588000 | embryo | female XEN cells | -- | RE79 long-range enhancer TF-binding validation; database working interval |
| E_02227 | chr18:60811244~60811580 | multiple tissues | primary mouse macrophages | -- | Enhancer essentiality assay; Functional perturbation assay; In vivo macrophage-development assay |
| E_02228 | chr21:40149729~40317726 | colon | SW480 | colorectal carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_02229 | chr18:61241648~61241998 | embryo | embryonic macrophages | -- | Endogenous enhancer deletion; tissue-specific macrophage-development phenotyping; enhancer/TF chromatin profiling; Endogenous enhancer perturbation; In vivo functional validation |
| E_02230 | chr18:61241648~61241998 | heart | heart resident macrophages | -- | Endogenous enhancer deletion; tissue-specific macrophage-development phenotyping; enhancer/TF chromatin profiling; Endogenous enhancer perturbation; In vivo functional validation |
| E_02231 | chr18:61241648~61241998 | kidney | kidney resident macrophages | -- | Endogenous enhancer deletion; tissue-specific macrophage-development phenotyping; enhancer/TF chromatin profiling; Endogenous enhancer perturbation; In vivo functional validation |
| E_02232 | chr18:61241648~61241998 | embryo | mouse embryonic stem-cell macrophage differentiation | -- | Endogenous enhancer deletion; tissue-specific macrophage-development phenotyping; enhancer/TF chromatin profiling; Endogenous enhancer perturbation; In vivo functional validation |
| E_02233 | chr18:61241648~61241998 | peritoneal cavity | peritoneal resident macrophages | -- | Endogenous enhancer deletion; tissue-specific macrophage-development phenotyping; enhancer/TF chromatin profiling; Endogenous enhancer perturbation; In vivo functional validation |
| E_02234 | chr18:61241648~61241998 | skin of body | skin resident macrophages | -- | Endogenous enhancer deletion; tissue-specific macrophage-development phenotyping; enhancer/TF chromatin profiling; Endogenous enhancer perturbation; In vivo functional validation |
| E_02235 | chr5:44385797~44386845 | outflow tract | C3H/10T1/2 clone 8 | -- | Enhancer activity assay |
| E_02236 | chrX:103628000~103668000 | embryo | female trophoblast stem cells | -- | RE97 long-range enhancer TF-binding and in vivo functional validation; database working interval |
| E_02237 | chrX:103628000~103668000 | embryo | female XEN cells | -- | RE97 long-range enhancer TF-binding and in vivo functional validation; database working interval |
| E_02238 | chr13:116322276~116325052 | sinoatrial node | FACS-sorted neonatal mouse sinoatrial node pacemaker cells | -- | Enhancer discovery assay; in vivo enhancer activity assay; endogenous enhancer perturbation assay |
| E_02239 | chr4:111553081~111553310 | uterine cervix | HeLa | atrial fibrillation | TF binding assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_02240 | chr4:111544012~111544682 | embryo | Danio rerio embryos | atrial fibrillation | In vivo enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_02241 | chr4:111552482~111553989 | embryo | Danio rerio embryos | atrial fibrillation | In vivo enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_02242 | chr4:111574843~111575952 | embryo | Danio rerio embryos | atrial fibrillation | In vivo enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_02243 | chr5:44385797~44386845 | outflow tract | human embryonic outflow tract | -- | Enhancer activity assay; TF binding assay |
| E_02244 | chr5:44385797~44386845 | outflow tract | human embryonic outflow tract | -- | Enhancer activity assay;TF binding assay |
| E_02245 | chr5:115574958~115575553 | nervous system | NS/PCs | -- | Enhancer activity assay; cis-regulatory deletion mapping |
| E_02246 | chr5:115574958~115575553 | nervous system | mouse embryonic stem cells | -- | Enhancer activity assay; cis-regulatory deletion mapping |
| E_02247 | chr5:115502658~115512658 | nervous system | NS/PCs | -- | Candidate enhancer activity assay; BAC deletion mapping |
| E_02248 | chr5:115502658~115512658 | nervous system | mouse embryonic stem cells | -- | Candidate enhancer activity assay; BAC deletion mapping |
| E_02249 | chr11:5279732~5280272 | blood | primary erythroblasts | -- | Functional perturbation assay, Enhancer activity assay |
| E_02250 | chr18:61241648~61241998 | bone marrow | bone-marrow monocytes and progenitors | -- | Endogenous enhancer deletion; tissue-specific macrophage-development phenotyping; enhancer/TF chromatin profiling |
| E_02251 | chr11:5279732~5280272 | blood / hematopoietic system | K-562 | Erythrocytic Leukemia | TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_02252 | chr11:5279732~5280272 | blood / hematopoietic system | K-562 | Erythrocytic Leukemia | TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_02253 | chr11:5279732~5280272 | blood / hematopoietic system | K-562 | Erythrocytic Leukemia | TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_02254 | chr11:5279732~5280272 | blood / hematopoietic system | K-562 | Erythrocytic Leukemia | TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_02255 | chr11:5279732~5280272 | blood / hematopoietic system | K-562 | Erythrocytic Leukemia | TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_02256 | chr6:135418600~135418700 | blood | Kasumi-1 | acute myeloid leukemia | Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_02257 | chr5:44385749~44386845 | heart | Human Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02258 | chr5:44385749~44386845 | heart | Human Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02259 | chr5:44385749~44386845 | heart | Human Embryos | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02260 | chr20:20392790~20394473 | cervical lymph node | NCI-H660 | neuroendocrine prostate cancer | Chromatin interaction assay; Regulatory element annotation |
| E_02261 | chr5:44385797~44386845 | outflow tract | C3H/10T1/2 clone 8 | -- | Enhancer activity assay |
| E_02262 | chr12:4808272~4809572 | umbilical vein | HUVEC-C | -- | Chromatin interaction assay, Enhancer activity assay |
| E_02263 | chr4:111553081~111553310 | heart | HL-1 | atrial fibrillation | Enhancer activity assay |
| E_02264 | chr6:135418600~135418700 | -- | Primary human CD34+ hematopoietic progenitor cells from non-leukemic donor | -- | Functional perturbation assay |
| E_02265 | chr10:177510950~177511040 | thymus | mTEC | -- | Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02266 | chr1:214150857~214151185 | lymphatic vessel | primary human lymphatic endothelial cells | acute myeloid leukemia | Lymphatic enhancer activity; TF binding; TF-site functional dissection |
| E_02267 | chr12:8036824~8048824 | -- | HeLa | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_02268 | chr18:61108475~61108975 | embryo | Csf1r enhancer-deletion mouse | -- | Canonical Csf1r FIRE enhancer; current mm10 interval standardized to chr18:61108475-61108975; in vivo FIRE deletion phenotype; Endogenous enhancer perturbation; In vivo functional validation |
| E_02269 | chr18:61108475~61108975 | skin of body | Csf1r enhancer-deletion mouse | -- | Canonical Csf1r FIRE enhancer; current mm10 interval standardized to chr18:61108475-61108975; in vivo FIRE deletion phenotype; Endogenous enhancer perturbation; In vivo functional validation |
| E_02270 | chr12:8036824~8048824 | -- | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_02271 | chr1:214150511~214151337 | dermis | Primary adult human dermal lymphatic endothelial cells (hLECs) | lymphedema | TF binding assay; Enhancer activity assay |
| E_02272 | chr1:214150511~214151337 | dermis | Primary adult human dermal lymphatic endothelial cells (hLECs) | lymphedema | TF binding assay; Enhancer activity assay |
| E_02273 | chr1:214150857~214151185 | lymphatic vessel | primary human lymphatic endothelial cells | acute myeloid leukemia | Lymphatic enhancer activity; direct TF occupancy; TF-site functional dissection |
| E_02274 | chr1:214150857~214151185 | lymphatic vessel | primary human lymphatic endothelial cells | acute myeloid leukemia | Lymphatic enhancer activity and TF occupancy |
| E_02275 | chr1:214150857~214151185 | lymphatic vessel | primary human lymphatic endothelial cells | acute myeloid leukemia | Lymphatic enhancer activity; direct TF occupancy; TF-site functional dissection |
| E_02276 | chr1:214150857~214151185 | lymphatic vessel | primary human lymphatic endothelial cells | acute myeloid leukemia | Lymphatic enhancer activity; direct TF occupancy; TF-site functional dissection |
| E_02277 | chr1:214150857~214151185 | lymphatic vessel | primary human lymphatic endothelial cells | acute myeloid leukemia | Lymphatic enhancer activity and TF occupancy |
| E_02278 | chr5:44385797~44386845 | outflow tract | C3H/10T1/2 clone 8 | -- | Enhancer activity assay; TF binding assay |
| E_02279 | chr5:44385797~44386845 | outflow tract | C3H/10T1/2 clone 8 | -- | Enhancer activity assay;TF binding assay |
| E_02280 | chr2:164763372~164764407 | placenta | ectoplacental cone | -- | Enhancer activity assay; Cross-species cis-regulatory comparison |
| E_02281 | chr12:8035824~8037824 | -- | HeLa | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_02282 | chr12:8035824~8037824 | -- | HEK-293 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_02283 | chr18:61108475~61108975 | multiple tissues | Csf1r enhancer-deletion mouse | -- | Canonical Csf1r FIRE enhancer; current mm10 interval standardized to chr18:61108475-61108975; in vivo FIRE deletion phenotype |
| E_02284 | chr1:214150511~214151337 | lymphatic vessel | K-562 | Lymphedema | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_02285 | chr1:214150511~214151337 | lymphatic vessel | K-562 | Lymphedema | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_02286 | chr1:214150511~214151337 | lymphatic vessel | K-562 | Lymphedema | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_02287 | chr6:135502600~135502750 | blood | healthy human cohort | -- | GWAS-locus association and expression analysis |
| E_02288 | chr20:48682144~48683144 | colon | SW480 | colorectal carcinoma | Enhancer activity assay, Functional perturbation assay; Disease-variant functional analysis |
| E_02289 | chr8:128748243~128748308 | brain | Neural stem | malignant glioma | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Disease-variant functional analysis |
| E_02290 | chr16:17253000~17253100 | adipose tissue | 3T3-L1 | obesity | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay |
| E_02291 | chr16:17266000~17266100 | adipose tissue | 3T3-L1 | obesity | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay |
| E_02292 | chr8:128750000~129000000 | breast | MCF-7 | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; In vivo functional validation |
| E_02293 | chrX:114038200~114039000 | inner cell mass | WA01 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_02294 | chr16:47657923~47659423 | blood | K-562 | chronic myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay |
| E_02295 | chrX:827128~827691 | lung | Human lung adenocarcinoma cell | acute promyelocytic leukemia | Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_02296 | chr2:104914099~104915125 | testis | Sertoli cells | -- | Enhancer activity assay; Endogenous enhancer perturbation; Chromatin-state profiling |
| E_02297 | chr6:91004796~91006944 | blood | primary human naive B cells | -- | Enhancer activity assay; TF binding assay; Cell-fate functional perturbation assay; Chromatin-state profiling |
| E_02298 | chr14:98602411~98675204 | blood | primary human t(5 | T-cell acute lymphoblastic leukemia | Chromatin interaction assay; Architectural-factor occupancy assay; Functional perturbation assay |
| E_02299 | chr8:128840000~128890000 | kidney | MRT patient-derived organoids (P103) | rhabdoid tumor | Chromatin interaction assay, Enhancer activity assay, TF binding assay, Functional perturbation assay; Chromatin-state profiling |
| E_02300 | chr1:47679000~47722000 | blood | Human chronic myeloid leukemia cell | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay; In vivo functional validation |
| E_02301 | chr6:12826550~12826620 | coronary artery | hESC-derived endothelial cells | myocardial infarction | Regulatory variant functional assay; TF binding assay; Enhancer activity assay; Functional perturbation assay |
| E_02302 | chr8:126800000~126900000 | kidney | MRT patient-derived organoids (P103) | rhabdoid tumor | Chromatin interaction assay, Enhancer activity assay, TF binding assay, Functional perturbation assay; Chromatin-state profiling |
| E_02303 | chr8:129440000~129740000 | kidney | MRT patient-derived organoids (P60) | rhabdoid tumor | Chromatin interaction assay, Enhancer activity assay, TF binding assay, Functional perturbation assay; Chromatin-state profiling |
| E_02304 | chr1:160536893~160537651 | -- | HL-60,293T | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02305 | chr1:160536893~160537651 | -- | HL-60,293T | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02306 | chr1:160536893~160537651 | -- | HL-60,293T | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02307 | chr1:160542651~160543257 | -- | HL-60,293T | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02308 | chr1:160542651~160543257 | -- | HL-60,293T | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02309 | chr1:160542651~160543257 | -- | HL-60,293T | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02310 | chr5:149457542~149458807 | -- | HL-60,293T | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02311 | chr5:149457542~149458807 | -- | HL-60,293T | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02312 | chr5:149457542~149458807 | -- | HL-60,293T | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02313 | chr7:35156394~35156899 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02314 | chr7:35156394~35156899 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02315 | chr7:35156394~35156899 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02316 | chr7:35156394~35156899 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02317 | chr7:35156394~35156899 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02318 | chr7:35156394~35156899 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02319 | chr7:35156536~35156974 | bone marrow | primary myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02320 | chr7:35156536~35156974 | bone marrow | primary myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02321 | chr7:35156536~35156974 | bone marrow | primary myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02322 | chr7:35156536~35156974 | bone marrow | primary myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02323 | chr7:35156536~35156974 | bone marrow | primary myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02324 | chr7:35156536~35156974 | bone marrow | primary myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02325 | chr13:53463266~53463541 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02326 | chr13:53463266~53463541 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02327 | chr13:53463266~53463541 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02328 | chr13:53463266~53463541 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02329 | chr13:53463266~53463541 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02330 | chr13:53463266~53463541 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02331 | chr17:44494486~44495486 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02332 | chr17:44494486~44495486 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02333 | chr17:44494486~44495486 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02334 | chr17:44494486~44495486 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02335 | chr17:44494486~44495486 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02336 | chr17:44494486~44495486 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02337 | chr17:44494598~44494816 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02338 | chr17:44494598~44494816 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02339 | chr17:44494598~44494816 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02340 | chr17:44494598~44494816 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02341 | chr17:44494598~44494816 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02342 | chr17:44494598~44494816 | blood / hematopoietic system | C2C12,Primary Bone Marrow每Mesenchymal Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02343 | chr14:98602411~98675204 | blood | 14) T-ALL cells | T-cell acute lymphoblastic leukemia | Chromatin interaction assay; Architectural-factor occupancy assay; Functional perturbation assay |
| E_02344 | chr6:91004796~91006944 | blood / hematopoietic system | B Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02345 | chr6:12826550~12826620 | aorta | hESC-derived endothelial cells | coronary artery disease | Enhancer activity assay, TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02346 | chr6:12902957~12904957 | coronary artery | HUVEC and hESC-derived endothelial cells | coronary artery disease | TF binding assay; Allele-specific cis-regulatory assay; Functional genome-editing assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02347 | chr13:53476414~53476689 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02348 | chr13:53476414~53476689 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02349 | chr14:98602411~98675204 | blood | RTG-P1 | T-cell acute lymphoblastic leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_02350 | chr7:35156536~35156974 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02351 | chr7:35156536~35156974 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02352 | chr7:35156536~35156974 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02353 | chr7:35156536~35156974 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02354 | chr7:35156536~35156974 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02355 | chr7:35156536~35156974 | bone marrow | Primary mouse myeloid progenitors | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02356 | chr11:5222500~5323700 | blood | K-562 | -- | Enhancer activity assay; Functional perturbation assay |
| E_02357 | chr17:44815967~44816185 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02358 | chr17:44815967~44816185 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02359 | chr13:53476414~53476689 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02360 | chr17:44815967~44816185 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02361 | chr7:134136598~134137038 | bone marrow | 32Dcl3 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; In vivo enhancer deletion assay |
| E_02362 | chr5:149400000~149401000 | bone marrow | Myeloid tissue | -- | Functional perturbation assay |
| E_02363 | chr11:5222500~5323700 | blood | K-562 | -- | Enhancer activity assay; Functional perturbation assay |
| E_02364 | chr11:5222500~5323700 | blood | K-562 | -- | Enhancer activity assay; Functional perturbation assay |
| E_02365 | chr11:5222500~5323700 | blood | K-562 | -- | TF binding assay; Functional perturbation assay |
| E_02366 | chr16:29018500~29021500 | bone marrow | Myeloid tissue | -- | Functional perturbation assay |
| E_02367 | chr7:35156353~35161233 | blood / hematopoietic system | Myeloid Cells | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02368 | chr6:6770399~6771465 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_02369 | chr6:6770399~6771465 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_02370 | chr6:6770399~6771465 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_02371 | chr2:105072843~105076843 | -- | Sertoli cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02372 | chr19:33790000~33793000 | blood | hematopoietic progenitor cells | -- | Enhancer perturbation assay |
| E_02373 | chr8:129631847~129635071 | kidney | HEK293T | IDH-mutant low-grade glioma | Enhancer activity assay; Functional perturbation assay |
| E_02374 | chr16:47658623~47659423 | blood | K-562 | chronic myeloid leukemia | Enhancer activity assay |
| E_02375 | chr17:44819323~44819541 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, TF binding assay |
| E_02376 | chr17:44819323~44819541 | bone element | MC3T3-E1 | -- | Enhancer activity assay, TF binding assay |
| E_02377 | chr17:44819323~44819541 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, TF binding assay |
| E_02378 | chr17:44819323~44819541 | bone element | MC3T3-E1 | -- | Enhancer activity assay, TF binding assay |
| E_02379 | chr17:44819323~44819541 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, TF binding assay |
| E_02380 | chr17:44819323~44819541 | bone element | MC3T3-E1 | -- | Enhancer activity assay, TF binding assay |
| E_02381 | chr17:45201170~45201388 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay |
| E_02382 | chr5:159927785~159928129 | blood | primary peripheral blood mononuclear cells from patients with SLE | systemic lupus erythematosus | Functional perturbation assay; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_02383 | chr3:185824281~185824602 | tongue | CAL-27 | tongue squamous cell carcinoma | Enhancer activity assay, TF binding assay; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02384 | chr11:102245603~102246344 | nasopharynx | 5-8F | nasopharyngeal carcinoma | Enhancer activity; chromatin-regulator binding; functional perturbation; enhancer/reporter validation; In vivo functional validation |
| E_02385 | chr11:102245603~102246344 | nasopharynx | HNE-1 | nasopharyngeal carcinoma | Enhancer activity; chromatin-regulator binding; functional perturbation; enhancer/reporter validation; In vivo functional validation |
| E_02386 | chr7:22755717~22757217 | prostate gland | M2 macrophage | prostate cancer | Enhancer activity assay, Functional perturbation assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02387 | chr1:47644434~47659486 | colon | HT-29 | colorectal cancer | Super enhancer activity assay, Functional perturbation assay; In vivo functional validation |
| E_02388 | chr6:88093745~88094001 | bone marrow | Primary Mouse Bone Marrow Cells | -- | Functional perturbation assay, TF binding assay, Chromatin interaction assay |
| E_02389 | chr12:12769300~12769800 | aorta | JHU006i-1 | coronary artery disease | Enhancer activity assay, Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02390 | chr9:139390200~139390700 | aorta | JHU006i-1 | coronary artery disease | Enhancer activity assay, Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02391 | chr4:56908277~56909126 | aorta | Primary human aortic endothelial cells (HAEC | coronary artery disease | Enhancer activity assay; Allele-specific regulatory assay; Genetic association assay; eQTL colocalization assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02392 | chr3:94294960~94295960 | small intestine | primary mouse type 17 immune cells (Th17, ILC3, ROR污t+ Treg, 污汛T and APC populations) | -- | In vivo causal cis-regulatory deletion; TF-site dissection; Chromatin interaction assay |
| E_02393 | chr3:94294960~94295960 | small intestine | primary mouse type 17 immune cells (Th17, ILC3, ROR污t+ Treg, 污汛T and APC populations) | -- | In vivo causal cis-regulatory deletion; TF-site dissection; Chromatin interaction assay |
| E_02394 | chr3:94294960~94295960 | small intestine | primary mouse type 17 immune cells (Th17, ILC3, ROR污t+ Treg, 污汛T and APC populations) | -- | In vivo causal cis-regulatory deletion; TF-site dissection; Chromatin interaction assay |
| E_02395 | chr7:150955147~150956502 | blood | Primary monocytes | -- | Enhancer activity assay, Functional perturbation assay; Chromatin interaction assay; Chromatin-state profiling |
| E_02396 | chr21:42660000~42661000 | breast | MCF-7 | -- | Functional perturbation assay, Chromatin interaction assay |
| E_02397 | chr21:42660000~42661000 | breast | MCF-7 | -- | Functional perturbation assay, Chromatin interaction assay |
| E_02398 | chr21:42660000~42661000 | breast | MCF-7 | -- | Functional perturbation assay, Chromatin interaction assay |
| E_02399 | chr16:10433585~10433748 | spleen | Bone marrow-derived macrophages | -- | Functional perturbation assay; In vivo functional validation |
| E_02400 | chr16:10480585~10480785 | embryo | Mouse Embryonic Stem Cells (mESCs | -- | Functional perturbation assay |
| E_02401 | chr16:10480585~10480785 | embryo | 129xCast F1 | -- | Functional perturbation assay |
| E_02402 | chr16:10480585~10480785 | embryo | v6.5) | -- | Functional perturbation assay |
| E_02403 | chr2:226999986~227001986 | cornea | primary human corneal epithelial cells | corneal astigmatism | Disease-associated enhancer variant assay; TF binding assay |
| E_02404 | chr17:45890060~45890829 | bone marrow | Bone marrow-derived macrophages | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Chromatin interaction assay |
| E_02405 | chr7:117228049~117229449 | intestine | Caco-2 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02406 | chr7:117228049~117229449 | intestine | Caco-2 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02407 | chr7:117228049~117229449 | intestine | Caco-2 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02408 | chr7:117228049~117229449 | intestine | Caco-2 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02409 | chr9:119378051~119379479 | heart | mouse ventricular conduction system | -- | In vivo enhancer validation; TF-site functional dissection; Disease-variant functional analysis; In vivo functional validation |
| E_02410 | chr9:119378051~119379479 | heart | HL-1 reporter validation | -- | In vivo enhancer validation; TF-site functional dissection; Disease-variant functional analysis; In vivo functional validation |
| E_02411 | chr16:1600000~1600110 | blood | K-562 | -- | Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay; In vivo functional validation |
| E_02412 | chr15:73142260~73142810 | brain | F1 hybrid ESCs / Ngn2-induced neuronal differentiation | -- | Enhancer activation; allele-specific chromatin interaction assay; Chromatin interaction assay |
| E_02413 | chr15:73142260~73142810 | brain | B6--CAST reciprocal-hybrid mouse brain/cortex | -- | Enhancer activation assay; allele-specific chromatin interaction assay |
| E_02414 | chr15:73142260~73142810 | brain | F1 hybrid ESCs | -- | Enhancer activation assay; allele-specific chromatin interaction assay |
| E_02415 | chr15:73142260~73142810 | brain | Ngn2-induced neurons | -- | Enhancer activation assay; allele-specific chromatin interaction assay |
| E_02416 | chr15:73148730~73149280 | brain | F1 hybrid ESCs / Ngn2-induced neuronal differentiation | -- | Enhancer activation; allele-specific chromatin interaction assay; Chromatin interaction assay |
| E_02417 | chr15:73148730~73149280 | brain | B6--CAST reciprocal-hybrid mouse brain/cortex | -- | Enhancer activation assay; allele-specific chromatin interaction assay |
| E_02418 | chr15:73148730~73149280 | brain | F1 hybrid ESCs | -- | Enhancer activation assay; allele-specific chromatin interaction assay |
| E_02419 | chr15:73148730~73149280 | brain | Ngn2-induced neurons | -- | Enhancer activation assay; allele-specific chromatin interaction assay |
| E_02420 | chr6:135323137~135323537 | blood | K-562 | -- | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay; Disease-variant functional analysis |
| E_02421 | chr17:44839209~44839551 | bone element | Primary mouse osteoblasts | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; Disease-variant functional analysis |
| E_02422 | chr4:56908277~56909126 | aorta | Lonza CC-25350) | coronary artery disease | Enhancer activity assay; Allele-specific regulatory assay; Genetic association assay; eQTL colocalization assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02423 | chr2:227000886~227001086 | cornea | primary human corneal epithelial cells | astigmatism | Corneal enhancer mapping; allele-specific reporter; TF occupancy/target regulation |
| E_02424 | chr16:163380~163907 | pleural effusion | K-562 | -- | Enhancer activity assay; TF binding motif functional assay; Functional perturbation assay; Enhanceosome assembly assay; Endogenous enhancer perturbation; TF binding assay; In vivo functional validation |
| E_02425 | chr16:163380~163907 | pleural effusion | K-562 | -- | TF binding assay; Functional perturbation assay; Enhancer repression assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02426 | chr2:226998914~227004586 | cornea | primary human corneal epithelial cells | -- | Enhancer profiling; TF binding assay; Chromatin-state profiling; Disease-variant functional analysis |
| E_02427 | chr6:135321297~135321697 | blood | K-562 | -- | Enhancer activity assay, Functional perturbation assay; Disease-variant functional analysis |
| E_02428 | chr17:44464986~44466986 | -- | Osteoblast-Specific Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02429 | chr17:44464986~44466986 | -- | Osteoblast-Specific Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02430 | chr17:44464986~44466986 | -- | Osteoblast-Specific Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02431 | chr17:44464986~44466986 | -- | Osteoblast-Specific Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02432 | chr17:44464986~44466986 | -- | Osteoblast-Specific Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02433 | chr17:44464986~44466986 | -- | Osteoblast-Specific Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02434 | chr17:44464986~44466986 | -- | Osteoblast-Specific Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02435 | chr9:119469800~119469811 | heart | HL-1 | Cardiac Conduction System Disease | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_02436 | chr9:119469879~119469890 | heart | HL-1 | Cardiac Conduction System Disease | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_02437 | chr9:119469902~119469913 | heart | HL-1 | Cardiac Conduction System Disease | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_02438 | chr4:56908277~56909126 | -- | WTC-CLYBL-dCas9-TagBFP-KRAB-cl391 | coronary artery disease | Enhancer activity assay; Functional perturbation assay; Genetic association assay; eQTL colocalization assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02439 | chr9:119378051~119379479 | heart | ventricular conduction system in vivo | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; In vivo enhancer reporter assay |
| E_02440 | chr11:33944788~33945188 | blood | K-562 | -- | Multiplex endogenous enhancer perturbation with single-cell transcriptomic target mapping; Disease-variant functional analysis |
| E_02441 | chr11:33944788~33945188 | blood | K-562 | -- | Multiplex endogenous enhancer perturbation with single-cell transcriptomic target mapping; Disease-variant functional analysis |
| E_02442 | chr6:135321297~135321697 | blood | K-562 | -- | Multiplex endogenous enhancer perturbation with single-cell transcriptomic target mapping; Disease-variant functional analysis |
| E_02443 | chr6:135323137~135323537 | blood | K-562 | -- | Multiplex endogenous enhancer perturbation with single-cell transcriptomic target mapping; Disease-variant functional analysis |
| E_02444 | chr16:80617~80837 | blood / hematopoietic system | K-562 | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02445 | chr17:31172998~31173656 | bone marrow | Bone marrow-derived macrophages | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay; Chromatin interaction assay |
| E_02446 | chr2:226998914~227004586 | -- | Human Corneal Epithelial Cells | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_02447 | chr17:31172998~31173656 | -- | COS-1 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_02448 | chr17:45890060~45890829 | -- | COS-1 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_02449 | chr2:10860000~10861000 | breast | MCF-7 | -- | Functional perturbation assay |
| E_02450 | chr12:110928658~110929096 | heart | Ventricular cardiomyocytes | -- | Enhancer activity assay; Chromatin interaction assay; Chromatin-state profiling |
| E_02451 | chr12:110931149~110931877 | heart | Ventricular cardiomyocytes | -- | Enhancer activity assay; Chromatin interaction assay; Chromatin-state profiling |
| E_02452 | chr6:31092587~31094587 | cornea | primary human corneal epithelial cells | Stevens-Johnson syndrome-associated corneal phenotype | Disease-associated enhancer variant functional assay |
| E_02453 | chr11:33944788~33945188 | blood | K-562 | -- | Enhancer activity assay, Functional perturbation assay; Disease-variant functional analysis |
| E_02454 | chr12:54304291~54304691 | blood | K-562 | -- | Enhancer activity assay, Functional perturbation assay; Disease-variant functional analysis |
| E_02455 | chr6:31092587~31094587 | cornea | primary human corneal epithelial cells | -- | Enhancer profiling; Enhancer activity assay; Chromatin-state profiling; Disease-variant functional analysis |
| E_02456 | chr17:44838751~44840051 | bone element | Primary mouse osteoblasts | -- | Enhancer activity assay, TF binding assay; Disease-variant functional analysis |
| E_02457 | chr17:44839381~44839469 | bone element | Primary mouse osteoblasts | -- | Enhancer activity assay, TF binding assay; Disease-variant functional analysis |
| E_02458 | chr12:110907461~110909456 | heart | Ventricular cardiomyocytes | -- | Enhancer-promoter linkage analysis; Chromatin accessibility analysis; Chromatin interaction assay; Chromatin-state profiling |
| E_02459 | chr6:31092587~31094587 | -- | Human Corneal Epithelial Cells | -- | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_02460 | chr6:88116954~88117210 | spleen | Primary adult mouse splenic HSPCs from WT, Gata2 -77+/-, and Gata2+/- mice | -- | In vivo endogenous enhancer haploinsufficiency analysis; hematopoietic progenitor survival and cell-cycle analysis; hematopoietic compartment phenotyping |
| E_02461 | chr16:10440279~10442279 | -- | Macrophage | -- | TF-binding/chromatin assay |
| E_02462 | chr3:94384282~94384650 | small intestine | Primary intestinal ILC3 and ROR污t+ antigen-presenting cells | -- | OCR369 endogenous enhancer deletion; RUNX3 binding; enhancer-promoter looping; intestinal immune-homeostasis phenotyping |
| E_02463 | chr1:53893000~53895000 | liver | Hep-G2 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_02464 | chr9:133252439~133252657 | stomach | KATO III | -- | Endogenous enhancer deletion; direct TF binding; enhancer activity and TF dependency; Enhancer activity assay; Endogenous enhancer perturbation; TF binding assay |
| E_02465 | chr2:11623044~11625344 | mammary gland | MCF-7 | breast cancer | Enhancer functional assay; chromatin remodeling assay |
| E_02466 | chr10:128326106~128327832 | embryo | posterior embryonic tissues | -- | Enhancer activity assay; Functional perturbation assay |
| E_02467 | chr7:45416017~45418912 | pituitary gland | LbetaT2 | -- | Enhancer activity assay; Chromatin interaction assay; Chromatin regulator binding assay; Functional perturbation assay; Non-canonical DNA structure assay |
| E_02468 | chr11:97938123~97980122 | skeletal muscle tissue | Myofibers | -- | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay |
| E_02469 | chr11:97938123~97980122 | skeletal muscle tissue | Myofibers | -- | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay |
| E_02470 | chr11:97938123~97980122 | skeletal muscle tissue | Myofibers | -- | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay |
| E_02471 | chr11:97938123~97980122 | skeletal muscle tissue | Myofibers | -- | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay |
| E_02472 | chr11:97938123~97980122 | skeletal muscle tissue | Myofibers | -- | Chromatin interaction assay, Functional perturbation assay, Enhancer activity assay |
| E_02473 | chr9:71241739~71242765 | alimentary part of gastrointestinal system | E14.5 fetal lung | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02474 | chr8:129234315~129239315 | lymph node | EB5 [Mouse ESC] | primary effusion lymphoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_02475 | chr8:129254315~129259315 | lymph node | EB5 [Mouse ESC] | primary effusion lymphoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_02476 | chr8:129278315~129283315 | lymph node | EB5 [Mouse ESC] | primary effusion lymphoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_02477 | chr15:38850262~38850330 | blood | primary human T cells | systemic lupus erythematosus | Allele-specific enhancer activity; enhancer-binding regulator identification; functional perturbation; Enhancer activity assay; TF binding assay; Disease-variant functional analysis |
| E_02478 | chr7:94374796~94376944 | lung | primary human lung fibroblasts from systemic sclerosis patients and healthy controls | systemic sclerosis | Enhancer activity assay; TF binding assay; Functional perturbation assay; Myofibroblast differentiation assay |
| E_02479 | chr7:94374796~94376944 | lung | primary human lung fibroblasts from systemic sclerosis patients and healthy controls | systemic sclerosis | Enhancer activity assay; TF binding assay; Functional perturbation assay; Myofibroblast differentiation assay |
| E_02480 | chr7:150700000~150705000 | -- | Endothelial Cells (ECs) | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02481 | chr7:150700000~150705000 | -- | Endothelial Cells (ECs) | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02482 | chr5:9034150~9036900 | liver | Liver | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02483 | chr5:9034150~9036900 | liver | Liver | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02484 | chr5:9037806~9041881 | liver | Liver | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02485 | chr5:9037806~9041881 | liver | Liver | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02486 | chr5:9038118~9038593 | liver | Liver | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02487 | chr5:9038118~9038593 | liver | Liver | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02488 | chr11:100855351~100856351 | mammary gland | Primary mammary epithelial cells | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02489 | chr2:9593387~9600910 | thymus | primary mouse thymocytes | -- | Enhancer activity assay; TF binding assay; in vivo functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02490 | chr2:9593387~9600910 | thymus | primary mouse thymocytes | -- | Enhancer activity assay; TF binding assay; in vivo functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02491 | chr9:99032500~99033051 | heart | Mouse atrial cardiomyocyte cell | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02492 | chr7:94002773~94005073 | skin of body | Primary human dermal fibroblasts from systemic sclerosis patients | systemic sclerosis | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02493 | chr3:94384282~94384650 | small intestine | MNK-3 ILC3-like cells for mechanistic assays | -- | OCR369 endogenous enhancer deletion; RUNX3 binding; enhancer-promoter looping; intestinal immune-homeostasis phenotyping |
| E_02494 | chr11:32145540~32169344 | -- | ES-E14TG2a | -- | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_02495 | chr11:32145540~32169344 | -- | ES-E14TG2a | -- | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_02496 | chr8:128172101~128172473 | lymph node | SU-DHL-5 | diffuse large B-cell lymphoma | Enhancer activity assay; Functional perturbation assay |
| E_02497 | chr8:128172101~128172473 | lymph node | SU-DHL-5 | diffuse large B-cell lymphoma | Enhancer activity assay; Functional perturbation assay |
| E_02498 | chr8:128172101~128172473 | lymph node | SU-DHL-5 | diffuse large B-cell lymphoma | Enhancer activity assay; Functional perturbation assay |
| E_02499 | chr8:128172101~128172473 | ascitic fluid | HT | diffuse large B-cell lymphoma | Enhancer activity assay; Functional perturbation assay |
| E_02500 | chr8:128172101~128172473 | ascitic fluid | HT | diffuse large B-cell lymphoma | Enhancer activity assay; Functional perturbation assay |
| E_02501 | chr8:128172101~128172473 | ascitic fluid | HT | diffuse large B-cell lymphoma | Enhancer activity assay; Functional perturbation assay |
| E_02502 | chr8:129180000~129190000 | lymph node | Karpas-422 | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_02503 | chr8:129180000~129190000 | lymph node | Karpas-422 | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_02504 | chr8:129180000~129190000 | lymph node | Karpas-422 | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_02505 | chr7:156791087~156791875 | embryonic limb bud | Embryonic limb bud / zone of polarizing activity mesenchyme | Preaxial polydactyly / triphalangeal thumb-polydactyly spectrum | Enhancer activity assay; TF-binding assay; endogenous functional perturbation; developmental phenotyping; Disease-variant functional analysis |
| E_02506 | chr7:156791087~156791875 | embryonic limb bud | human ZRS sequence with endogenous mouse ortholog validation | Preaxial polydactyly / triphalangeal thumb-polydactyly spectrum | Enhancer activity assay; TF-binding assay; endogenous functional perturbation; developmental phenotyping; Disease-variant functional analysis |
| E_02507 | chr7:156791087~156791875 | embryonic limb bud | Embryonic limb-bud/ZPA mesenchyme | Preaxial polydactyly / triphalangeal thumb-polydactyly spectrum | Disease-variant enhancer activity; TF-binding affinity; endogenous developmental perturbation; in vivo phenotyping |
| E_02508 | chr7:156791087~156791875 | embryonic limb bud | human ZRS sequence with endogenous mouse developmental validation | Preaxial polydactyly / triphalangeal thumb-polydactyly spectrum | Disease-variant enhancer activity; TF-binding affinity; endogenous developmental perturbation; in vivo phenotyping |
| E_02509 | chr7:156791087~156791875 | embryonic limb bud | Embryonic limb-bud/ZPA mesenchyme | Preaxial polydactyly / triphalangeal thumb-polydactyly spectrum | Disease-variant enhancer activity; TF-binding affinity; endogenous developmental perturbation; in vivo phenotyping |
| E_02510 | chr7:156791087~156791875 | embryonic limb bud | human ZRS sequence with endogenous mouse developmental validation | Preaxial polydactyly / triphalangeal thumb-polydactyly spectrum | Disease-variant enhancer activity; TF-binding affinity; endogenous developmental perturbation; in vivo phenotyping |
| E_02511 | chr7:156791087~156791875 | embryonic limb bud | Embryonic limb-bud/ZPA mesenchyme | Preaxial polydactyly / triphalangeal thumb-polydactyly spectrum | Disease-variant enhancer activity; TF-binding affinity; endogenous developmental perturbation; in vivo phenotyping |
| E_02512 | chr7:156791087~156791875 | embryonic limb bud | human ZRS sequence with endogenous mouse developmental validation | Preaxial polydactyly / triphalangeal thumb-polydactyly spectrum | Disease-variant enhancer activity; TF-binding affinity; endogenous developmental perturbation; in vivo phenotyping |
| E_02513 | chr14:56245000~56285000 | -- | Endothelial Cells (ECs) | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02514 | chr14:56245000~56285000 | -- | Endothelial Cells (ECs) | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02515 | chr6:128542796~128543720 | kidney | Conventional dendritic cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, In vivo functional assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02516 | chr6:128542796~128543720 | kidney | Conventional dendritic cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, In vivo functional assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02517 | chr6:128542796~128543720 | kidney | Conventional dendritic cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, In vivo functional assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02518 | chr6:128542796~128543720 | kidney | Conventional dendritic cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, In vivo functional assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02519 | chr6:128542796~128543720 | kidney | Conventional dendritic cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, In vivo functional assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02520 | chr6:128542796~128543720 | kidney | Conventional dendritic cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, In vivo functional assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02521 | chr6:128542796~128543720 | kidney | Conventional dendritic cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, In vivo functional assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02522 | chr6:128542796~128543720 | kidney | Conventional dendritic cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, In vivo functional assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02523 | chr6:128542796~128543720 | kidney | Conventional dendritic cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, In vivo functional assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; In vivo functional validation |
| E_02524 | chr11:69329684~69330954 | breast | MCF-7 | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation; Disease-associated enhancer analysis |
| E_02525 | chr11:69329684~69330954 | breast | T-47D | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation; Disease-associated enhancer analysis |
| E_02526 | chr7:94002773~94005073 | -- | Fibroblasts | systemic sclerosis | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_02527 | chr7:94002773~94005073 | -- | Fibroblasts | systemic sclerosis | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_02528 | chr17:69107686~69108045 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay; Enhancer activity assay; Disease-variant functional analysis |
| E_02529 | chr6:35666288~35666763 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_02530 | chr6:35666288~35666763 | prostate gland | VCaP | prostate cancer | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin regulatory assay; In vivo functional validation |
| E_02531 | chr6:35677658~35677924 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_02532 | chr6:35677658~35677924 | prostate gland | VCaP | prostate cancer | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin regulatory assay; In vivo functional validation |
| E_02533 | chr6:35686677~35687097 | prostate gland | LNCaP | prostate cancer | TF binding assay; Enhancer activity assay; Functional perturbation assay; In vivo functional validation |
| E_02534 | chr6:35686677~35687097 | prostate gland | VCaP | prostate cancer | TF binding assay; Enhancer activity assay; Functional perturbation assay; In vivo functional validation |
| E_02535 | chr5:28395077~28395877 | forelimb bud | Embryonic limb bud mesenchymal cells | -- | Enhancer activity assay, TF binding assay; Disease-variant functional analysis |
| E_02536 | chr10:128326106~128327832 | embryo | Mouse embryos (E8.5-E9.5 | -- | Enhancer activity assay; Functional perturbation assay |
| E_02537 | chr10:128326106~128327832 | embryo | Gdf11 WT and HCR-deficient mice) | -- | Enhancer activity assay; Functional perturbation assay |
| E_02538 | chr15:38850262~38850330 | blood | Jurkat E6.1 | systemic lupus erythematosus | Allele-specific enhancer activity; enhancer-binding regulator identification; functional perturbation; Enhancer activity assay; TF binding assay; Disease-variant functional analysis |
| E_02539 | chr6:36635000~36635100 | skin of prepuce of penis | BJ [Human fibroblast] | -- | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_02540 | chr6:36635000~36635100 | skin of body | BJ-hTERT-indRASG12V fibroblasts | -- | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_02541 | chr11:69329684~69330954 | colon | HCT 116 | -- | Enhancer activity assay; Endogenous enhancer perturbation |
| E_02542 | chr2:9515156~9522270 | thymus | Thymocytes (ETP/DN/DP/CD4 SP) | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02543 | chr11:32145028~32146147 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02544 | chr11:32145028~32146147 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02545 | chr11:32145028~32146147 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02546 | chr11:32145028~32146147 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02547 | chr11:32145028~32146147 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02548 | chr11:32145028~32146147 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02549 | chr11:32145028~32146147 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02550 | chr11:32145028~32146147 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02551 | chr11:32150550~32151858 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02552 | chr11:32150550~32151858 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02553 | chr11:32150550~32151858 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02554 | chr11:32150550~32151858 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02555 | chr11:32150550~32151858 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02556 | chr11:32150550~32151858 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02557 | chr11:32150550~32151858 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02558 | chr11:32150550~32151858 | -- | ES-E14TG2a | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02559 | chr15:38850022~38850502 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02560 | chr6:36634056~36636070 | skin of prepuce of penis | BJ [Human fibroblast] | -- | Enhancer activity assay; TF binding assay; Enhancer RNA assay; Functional perturbation assay; Oncogene-induced senescence assay |
| E_02561 | chr6:36634056~36636070 | foreskin | BJ [Human fibroblast] | -- | Pooled enhancer screen; endogenous enhancer perturbation; reporter validation; target-gene and senescence phenotype validation |
| E_02562 | chr6:36631690~36640853 | -- | BJ | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_02563 | chr6:36640690~36643070 | -- | BJ | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_02564 | chr6:127006796~127007720 | bone | in vivo mouse tissues | chronic kidney disease | Enhancer discovery; endogenous enhancer deletion; stimulus-response and in vivo phenotypic validation |
| E_02565 | chr9:99032500~99033051 | heart | neonatal rat ventricular cardiomyocytes | -- | Enhancer activity assay; Functional perturbation assay; TF binding assay |
| E_02566 | chr11:9746900~9747200 | mammary gland | Primary MECs | -- | Functional perturbation assay |
| E_02567 | chr2:116230440~116232740 | mammary gland | BT-474 | Breast invasive carcinoma | Luciferase reporter assay, loss-of-function ASO/shRNA knockdown, ChIP-qPCR, Pol II ChIA-PET chromatin interaction |
| E_02568 | chr2:116230440~116232740 | mammary gland | MCF-7 | Breast invasive carcinoma | Luciferase reporter assay, loss-of-function ASO/shRNA knockdown, ChIP-qPCR, Pol II ChIA-PET chromatin interaction |
| E_02569 | chr2:116230440~116232740 | mammary gland | BT-474 | Breast invasive carcinoma | Luciferase reporter assay, loss-of-function ASO/shRNA knockdown, ChIP-qPCR, Pol II ChIA-PET chromatin interaction |
| E_02570 | chr2:116230440~116232740 | mammary gland | MCF-7 | Breast invasive carcinoma | Luciferase reporter assay, loss-of-function ASO/shRNA knockdown, ChIP-qPCR, Pol II ChIA-PET chromatin interaction |
| E_02571 | chr17:69107686~69108045 | prostate gland | prostate cancer cells and primary prostate tissues | prostate cancer | Risk-enhancer mapping; TF occupancy; enhancer-promoter looping |
| E_02572 | chr8:128172101~128172473 | inguinal part of abdomen | BJAB | diffuse large B-cell lymphoma | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02573 | chr7:156791087~156791875 | developing limb | ZRS transgenic developmental model | polydactyly | Enhancer activity assay; TF-binding-affinity assay; enhancer variant functional assay; developmental phenotype assay |
| E_02574 | chr6:127006796~127007720 | kidney | Bone marrow-derived mesenchymal stem cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_02575 | chr6:127006796~127007720 | kidney | Bone marrow-derived mesenchymal stem cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_02576 | chr6:127006796~127007720 | kidney | Bone marrow-derived mesenchymal stem cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_02577 | chr6:127006796~127007720 | kidney | Bone marrow-derived mesenchymal stem cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_02578 | chr6:127006796~127007720 | kidney | Bone marrow-derived mesenchymal stem cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_02579 | chr6:127006796~127007720 | kidney | Bone marrow-derived mesenchymal stem cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_02580 | chr6:127006796~127007720 | kidney | Bone marrow-derived mesenchymal stem cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_02581 | chr6:127006796~127007720 | kidney | Bone marrow-derived mesenchymal stem cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_02582 | chr6:127006796~127007720 | kidney | Bone marrow-derived mesenchymal stem cells | chronic kidney disease | Functional genomics assay, Epigenomic profiling assay, Genome editing assay, Transcriptional regulation assay, In vivo functional assay |
| E_02583 | chr6:126984000~126986000 | bone tissue | IDG-SW3 | chronic kidney disease | Candidate enhancer identification; Epigenomic profiling; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_02584 | chr6:127030000~127032000 | bone tissue | IDG-SW3 | chronic kidney disease | Candidate enhancer identification; Epigenomic profiling; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_02585 | chr6:127006796~127007720 | bone | osteocytes | chronic kidney disease | Enhancer discovery; endogenous enhancer deletion; stimulus-response and in vivo phenotypic validation |
| E_02586 | chr7:155594277~155595077 | forelimb bud | Embryonic limb bud mesenchymal cells | -- | Functional perturbation assay, Enhancer activity assay; Disease-variant functional analysis |
| E_02587 | chr15:38850022~38850502 | kidney | HEK293 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02588 | chr6:127033997~127036097 | kidney | Osteocyte Cell Lines | chronic kidney disease | TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_02589 | chr6:127033997~127036097 | kidney | Osteocyte Cell Lines | chronic kidney disease | TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_02590 | chr17:69108466~69108765 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay; Enhancer activity assay; Disease-variant functional analysis |
| E_02591 | chr11:100859351~100885169 | -- | Mammary Epithelium | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_02592 | chr2:10136078~10138078 | blood / hematopoietic system | T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02593 | chr2:10136078~10138078 | blood / hematopoietic system | T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02594 | chr2:10136078~10138078 | blood / hematopoietic system | T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02595 | chr17:69107686~69108045 | prostate gland | LNCaP | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_02596 | chr17:69107686~69108045 | prostate gland | LNCaP | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_02597 | chr17:69108466~69108765 | prostate gland | LNCaP | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_02598 | chr17:69108466~69108765 | prostate gland | LNCaP | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_02599 | chr17:69107686~69108045 | prostate gland | VCaP | prostate cancer | TF binding assay; High-throughput regulatory profiling; Enhancer activity assay; Disease-variant functional analysis |
| E_02600 | chr7:94002773~94005073 | skin of body | Primary human dermal fibroblasts from systemic sclerosis patients | systemic sclerosis | TF binding assay; Enhancer activity assay |
| E_02601 | chr7:94002773~94005073 | connective tissue | primary dermal fibroblasts | systemic sclerosis | Enhancer activity assay; TF binding assay; Gene-expression perturbation assay |
| E_02602 | chr7:94002773~94005073 | connective tissue | primary dermal fibroblasts | systemic sclerosis | Enhancer activity assay; TF binding assay; Gene-expression perturbation assay |
| E_02603 | chr9:71241739~71242765 | alimentary part of gastrointestinal system | mouse embryonic mesendoderm | -- | Enhancer activity assay; TF binding assay |
| E_02604 | chr15:38845678~38847678 | blood | Jurkat E6.1 | systemic lupus erythematosus | Genetic fine-mapping; allele-specific enhancer activity; Enhancer activity assay; Disease-variant functional analysis |
| E_02605 | chr15:38846389~38846967 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_02606 | chr6:35630433~35630733 | prostate gland | LNCaP | prostate cancer | Androgen-responsive enhancer assay; AR occupancy; chromatin-remodeling analysis; target-gene perturbation |
| E_02607 | chr6:35630433~35630733 | prostate gland | LNCaP | prostate cancer | AR enhancer subsite validation; chromatin recruitment analysis |
| E_02608 | chr6:35630433~35630733 | prostate gland | VCaP | prostate cancer | Androgen-responsive enhancer assay; AR occupancy; chromatin-remodeling analysis; target-gene perturbation |
| E_02609 | chr6:35630433~35630733 | prostate gland | VCaP | prostate cancer | AR enhancer subsite validation; chromatin recruitment analysis |
| E_02610 | chr6:35641433~35641733 | prostate gland | LNCaP | prostate cancer | Androgen-responsive enhancer assay; AR occupancy; chromatin-remodeling analysis; target-gene perturbation |
| E_02611 | chr6:35641433~35641733 | prostate gland | LNCaP | prostate cancer | AR enhancer subsite validation; chromatin recruitment analysis |
| E_02612 | chr6:35641433~35641733 | prostate gland | VCaP | prostate cancer | Androgen-responsive enhancer assay; AR occupancy; chromatin-remodeling analysis; target-gene perturbation |
| E_02613 | chr6:35641433~35641733 | prostate gland | VCaP | prostate cancer | AR enhancer subsite validation; chromatin recruitment analysis |
| E_02614 | chr15:58038775~58039647 | alimentary part of gastrointestinal system | -- | -- | Enhancer activity assay; Comparative enhancer analysis |
| E_02615 | chr7:94002773~94005073 | lung | Lung Myofibroblast | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_02616 | chr9:99131669~99132862 | heart | Ventricular Cardiomyocytes (NRVMs) | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_02617 | chr15:38846389~38846967 | kidney | HEK293 | -- | Enhancer activity assay |
| E_02618 | chr7:156791087~156791875 | limb bud | -- | polydactyly of a triphalangeal thumb | TF binding assay; Disease-associated enhancer variant analysis; Disease-variant functional analysis |
| E_02619 | chr7:156791087~156791875 | limb bud | -- | polydactyly of a triphalangeal thumb | TF binding assay; Disease-associated enhancer variant analysis; Disease-variant functional analysis |
| E_02620 | chr7:45416017~45418912 | pituitary gland | AlphaT3-1 | -- | Chromatin interaction assay; Hormonal response assay; Enhancer-associated RNA expression assay |
| E_02621 | chr2:11623044~11625344 | mammary gland | BT-474 | breast cancer | Enhancer functional assay; chromatin remodeling assay |
| E_02622 | chr7:45416017~45418912 | pituitary gland | Primary pituitary gonadotrope-derived cells from male and female mice | -- | Enhancer-associated eRNA validation; Physiological regulatory assay |
| E_02623 | chr1:204379236~204380236 | bone marrow | NCI-H929 | plasma cell myeloma | Super enhancer activity assay, Functional perturbation assay |
| E_02624 | chr13:28840000~28850000 | blood | SEM | KMT2A-rearranged acute lymphoblastic leukemia | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay |
| E_02625 | chr13:28840000~28850000 | blood | SEM | KMT2A-rearranged acute lymphoblastic leukemia | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin interaction assay |
| E_02626 | chr2:38181326~38182075 | heart | injured adult zebrafish cardiac endothelial cells | -- | Enhancer activity assay; TF-motif binding assay; Endogenous functional perturbation assay |
| E_02627 | chr9:36980000~37150820 | pleural effusion | SU-DHL-10 | diffuse large B-cell lymphoma | Super-enhancer retargeting; Chromatin interaction assay; Functional perturbation assay |
| E_02628 | chr17:63643401~63643706 | kidney | mIMCD3 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; In vivo enhancer editing |
| E_02629 | chr11:57660605~57661348 | heart left ventricle | mouse embryonic left ventricular myocardium and ventricular conduction system | acute promyelocytic leukemia | In vivo enhancer activity assay; endogenous enhancer perturbation assay; regulatory variant functional assay; cardiac electrophysiology; Endogenous enhancer perturbation; TF binding assay; Disease-variant functional analysis; In vivo functional validation |
| E_02630 | chr8:128754419~128756419 | colon | HCT 116 | colorectal cancer | Enhancer activity assay; Functional perturbation assay; TF binding assay |
| E_02631 | chr16:15600300~15601300 | prostate gland | VCaP | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02632 | chr4:147962887~147964479 | heart | 293T | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_02633 | chr4:147962887~147964479 | heart | 293T | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_02634 | chr6:53306407~53314482 | bone marrow | Primary pediatric T-ALL bone marrow cells | T-cell acute lymphoblastic leukemia | Super-enhancer identification assay; Chromatin-state profiling; In vivo functional validation |
| E_02635 | chr17:37648901~37649206 | kidney | Kidney Tubule Primary Cells | -- | Enhancer activity assay, TF binding assay |
| E_02636 | chr4:147333142~147344738 | heart | mouse ventricular myocardium | -- | In vivo enhancer-cluster genetic dissection; chromatin topology analysis; enhancer-subdomain perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_02637 | chr4:147333142~147344738 | heart | mouse ventricular myocardium | -- | In vivo enhancer-cluster genetic dissection; chromatin topology analysis; enhancer-subdomain perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_02638 | chr4:147333142~147344738 | heart | mouse ventricular myocardium | -- | In vivo enhancer-cluster genetic dissection; chromatin topology analysis; enhancer-subdomain perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_02639 | chr4:147333142~147344738 | heart | mouse ventricular myocardium | -- | In vivo enhancer-cluster genetic dissection; chromatin topology analysis; enhancer-subdomain perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_02640 | chr4:147333142~147344738 | heart | mouse ventricular myocardium | -- | In vivo enhancer-cluster genetic dissection; chromatin topology analysis; enhancer-subdomain perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_02641 | chr4:147333142~147344738 | heart | mouse ventricular myocardium | -- | In vivo enhancer-cluster genetic dissection; chromatin topology analysis; enhancer-subdomain perturbation; Endogenous enhancer perturbation; In vivo functional validation |
| E_02642 | chr12:68434020~68435020 | blood | CCR5+ Th1 effector memory CD4+ T cells | -- | Chromatin interaction assay; TF binding assay; Functional perturbation assay |
| E_02643 | chr12:68551520~68552520 | blood | CCR5+ Th1 effector memory CD4+ T cells | -- | Chromatin interaction assay; TF binding assay; Functional perturbation assay |
| E_02644 | chr12:68616020~68617020 | blood | CCR5+ Th1 effector memory CD4+ T cells | -- | Chromatin interaction assay; TF binding assay; Functional perturbation assay |
| E_02645 | chr6:31247578~31247900 | embryo | WA01 | -- | CRISPR screen; enhancer activity assay; functional perturbation assay; Endogenous enhancer perturbation |
| E_02646 | chr22:24236392~24237411 | blood | CCRF-CEM C7A | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Functional perturbation assay |
| E_02647 | chr14:55525638~55525795 | retina | mouse retina in vivo | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_02648 | chr7:19411994~19412088 | skeletal muscle tissue | MM14 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin-state profiling |
| E_02649 | chr7:19411994~19412088 | skeletal muscle tissue | MM14 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin-state profiling |
| E_02650 | chr7:19145920~19146014 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; TF binding assay; Chromatin-state profiling |
| E_02651 | chr6:53306407~53314482 | blood | J.gamma1 | T-cell acute lymphoblastic leukemia | Super-enhancer identification assay; Functional perturbation assay; Transcriptomic pathway analysis; Chromatin-state profiling; In vivo functional validation |
| E_02652 | chr6:53306407~53314482 | blood | J.gamma1 | T-cell acute lymphoblastic leukemia | Super-enhancer identification assay; Enhancer chromatin-state assay; Functional perturbation assay; Chromatin-state profiling; In vivo functional validation |
| E_02653 | chr6:31139599~31139921 | embryo | WA01 | -- | High-throughput cis-regulatory screen; enhancer activity assay; endogenous enhancer deletion; Endogenous enhancer perturbation |
| E_02654 | chr6:31139599~31139921 | embryonic stem-cell culture | WA01 | -- | High-throughput cis-regulatory screen; endogenous functional perturbation; enhancer activity assay |
| E_02655 | chr11:75210000~75210304 | retina | Primary Retinal Cells | -- | Enhancer activity assay; In vivo functional validation |
| E_02656 | chr6:30646843~30647217 | embryo | WA01 | -- | High-throughput cis-regulatory screen; endogenous cis-regulatory perturbation; Endogenous enhancer perturbation |
| E_02657 | chr6:31126537~31126685 | embryo | WA01 | -- | High-throughput cis-regulatory screen; endogenous cis-regulatory perturbation; Endogenous enhancer perturbation |
| E_02658 | chr14:55525638~55525795 | retina | mouse retina in vivo | -- | Enhancer activity assay; TF binding assay; In vivo functional validation |
| E_02659 | chr14:55525638~55525795 | retina | mouse retina in vivo | -- | Enhancer activity assay; TF binding assay; In vivo functional validation |
| E_02660 | chr14:55525638~55525795 | retina | mouse retina in vivo | -- | Enhancer activity assay; TF binding assay; In vivo functional validation |
| E_02661 | chr6:30646843~30647217 | embryonic stem-cell culture | WA01 | -- | High-throughput cis-regulatory screen; endogenous functional perturbation; enhancer activity assay |
| E_02662 | chr6:31126537~31126685 | embryonic stem-cell culture | WA01 | -- | High-throughput cis-regulatory screen; endogenous functional perturbation; enhancer activity assay |
| E_02663 | chr6:31139599~31139921 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; Chromatin interaction assay; Endogenous enhancer perturbation; Genetic-variant functional analysis; In vivo functional validation |
| E_02664 | chr6:30904342~30904788 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02665 | chr6:30646843~30647217 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02666 | chr6:31126537~31126685 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02667 | chr7:19411995~19412089 | skeletal muscle tissue | MM14 skeletal muscle cells | -- | Enhancer activity assay; TF binding assay; transgenic functional validation |
| E_02668 | chr7:19411995~19412089 | skeletal muscle tissue | MM14 skeletal muscle cells | -- | Enhancer activity assay; TF binding assay; transgenic functional validation |
| E_02669 | chr7:19411995~19412089 | skeletal muscle tissue | MM14 skeletal muscle cells | -- | Enhancer activity assay; TF binding assay; transgenic functional validation |
| E_02670 | chr12:68482000~68483000 | blood | CD4+ Th1 T Cells | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_02671 | chr12:68546500~68547500 | blood | CD4+ Th1 T Cells | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_02672 | chr12:68664000~68665000 | blood | CD4+ Th1 T Cells | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay |
| E_02673 | chr11:57660605~57661348 | left cardiac ventricle | genetically engineered mouse embryos and adult mice | -- | In vivo enhancer activity assay; TF binding assay; Functional enhancer deletion assay; Regulatory variant functional assay |
| E_02674 | chr6:30754822~30755196 | inner cell mass | WA01 | -- | Functional perturbation assay, Genetic screen; Endogenous enhancer perturbation |
| E_02675 | chr6:30904342~30904788 | inner cell mass | WA01 | -- | Functional perturbation assay, Genetic screen; Endogenous enhancer perturbation |
| E_02676 | chr6:31234516~31234664 | inner cell mass | WA01 | -- | Functional perturbation assay, Genetic screen; Endogenous enhancer perturbation |
| E_02677 | chr22:24236392~24237411 | synovium | primary rheumatoid arthritis fibroblast-like synoviocytes | rheumatoid arthritis | Enhancer activity assay; Chromatin accessibility assay |
| E_02678 | chr14:55518040~55518674 | brain | HEK-293 | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02679 | chr14:55518040~55518674 | brain | HEK-293 | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02680 | chr14:55518040~55518674 | brain | HEK-293 | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02681 | chr14:55518040~55518674 | brain | HEK-293 | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02682 | chr22:24236570~24237410 | layer of synovial tissue | primary rheumatoid-arthritis fibroblast-like synoviocytes / SW982 | rheumatoid arthritis | Cell-type-specific intronic enhancer mapping; cis-element mutagenesis; TF-binding assay; TF binding assay |
| E_02683 | chr22:24236392~24237411 | blood | THP-1 | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay |
| E_02684 | chr14:55524862~55525285 | retina | mouse retina in vivo | -- | Promoter/enhancer cis-regulatory analysis; TF-binding analysis |
| E_02685 | chr14:55525638~55525920 | retina | mouse retina in vivo | -- | In vivo enhancer/promoter dissection; TF-binding analysis |
| E_02686 | chr14:55525638~55525920 | retina | mouse retina in vivo | -- | In vivo enhancer/promoter dissection; TF-binding analysis |
| E_02687 | chr7:19409838~19410044 | skeletal muscle tissue | MM14 | -- | Enhancer activity assay; TF binding assay; Chromatin-state profiling |
| E_02688 | chr7:19409838~19410044 | skeletal muscle tissue | MM14 | -- | Enhancer activity assay; TF binding assay; Chromatin-state profiling |
| E_02689 | chr22:24236570~24237410 | blood | HEK293T | -- | Cell-type-specific intronic enhancer mapping; cis-element mutagenesis; TF-binding assay; TF binding assay |
| E_02690 | chr22:24236570~24237410 | blood | THP-1 | -- | Cell-type-specific intronic enhancer mapping; cis-element mutagenesis; TF-binding assay; TF binding assay |
| E_02691 | chr22:24236392~24237411 | kidney | HEK293T | -- | Enhancer activity assay; TF binding assay |
| E_02692 | chr22:24236570~24237410 | blood | CCRF-CEM C7A | -- | Cell-type-specific intronic enhancer mapping; cis-element mutagenesis; TF-binding assay |
| E_02693 | chr22:24236392~24237411 | -- | SW982 | -- | Enhancer activity assay |
| E_02694 | chr22:24236392~24237411 | blood | THP-1 | rheumatoid arthritis | Enhancer activity assay |
| E_02695 | chr22:24236392~24237411 | kidney | HEK293T | rheumatoid arthritis | Enhancer activity assay |
| E_02696 | chr22:24236392~24237411 | layer of synovial tissue | SW982 | rheumatoid arthritis | Enhancer activity assay |
| E_02697 | chr22:24236392~24237411 | -- | CEMC7A | rheumatoid arthritis | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_02698 | chr22:24236392~24237411 | -- | THP-1 | rheumatoid arthritis | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_02699 | chr22:24236392~24237411 | -- | 293T | rheumatoid arthritis | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_02700 | chr22:24236392~24237411 | -- | SW982 | rheumatoid arthritis | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_02701 | chr14:55525638~55525920 | retina | mouse retina in vivo | -- | In vivo enhancer/promoter dissection; TF binding |
| E_02702 | chr7:19409838~19410044 | -- | MM14 | -- | TF-binding/chromatin assay |
| E_02703 | chr11:112217279~112217835 | gonad | Embryonic gonadal cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02704 | chr1:32753965~32762956 | liver | Hep-G2 | hepatocellular carcinoma | Super-enhancer activity assay; Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_02705 | chr1:32753965~32762956 | liver | Huh-7 | hepatocellular carcinoma | Super-enhancer activity assay; Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation; Chromatin-state profiling; In vivo functional validation |
| E_02706 | chr11:112200000~112204700 | mesonephric smooth muscle tissue | Embryonic gonad cells (E11.5) | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02707 | chr20:49345710~49345732 | heart | AC16 [Human hybrid cardiomyocyte] | familial ST-depression syndrome | Enhancer activity assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02708 | chr14:78613540~78616951 | bone tissue | Primary calvaria-derived osteoblasts from WT and RL-D4-KO mice | periodontitis | Functional enhancer perturbation assay; Target-gene expression assay; In vivo disease phenotype validation; TF binding evidence; Endogenous enhancer perturbation; In vivo functional validation |
| E_02709 | chr14:78376100~78379511 | bone tissue | Primary calvaria-derived osteoblasts from WT and RL-D4-KO mice | periodontitis | Functional enhancer perturbation assay; Target-gene expression assay; In vivo disease phenotype validation; TF binding evidence; Endogenous enhancer perturbation; In vivo functional validation |
| E_02710 | chr2:169760000~169760653 | pancreas | Pancreatic islet cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02711 | chr1:42614062~42616745 | colon | HCT 116 | colorectal cancer | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation; Chromatin-state profiling |
| E_02712 | chr2:11633299~11641134 | breast | MCF-7 | Breast Cancer | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_02713 | chr16:163380~163907 | blood | Primary human CD34+ HSPC-derived erythroid cells | alpha thalassemia spectrum | Enhancer activity assay; TF binding assay; Functional perturbation assay; Gene expression assay; Chromatin-state assay |
| E_02714 | chr16:163380~163907 | blood | Primary human CD34+ HSPC-derived erythroid cells | alpha thalassemia spectrum | Enhancer activity assay; TF binding assay; Functional perturbation assay; Gene expression assay; Chromatin-state assay |
| E_02715 | chr17:26076200~26076350 | liver | Primary human hepatocyte | -- | Enhancer activity assay; Endogenous enhancer perturbation; Chromatin interaction assay; In vivo functional validation |
| E_02716 | chr1:42614062~42616745 | bone marrow | Primary AML blasts | acute myeloid leukemia | Enhancer activity assay, Functional perturbation assay |
| E_02717 | chr8:29256000~29256500 | breast | MCF-7 | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Disease-variant functional analysis |
| E_02718 | chr12:61890000~61895000 | uterine cervix | Human cervical adenocarcinoma cell | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Disease-variant functional analysis |
| E_02719 | chr12:61890000~61895000 | uterine cervix | Human cervical adenocarcinoma cell | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Disease-variant functional analysis |
| E_02720 | chr12:61890000~61895000 | uterine cervix | Human cervical adenocarcinoma cell | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Disease-variant functional analysis |
| E_02721 | chr12:2880430~3018116 | uterine cervix | HeLa | cervical cancer | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay |
| E_02722 | chr12:2880430~3018116 | breast | MCF-7 | breast carcinoma | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay |
| E_02723 | chr11:44390082~44390626 | bone marrow | Primary bone marrow-derived macrophages | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02724 | chr12:2880430~3018116 | bone tissue | U2OS | osteosarcoma | Functional perturbation assay, Chromatin interaction assay, Enhancer activity assay |
| E_02725 | chr7:66375715~66378251 | face | Primary mouse embryonic face tissue (e10.5-e15.5 | -- | Enhancer activity assay; Cell-type-resolved enhancer activity assay; In vivo functional validation |
| E_02726 | chr8:98367000~98370806 | face | Primary human embryonic face tissue (CS13-CS23) | -- | Enhancer activity assay; Cross-species functional comparison; In vivo functional validation |
| E_02727 | chr15:34751000~34754612 | face | Primary mouse embryonic face tissue | -- | Enhancer activity assay; Cross-species functional comparison; In vivo functional validation |
| E_02728 | chr20:61300000~61600000 | blood | REC-1 | breast cancer | Chromatin interaction assay, Functional perturbation assay |
| E_02729 | chr10:24116247~24118247 | cartilage tissue | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay; Enhancer activity assay |
| E_02730 | chr10:24179247~24181247 | articular cartilage of joint | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay; Enhancer activity assay |
| E_02731 | chr10:24214247~24216247 | dermis | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay; Enhancer activity assay |
| E_02732 | chr10:24115343~24117739 | cartilage tissue | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay; Enhancer activity assay |
| E_02733 | chr10:24177496~24180069 | articular cartilage of joint | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay; Enhancer activity assay |
| E_02734 | chr10:24212605~24214888 | dermis | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay; Enhancer activity assay |
| E_02735 | chr10:79521460~79522010 | dermis | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay; Enhancer activity assay |
| E_02736 | chr10:79544630~79545180 | articular cartilage of joint | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay; Enhancer activity assay |
| E_02737 | chr10:79567820~79568370 | cartilage tissue | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay; Enhancer activity assay |
| E_02738 | chr7:143459000~143459700 | embryonic mesenchyme / fibroblast model | Immortalized and primary mouse embryonic fibroblasts | -- | FOXD1-responsive Cdkn1c intronic reporter element; candidate enhancer evidence only (no endogenous enhancer deletion in this paper) |
| E_02739 | chr18:24562000~24562200 | embryo | ESCs | -- | Functional perturbation assay |
| E_02740 | chr18:24570000~24570200 | embryo | ESCs | -- | Functional perturbation assay |
| E_02741 | chr8:109142000~109142200 | embryo | ESCs | -- | Functional perturbation assay |
| E_02742 | chr8:109150000~109150200 | embryo | ESCs | -- | Functional perturbation assay |
| E_02743 | chr8:84177152~84178151 | embryo | tetON Foxd3 mouse embryonic stem cells | -- | Enhancer activity assay; TF binding assay; Enhancer decommissioning assay; Functional perturbation assay |
| E_02744 | chr10:51546800~51547317 | uterine cervix | HeLa | cervical cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_02745 | chr10:51546800~51547317 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02746 | chr10:51546800~51547317 | uterine cervix | HeLa | cervical cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_02747 | chr10:51546800~51547317 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02748 | chr10:51546800~51547317 | uterine cervix | HeLa | cervical cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_02749 | chr10:51546800~51547317 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02750 | chr10:51546800~51547317 | uterine cervix | HeLa | cervical cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_02751 | chr10:51546800~51547317 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02752 | chr11:101981958~101982582 | colon | HCT 116 | colorectal carcinoma | Enhancer activity assay;TF binding assay;functional perturbation assay |
| E_02753 | chr12:114701207~114704691 | heart | Primary cardiomyocytes | -- | Enhancer activity assay; Disease-variant functional analysis; In vivo functional validation |
| E_02754 | chr6:35505138~35511492 | lung | A549 | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02755 | chr6:35505138~35511492 | lung | VCaP | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02756 | chr6:35616283~35622638 | lung | A549 | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02757 | chr6:35616283~35622638 | lung | VCaP | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02758 | chr6:35636622~35642872 | lung | A549 | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02759 | chr6:35636622~35642872 | lung | VCaP | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02760 | chr1:41975300~41976076 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02761 | chr1:134976575~134977476 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02762 | chr1:140396600~140397726 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02763 | chr1:165828000~165828801 | midbrain | E11.5 mouse embryonic midbrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02764 | chr1:167864800~167866051 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02765 | chr1:192551300~192552876 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02766 | chr2:137073600~137074376 | midbrain | E11.5 mouse embryonic midbrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02767 | chr3:5224600~5225676 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02768 | chr3:30006475~30007726 | midbrain | E11.5 mouse embryonic midbrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02769 | chr3:34986900~34988201 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02770 | chr3:55558975~55559751 | limb | E11.5 mouse embryonic limb tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02771 | chr3:84741550~84742501 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02772 | chr3:141901125~141902126 | midbrain | E11.5 mouse embryonic midbrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02773 | chr4:5888950~5890926 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02774 | chr4:6840325~6841401 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02775 | chr4:44864575~44865251 | limb | E11.5 mouse embryonic limb tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02776 | chr4:71828300~71829751 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02777 | chr4:97774675~97775901 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02778 | chr5:74828975~74829601 | limb | E11.5 mouse embryonic limb tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02779 | chr6:28346175~28347126 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02780 | chr6:51026850~51028001 | forebrain | E11.5 mouse embryonic forebrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02781 | chr6:51146275~51148026 | midbrain | E11.5 mouse embryonic midbrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02782 | chr6:144260800~144262201 | midbrain | E11.5 mouse embryonic midbrain tissue | -- | Enhancer-associated chromatin profiling; In vivo enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_02783 | chr12:2880430~3018116 | -- | HEK293T | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_02784 | chr10:24085247~24087247 | periosteum | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay |
| E_02785 | chr10:24084485~24085909 | periosteum | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay |
| E_02786 | chr10:79590140~79590690 | periosteum | E15.5 transgenic mouse embryo | -- | In vivo enhancer activity assay |
| E_02787 | chr6:35574362~35576362 | lung | A549 | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02788 | chr13:30108722~30109111 | -- | Embryonic Stem Cell,Epiblast-like Cells (EpiLCs) | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_02789 | chr13:30123333~30124861 | -- | Embryonic Stem Cell,Epiblast-like Cells (EpiLCs) | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_02790 | chr13:30144166~30145833 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_02791 | chr8:106608533~106609800 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_02792 | chr8:106610533~106611666 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_02793 | chr11:44390069~44390173 | ascitic fluid | RAW 264.7 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02794 | chr7:143459000~143459700 | embryo | immortalized mouse embryonic fibroblasts | -- | Enhancer activity assay; transcription-factor-dependent reporter assay; signaling perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02795 | chr7:66375715~66378251 | face | reporter e11.5) | -- | Enhancer activity assay; Cell-type-resolved enhancer activity assay; In vivo functional validation |
| E_02796 | chr8:98367000~98370806 | face | transgenic mouse embryo reporter assay (e12.5) | -- | Enhancer activity assay; Cross-species functional comparison; In vivo functional validation |
| E_02797 | chr15:34751000~34754612 | face | transgenic mouse embryo reporter assay (e12.5) | -- | Enhancer activity assay; Cross-species functional comparison; In vivo functional validation |
| E_02798 | chr9:55546300~55546600 | embryo | Sensory neurons | -- | Enhancer activity assay; In vivo functional validation |
| E_02799 | chr7:143459000~143459700 | embryonic mesenchyme / fibroblast model | O9-1 cranial neural crest cells | -- | FOXD1-responsive Cdkn1c intronic reporter element; candidate enhancer evidence only (no endogenous enhancer deletion in this paper) |
| E_02800 | chr10:51546800~51547317 | prostate gland | DU145 | prostate cancer | Enhancer activity assay; Chromatin interaction assay; TF binding assay; Disease-variant functional analysis |
| E_02801 | chr10:51546800~51547317 | prostate gland | DU145 | prostate cancer | Enhancer activity assay; Chromatin interaction assay; TF binding assay; Disease-variant functional analysis |
| E_02802 | chr10:51546800~51547317 | prostate gland | DU145 | prostate cancer | Enhancer activity assay; Chromatin interaction assay; TF binding assay; Disease-variant functional analysis |
| E_02803 | chr10:51546800~51547317 | prostate gland | DU145 | prostate cancer | Enhancer activity assay; Chromatin interaction assay; TF binding assay; Disease-variant functional analysis |
| E_02804 | chr12:114463712~114464080 | heart | HeLa | Congenital Heart Disease | TF-binding/chromatin assay; Genetic-variant functional analysis; In vivo functional validation; Disease-associated enhancer analysis |
| E_02805 | chr12:114701207~114704691 | heart | HeLa | Congenital Heart Disease | TF-binding/chromatin assay; Genetic-variant functional analysis; In vivo functional validation; Disease-associated enhancer analysis |
| E_02806 | chr12:114853271~114858238 | heart | HeLa | Congenital Heart Disease | TF-binding/chromatin assay; Genetic-variant functional analysis; In vivo functional validation; Disease-associated enhancer analysis |
| E_02807 | chr6:35505138~35511492 | lung | A-549 | -- | Enhancer activity assay; TF binding assay; In vivo functional validation |
| E_02808 | chr12:114463712~114464080 | heart | 293T | Congenital Heart Disease | TF-binding/chromatin assay; Genetic-variant functional analysis; In vivo functional validation; Disease-associated enhancer analysis |
| E_02809 | chr12:114701207~114704691 | heart | 293T | Congenital Heart Disease | TF-binding/chromatin assay; Genetic-variant functional analysis; In vivo functional validation; Disease-associated enhancer analysis |
| E_02810 | chr12:114853271~114858238 | heart | 293T | Congenital Heart Disease | TF-binding/chromatin assay; Genetic-variant functional analysis; In vivo functional validation; Disease-associated enhancer analysis |
| E_02811 | chr5:141952000~141952800 | embryo | Mouse embryonic stem cells (LF2 strain) | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay, Enhancer decommissioning assay |
| E_02812 | chr5:141952000~141952800 | embryo | Mouse embryonic stem cells (LF2 strain) | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay, Enhancer decommissioning assay |
| E_02813 | chr5:141952000~141952800 | embryo | Mouse embryonic stem cells (LF2 strain) | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay, Enhancer decommissioning assay |
| E_02814 | chr5:141952000~141952800 | embryo | Mouse embryonic stem cells (LF2 strain) | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay, Enhancer decommissioning assay |
| E_02815 | chr2:213700000~214600000 | blood | DND-41 | T-cell acute lymphoblastic leukemia | Chromatin interaction assay, Functional perturbation assay |
| E_02816 | chr6:35628362~35641362 | lung | A549 | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_02817 | chr7:143112640~143113190 | embryo | immortalized mouse embryonic fibroblasts | -- | Enhancer activity assay; Functional signaling perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_02818 | chr3:30300000~31100000 | blood | iPSC-derived erythroblasts | -- | Chromatin interaction assay, Functional perturbation assay |
| E_02819 | chr7:143459000~143460200 | embryonic craniofacial mesenchyme | immortalized mouse embryonic fibroblasts | -- | Enhancer activity assay; Functional signaling perturbation assay |
| E_02820 | chr8:128540000~128620000 | saliva-secreting gland | ACC patient-derived xenograft cell lines (ACCX2, ACCX9, ACCX12, ACCX19, ACCX22) | salivary gland adenoid cystic carcinoma | Chromatin interaction assay, TF binding assay |
| E_02821 | chr10:51546800~51547317 | prostate gland | BPH-1 | -- | Enhancer activity assay; Chromatin interaction assay; TF binding assay |
| E_02822 | chr10:51546800~51547317 | prostate gland | BPH-1 | -- | Enhancer activity assay; Chromatin interaction assay; TF binding assay |
| E_02823 | chr10:51546800~51547317 | prostate gland | BPH-1 | -- | Enhancer activity assay; Chromatin interaction assay; TF binding assay |
| E_02824 | chr10:51546800~51547317 | prostate gland | BPH-1 | -- | Enhancer activity assay; Chromatin interaction assay; TF binding assay |
| E_02825 | chr1:41975300~41976076 | forebrain | transgenic mouse embryo | -- | Transgenic reporter assay |
| E_02826 | chr1:134976575~134977476 | forebrain | transgenic mouse embryo | -- | Transgenic reporter assay |
| E_02827 | chr1:140396600~140397726 | forebrain | transgenic mouse embryo | -- | Transgenic reporter assay |
| E_02828 | chr3:55558975~55559751 | limb | transgenic mouse embryo | -- | Transgenic reporter assay |
| E_02829 | chr6:144260800~144262201 | midbrain | transgenic mouse embryo | -- | Transgenic reporter assay |
| E_02830 | chr20:48915257~48915803 | breast | MDA-MB-157 | breast cancer | Chromatin interaction assay; Epigenomic enhancer profiling; Cross-database enhancer annotation |
| E_02831 | chr7:143459172~143459787 | -- | Mouse Embryonic Fibroblasts | -- | Enhancer activity assay; Endogenous enhancer perturbation |
| E_02832 | chr7:143462624~143463585 | -- | Mouse Embryonic Fibroblasts | -- | Enhancer activity assay; Endogenous enhancer perturbation |
| E_02833 | chr11:44390069~44390173 | bone marrow | Bone marrow-derived macrophages (BMDM) | -- | TF binding assay; Functional perturbation assay |
| E_02834 | chr1:204518514~204561889 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02835 | chr1:204518514~204561889 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02836 | chr1:204518514~204561889 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02837 | chr1:204518514~204561889 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02838 | chr1:204518514~204561889 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02839 | chr1:204518514~204561889 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02840 | chr1:204518514~204561889 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02841 | chr1:204518514~204561889 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02842 | chr8:128520000~128551676 | stomach | OE33 | esophageal adenocarcinoma | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02843 | chr8:128520000~128551676 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02844 | chr8:128520000~128551676 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02845 | chr8:128520000~128551676 | stomach | OE33 | esophageal adenocarcinoma | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02846 | chr8:128520000~128551676 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02847 | chr8:128520000~128551676 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02848 | chr8:128520000~128551676 | stomach | OE33 | esophageal adenocarcinoma | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02849 | chr8:128520000~128551676 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02850 | chr8:128520000~128551676 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02851 | chr8:128520000~128551676 | stomach | OE33 | esophageal adenocarcinoma | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02852 | chr8:128520000~128551676 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02853 | chr8:128520000~128551676 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02854 | chr2:85750614~85811383 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02855 | chr2:85750614~85811383 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02856 | chr2:85750614~85811383 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02857 | chr2:85750614~85811383 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, TF binding assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02858 | chr8:128540000~128620000 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, TF binding assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02859 | chr10:24357349~24375452 | -- | Embryonic Limb | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02860 | chr10:24449590~24469418 | -- | Embryonic Limb | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02861 | chr10:24483642~24503469 | -- | Embryonic Limb | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02862 | chr8:48581590~48583174 | face | Primary human embryonic face tissue (CS13-CS23) | -- | Enhancer activity assay; Cell-type-resolved enhancer activity assay |
| E_02863 | chr8:48581590~48583174 | face | transgenic mouse embryonic face reporter tissue (e11.5) | -- | Enhancer activity assay; Cell-type-resolved enhancer activity assay |
| E_02864 | chr17:26077792~26078792 | lung | A549 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_02865 | chr10:24386336~24406594 | -- | Embryonic Limb | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02866 | chr1:204518514~204561889 | prostate gland | BPH-1 | -- | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02867 | chr1:204518514~204561889 | prostate gland | BPH-1 | -- | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02868 | chr1:204518514~204561889 | prostate gland | BPH-1 | -- | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02869 | chr1:204518514~204561889 | prostate gland | BPH-1 | -- | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02870 | chr2:85750614~85811383 | prostate gland | RWPE-1 | -- | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02871 | chr2:85750614~85811383 | prostate gland | RWPE-1 | -- | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02872 | chr2:85750614~85811383 | prostate gland | RWPE-1 | -- | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02873 | chr2:85750614~85811383 | prostate gland | RWPE-1 | -- | Chromatin interaction assay, TF binding assay, Gene expression assay |
| E_02874 | chr11:44390069~44390173 | peritoneal cavity | thioglycollate-elicited peritoneal-derived macrophages (PDM) | -- | Functional perturbation assay |
| E_02875 | chr11:65200000~66000000 | blood | REC-1 | breast cancer | Chromatin interaction assay |
| E_02876 | chr20:48400000~49200000 | breast | HCC1599 | breast cancer | Chromatin interaction assay |
| E_02877 | chr20:48400000~49200000 | breast | MDA-MB-157 | breast cancer | Chromatin interaction assay; Enhancer activity profiling |
| E_02878 | chr10:24102250~24104250 | connective tissue | Fibroblasts | -- | Transgenic reporter assay, Developmental regulation assay; Enhancer activity assay |
| E_02879 | chr11:65200000~66000000 | blood | DND-41 | T-cell acute lymphoblastic leukemia | Chromatin interaction assay |
| E_02880 | chr11:101421506~101422130 | umbilical vein | HUVEC-C | -- | Enhancer activity assay |
| E_02881 | chr2:20850000~20880000 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02882 | chr2:20850000~20880000 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02883 | chr1:204518514~204561889 | prostate gland | RWPE-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02884 | chr1:204518514~204561889 | prostate gland | RWPE-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02885 | chr1:204518514~204561889 | prostate gland | RWPE-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02886 | chr1:204518514~204561889 | prostate gland | RWPE-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02887 | chr8:128520000~128551676 | prostate gland | BPH-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02888 | chr8:128520000~128551676 | prostate gland | BPH-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02889 | chr8:128520000~128551676 | prostate gland | BPH-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02890 | chr8:128520000~128551676 | prostate gland | BPH-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02891 | chr6:122800000~122850000 | prostate gland | DU145 | prostate cancer | Chromatin interaction assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02892 | chr6:122800000~122850000 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay, Gene expression assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_02893 | chr2:85750614~85811383 | prostate gland | BPH-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02894 | chr2:85750614~85811383 | blood | LCL-29092 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02895 | chr2:85750614~85811383 | blood | LCL-32370 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02896 | chr2:85750614~85811383 | prostate gland | RWPE-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02897 | chr2:85750614~85811383 | prostate gland | BPH-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02898 | chr2:85750614~85811383 | blood | LCL-29092 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02899 | chr2:85750614~85811383 | blood | LCL-32370 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02900 | chr2:85750614~85811383 | prostate gland | RWPE-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02901 | chr2:85750614~85811383 | prostate gland | BPH-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02902 | chr2:85750614~85811383 | blood | LCL-29092 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02903 | chr2:85750614~85811383 | blood | LCL-32370 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02904 | chr2:85750614~85811383 | prostate gland | RWPE-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02905 | chr2:85750614~85811383 | prostate gland | BPH-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02906 | chr2:85750614~85811383 | blood | LCL-29092 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02907 | chr2:85750614~85811383 | blood | LCL-32370 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02908 | chr2:85750614~85811383 | prostate gland | RWPE-1 | -- | Chromatin interaction assay; TF binding assay; Gene expression assay |
| E_02909 | chr11:101981958~101982137 | colon | HCT 116,SW620,SW480,RKO | colorectal cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_02910 | chr8:128220000~128250000 | heart | Primary cardiomyocytes | -- | Chromatin interaction assay, Gene expression assay |
| E_02911 | chr12:114463712~114464080 | blood | GM12878 | -- | Enhancer activity assay |
| E_02912 | chr2:172513228~172520500 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_02913 | chr2:172541319~172544955 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_02914 | chr2:172574046~172577682 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_02915 | chr11:44390342~44392251 | blood / hematopoietic system | Myeloid Cells,T Cell | Autoimmune and Inflammatory Diseases | Enhancer activity assay; Disease-associated enhancer analysis |
| E_02916 | chr8:128220000~128250000 | blood | LCL-29092 | -- | Chromatin interaction assay, Gene expression assay |
| E_02917 | chr2:20850000~20880000 | prostate gland | BPH-1 | -- | Chromatin interaction assay; Gene expression assay |
| E_02918 | chr2:20850000~20880000 | blood | LCL-29092 | -- | Chromatin interaction assay; Gene expression assay |
| E_02919 | chr2:20850000~20880000 | blood | LCL-32370 | -- | Chromatin interaction assay; Gene expression assay |
| E_02920 | chr2:20850000~20880000 | prostate gland | RWPE-1 | -- | Chromatin interaction assay; Gene expression assay |
| E_02921 | chr6:122800000~122850000 | prostate gland | BPH-1 | -- | Chromatin interaction assay; Gene expression assay |
| E_02922 | chr6:122800000~122850000 | prostate gland | RWPE-1 | -- | Chromatin interaction assay; Gene expression assay |
| E_02923 | chr11:101981958~101982582 | lymph node | SW620 | colorectal carcinoma | Supporting functional assay |
| E_02924 | chr7:143459000~143459700 | facial mesenchyme | O9-1 | -- | Enhancer-associated developmental regulatory validation; signaling perturbation assay |
| E_02925 | chr11:101981958~101982582 | colon | SW480 | colorectal carcinoma | Supporting expression assay |
| E_02926 | chr11:101981958~101982582 | colon | RKO | colorectal carcinoma | Supporting expression assay |
| E_02927 | chr11:101981958~101982582 | colon | LS 174T | colorectal carcinoma | Supporting expression assay |
| E_02928 | chr11:101981958~101982582 | colon | HT-29 | colorectal carcinoma | Supporting expression assay |
| E_02929 | chr11:44389500~44390500 | blood | RAW 264.7 | -- | Distal enhancer assay; TF-binding assay; cytokine-dependent repression |
| E_02930 | chr12:31875800~31876373 | spleen | CD4+ T cells | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_02931 | chr10:118172284~118172884 | blood | primary naive CD4+ T cells differentiated to Th22 cells | -- | Enhancer activity assay; TF-binding assay; differentiation-associated enhancer assay; Endogenous enhancer perturbation; TF binding assay |
| E_02932 | chr2:43219398~43221398 | lung | BEAS-2B | -- | Enhancer activity assay; TF binding assay; In vivo functional validation |
| E_02933 | chr6:115598005~115604631 | embryo | mouse embryonic stem cells | -- | Chromatin interaction assay; Structural TF perturbation assay |
| E_02934 | chr6:43891400~43898360 | blood / hematopoietic system | K-562 | hematologic malignancy | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02935 | chr9:37370916~37371635 | blood | Primary CLL cells | B-cell chronic lymphocytic leukemia | Regulatory variant assay; Chromatin interaction assay; Functional enhancer perturbation |
| E_02936 | chr7:116735000~116735500 | prostate gland | LNCaP C4-2B | melanoma | Functional perturbation assay; Endogenous enhancer perturbation |
| E_02937 | chr7:117085371~117085720 | bronchus | 16HBE14o- | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_02938 | chr17:80721358~80818896 | embryo | Mouse Embryonic Stem Cells (v6.5) | -- | Enhancer activity assay, Functional perturbation assay |
| E_02939 | chr2:234762042~234764060 | breast | BT-549 | triple-negative breast carcinoma | Enhancer activity assay; TF binding assay; functional perturbation assay |
| E_02940 | chr2:234762042~234764060 | breast | MDA-MB-231 | triple-negative breast carcinoma | Enhancer activity assay; TF binding assay; functional perturbation assay |
| E_02941 | chr2:234762042~234764060 | breast | BT-549 | triple-negative breast carcinoma | Enhancer activity assay; TF binding assay; functional perturbation assay |
| E_02942 | chr2:234762042~234764060 | breast | MDA-MB-231 | triple-negative breast carcinoma | Enhancer activity assay; TF binding assay; functional perturbation assay |
| E_02943 | chr3:15768491~15768703 | blood | Multiple myeloma cells | plasma cell myeloma | Enhancer activity assay |
| E_02944 | chr3:15768491~15768703 | blood | Multiple myeloma cells | plasma cell myeloma | Enhancer activity assay |
| E_02945 | chr3:15768491~15768703 | blood | Multiple myeloma cells | plasma cell myeloma | Enhancer activity assay |
| E_02946 | chr3:15768491~15768703 | blood | Multiple myeloma cells | plasma cell myeloma | Enhancer activity assay |
| E_02947 | chr17:70397161~70432161 | breast | MDA-MB-157 | breast carcinoma | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_02948 | chr17:70447161~70494161 | breast | MDA-MB-157 | breast carcinoma | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_02949 | chr5:74684243~74687892 | breast | Breast Cancer Cell | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02950 | chr5:74684243~74687892 | breast | Breast cancer drug-resistant cell | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02951 | chr5:74684243~74687892 | breast | MDA-MB-231 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_02952 | chr17:44421760~44428310 | colon | CRC patient tumor tissue | colorectal cancer | Super-enhancer identification; Functional validation; Chromatin-state profiling; Disease-variant functional analysis |
| E_02953 | chr9:123924740~123931280 | colon | CRC patient tumor tissue | colorectal cancer | Super-enhancer identification; Functional validation; Chromatin-state profiling; Disease-variant functional analysis |
| E_02954 | chr19:15311000~15312500 | lung | A-549 | lung adenocarcinoma | Functional perturbation assay, TF binding assay |
| E_02955 | chr19:15311000~15312500 | lung | NCI-H460 | lung adenocarcinoma | Functional perturbation assay, TF binding assay |
| E_02956 | chr19:15311000~15312500 | lung | A-549 | lung adenocarcinoma | Functional perturbation assay, TF binding assay |
| E_02957 | chr19:15311000~15312500 | lung | NCI-H460 | lung adenocarcinoma | Functional perturbation assay, TF binding assay |
| E_02958 | chr19:15311000~15312500 | lung | A-549 | lung adenocarcinoma | Functional perturbation assay, TF binding assay |
| E_02959 | chr19:15311000~15312500 | lung | NCI-H460 | lung adenocarcinoma | Functional perturbation assay, TF binding assay |
| E_02960 | chr7:105856018~105860658 | colon | HCT 116 | colorectal carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay; In vivo functional validation |
| E_02961 | chr7:105856018~105860658 | lung | NCI-H460 | lung adenocarcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay; In vivo functional validation |
| E_02962 | chr7:105856018~105860658 | brain | U-87MG ATCC | glioblastoma | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_02963 | chr8:18742000~18744000 | liver | ARID1A-deficient mouse hepatocellular carcinoma cells | hepatocellular carcinoma | Enhancer chromatin-state assay; chromatin-remodeler occupancy assay; functional perturbation assay; Endogenous enhancer perturbation; TF binding assay; In vivo functional validation |
| E_02964 | chr1:131920349~131962471 | liver | Liver,Kidney | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_02965 | chr1:131920349~131962471 | liver | Liver,Kidney | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_02966 | chr1:131920349~131962471 | liver | Liver,Kidney | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_02967 | chr1:131878852~131942815 | liver | Liver,Kidney | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_02968 | chr1:131878852~131942815 | liver | Liver,Kidney | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_02969 | chr1:131878852~131942815 | liver | Liver,Kidney | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_02970 | chr8:129046628~129096067 | blood / hematopoietic system | K-562 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02971 | chr8:130569971~130616320 | blood / hematopoietic system | K-562 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02972 | chr8:130693569~130739918 | blood / hematopoietic system | K-562 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02973 | chr5:118432886~118452483 | extraembryonic ectoderm | Trophoblast Stem Cell | -- | Functional perturbation assay, Chromatin interaction assay |
| E_02974 | chr3:181465000~181468600 | lung | NCI-H1299 | lung adenocarcinoma | Functional perturbation assay; In vivo functional validation |
| E_02975 | chr3:181432912~181433312 | lung | Lung Adenocarcinoma | Lung Cancer | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_02976 | chr16:68779512~68779800 | colon | HCT 116 | colorectal carcinoma | Enhancer activity assay, TF binding assay |
| E_02977 | chr7:116374406~116376406 | skin | COLO 829 | Melanoma | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_02978 | chr2:91067374~91069374 | blood / hematopoietic system | Bone Marrow Cell,Leukemic Stem Cell,Hematopoietic Stem Cell,416B | Leukemia | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_02979 | chr2:91067374~91069374 | blood / hematopoietic system | Bone Marrow Cell,Leukemic Stem Cell,Hematopoietic Stem Cell,416B | Leukemia | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_02980 | chr2:91067374~91069374 | blood / hematopoietic system | Bone Marrow Cell,Leukemic Stem Cell,Hematopoietic Stem Cell,416B | Leukemia | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_02981 | chr11:8301851~8303851 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL) | T-Cell leukemia | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_02982 | chr11:8301851~8303851 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL) | T-Cell leukemia | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_02983 | chr6:43740121~43741621 | blood | K-562 | hematopoietic malignancy | Functional perturbation assay |
| E_02984 | chr17:70530161~70632161 | breast | MDA-MB-157 | breast carcinoma | Regulatory element functional validation, 3D chromatin interaction mapping |
| E_02985 | chr8:128206162~128314310 | colon | HCT 116 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_02986 | chr3:15768491~15768703 | bone marrow | CD34+ HSPCs | -- | Enhancer activity assay |
| E_02987 | chr19:11377207~11384314 | blood | primary B-ALL) | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_02988 | chr2:167687771~167689503 | -- | Monocytes | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02989 | chr2:167687771~167689503 | -- | Monocytes | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02990 | chr2:167687771~167689503 | -- | Monocytes | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02991 | chr8:120737580~120746913 | -- | Monocytes | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02992 | chr8:120737580~120746913 | -- | Monocytes | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02993 | chr8:120737580~120746913 | -- | Monocytes | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02994 | chr4:66837166~66852551 | -- | Dendritic Cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02995 | chr4:66837166~66852551 | -- | Dendritic Cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02996 | chr4:66837166~66852551 | -- | Dendritic Cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_02997 | chr9:75595800~75602900 | breast | MCF-7 | lung adenocarcinoma | Enhancer activity assay; In vivo functional validation |
| E_02998 | chr19:17951290~18000085 | blood | primary B-ALL) | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_02999 | chr10:102743948~102816262 | blood | primary B-ALL) | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03000 | chr17:77922269~77927433 | colon | 73 paired colorectal-cancer patient tissues | colorectal cancer | Super-enhancer identification; endogenous epigenomic perturbation; oncogenic functional validation |
| E_03001 | chr9:123663103~123669339 | colon | 73 paired colorectal-cancer patient tissues | colorectal cancer | Super-enhancer identification; endogenous epigenomic perturbation; oncogenic functional validation |
| E_03002 | chr8:67740000~67741000 | liver | Primary Human Hepatocellular Carcinoma Cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03003 | chr2:28950000~28970000 | bone marrow | LSK hematopoietic stem cells | acute myeloid leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03004 | chr19:11377207~11384314 | blood | ETV6-deficient B-ALL panel (Reh | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03005 | chr19:11377207~11384314 | blood | AT-1/AT-2 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03006 | chr19:11377207~11384314 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03007 | chr19:11377207~11384314 | blood | MUTZ-5 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03008 | chr19:11377207~11384314 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Functional perturbation assay |
| E_03009 | chr18:21704916~21870953 | blood | primary B-ALL) | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03010 | chr18:41955234~42087830 | blood | primary B-ALL) | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03011 | chr2:217799791~218033982 | blood | primary B-ALL) | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03012 | chr19:15311000~15312500 | lung | H2023 | lung adenocarcinoma | Functional perturbation assay; TF binding assay |
| E_03013 | chr2:130135200~130141800 | esophagus | esophageal squamous cell carcinoma samples | esophageal squamous cell carcinoma | Super-enhancer epigenetic silencing analysis; In vivo functional validation |
| E_03014 | chr19:17951290~18000085 | blood | ETV6-deficient B-ALL panel (Reh | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03015 | chr19:17951290~18000085 | blood | AT-1/AT-2 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03016 | chr19:17951290~18000085 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03017 | chr19:17951290~18000085 | blood | MUTZ-5 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03018 | chr19:17951290~18000085 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Functional perturbation assay |
| E_03019 | chr10:102743948~102816262 | blood | ETV6-deficient B-ALL panel (Reh | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03020 | chr10:102743948~102816262 | blood | AT-1/AT-2 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03021 | chr10:102743948~102816262 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03022 | chr10:102743948~102816262 | blood | MUTZ-5 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03023 | chr10:102743948~102816262 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Functional perturbation assay |
| E_03024 | chr17:77922269~77927433 | colon | HCT116, RKO and SW620 functional-validation models | colorectal cancer | Super-enhancer identification; endogenous epigenomic perturbation; oncogenic functional validation |
| E_03025 | chr9:123663103~123669339 | colon | HCT116, RKO and SW620 functional-validation models | colorectal cancer | Super-enhancer identification; endogenous epigenomic perturbation; oncogenic functional validation |
| E_03026 | chr18:21704916~21870953 | blood | ETV6-deficient B-ALL panel (Reh | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03027 | chr18:21704916~21870953 | blood | AT-1/AT-2 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03028 | chr18:21704916~21870953 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03029 | chr18:21704916~21870953 | blood | MUTZ-5 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03030 | chr18:21704916~21870953 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Functional perturbation assay |
| E_03031 | chr18:41955234~42087830 | blood | ETV6-deficient B-ALL panel (Reh | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03032 | chr18:41955234~42087830 | blood | AT-1/AT-2 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03033 | chr18:41955234~42087830 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03034 | chr18:41955234~42087830 | blood | MUTZ-5 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03035 | chr18:41955234~42087830 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Functional perturbation assay |
| E_03036 | chr2:217799791~218033982 | blood | ETV6-deficient B-ALL panel (Reh | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03037 | chr2:217799791~218033982 | blood | AT-1/AT-2 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03038 | chr2:217799791~218033982 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03039 | chr2:217799791~218033982 | blood | MUTZ-5 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Endogenous functional perturbation assay |
| E_03040 | chr2:217799791~218033982 | blood | UoC-B6 | B-cell acute lymphoblastic leukemia | Enhancer activity/occupancy assay; TF binding assay; Functional perturbation assay |
| E_03041 | chr11:33524486~33543505 | embryo | Embryonic Stem Cells (mESCs) | -- | Functional perturbation assay |
| E_03042 | chr4:123618309~123637993 | embryo | Embryonic Stem Cells (mESCs) | -- | Functional perturbation assay |
| E_03043 | chr6:122698567~122721126 | embryo | Mouse Embryonic Stem Cells (v6.5) | -- | Enhancer activity assay |
| E_03044 | chr3:34546571~34552571 | embryo | Mouse Embryonic Stem Cells (v6.5) | -- | Enhancer activity assay |
| E_03045 | chr11:8264000~8265500 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_03046 | chr6:100282437~100393986 | embryo | Mouse Embryonic Stem Cells (v6.5) | -- | Enhancer activity assay |
| E_03047 | chr9:78368337~78376479 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03048 | chr9:78368337~78376479 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03049 | chr13:28545205~28547205 | colon | Colorectal Cancer | colorectal cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03050 | chr16:68777928~68779928 | colon | Colorectal Cancer | colorectal cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03051 | chr3:184276287~184278287 | colon | Colorectal Cancer | colorectal cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03052 | chr14:18175266~18186392 | -- | Hepatocellular Carcinoma | hepatocellular carcinoma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03053 | chr11:47394824~47395023 | bone marrow | AML/ETO9a leukemia stem-cell models | RUNX1::RUNX1T1-associated acute myeloid leukemia | Endogenous TF-site enhancer perturbation |
| E_03054 | chr6:145855899~145856116 | blood | RAW 264.7 | -- | Enhancer activity assay; Chromatin-state profiling; In vivo functional validation |
| E_03055 | chrX:49273000~49274000 | blood | Primary human CD4+ T cells differentiated into iTreg cells | -- | TF binding assay; Chromatin accessibility assay; Histone modification assay; Functional perturbation assay |
| E_03056 | chr12:6444399~6447744 | blood | iPSC-derived macrophages | -- | Enhancer activity assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis |
| E_03057 | chr4:111399594~111399691 | liver | Hep-G2 | hepatocellular carcinoma | TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation; Chromatin-state profiling; Disease-variant functional analysis; In vivo functional validation |
| E_03058 | chr11:85780828~85780847 | lymph node | SMZ-1 | type 2 diabetes mellitus | Regulatory element functional validation, 3D chromatin interaction mapping; In vivo functional validation |
| E_03059 | chr8:127580017~127580036 | lymph node | SMZ-1 | type 2 diabetes mellitus | Regulatory element functional validation, 3D chromatin interaction mapping; In vivo functional validation |
| E_03060 | chr13:20993543~20994585 | kidney | HEK293T | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03061 | chr12:105800000~105801000 | cranial neural crest | hCNCC cells | -- | Chromatin interaction assay, Functional perturbation assay |
| E_03062 | chr8:128747000~128748000 | blood | K-562 | -- | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation |
| E_03063 | chrX:66118920~66127943 | prostate gland | 22Rv1 | prostate cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_03064 | chrX:66118920~66127943 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_03065 | chrX:49260470~49261090 | blood | Primary human CD4+ T cells differentiated into iTreg cells | -- | Functional perturbation assay; Enhancer epigenetic-state assay; Chromatin accessibility assay |
| E_03066 | chr20:21576001~21577647 | muscle organ | A-673-dHALO and A-673 EWSR1::FLI1-knockout derivatives | Ewing sarcoma | Enhancer-associated functional perturbation assay |
| E_03067 | chr2:29880537~29880842 | skeletal muscle tissue | RH 4 | alveolar rhabdomyosarcoma | Enhancer activity assay, Super-enhancer profiling |
| E_03068 | chr17:42078635~42079129 | liver | Hep-G2 | -- | Enhancer activity assay; TF binding assay; Functional variant assay; Endogenous enhancer perturbation |
| E_03069 | chr6:160112271~160112612 | prostate gland | PC-3 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; In vivo functional validation |
| E_03070 | chr11:5301801~5302175 | pleural effusion | K-562 | -- | Enhancer activity assay; Functional perturbation assay; Chromatin accessibility assay; Enhancer-promoter communication assay; Endogenous enhancer perturbation; TF binding assay |
| E_03071 | chr11:5301801~5302175 | pleural effusion | K-562 | -- | Enhancer activity assay; Functional perturbation assay; Chromatin accessibility assay; Enhancer-promoter communication assay; Endogenous enhancer perturbation; TF binding assay |
| E_03072 | chr4:111397892~111402926 | kidney | HEK293 | Axenfeld-Rieger syndrome | Enhancer activity assay; Functional perturbation assay |
| E_03073 | chr8:121503787~121504483 | bone marrow | plasmacytoid dendritic cells | -- | Enhancer switching; E-box TF input; endogenous enhancer deletion; lineage-fate analysis |
| E_03074 | chr15:66074477~66098025 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03075 | chr15:66074477~66098025 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03076 | chr15:66074477~66098025 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03077 | chr15:66074477~66098025 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03078 | chr15:66074477~66098025 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03079 | chr15:66074477~66098025 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03080 | chr15:66074477~66098025 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03081 | chr15:66074477~66098025 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03082 | chr17:31209116~31240452 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03083 | chr17:31209116~31240452 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03084 | chr17:31209116~31240452 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03085 | chr17:31209116~31240452 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03086 | chr17:31209116~31240452 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03087 | chr17:31209116~31240452 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03088 | chr17:31209116~31240452 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03089 | chr17:31209116~31240452 | blood / hematopoietic system | Erythroleukemia Cell,B lymphoblastoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03090 | chr17:35502632~35504632 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03091 | chr17:35502632~35504632 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03092 | chr17:35502632~35504632 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03093 | chr17:35502632~35504632 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03094 | chr6:122700483~122702483 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03095 | chr6:122700483~122702483 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03096 | chr6:122700483~122702483 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03097 | chr6:122700483~122702483 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03098 | chr21:39823183~39825183 | blood | MOLT-4 | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF occupancy assay; Functional perturbation assay; In vivo enhancer reporter assay |
| E_03099 | chr21:39823183~39825183 | blood | MOLT-4 | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF occupancy assay; Functional perturbation assay; In vivo enhancer reporter assay |
| E_03100 | chr21:39823183~39825183 | blood | MOLT-4 | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF occupancy assay; Functional perturbation assay; In vivo enhancer reporter assay |
| E_03101 | chr21:39823183~39825183 | blood | MOLT-4 | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF occupancy assay; Functional perturbation assay; In vivo enhancer reporter assay |
| E_03102 | chr21:39823183~39825183 | blood | MOLT-4 | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF occupancy assay; Functional perturbation assay; In vivo enhancer reporter assay |
| E_03103 | chr21:39823183~39825183 | blood | MOLT-4 | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF occupancy assay; Functional perturbation assay; In vivo enhancer reporter assay |
| E_03104 | chr13:20993543~20994585 | respiratory airway | Small airway epithelial cells (SAEC) | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_03105 | chr8:121503787~121504483 | bone marrow | common dendritic cell progenitors | -- | Enhancer switching; E-box TF input; endogenous enhancer deletion; lineage-fate analysis |
| E_03106 | chr8:121503787~121504483 | bone marrow | pre-cDC1 | -- | Enhancer switching; E-box TF input; endogenous enhancer deletion; lineage-fate analysis |
| E_03107 | chr8:121503787~121504483 | bone marrow | pre-cDC1 | -- | Enhancer switching; E-box TF input; endogenous enhancer deletion; lineage-fate analysis |
| E_03108 | chr11:69622001~69622601 | orbital region | SK-N-MC | Ewing sarcoma | Enhancer-associated functional perturbation assay; in vivo xenograft assay; In vivo functional validation |
| E_03109 | chr20:21576001~21577647 | orbital region | SK-N-MC | Ewing sarcoma | Enhancer-associated functional perturbation assay; in vivo xenograft assay; In vivo functional validation |
| E_03110 | chr12:54624604~54625309 | orbital region | SK-N-MC | Ewing sarcoma | Enhancer-associated functional perturbation assay; In vivo functional validation |
| E_03111 | chr20:21576001~21577647 | -- | EWS-502 dTAG derivative | Ewing sarcoma | Enhancer-associated functional perturbation assay |
| E_03112 | chr6:122652547~122653538 | embryo | mouse embryonic stem cells | -- | Enhancer activity assay, Functional perturbation assay |
| E_03113 | chr11:17666830~17677080 | blood / hematopoietic system | Human Fibroblast Cell Lines | alveolar rhabdomyosarcoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03114 | chr11:17666830~17677080 | blood / hematopoietic system | Human Fibroblast Cell Lines | alveolar rhabdomyosarcoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03115 | chr17:35643073~35645472 | embryo | HMC-1 | -- | Enhancer activity assay, Functional perturbation assay |
| E_03116 | chr17:42078768~42079095 | liver | patient genomic DNA | hyperammonemia due to N-acetylglutamate synthase deficiency | Disease-variant enhancer activity; TF-binding assay |
| E_03117 | chr6:122702344~122703335 | embryo | Nanog-GFP mouse embryonic stem cells | -- | Enhancer repression assay; functional perturbation assay; Enhancer activity assay |
| E_03118 | chr6:122702344~122703335 | embryo | Nanog-GFP mouse embryonic stem cells | -- | Enhancer repression assay; functional perturbation assay; Enhancer activity assay |
| E_03119 | chr6:122702344~122703335 | epiblast (generic) | mouse epiblast stem cells | -- | Enhancer activation assay; functional perturbation assay; Enhancer activity assay |
| E_03120 | chr6:122702344~122703335 | epiblast (generic) | mouse epiblast stem cells | -- | Enhancer activation assay; functional perturbation assay; Enhancer activity assay |
| E_03121 | chr17:42078768~42079095 | liver | HepG2 enhancer-reporter model | hyperammonemia due to N-acetylglutamate synthase deficiency | Disease-variant enhancer activity; TF-binding assay |
| E_03122 | chr21:39823183~39825183 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL),Molt4,REH,416B | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03123 | chr21:39823183~39825183 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL),Molt4,REH,416B | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03124 | chr21:39823183~39825183 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL),Molt4,REH,416B | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03125 | chr21:39823183~39825183 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL),Molt4,REH,416B | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03126 | chr8:124371000~124371500 | spleen | Mature cDC1 | -- | Enhancer activity assay, TF binding assay |
| E_03127 | chr8:124371000~124371500 | spleen | Mature cDC1 | -- | Enhancer activity assay, TF binding assay |
| E_03128 | chr16:95439106~95439643 | bone marrow | mouse hematopoietic enhancer reporter/transgenic models | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03129 | chr16:95439106~95439643 | bone marrow | human T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03130 | chr16:95439106~95439643 | thymus | mouse hematopoietic enhancer reporter/transgenic models | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03131 | chr16:95439106~95439643 | thymus | human T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03132 | chr16:95439106~95439643 | bone marrow | mouse hematopoietic enhancer reporter/transgenic models | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03133 | chr16:95439106~95439643 | bone marrow | human T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03134 | chr16:95439106~95439643 | thymus | mouse hematopoietic enhancer reporter/transgenic models | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03135 | chr16:95439106~95439643 | thymus | human T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03136 | chr16:95439106~95439643 | bone marrow | mouse hematopoietic enhancer reporter/transgenic models | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03137 | chr16:95439106~95439643 | bone marrow | human T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03138 | chr16:95439106~95439643 | thymus | mouse hematopoietic enhancer reporter/transgenic models | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03139 | chr16:95439106~95439643 | thymus | human T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03140 | chr16:95439106~95439643 | bone marrow | mouse hematopoietic enhancer reporter/transgenic models | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03141 | chr16:95439106~95439643 | bone marrow | human T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03142 | chr16:95439106~95439643 | thymus | mouse hematopoietic enhancer reporter/transgenic models | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03143 | chr16:95439106~95439643 | thymus | human T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03144 | chr16:95439106~95439643 | bone marrow | mouse hematopoietic enhancer reporter/transgenic models | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03145 | chr16:95439106~95439643 | bone marrow | human T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03146 | chr16:95439106~95439643 | thymus | mouse hematopoietic enhancer reporter/transgenic models | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03147 | chr16:95439106~95439643 | thymus | human T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer reporter/transgenic validation; leukemia regulatory mechanism |
| E_03148 | chr21:39823183~39825183 | blood | MOLT-4 | acute lymphoblastic leukemia | Enhancer activity assay; High-throughput profiling |
| E_03149 | chr21:39823183~39825183 | blood | MOLT-4 | acute lymphoblastic leukemia | Enhancer activity assay; High-throughput profiling |
| E_03150 | chr21:39823183~39825183 | blood | MOLT-4 | acute lymphoblastic leukemia | Enhancer activity assay; High-throughput profiling |
| E_03151 | chr21:39823183~39825183 | blood | MOLT-4 | acute lymphoblastic leukemia | Enhancer activity assay; High-throughput profiling |
| E_03152 | chr21:39823183~39825183 | blood | MOLT-4 | acute lymphoblastic leukemia | Enhancer activity assay; High-throughput profiling |
| E_03153 | chr21:39823183~39825183 | blood | MOLT-4 | acute lymphoblastic leukemia | Enhancer activity assay; High-throughput profiling |
| E_03154 | chr21:39823183~39825183 | blood | MOLT-4 | acute lymphoblastic leukemia | Enhancer activity assay; High-throughput profiling |
| E_03155 | chr21:39823183~39825183 | blood | MOLT-4 | acute lymphoblastic leukemia | Enhancer activity assay; High-throughput profiling |
| E_03156 | chr6:160101620~160102231 | -- | PC-3 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03157 | chr6:160101890~160102231 | -- | PC-3 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03158 | chr11:5266021~5266708 | blood / hematopoietic system | K-562 | -- | Experimentally supported enhancer study |
| E_03159 | chr11:5266021~5266708 | blood / hematopoietic system | K-562 | -- | Experimentally supported enhancer study |
| E_03160 | chr8:120777048~120777744 | bone marrow | common dendritic cell progenitor / pre-cDC1 | -- | Stage-specific enhancer assay; enhancer genetic perturbation; E-box mutagenesis |
| E_03161 | chr8:120768340~120768887 | bone marrow | pre-cDC1 / mature cDC1 | -- | Stage-specific enhancer switching; genetic perturbation |
| E_03162 | chr11:5266021~5266708 | blood | K-562 | -- | Enhancer activity assay |
| E_03163 | chr11:5266021~5266708 | blood | K-562 | -- | Enhancer activity assay |
| E_03164 | chr17:42078932~42079032 | -- | Ureagenesis | -- | Enhancer activity assay |
| E_03165 | chr13:26191020~26272468 | liver | Huh-7 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay; Chromatin-state profiling |
| E_03166 | chr10:50623698~50625698 | -- | Hypothalamus | Haploinsufficiency | TF-binding/chromatin assay; Endogenous enhancer perturbation; Genetic-variant functional analysis; In vivo functional validation; Disease-associated enhancer analysis |
| E_03167 | chr16:21480000~21482000 | embryo | mouse gastrula | -- | Enhancer activity assay, Functional perturbation assay |
| E_03168 | chrX:106959618~106962917 | -- | U-2 OS | -- | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation |
| E_03169 | chrX:106960488~106960865 | lung | A-549 | -- | GR-bound GILZ/TSC22D3 GBS1 enhancer interval; endogenous deletion and cell-type-specific wiring; Endogenous enhancer perturbation |
| E_03170 | chr6:45322562~45322863 | bone marrow | Primary human KMT2A::AFF1 ALL blast | acute lymphoblastic leukemia | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03171 | chr6:45323829~45324130 | bone marrow | Primary human KMT2A::AFF1 ALL blast | acute lymphoblastic leukemia | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03172 | chr6:45328065~45328366 | bone marrow | Primary human KMT2A::AFF1 ALL blast | acute lymphoblastic leukemia | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03173 | chr6:45331117~45331418 | bone marrow | Primary human KMT2A::AFF1 ALL blast | acute lymphoblastic leukemia | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03174 | chr6:45333183~45333484 | bone marrow | Primary human KMT2A::AFF1 ALL blast | acute lymphoblastic leukemia | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03175 | chr6:45339859~45340160 | bone marrow | Primary human KMT2A::AFF1 ALL blast | acute lymphoblastic leukemia | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03176 | chr2:66577620~66583740 | bone marrow | Primary human KMT2A::AFF1 ALL blast | acute lymphoblastic leukemia | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03177 | chr11:27725730~27726223 | nucleus accumbens | GTEx human nucleus accumbens tissue | obesity | Genetic association analysis; eQTL/sQTL target-linking analysis; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_03178 | chr9:21980404~21981404 | uterine cervix | HeLa | glaucoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; Disease-variant functional analysis |
| E_03179 | chr14:57419008~57421445 | retina | Transgenic mouse embryo carrying human enhancer | -- | Enhancer activity assay; Chromatin interaction assay |
| E_03180 | chr10:63525013~63527013 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer RNA assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_03181 | chr10:63525013~63527013 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer RNA assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_03182 | chr10:63525013~63527013 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer RNA assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_03183 | chr11:112635500~112636792 | testis | Sertoli cells | -- | Enhancer activity assay, Functional perturbation assay, TF binding assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03184 | chr10:52388022~52388224 | definitive endoderm | P19 | -- | Enhancer activity assay; TF binding assay; Functional cis-element perturbation assay; In vivo functional validation |
| E_03185 | chr10:52388022~52388224 | definitive endoderm | P19 | -- | Enhancer activity assay; TF binding assay; Functional cis-element perturbation assay; In vivo functional validation |
| E_03186 | chr11:96200000~96202300 | endoderm | OMEGA-E | -- | Enhancer activity assay, TF binding assay, Transgenic reporter assay; In vivo functional validation |
| E_03187 | chr11:96201500~96202300 | endoderm | OMEGA-E | -- | Enhancer activity assay, TF binding assay; In vivo functional validation |
| E_03188 | chr5:107680655~107682655 | bone marrow | Mysm1-deficient HSCs | -- | Epigenetic enhancer regulation; TF occupancy; functional transactivation; Endogenous enhancer perturbation; In vivo functional validation |
| E_03189 | chr5:107680655~107682655 | bone marrow | wild-type HSCs | -- | Epigenetic enhancer regulation; TF occupancy; functional transactivation; Endogenous enhancer perturbation; In vivo functional validation |
| E_03190 | chr5:107680655~107682655 | bone marrow | Mysm1-deficient HSCs | -- | Epigenetic enhancer regulation; TF occupancy; functional transactivation; Endogenous enhancer perturbation; In vivo functional validation |
| E_03191 | chr5:107680655~107682655 | bone marrow | wild-type HSCs | -- | Epigenetic enhancer regulation; TF occupancy; functional transactivation; Endogenous enhancer perturbation; In vivo functional validation |
| E_03192 | chr19:55417234~55417304 | blood | NK-92 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Chromatin-state assay |
| E_03193 | chr22:38686443~38686999 | blood | B cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_03194 | chr22:38687301~38687766 | blood | B cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_03195 | chr22:38688102~38688577 | blood | B cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation |
| E_03196 | chr3:94294960~94295960 | small intestine | Primary mouse tissue-resident Th17 cells | -- | Rorc +11-kb/CNS11 enhancer occupancy by ROR汐/ROR污t; in vivo enhancer-reporter deletion and lineage-maintenance validation |
| E_03197 | chr3:94294960~94295960 | small intestine | Primary mouse tissue-resident Th17 cells | -- | Rorc +11-kb/CNS11 enhancer occupancy by ROR汐/ROR污t; in vivo enhancer-reporter deletion and lineage-maintenance validation |
| E_03198 | chr3:94294960~94295960 | small intestine | Primary small-intestinal lamina propria tissue-resident Th17 cells | -- | Rorc CNS11/+11-kb cis-regulatory element; ROR汐 occupancy; in vivo enhancer-reporter deletion and lineage-maintenance validation; exact 1001-bp CNS11 interval independently validated by PMID 41739921 |
| E_03199 | chr3:94294960~94295960 | small intestine | Primary small-intestinal lamina propria tissue-resident Th17 cells | -- | Rorc CNS11/+11-kb cis-regulatory element; ROR污t occupancy/feed-forward regulation; in vivo enhancer-reporter deletion and lineage-maintenance validation; exact 1001-bp CNS11 interval independently validated by PMID 41739921 |
| E_03200 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Epigenome editing assay; Endogenous enhancer perturbation |
| E_03201 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Epigenome editing assay; Endogenous enhancer perturbation |
| E_03202 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Epigenome editing assay; Endogenous enhancer perturbation |
| E_03203 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Epigenome editing assay; Endogenous enhancer perturbation |
| E_03204 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Epigenome editing assay; Endogenous enhancer perturbation |
| E_03205 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Epigenome editing assay; Endogenous enhancer perturbation |
| E_03206 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Epigenome editing assay; Endogenous enhancer perturbation |
| E_03207 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Epigenome editing assay; Endogenous enhancer perturbation |
| E_03208 | chr11:5280255~5281665 | blood | K-562 | -- | Enhancer activity assay; Functional perturbation assay; Gene expression assay; Chromatin-state assay; Endogenous enhancer perturbation |
| E_03209 | chr11:5280255~5281665 | blood | K-562 | -- | Enhancer activity assay; Functional perturbation assay; Gene expression assay; Chromatin-state assay; Endogenous enhancer perturbation |
| E_03210 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Enhancer chromatin-state assay; Epigenome-editing assay |
| E_03211 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Enhancer chromatin-state assay; Epigenome-editing assay |
| E_03212 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Enhancer chromatin-state assay; Epigenome-editing assay |
| E_03213 | chr11:5301862~5302715 | blood | K-562 | -- | Functional perturbation assay; Enhancer chromatin-state assay; Epigenome-editing assay |
| E_03214 | chr11:27725730~27726223 | brainstem | Cranial motor neurons | obesity | Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_03215 | chr14:57230000~57232400 | retina | Transgenic mouse embryo carrying human enhancer | -- | Enhancer activity assay; Chromatin interaction assay |
| E_03216 | chr10:52388022~52388224 | -- | P19 | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03217 | chr10:52388022~52388224 | -- | P19 | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03218 | chr19:55412800~55414400 | blood | NK-92 | -- | Cis-regulatory activity assay; TF-binding assay; transcription-factor perturbation assay |
| E_03219 | chr3:94294960~94295960 | small intestine | transgenic Rorc reporter mice | -- | Rorc +11-kb/CNS11 enhancer occupancy by ROR汐/ROR污t; in vivo enhancer-reporter deletion and lineage-maintenance validation |
| E_03220 | chr3:94294960~94295960 | small intestine | transgenic Rorc reporter mice | -- | Rorc +11-kb/CNS11 enhancer occupancy by ROR汐/ROR污t; in vivo enhancer-reporter deletion and lineage-maintenance validation |
| E_03221 | chr3:94294960~94295960 | small intestine | in vitro 2D2tg Th17 cells | -- | Rorc CNS11/+11-kb cis-regulatory element; ROR汐 occupancy; in vivo enhancer-reporter deletion and lineage-maintenance validation; exact 1001-bp CNS11 interval independently validated by PMID 41739921 |
| E_03222 | chr3:94294960~94295960 | small intestine | transgenic Rorc reporter mice | -- | Rorc CNS11/+11-kb cis-regulatory element; ROR汐 occupancy; in vivo enhancer-reporter deletion and lineage-maintenance validation; exact 1001-bp CNS11 interval independently validated by PMID 41739921 |
| E_03223 | chr3:94294960~94295960 | small intestine | in vitro 2D2tg Th17 cells | -- | Rorc CNS11/+11-kb cis-regulatory element; ROR污t occupancy/feed-forward regulation; in vivo enhancer-reporter deletion and lineage-maintenance validation; exact 1001-bp CNS11 interval independently validated by PMID 41739921 |
| E_03224 | chr3:94294960~94295960 | small intestine | transgenic Rorc reporter mice | -- | Rorc CNS11/+11-kb cis-regulatory element; ROR污t occupancy/feed-forward regulation; in vivo enhancer-reporter deletion and lineage-maintenance validation; exact 1001-bp CNS11 interval independently validated by PMID 41739921 |
| E_03225 | chr11:112634637~112637797 | testis | Sertoli cells | -- | Enhancer activity assay, Functional perturbation assay, TF binding assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03226 | chr19:55417234~55417304 | blood | NK-92 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03227 | chr2:109689202~109690258 | amygdala | Mouse amygdala tissue | -- | Functional perturbation assay, Enhancer activity assay |
| E_03228 | chr2:109689202~109690258 | amygdala | Female BE5.1KO mouse amygdala tissue | obesity | Functional perturbation assay; Target-gene expression assay; In vivo phenotypic validation; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_03229 | chr9:21980404~21981404 | kidney | HEK293 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03230 | chr11:5301600~5302400 | blood / hematopoietic system | K-562 | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03231 | chr11:5301600~5302400 | blood / hematopoietic system | K-562 | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03232 | chr11:5301600~5302400 | blood / hematopoietic system | K-562 | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03233 | chr10:90723100~90723900 | hypothalamus | in vivo mouse hypothalamus | obesity | Enhancer activation assay; In vivo functional perturbation assay |
| E_03234 | chr22:39072097~39074320 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03235 | chr22:39072097~39074320 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03236 | chr22:39072097~39074320 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03237 | chr22:39072097~39074320 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03238 | chr22:39072097~39074320 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03239 | chr22:39063777~39068917 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03240 | chr22:39063777~39068917 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03241 | chr22:39063777~39068917 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03242 | chr22:39063777~39068917 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03243 | chr22:39063777~39068917 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03244 | chr22:39094134~39100780 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03245 | chr22:39094134~39100780 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03246 | chr22:39094134~39100780 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03247 | chr22:39094134~39100780 | blood | MEC-1 | B-cell chronic lymphocytic leukemia | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03248 | chr11:112769652~112770944 | testis | primary XY fetal gonadal somatic cells | -- | In vivo enhancer loss-of-function; developmental enhancer assay |
| E_03249 | chr11:112769652~112770944 | testis | primary XY fetal gonadal somatic cells | -- | In vivo enhancer loss-of-function; developmental enhancer assay |
| E_03250 | chr10:52386564~52388864 | definitive endoderm | transient transgenic mouse embryos | -- | Promoter/enhancer-driven transgenic reporter assay; In vivo functional validation |
| E_03251 | chr14:48799494~48801489 | retina | E11.5 mouse embryo | -- | Enhancer activity assay; In vivo enhancer validation |
| E_03252 | chr9:22050310~22054084 | eye | IMR-90 | glaucoma | Allele-specific regulatory-element activity assay; TF binding assay; Repressor-function assay; Disease-variant functional analysis |
| E_03253 | chr9:22050310~22054084 | eye | human neural stem cells | glaucoma | Allele-specific regulatory-element activity assay; TF binding assay; Repressor-function assay; Disease-variant functional analysis |
| E_03254 | chr9:22050310~22054084 | eye | MCF-7 | glaucoma | Allele-specific regulatory-element activity assay; TF binding assay; Repressor-function assay |
| E_03255 | chr11:112769210~112772210 | gonad | Testis | -- | Endogenous enhancer perturbation; In vivo functional validation |
| E_03256 | chr20:55417234~55417304 | -- | NK-92,U-2 OS | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03257 | chr20:55417234~55417304 | -- | NK-92,U-2 OS | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03258 | chr16:21480000~21482000 | embryo | neural differentiation model | -- | Intragenic pre-marked enhancer with ectoderm/future-brain activity and endogenous functional requirement |
| E_03259 | chr5:107680655~107682655 | blood / hematopoietic system | Hematopoietic Cell,B Cell,T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03260 | chr5:107680655~107682655 | blood / hematopoietic system | Hematopoietic Cell,B Cell,T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03261 | chr7:4340200~4340800 | blood | mouse NK cells | -- | Cis-regulatory activity assay; conserved regulatory-element analysis; transcription-factor expression assay |
| E_03262 | chr5:98716000~98718000 | embryo | mESCs | -- | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_03263 | chr7:142855000~142857000 | embryo | Mouse embryonic stem cells (mESCs) | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03264 | chr2:226125612~226127012 | adipose tissue | Human Preadipocyte | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_03265 | chr15:89400200~89400500 | brain | Neural Progenitor Cells (NPCs) | -- | Functional perturbation assay, Enhancer activity assay; Disease-variant functional analysis |
| E_03266 | chr15:89400200~89400500 | brain | Neural Progenitor Cells (NPCs) | -- | Functional perturbation assay, Enhancer activity assay; Disease-variant functional analysis |
| E_03267 | chr14:37246515~37246652 | prostate gland | LNCaP | prostate cancer | Functional perturbation assay, Chromatin interaction assay; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_03268 | chr14:37278706~37279509 | prostate gland | LNCaP | prostate cancer | Functional perturbation assay, Chromatin interaction assay; Endogenous enhancer perturbation; Chromatin interaction assay |
| E_03269 | chr15:96725740~96737960 | heart | E11.5 Heart | Congenital Heart Disease | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03270 | chr8:128000000~128300000 | colon | CRC cells | colorectal cancer | Super-enhancer functional analysis; In vivo functional validation |
| E_03271 | chr2:233745300~233745811 | liver | ShP51 (PXR-expressing HepG2 derivative) | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03272 | chr2:233756747~233757190 | liver | ShP51 (PXR-expressing HepG2 derivative) | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03273 | chr9:137494462~137494862 | endometrium | 1390C1 | -- | CRISPR interference (CRISPRi) |
| E_03274 | chr9:137494462~137494862 | endometrium | 1390C1 | -- | CRISPR interference (CRISPRi) |
| E_03275 | chr9:137494462~137494862 | endometrium | 1390C1 | -- | CRISPR interference (CRISPRi) |
| E_03276 | chr9:137494462~137494862 | endometrium | 1390C1 | -- | CRISPR interference (CRISPRi) |
| E_03277 | chr9:137494462~137494862 | endometrium | 1390C1 | -- | CRISPR interference (CRISPRi) |
| E_03278 | chr7:54978916~55304142 | breast | BEN | multiple cancer types | Chromatin interaction assay, Functional perturbation assay |
| E_03279 | chr18:87758000~87762000 | retina | Primary retinal pigment epithelium (RPE) cells | proliferative vitreoretinopathy | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03280 | chr18:87758000~87762000 | retina | Primary retinal pigment epithelium (RPE) cells | proliferative vitreoretinopathy | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03281 | chr18:87758000~87762000 | retina | Primary retinal pigment epithelium (RPE) cells | proliferative vitreoretinopathy | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03282 | chr18:87758000~87762000 | retina | Primary retinal pigment epithelium (RPE) cells | proliferative vitreoretinopathy | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03283 | chr18:87758000~87762000 | retina | Primary retinal pigment epithelium (RPE) cells | proliferative vitreoretinopathy | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03284 | chr2:176265000~176270000 | bone tissue | A673 | Ewing sarcoma | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_03285 | chr2:176265000~176270000 | bone tissue | CHLA10 | Ewing sarcoma | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_03286 | chr2:176265000~176270000 | bone tissue | TC32 | Ewing sarcoma | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_03287 | chr4:55568410~55569020 | digestive tract | GIST48 | gastrointestinal stromal tumor | Enhancer occupancy assay; Pioneer-factor chromatin-accessibility assay; Functional perturbation assay |
| E_03288 | chr4:55568410~55569020 | digestive tract | GIST48 | gastrointestinal stromal tumor | Enhancer occupancy assay; lineage-TF co-occupancy assay; functional perturbation assay |
| E_03289 | chr4:55568410~55569020 | digestive tract | GIST-T1 | gastrointestinal stromal tumor | Enhancer occupancy assay; lineage-TF co-occupancy assay; functional perturbation assay |
| E_03290 | chr4:55568410~55569020 | digestive tract | GIST48 | gastrointestinal stromal tumor | Enhancer occupancy assay; Pioneer-factor chromatin-accessibility assay; Functional perturbation assay |
| E_03291 | chr4:55568410~55569020 | digestive tract | GIST48 | gastrointestinal stromal tumor | Enhancer occupancy assay; pioneer-factor chromatin-accessibility assay; functional perturbation assay |
| E_03292 | chr4:55568410~55569020 | digestive tract | GIST-T1 | gastrointestinal stromal tumor | Enhancer occupancy assay; pioneer-factor chromatin-accessibility assay; functional perturbation assay |
| E_03293 | chr11:2218986~2222624 | colon | HCT 116 | colorectal cancer | Enhancer activity assay; Chromatin interaction assay; Structural-variant enhancer-hijacking assay |
| E_03294 | chr11:2227598~2233058 | colon | HCT 116 | colorectal cancer | Enhancer activity assay; Chromatin interaction assay; Structural-variant enhancer-hijacking assay |
| E_03295 | chr11:2234046~2237062 | colon | HCT 116 | colorectal cancer | Enhancer activity assay; Chromatin interaction assay; Structural-variant enhancer-hijacking assay |
| E_03296 | chr11:2236031~2239626 | colon | HCT 116 | colorectal cancer | Enhancer activity assay; Chromatin interaction assay; Structural-variant enhancer-hijacking assay |
| E_03297 | chr11:98979280~98979880 | heart | COS-7 | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03298 | chr11:98979280~98979880 | heart | COS-7 | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03299 | chr11:98979280~98979880 | heart | COS-7 | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03300 | chr11:10070908~10071400 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03301 | chr11:10070908~10071400 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03302 | chr11:10070908~10071400 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03303 | chr11:10077283~10077800 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03304 | chr11:10077283~10077800 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03305 | chr11:10077283~10077800 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03306 | chr11:10081501~10082508 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03307 | chr11:10081501~10082508 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03308 | chr11:10081501~10082508 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03309 | chr11:10070908~10082508 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03310 | chr11:10070908~10082508 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03311 | chr11:10070908~10082508 | mammary gland | Primary Mouse Mammary Epithelial | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03312 | chr4:55520000~55580000 | digestive tract | GIST48 | gastrointestinal stromal tumor | Enhancer occupancy assay; Pioneer-factor chromatin-accessibility assay; Functional perturbation assay |
| E_03313 | chr11:32150550~32151858 | liver | primary Ter119+ erythroid cells | -- | Enhancer chromatin-state assay; Enhancer-derived transcription assay; Alternative-promoter assay; Functional deletion analysis |
| E_03314 | chr15:93405000~93406000 | heart | hiPSC-CMs | -- | Enhancer activity assay, Functional perturbation assay; TF binding assay; Chromatin-state profiling |
| E_03315 | chr18:68218430~68219367 | liver | primary Ter119+ erythroid cells | -- | Intragenic enhancer assay; Enhancer-derived transcription assay; Alternative-promoter assay |
| E_03316 | chr20:54119731~54198946 | breast | MCF-7 | multiple cancer types | TF binding assay, Functional perturbation assay |
| E_03317 | chr20:54119731~54198946 | breast | MCF-7 | multiple cancer types | TF binding assay, Functional perturbation assay |
| E_03318 | chr11:2219531~2239062 | lung | HCC-15 | Lung Cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03319 | chr1:107667300~107677300 | pigmented layer of retina | Primary retinal pigment epithelial cells from traumatic PVR and contralateral control eyes of 8-week-old male C57BL/6J mice | traumatic proliferative vitreoretinopathy | Enhancer characterization; Disease-associated chromatin profiling; Functional pathway perturbation assay |
| E_03320 | chr11:32145028~32146147 | liver | primary Ter119+ erythroid cells | -- | Enhancer chromatin-state assay; Enhancer transcription assay |
| E_03321 | chr11:32156048~32157191 | liver | primary Ter119+ erythroid cells | -- | Enhancer chromatin-state assay; Enhancer-derived transcription assay; Alternative-promoter assay |
| E_03322 | chr11:32165011~32165922 | liver | primary Ter119+ erythroid cells | -- | Enhancer chromatin-state assay; Enhancer-derived transcription assay; Alternative-promoter assay |
| E_03323 | chr11:32168783~32169689 | liver | primary Ter119+ erythroid cells | -- | Enhancer chromatin-state assay; Enhancer-derived transcription assay; Alternative-promoter assay |
| E_03324 | chr11:76772927~76773266 | liver | Hepatocytes | -- | Super-enhancer activity assay; Disease-variant functional analysis |
| E_03325 | chr2:233764355~233764676 | liver | Primary hepatocytes | -- | Enhancer activity assay; Disease-variant functional analysis |
| E_03326 | chr14:63196014~63196614 | heart | Cx30.2+ Cells | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03327 | chr1:13820000~13840000 | breast | BEN | multiple cancer types | TF binding assay, Gene expression correlation |
| E_03328 | chr11:32244715~32246895 | blood / hematopoietic system | Primary Erythroid Cell | -- | TF-binding/chromatin assay |
| E_03329 | chr11:32249976~32252156 | blood / hematopoietic system | Primary Erythroid Cell | -- | TF-binding/chromatin assay |
| E_03330 | chr11:32255189~32257369 | blood / hematopoietic system | Primary Erythroid Cell | -- | TF-binding/chromatin assay |
| E_03331 | chr11:32268128~32270308 | blood / hematopoietic system | Primary Erythroid Cell | -- | TF-binding/chromatin assay |
| E_03332 | chr11:32264052~32266232 | blood / hematopoietic system | Primary Erythroid Cell | -- | TF-binding/chromatin assay |
| E_03333 | chr20:54107388~54107945 | brain | D-566MG | glioblastoma | Super-enhancer activity assay |
| E_03334 | chr9:48605113~48605195 | adipose tissue | 3T3-L1 | obesity | Enhancer activity assay, TF binding assay; Endogenous enhancer perturbation |
| E_03335 | chr9:48606327~48606478 | adipose tissue | 3T3-L1 | obesity | Enhancer activity assay, TF binding assay; Endogenous enhancer perturbation |
| E_03336 | chr22:30195717~30197444 | lung | A-549 | lung carcinoma | Enhancer activity assay, TF binding assay; In vivo functional validation |
| E_03337 | chr17:64082103~64082506 | ovary | OVCAR-5 | ovarian carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; Endogenous enhancer perturbation; TF binding assay |
| E_03338 | chr21:32901686~32902140 | breast | MCF-7 | breast carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03339 | chr18:48949564~48951076 | liver | Huh-7 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay; Enhancer activity assay; TF binding assay; In vivo functional validation |
| E_03340 | chr4:28176897~28177065 | skeletal muscle tissue | Primary mouse myoblasts | -- | Enhancer activity assay; Functional perturbation assay |
| E_03341 | chr7:87574094~87575396 | bone marrow | Primary AML blasts | acute myeloid leukemia | Functional perturbation assay, TF binding assay, Enhancer activity assay, Chromatin interaction assay |
| E_03342 | chr11:5246600~5247600 | kidney | HEK293T | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03343 | chr11:33396000~33396331 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay; Enhancer activity assay; TF binding assay; In vivo functional validation |
| E_03344 | chr6:163826086~163833600 | liver | PLC/PRF/5 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; In vivo functional validation |
| E_03345 | chr5:137465620~137479420 | kidney | Renal EPO-producing (REP) Cells | Renal Anemia | Enhancer activity assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03346 | chr5:148785000~148815000 | heart | Cardiac Progenitor Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_03347 | chr8:128413174~128414429 | colon | HCT 116 | colorectal cancer | Chromatin interaction assay; Functional perturbation assay; Genetic variant-associated regulatory analysis; Disease-variant functional analysis |
| E_03348 | chr4:28176897~28177065 | skeletal muscle tissue | Satellite cells | -- | Enhancer activity assay; Functional perturbation assay |
| E_03349 | chr4:140235012~140235389 | blood | Mouse erythroblast cell | -- | Chromatin interaction assay, Functional perturbation assay |
| E_03350 | chr4:140385104~140385471 | blood | Mouse erythroblast cell | -- | Chromatin interaction assay, Functional perturbation assay |
| E_03351 | chr3:34824938~34837938 | embryo | ES-R1 | -- | CRISPR deletion functional assay |
| E_03352 | chr3:34824938~34837938 | embryo | ES-R1 | -- | CRISPR deletion functional assay |
| E_03353 | chr3:34824938~34837938 | embryo | ES-R1 | -- | CRISPR deletion functional assay |
| E_03354 | chr15:55288865~55289335 | pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer activity assay; Chromatin architectural-protein binding assay; Endogenous functional perturbation assay |
| E_03355 | chr15:55288865~55289335 | pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer activity assay; Chromatin architectural-protein binding assay; Endogenous functional perturbation assay |
| E_03356 | chr15:55288865~55289335 | pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer activity assay; Chromatin architectural-protein binding assay; Endogenous functional perturbation assay |
| E_03357 | chr9:27519197~27520919 | skin of body | Normal human keratinocytes | -- | Enhancer activity assay; Functional perturbation assay |
| E_03358 | chr9:27519197~27520919 | skin of body | Normal human keratinocytes | -- | Enhancer activity assay; Functional perturbation assay |
| E_03359 | chr9:27519197~27520919 | skin of body | Normal human keratinocytes | -- | Enhancer activity assay; Functional perturbation assay |
| E_03360 | chr9:27519197~27520919 | skin of body | Normal human keratinocytes | -- | Enhancer activity assay; Functional perturbation assay |
| E_03361 | chr7:35156536~35156974 | bone marrow | primary murine myeloid progenitor cells expressing Hoxa9 | acute myeloid leukemia model | Enhancer activity assay; TF binding assay; functional perturbation |
| E_03362 | chr7:46351197~46355693 | -- | C2C12 | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03363 | chr18:60793273~60794103 | blood | Jurkat | -- | TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_03364 | chr18:60793273~60794103 | blood | Jurkat | -- | TF binding assay; Chromatin interaction assay; Functional perturbation assay |
| E_03365 | chr1:183149939~183150336 | colon | Caco-2 | -- | Enhancer activity assay; Functional perturbation assay |
| E_03366 | chr1:183149939~183150336 | colon | Caco-2 | -- | Enhancer activity assay; Functional perturbation assay |
| E_03367 | chr1:183149939~183150336 | colon | Caco-2 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03368 | chr10:43569015~43569494 | -- | SK-N-BE | neuroblastoma | Enhancer activity assay; TF binding assay; DNA methylation assay; Functional perturbation assay |
| E_03369 | chr11:5225000~5226000 | uterine cervix | HeLa | cervical cancer | Functional perturbation assay |
| E_03370 | chr11:5225000~5226000 | blood | K-562 | chronic myeloid leukemia | Functional perturbation assay |
| E_03371 | chr7:126406352~126406616 | blood / hematopoietic system | B Cell,T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03372 | chr7:126406352~126406616 | blood / hematopoietic system | B Cell,T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03373 | chr7:126406352~126406616 | blood / hematopoietic system | B Cell,T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03374 | chr11:5225000~5226000 | bone element | SaOS-2 | osteosarcoma | Functional perturbation assay |
| E_03375 | chr7:35156536~35156974 | bone marrow | common myeloid progenitors from Vav-NUP98-HOXD13 mice | acute myeloid leukemia model | Enhancer activity assay; TF binding assay; functional perturbation |
| E_03376 | chr11:5225000~5226000 | kidney | HEK293 | -- | Functional perturbation assay |
| E_03377 | chr7:46366985~46368584 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; TF binding assay; Functional cis-element perturbation assay |
| E_03378 | chr11:17710000~17711000 | uterine cervix | HeLa | cervical cancer | Functional perturbation assay |
| E_03379 | chr11:17710000~17711000 | blood | K-562 | chronic myeloid leukemia | Functional perturbation assay |
| E_03380 | chr6:31130000~31131000 | uterine cervix | HeLa | cervical cancer | Functional perturbation assay |
| E_03381 | chr6:31130000~31131000 | blood | K-562 | chronic myeloid leukemia | Functional perturbation assay |
| E_03382 | chr5:137489416~137503216 | kidney | Renal EPO-producing (REP) cells | anemia | Enhancer activity assay; Functional perturbation assay; In vivo transgenic rescue assay; Gene expression assay |
| E_03383 | chr7:27930056~27930423 | -- | G1E-ER4 | -- | TF binding assay; Functional perturbation assay |
| E_03384 | chr11:17710000~17711000 | kidney | HEK293 | -- | Functional perturbation assay |
| E_03385 | chr6:31130000~31131000 | kidney | HEK293 | -- | Functional perturbation assay |
| E_03386 | chr9:27519749~27519900 | zone of skin | Normal human keratinocytes | -- | Enhancer activity assay |
| E_03387 | chr9:27520189~27520340 | zone of skin | Normal human keratinocytes | -- | Enhancer activity assay |
| E_03388 | chr5:148781015~148839604 | heart | Human fetal cardiac precursor cells | -- | Super-enhancer profiling; Functional perturbation assay; lncRNA regulatory assay |
| E_03389 | chr7:35912057~35912683 | bone marrow | 32Dcl3 | acute myeloid leukemia | Enhancer activity assay |
| E_03390 | chr7:35156536~35156974 | bone marrow | NUP98-HOXD13 transgenic mouse marrow progenitors | acute myeloid leukemia | Enhancer activity assay |
| E_03391 | chr8:128230172~128243000 | colon | HCT 116,RKO | colorectal cancer | Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03392 | chr7:126416668~126416932 | bone marrow | Primary multipotent hematopoietic progenitors | -- | Epigenetic priming assay; TF binding assay; Chromatin accessibility assay |
| E_03393 | chr7:126416668~126416932 | bone marrow | Primary pro-B cells | -- | TF binding assay; Chromatin accessibility assay; Enhancer-state assay |
| E_03394 | chr7:126416668~126416932 | spleen | Primary splenic B cells | -- | TF binding assay; Chromatin accessibility assay; Enhancer-state assay |
| E_03395 | chr7:126416668~126416932 | thymus | Primary thymocytes | -- | TF binding assay; Chromatin accessibility assay |
| E_03396 | chr18:60786011~60788011 | -- | Human T Lymphoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_03397 | chr18:60786011~60788011 | -- | Human T Lymphoid Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_03398 | chr10:43569296~43572684 | -- | SK-N-BE | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03399 | chr10:43569296~43572684 | -- | SK-N-BE | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03400 | chr10:43569045~43569456 | -- | SK-N-BE | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03401 | chr10:43569045~43569456 | -- | SK-N-BE | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03402 | chr7:46351197~46355694 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; Chromatin binding assay; Wnt signaling perturbation assay |
| E_03403 | chr7:35912057~35912683 | bone marrow | 32Dcl3 | acute myeloid leukemia | Enhancer activity assay |
| E_03404 | chr7:126416980~126417244 | bone marrow | B-lineage progenitor / B cells | -- | Developmental enhancer priming; TF occupancy; chromatin-state analysis |
| E_03405 | chr7:126416980~126417244 | bone marrow | multipotent hematopoietic progenitor cells | -- | Developmental enhancer priming; TF occupancy; chromatin-state analysis |
| E_03406 | chr7:126416980~126417244 | bone marrow | B-lineage progenitor cells | -- | Developmental enhancer priming; TF occupancy; chromatin-state analysis |
| E_03407 | chr7:126416668~126416932 | spleen | Primary splenic B cells | -- | TF binding assay; Enhancer-state assay |
| E_03408 | chr7:126416668~126416932 | spleen | Primary splenic B cells | -- | TF binding assay; Enhancer-state assay |
| E_03409 | chr5:142650068~142650435 | -- | G1E-ER4 | -- | -- |
| E_03410 | chr6:125380026~125380393 | -- | G1E-ER4 | -- | -- |
| E_03411 | chr9:120150022~120150389 | -- | G1E-ER4 | -- | -- |
| E_03412 | chr12:115092472~115096258 | connective tissue | Pluripotent stem cell | -- | Chromatin interaction assay, Enhancer activity assay, Functional perturbation assay |
| E_03413 | chr2:44294900~44295100 | adrenal gland | Kelly | neuroblastoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03414 | chr22:44315438~44315637 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03415 | chr6:31137269~31137697 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03416 | chr12:10123456~10124567 | blood | K-562 | -- | Functional perturbation assay, Enhancer activity assay; Endogenous enhancer perturbation |
| E_03417 | chr6:34223538~34224727 | pleural effusion | K-562 | -- | Enhancer activation assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_03418 | chr4:95630001~95639906 | cerebellum | Cerebellar granule neurons | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03419 | chr4:95630001~95639906 | cerebellum | Cerebellar granule neurons | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03420 | chr11:97576234~97587534 | liver | Primary mouse hepatocytes | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; TF binding assay |
| E_03421 | chr15:4422074~4423282 | liver | Primary mouse hepatocytes | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; TF binding assay |
| E_03422 | chr2:171152164~171153352 | liver | Primary mouse hepatocytes | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; TF binding assay |
| E_03423 | chr8:56652281~56653526 | liver | Primary mouse hepatocytes | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; TF binding assay |
| E_03424 | chr18:61108475~61108975 | bone marrow | primary B220+ bone marrow B cells | -- | Enhancer/antisense-promoter activity assay; TF binding assay; Functional perturbation assay |
| E_03425 | chr6:43210000~43211000 | brain | iPSC-derived excitatory neurons | -- | Functional perturbation assay, Enhancer activity assay |
| E_03426 | chr3:128322357~128323157 | bone marrow | MOLM-1 | acute myeloid leukemia with inv(3)/t(3; 3); MECOM-rearranged AML | Functional dissection of hijacked enhancer TF complex; enhancer-promoter interaction; TF-site mutagenesis |
| E_03427 | chr3:128322357~128323157 | bone marrow | MUTZ-3 | acute myeloid leukemia with inv(3)/t(3; 3); MECOM-rearranged AML | Functional dissection of hijacked enhancer TF complex; enhancer-promoter interaction; TF-site mutagenesis |
| E_03428 | chr3:128322357~128323157 | bone marrow | HNT-34 | acute myeloid leukemia with inv(3)/t(3; 3); MECOM-rearranged AML | Functional dissection of hijacked enhancer TF complex; enhancer-promoter interaction; TF-site mutagenesis |
| E_03429 | chr3:128322357~128323157 | bone marrow | MOLM-1 | acute myeloid leukemia with inv(3)/t(3; 3); MECOM-rearranged AML | Functional dissection of hijacked enhancer TF complex; enhancer-promoter interaction; TF-site mutagenesis |
| E_03430 | chr3:128322357~128323157 | bone marrow | MUTZ-3 | acute myeloid leukemia with inv(3)/t(3; 3); MECOM-rearranged AML | Functional dissection of hijacked enhancer TF complex; enhancer-promoter interaction; TF-site mutagenesis |
| E_03431 | chr3:128322357~128323157 | bone marrow | HNT-34 | acute myeloid leukemia with inv(3)/t(3; 3); MECOM-rearranged AML | Functional dissection of hijacked enhancer TF complex; enhancer-promoter interaction; TF-site mutagenesis |
| E_03432 | chr4:95048663~95059853 | cerebellum | Mouse Cerebellar Granule Neurons | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03433 | chr15:63255515~63256347 | thymus | N-Me GATA-site mutant mouse DN3 thymocytes | T-cell acute lymphoblastic leukemia | Endogenous TF-site perturbation; enhancer accessibility assay; enhancer-promoter interaction assay |
| E_03434 | chr15:63611116~63611556 | bone marrow | primary mouse hematopoietic stem/progenitor cells | -- | In-vivo enhancer-module deletion and hematopoietic phenotyping |
| E_03435 | chr15:63616791~63618232 | bone marrow | primary mouse hematopoietic stem/progenitor cells | -- | In-vivo enhancer-module deletion and hematopoietic phenotyping |
| E_03436 | chr15:63657837~63659699 | bone marrow | primary mouse hematopoietic stem/progenitor cells | -- | In-vivo enhancer-module deletion and lineage phenotyping |
| E_03437 | chr15:63665359~63665959 | bone marrow | primary mouse hematopoietic stem/progenitor cells | -- | In-vivo enhancer-module analysis |
| E_03438 | chr15:63678942~63679359 | bone marrow | primary mouse hematopoietic stem/progenitor cells | -- | In-vivo enhancer-module analysis |
| E_03439 | chr15:63704706~63705184 | bone marrow | primary mouse hematopoietic stem/progenitor cells | -- | In-vivo enhancer-module deletion and hematopoietic phenotyping |
| E_03440 | chr15:63709542~63709926 | bone marrow | primary mouse hematopoietic stem/progenitor cells | -- | In-vivo enhancer-module analysis |
| E_03441 | chr15:63736276~63736746 | bone marrow | primary mouse hematopoietic stem/progenitor cells | -- | In-vivo enhancer-module analysis |
| E_03442 | chr10:123099588~123100426 | -- | GMSM-K (human embry-onic oral epithelial cells) | -- | Enhancer activity assay; Chromatin interaction assay; Genetic-variant functional analysis; In vivo functional validation |
| E_03443 | chr6:138229810~138230149 | bone marrow | K-562 | systemic lupus erythematosus | Enhancer activity assay, Chromatin interaction assay, TF binding assay; Enhancer activity assay; TF binding assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_03444 | chr11:3217000~3222000 | bone marrow | Primary Murine Erythroblasts | -- | Enhancer activity assay, TF binding assay; In vivo functional validation |
| E_03445 | chr11:3222000~3227000 | bone marrow | Primary Murine Erythroblasts | -- | Enhancer activity assay, TF binding assay; In vivo functional validation |
| E_03446 | chr11:3231000~3236000 | bone marrow | Primary Murine Erythroblasts | -- | Enhancer activity assay, TF binding assay; In vivo functional validation |
| E_03447 | chr11:3235000~3240000 | bone marrow | Primary Murine Erythroblasts | -- | Enhancer activity assay, TF binding assay; In vivo functional validation |
| E_03448 | chr15:63510497~63510914 | bone marrow | MEPs | acute myeloid leukemia | Functional perturbation assay |
| E_03449 | chr15:63567831~63568301 | bone marrow | MEPs | acute myeloid leukemia | Functional perturbation assay |
| E_03450 | chr6:138229810~138230149 | blood | EBV-transformed lymphoblastoid cells from risk and non-risk donors | Systemic lupus erythematosus | Enhancer activity; TF binding; long-range enhancer-promoter looping |
| E_03451 | chr6:138229810~138230149 | blood | EBV-transformed lymphoblastoid cells from risk and non-risk donors | Systemic lupus erythematosus | Enhancer activity; TF binding; long-range enhancer-promoter looping |
| E_03452 | chr6:138229810~138230149 | blood | EBV-transformed lymphoblastoid cells from risk and non-risk donors | Systemic lupus erythematosus | Enhancer activity; TF binding; long-range enhancer-promoter looping |
| E_03453 | chr6:138229810~138230149 | blood | EBV-transformed lymphoblastoid cells from risk and non-risk donors | Systemic lupus erythematosus | Enhancer activity; chromatin organizer dependency; enhancer-promoter looping |
| E_03454 | chr16:94867~95418 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03455 | chr16:94867~95418 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03456 | chr16:94867~95418 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03457 | chr16:94867~95418 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03458 | chr16:94867~95418 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03459 | chr16:94867~95418 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03460 | chr16:103290~103957 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03461 | chr16:103290~103957 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03462 | chr16:103290~103957 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03463 | chr16:103290~103957 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03464 | chr16:103290~103957 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03465 | chr16:103290~103957 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03466 | chr16:109787~110385 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03467 | chr16:109787~110385 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03468 | chr16:109787~110385 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03469 | chr16:109787~110385 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03470 | chr16:132962~133361 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03471 | chr16:132962~133361 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03472 | chr16:132962~133361 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03473 | chr16:132962~133361 | blood | Primary human erythroblasts | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03474 | chr11:32145028~32146147 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03475 | chr11:32145028~32146147 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03476 | chr11:32145028~32146147 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03477 | chr11:32145028~32146147 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03478 | chr11:32145028~32146147 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03479 | chr11:32145028~32146147 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03480 | chr11:32150550~32151858 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03481 | chr11:32150550~32151858 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03482 | chr11:32150550~32151858 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03483 | chr11:32150550~32151858 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03484 | chr11:32150550~32151858 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03485 | chr11:32150550~32151858 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03486 | chr11:32156048~32157191 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03487 | chr11:32156048~32157191 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03488 | chr11:32156048~32157191 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03489 | chr11:32156048~32157191 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03490 | chr11:32165011~32165922 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03491 | chr11:32165011~32165922 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03492 | chr11:32165011~32165922 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03493 | chr11:32165011~32165922 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03494 | chr11:32165011~32165922 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03495 | chr11:32165011~32165922 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03496 | chr11:32168783~32169689 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03497 | chr11:32168783~32169689 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03498 | chr11:32168783~32169689 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03499 | chr11:32168783~32169689 | spleen | Primary erythroid cells from humanized mouse | -- | TF binding assay; Chromatin modification assay; In vivo functional validation |
| E_03500 | chr4:49550000~49600000 | cerebellum | Mouse Cerebellar Granule Neurons | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03501 | chr16:163406~163841 | blood | primary human erythroid cells | -- | Locus-wide enhancer/chromatin-state mapping; TF occupancy analysis; In vivo functional validation |
| E_03502 | chr16:163406~163841 | blood | primary human erythroid cells | -- | Locus-wide enhancer/chromatin-state mapping; TF occupancy analysis; In vivo functional validation |
| E_03503 | chr15:63648126~63648667 | bone marrow | primary mouse HSC/progenitors | -- | In-vivo enhancer-module deletion; HSC functional analysis |
| E_03504 | chr3:128322357~128323157 | bone marrow | MOLM-1 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03505 | chr3:128322357~128323157 | bone marrow | MUTZ-3 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03506 | chr3:128322357~128323157 | bone marrow | HNT-34 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03507 | chr3:128322357~128323157 | bone marrow | MOLM-1 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03508 | chr3:128322357~128323157 | bone marrow | MUTZ-3 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03509 | chr3:128322357~128323157 | bone marrow | HNT-34 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03510 | chr3:128322357~128323157 | bone marrow | MOLM-1 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03511 | chr3:128322357~128323157 | bone marrow | MUTZ-3 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03512 | chr3:128322357~128323157 | bone marrow | HNT-34 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03513 | chr3:128322357~128323157 | bone marrow | MOLM-1 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03514 | chr3:128322357~128323157 | bone marrow | MUTZ-3 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03515 | chr3:128322357~128323157 | bone marrow | HNT-34 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03516 | chr3:128322357~128323157 | bone marrow | MOLM-1 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03517 | chr3:128322357~128323157 | bone marrow | MUTZ-3 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03518 | chr3:128322357~128323157 | bone marrow | HNT-34 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03519 | chr3:128322357~128323157 | bone marrow | MOLM-1 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03520 | chr3:128322357~128323157 | bone marrow | MUTZ-3 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03521 | chr3:128322357~128323157 | bone marrow | HNT-34 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03522 | chr3:128322357~128323157 | bone marrow | MOLM-1 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03523 | chr3:128322357~128323157 | bone marrow | MUTZ-3 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03524 | chr3:128322357~128323157 | bone marrow | HNT-34 | MECOM-rearranged acute myeloid leukemia | TF-complex dissection at a hijacked enhancer; enhancer-promoter interaction; functional TF perturbation |
| E_03525 | chr8:130180065~130180972 | blood | Jurkat E6.1 | T-cell acute lymphoblastic leukemia | TF-dependent enhancer mechanism; chromatin accessibility assay; enhancer-promoter interaction assay |
| E_03526 | chr6:138229810~138230149 | blood | THP-1 | Systemic lupus erythematosus | Enhancer activity; TF binding; long-range enhancer-promoter looping |
| E_03527 | chr6:138229810~138230149 | blood | THP-1 | Systemic lupus erythematosus | Enhancer activity; TF binding; long-range enhancer-promoter looping |
| E_03528 | chr6:138229810~138230149 | blood | THP-1 | Systemic lupus erythematosus | Enhancer activity; TF binding; long-range enhancer-promoter looping |
| E_03529 | chr6:138229810~138230149 | blood | THP-1 | Systemic lupus erythematosus | Enhancer activity; chromatin organizer dependency; enhancer-promoter looping |
| E_03530 | chr3:128322411~128323124 | Bone marrow / hematopoietic system | MUTZ-3 | Acute myeloid leukemia with MECOM rearrangement [3q-AML] | TF-site functional validation; enhancer complex characterization; enhancer-promoter interaction |
| E_03531 | chr3:128322411~128323124 | Bone marrow / hematopoietic system | HNT-34 | Acute myeloid leukemia with MECOM rearrangement [3q-AML] | TF-site functional validation; enhancer complex characterization; enhancer-promoter interaction |
| E_03532 | chr3:128322411~128323124 | Bone marrow / hematopoietic system | MUTZ-3 | Acute myeloid leukemia with MECOM rearrangement [3q-AML] | TF-site functional validation; enhancer complex characterization; enhancer-promoter interaction |
| E_03533 | chr3:128322411~128323124 | Bone marrow / hematopoietic system | HNT-34 | Acute myeloid leukemia with MECOM rearrangement [3q-AML] | TF-site functional validation; enhancer complex characterization; enhancer-promoter interaction |
| E_03534 | chr6:138229810~138230149 | blood | HEK293T | Systemic lupus erythematosus | Enhancer activity; TF binding; long-range enhancer-promoter looping |
| E_03535 | chr6:138229810~138230149 | blood | HEK293T | Systemic lupus erythematosus | Enhancer activity; TF binding; long-range enhancer-promoter looping |
| E_03536 | chr6:138229810~138230149 | blood | HEK293T | Systemic lupus erythematosus | Enhancer activity; TF binding; long-range enhancer-promoter looping |
| E_03537 | chr6:138229810~138230149 | blood | HEK293T | Systemic lupus erythematosus | Enhancer activity; chromatin organizer dependency; enhancer-promoter looping |
| E_03538 | chr15:63611116~63736746 | bone marrow | mouse MLL-AF9 leukemia and HSC/progenitor models | acute myeloid leukemia | Enhancer-cluster perturbation in normal and leukemic hematopoietic hierarchies |
| E_03539 | chr17:54754755~54758235 | -- | GMSM-K (human embry-onic oral epithelial cells) | -- | Enhancer activity assay; Genetic-variant functional analysis; In vivo functional validation |
| E_03540 | chr17:54775600~54778000 | -- | GMSM-K (human embry-onic oral epithelial cells) | -- | Enhancer activity assay; Genetic-variant functional analysis; In vivo functional validation |
| E_03541 | chr8:130180065~130180972 | bone marrow | primary T-ALL | T-cell acute lymphoblastic leukemia | TF-dependent enhancer accessibility; leukemia initiation and maintenance |
| E_03542 | chr8:130180065~130180972 | blood | primary T-ALL | T-cell acute lymphoblastic leukemia | TF-dependent enhancer accessibility; leukemia initiation and maintenance |
| E_03543 | chr8:130180217~130180629 | blood | primary T-ALL | T-cell acute lymphoblastic leukemia | TF-dependent enhancer chromatin opening; enhancer activity; leukemia initiation and maintenance |
| E_03544 | chr8:130180217~130180629 | bone marrow | primary T-ALL | T-cell acute lymphoblastic leukemia | TF-dependent enhancer chromatin opening; enhancer activity; leukemia initiation and maintenance |
| E_03545 | chr8:130180065~130180972 | thymus | human T-ALL and mouse T-ALL models | T-cell acute lymphoblastic leukemia | TF-dependent enhancer accessibility and leukemia functional validation |
| E_03546 | chr8:130180065~130180972 | bone marrow | human T-ALL cell models | T-cell acute lymphoblastic leukemia | TF-dependent enhancer accessibility; leukemia initiation and maintenance |
| E_03547 | chr8:130180065~130180972 | bone marrow | mouse T-ALL | T-cell acute lymphoblastic leukemia | TF-dependent enhancer accessibility; leukemia initiation and maintenance |
| E_03548 | chr8:130180065~130180972 | blood | human T-ALL cell models | T-cell acute lymphoblastic leukemia | TF-dependent enhancer accessibility; leukemia initiation and maintenance |
| E_03549 | chr8:130180065~130180972 | blood | mouse T-ALL | T-cell acute lymphoblastic leukemia | TF-dependent enhancer accessibility; leukemia initiation and maintenance |
| E_03550 | chr18:61235500~61235837 | blood | 293T cyno BCMA | -- | Enhancer activity assay, TF binding assay |
| E_03551 | chr8:130180217~130180629 | blood | human T-ALL cells | T-cell acute lymphoblastic leukemia | TF-dependent enhancer chromatin opening; enhancer activity; leukemia initiation and maintenance |
| E_03552 | chr8:130180217~130180629 | blood | mouse NOTCH1-driven T-ALL | T-cell acute lymphoblastic leukemia | TF-dependent enhancer chromatin opening; enhancer activity; leukemia initiation and maintenance |
| E_03553 | chr8:130180217~130180629 | bone marrow | human T-ALL cells | T-cell acute lymphoblastic leukemia | TF-dependent enhancer chromatin opening; enhancer activity; leukemia initiation and maintenance |
| E_03554 | chr8:130180217~130180629 | bone marrow | mouse NOTCH1-driven T-ALL | T-cell acute lymphoblastic leukemia | TF-dependent enhancer chromatin opening; enhancer activity; leukemia initiation and maintenance |
| E_03555 | chr18:61099404~61099740 | blood / hematopoietic system | B Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03556 | chr11:3210000~3215000 | bone marrow | Primary Murine Erythroblasts | -- | Enhancer activity assay, TF binding assay |
| E_03557 | chr15:63714919~63952099 | blood / hematopoietic system | Bone Marrow | Leukaemia | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03558 | chr17:54754755~54758235 | optic fissure | patient DNA | orofacial cleft | Targeted risk-locus sequencing; functional enhancer-variant validation |
| E_03559 | chr17:54775600~54778000 | optic fissure | patient DNA | orofacial cleft | Targeted risk-locus sequencing; functional enhancer-variant validation |
| E_03560 | chr10:123099588~123100426 | bone element | MC3T3-E1 | -- | Enhancer activity assay |
| E_03561 | chr17:54776294~54777215 | Palatal epithelium | GMSM-K | -- | Enhancer activity assay |
| E_03562 | chr17:54754755~54758235 | optic fissure | embryonic neural-crest/craniofacial enhancer reporter models | orofacial cleft | Targeted risk-locus sequencing; functional enhancer-variant validation |
| E_03563 | chr17:54775600~54778000 | optic fissure | embryonic neural-crest/craniofacial enhancer reporter models | orofacial cleft | Targeted risk-locus sequencing; functional enhancer-variant validation |
| E_03564 | chr10:35949193~35950411 | cerebral cortex | -- | -- | in vivo reporter assay; genome editing; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_03565 | chr3:136050468~136050668 | kidney | HEK293 | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03566 | chr16:30669227~30670310 | neural tissue | hESC-derived NPCs | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_03567 | chr19:17438298~17439337 | neural tissue | hESC-derived NPCs | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; Enhancer activity assay; Disease-variant functional analysis |
| E_03568 | chr3:172549013~172551013 | breast | HCC1806 | triple-negative breast carcinoma | Enhancer variant functional assay; TF binding assay; genome editing assay |
| E_03569 | chr2:69342699~69343679 | connective tissue | Primary fibroblasts | -- | Chromatin interaction assay, Enhancer activity assay, Functional perturbation assay; Disease-variant functional analysis |
| E_03570 | chr2:177480000~177490000 | brain | normal human cortical astrocytes | glioma | Enhancer activity assay; eRNA assay; Chromatin interaction assay; Functional perturbation assay |
| E_03571 | chr15:79850614~79850824 | heart | Mouse Cardiac Endothelial Cells (MCECs) | -- | Enhancer activity assay, TF binding assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03572 | chr10:23930200~23931190 | olfactory epithelium | Olfactory sensory neuron (OSN) | -- | Enhancer activity assay; In vivo endogenous enhancer deletion; Cis-regulation assay |
| E_03573 | chr10:23987501~23988362 | olfactory epithelium | Olfactory sensory neuron (OSN) | -- | Enhancer activity assay; In vivo endogenous enhancer deletion; Cis-regulation assay |
| E_03574 | chr6:7563220~7563274 | bronchus | Primary normal human bronchial epithelial cells | idiopathic pulmonary fibrosis | Disease-variant functional analysis; endogenous enhancer/regulatory-core deletion; CRISPRi; single-base editing; target-gene expression validation |
| E_03575 | chr5:135012000~135012856 | forebrain | Embryonic neural progenitor | -- | Enhancer activity assay, TF binding assay; In vivo functional validation |
| E_03576 | chr7:45920458~45923258 | liver | Hep G2 | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03577 | chr8:130180065~130180972 | blood | NUP214-ABL1/TLX1-positive T-ALL cells | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03578 | chr1:13093655~13096290 | embryo | D2 epiblast-like cells (+Dox Nanog) | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Germline specification assay |
| E_03579 | chr10:44390290~44390668 | embryo | D2 epiblast-like cells (+Dox Nanog) | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; Germline specification assay |
| E_03580 | chr5:28889688~28890461 | nervous system | Neural progenitor | -- | Enhancer activity assay, Functional perturbation assay; In vivo functional validation |
| E_03581 | chr8:87424785~87425735 | blood | Mouse erythroid progenitor cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03582 | chr3:34563695~34565695 | brain | Axial Stem Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; In vivo functional validation |
| E_03583 | chr14:60973427~60975430 | -- | Eye | Primary Open-Angle Glaucoma | Enhancer activity assay; Chromatin interaction assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03584 | chr11:109985003~109985222 | -- | Osteosarcoma Stem Cells | osteosarcoma | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_03585 | chr11:109985003~109985222 | -- | Osteosarcoma Stem Cells | osteosarcoma | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_03586 | chr10:118255061~118255451 | -- | primary mouse CD4-positive T cells | -- | Endogenous enhancer deletion assay; Epigenetic mechanism assay; TF binding assay |
| E_03587 | chr10:118255061~118255451 | -- | primary mouse CD4-positive T cells | -- | Endogenous enhancer deletion assay; Epigenetic mechanism assay; TF binding assay |
| E_03588 | chr10:118255061~118255451 | -- | primary mouse CD4-positive T cells | -- | Endogenous enhancer deletion assay; Epigenetic mechanism assay; TF binding assay |
| E_03589 | chr6:7563220~7563274 | bronchus | 16HBE14o- | idiopathic pulmonary fibrosis | Disease-variant functional analysis; endogenous enhancer/regulatory-core deletion; CRISPRi; single-base editing; target-gene expression validation |
| E_03590 | chr15:52316013~52316633 | islet of Langerhans | Beta-TC-3 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03591 | chr15:52316213~52316412 | islet of Langerhans | Beta-TC-3 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03592 | chr8:84899088~84902859 | blood / hematopoietic system | Murine erythroleukemia (MEL) line 745A,32DEpo1,293T | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_03593 | chr2:69343058~70165537 | pulmonary lobule | hCNCC | -- | Chromatin interaction assay, Functional perturbation assay |
| E_03594 | chr9:60714330~60714960 | bone tissue | mOS-482 | osteosarcoma | Enhancer activity assay; TF binding assay |
| E_03595 | chr1:100900000~100900243 | bone element | TASH | osteosarcoma | Enhancer activity assay |
| E_03596 | chr15:52315678~52316298 | islet of Langerhans | Beta-TC-3 | -- | Intronic enhancer discovery; cell-type-specific reporter assay; direct TF-binding assay |
| E_03597 | chr9:60714330~60714960 | bone tissue | murine osteosarcoma cells | osteosarcoma | Enhancer activity assay; TF binding assay |
| E_03598 | chr8:10368745~10368945 | kidney | HEK293 | -- | Enhancer activity assay, Chromatin interaction assay |
| E_03599 | chr15:52153900~52154520 | pancreas | #NAME? | -- | Enhancer activity assay; cell-type specificity assay; direct TF binding |
| E_03600 | chr15:52315878~52316077 | islet of Langerhans | Beta-TC-3 | -- | Enhancer-core dissection; TF-site mutagenesis; reporter assay |
| E_03601 | chr15:52315678~52316298 | pancreas | Islet B-Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03602 | chr3:34668443~34668497 | embryo | Mouse embryonic tissue | -- | Enhancer activity assay |
| E_03603 | chr14:60974427~60974430 | retina | HEK293 | open-angle glaucoma | Enhancer variant functional assay |
| E_03604 | chr14:60974427~60974430 | eye | HEK293 | open-angle glaucoma | Enhancer variant functional assay |
| E_03605 | chr15:52315678~52316298 | pancreas | developing mouse pancreatic beta cells | -- | Developmental expression correlation plus functionally validated enhancer A |
| E_03606 | chr15:52159003~52159479 | pancreas | #NAME? | -- | Enhancer activity assay; cell-type comparison |
| E_03607 | chr15:52320781~52321257 | islet of Langerhans | Alpha-TC-6 / Beta-TC-3 comparison | -- | Comparative intronic enhancer reporter assay |
| E_03608 | chr15:52321116~52321592 | islet of Langerhans | Beta-TC-3 | -- | Enhancer activity assay |
| E_03609 | chr15:52159003~52159479 | pancreas | #NAME? | -- | Enhancer activity assay; cell-type comparison |
| E_03610 | chr15:52316013~52316633 | islet of Langerhans | alphaTC1 Clone 6 | -- | Enhancer activity assay |
| E_03611 | chr15:52321116~52321592 | islet of Langerhans | alphaTC1 Clone 6 | -- | Enhancer activity assay |
| E_03612 | chr5:133050976~133051978 | liver | HCCLM3 | hepatocellular carcinoma | Super-enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03613 | chr13:48974891~48975426 | breast | HCC1806 | triple-negative breast carcinoma | Enhancer functional perturbation assay |
| E_03614 | chr2:239200000~239250000 | lung | H4-II-E-C3 | lung adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03615 | chr12:6933000~6941000 | pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer activity assay, Functional perturbation assay, TF binding assay; In vivo functional validation |
| E_03616 | chr7:54960823~54970827 | nasopharynx | S18 | nasopharyngeal carcinoma | Enhancer activity assay, Functional perturbation assay; Chromatin-state profiling; In vivo functional validation |
| E_03617 | chr10:102880001~102881789 | pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03618 | chr19:13110271~13175850 | bone marrow | NB4 | T-cell acute lymphoblastic leukemia | Super enhancer activity assay, Functional perturbation assay; TF binding assay; Chromatin-state profiling |
| E_03619 | chr10:23508400~23508721 | pancreas | Pancreatic Multipotent Progenitor Cells (MPCs) | -- | Functional perturbation assay, Enhancer activity assay |
| E_03620 | chr2:14492567~14492959 | pancreas | Pancreatic Multipotent Progenitor Cells (MPCs) | -- | Functional perturbation assay, Enhancer activity assay |
| E_03621 | chr3R:7795000~7796400 | embryo | embryonic cell | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03622 | chr3R:7795000~7796400 | embryo | embryonic cell | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03623 | chr8:123455000~123472000 | kidney | Pkd1-null tubule epithelial cells (PN) | polycystic kidney disease | Functional perturbation assay, Enhancer activity assay |
| E_03624 | chr2R:10788877~10789168 | embryo | Drosophila embryo | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03625 | chr4:70849125~70849971 | saliva-secreting gland | AciCC primary tumor cells | salivary gland acinic cell carcinoma | Enhancer activity assay |
| E_03626 | chr7:5509938~5510616 | brain | glioma stem-like cells (GSCs) | glioblastoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03627 | chr11:5241525~5251525 | bone marrow | Primary erythroblasts | -- | Enhancer activity assay, Chromatin interaction assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_03628 | chr11:69329695~69333028 | pleural effusion | MCF-7 DR-GFP | breast carcinoma | Enhancer activity assay; Functional perturbation assay; Chromatin interaction assay |
| E_03629 | chr11:69329695~69333028 | pleural effusion | MCF-7 DR-GFP | breast carcinoma | Enhancer activity assay; Functional perturbation assay; Chromatin interaction assay |
| E_03630 | chr12:54359946~54360613 | esophagus | KYSE-30 | esophageal squamous cell carcinoma | Enhancer activity assay; Functional variant assay; Genetic association study; Disease-variant functional analysis; In vivo functional validation |
| E_03631 | chr11:5301485~5302895 | blood | K-562 | -- | Chromatin interaction assay; Functional perturbation assay |
| E_03632 | chr11:5305481~5306682 | blood | K-562 | -- | Chromatin interaction assay; Functional perturbation assay |
| E_03633 | chr17:62028371~62028917 | pituitary gland | HEK293 | -- | Enhancer-blocking assay; TF binding assay; functional perturbation assay; In vivo functional validation |
| E_03634 | chr8:128647663~128667652 | brain | Primary Medulloblastoma Tissue | Medulloblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_03635 | chr8:128647663~128667652 | brain | Primary Medulloblastoma Tissue | Medulloblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_03636 | chr8:128647663~128667652 | brain | Primary Medulloblastoma Tissue | Medulloblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_03637 | chr21:43781591~43782591 | blood / hematopoietic system | MCF-7 | Mixed-Lineage Leukemia 1 | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03638 | chr21:43781591~43782591 | blood / hematopoietic system | MDA-MB-231 | Mixed-Lineage Leukemia 1 | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03639 | chr21:43781591~43782591 | blood / hematopoietic system | 293T | Mixed-Lineage Leukemia 1 | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03640 | chr21:43772291~43774291 | blood / hematopoietic system | MCF-7 | Mixed-Lineage Leukemia 1 | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03641 | chr21:43772291~43774291 | blood / hematopoietic system | MDA-MB-231 | Mixed-Lineage Leukemia 1 | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03642 | chr21:43772291~43774291 | blood / hematopoietic system | 293T | Mixed-Lineage Leukemia 1 | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03643 | chr21:43771491~43773491 | blood / hematopoietic system | MCF-7 | Mixed-Lineage Leukemia 1 | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03644 | chr21:43771491~43773491 | blood / hematopoietic system | MDA-MB-231 | Mixed-Lineage Leukemia 1 | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03645 | chr21:43771491~43773491 | blood / hematopoietic system | 293T | Mixed-Lineage Leukemia 1 | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03646 | chr8:123455000~123472000 | kidney | Pkd1-heterozygous renal tubular epithelial cells | -- | Enhancer activity assay; Functional perturbation assay |
| E_03647 | chr17:62028371~62028917 | pituitary gland | HEK293 | -- | Enhancer-blocking assay; TF association assay; functional perturbation assay; In vivo functional validation |
| E_03648 | chr8:128310315~128312315 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03649 | chr8:128310315~128312315 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03650 | chr8:128310315~128312315 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03651 | chr2:221040922~221069549 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03652 | chr2:221040922~221069549 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03653 | chr2:221040922~221069549 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03654 | chr21:42770000~42770700 | breast | MCF-7 | breast cancer | Enhancer activity assay |
| E_03655 | chr11:69329695~69333028 | pleural effusion | MCF-7 DR-GFP | breast carcinoma | Functional perturbation assay |
| E_03656 | chr5:893433~1083433 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03657 | chr5:893433~1083433 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03658 | chr5:893433~1083433 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03659 | chr21:47716490~47892045 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03660 | chr21:47716490~47892045 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03661 | chr21:47716490~47892045 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03662 | chr5:121568382~121839811 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03663 | chr5:121568382~121839811 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03664 | chr5:121568382~121839811 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03665 | chr2:29511793~29765640 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03666 | chr2:29511793~29765640 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03667 | chr2:29511793~29765640 | -- | Medulloblastoma Cell Lines | Medulloblastoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03668 | chr7:103823354~103846754 | -- | 745A | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_03669 | chr7:103823354~103846754 | -- | 745A | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_03670 | chr7:103823354~103846754 | -- | 745A | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_03671 | chr14:67743318~67743610 | -- | GT1-7 | -- | Enhancer activity assay; TF binding assay; Functional cis-element perturbation assay |
| E_03672 | chr12:54357811~54358445 | -- | KYSE-30,KESY-150,ESCC | esophageal squamous cell carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_03673 | chr17:62028378~62028924 | -- | HeLa | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03674 | chr17:62028378~62028924 | -- | HeLa | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03675 | chr12:54359232~54361232 | esophagus | ESCC cell lines and human esophageal tissue | esophageal squamous cell carcinoma | Disease-associated allele-specific enhancer validation |
| E_03676 | chr17:62028378~62028924 | -- | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03677 | chr17:62028378~62028924 | -- | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03678 | chr7:5509938~5510616 | brain | U373MG/T98G-derived GSC model | glioblastoma | CEBPD binds PDGFA promoter (~-538 to +70); this paper does not establish the supplied chr7 interval as an enhancer |
| E_03679 | chr17:48110000~48150000 | zone of skin | A-375 | cutaneous melanoma | TF binding assay, Enhancer activity assay, Functional perturbation assay |
| E_03680 | chr8:128740000~128750000 | blood | K-562 | myeloid malignancy | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03681 | chr8:128740000~128750000 | blood | K-562 | myeloid malignancy | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_03682 | chr6:138226720~138233280 | blood / hematopoietic system | B Cell,Monocytes | Autoimmune Diseases | TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation; Disease-associated enhancer analysis |
| E_03683 | chr8:38291071~38304326 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03684 | chr16:86422446~86426834 | -- | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03685 | chr17:35643473~35645472 | embryo | Embryonic stem cells (ESCs) | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay, Functional perturbation assay; Chromatin interaction assay |
| E_03686 | chr10:12845744~12845755 | cartilage tissue | Hypertrophic MCT chondrocytes | -- | TF binding assay; Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03687 | chr5:131406243~131406930 | blood | Jurkat | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Cis-regulatory mapping |
| E_03688 | chr5:131406243~131406930 | blood | Jurkat | -- | Enhancer activity assay; TF binding assay; Chromatin accessibility assay; Cis-regulatory mapping |
| E_03689 | chr8:127329840~127331840 | cerebrospinal fluid | D458 Med | group 3 medulloblastoma | ecDNA MYC super-enhancer CRISPRi target site; Functional perturbation assay; Chromatin interaction assay |
| E_03690 | chr8:127329927~127331927 | cerebrospinal fluid | D458 Med | group 3 medulloblastoma | ecDNA MYC super-enhancer CRISPRi target site; Functional perturbation assay; Chromatin interaction assay |
| E_03691 | chr8:127330655~127330840 | brain | D-423MG | Medulloblastoma | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_03692 | chr2:73956813~73957241 | blood | B Cell | systemic lupus erythematosus | Enhancer activity assay, TF binding assay, Chromatin interaction assay; Enhancer activity assay; TF binding assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_03693 | chr17:46682000~46685000 | colon | HCT 116 | colorectal cancer | Functional perturbation assay |
| E_03694 | chr17:46692000~46695000 | colon | HCT 116 | colorectal cancer | Functional perturbation assay, TF binding assay |
| E_03695 | chr1:85865000~85866500 | colon | HCT 116 | colorectal carcinoma | Functional perturbation assay, TF binding assay, Enhancer activity assay |
| E_03696 | chr1:85868000~85869500 | colon | HCT 116 | colorectal carcinoma | Functional perturbation assay, TF binding assay, Enhancer activity assay |
| E_03697 | chr1:85870000~85870500 | colon | HCT 116 | colorectal carcinoma | Functional perturbation assay, TF binding assay, Enhancer activity assay |
| E_03698 | chr6:132265000~132266500 | breast | MCF-7 | breast carcinoma | Functional perturbation assay, TF binding assay, Enhancer activity assay |
| E_03699 | chr6:132270000~132270500 | colon | HCT 116 | colorectal carcinoma | Functional perturbation assay, TF binding assay, Enhancer activity assay |
| E_03700 | chr2R:9974054~9974699 | embryo | blastoderm cell | -- | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03701 | chr2R:9975013~9975699 | embryo | blastoderm cell | -- | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03702 | chr2R:9984101~9984849 | embryo | blastoderm cell | -- | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03703 | chr2R:9985221~9985886 | embryo | blastoderm cell | -- | Enhancer activity assay; Chromatin interaction assay; Functional perturbation assay |
| E_03704 | chr16:84000000~84001000 | zone of skin | BJ [Human fibroblast] | oncogene-induced cellular senescence | Functional perturbation assay, Senescence assay |
| E_03705 | chr1:22101842~22103407 | umbilical vein | HUVEC-C | -- | Enhancer functional assay |
| E_03706 | chr2:223164458~223165065 | skin of body | A-375 | melanoma | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03707 | chr2:223164458~223165065 | skin of body | SK-MEL-28 | melanoma | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03708 | chr10:43568986~43571244 | peripheral nervous system | Neuro-2a | Hirschsprung disease | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03709 | chr10:43571244~43572713 | peripheral nervous system | Neuro-2a | Hirschsprung disease | Promoter-proximal enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03710 | chr6:45413249~45414099 | thyroid gland | B-CPAP | thyroid gland papillary carcinoma | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03711 | chr6:45413249~45414099 | thyroid gland | TPC-1 | thyroid gland papillary carcinoma | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03712 | chr11:8271697~8279492 | -- | Neuroblastoma Cell Lines | neuroblastoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_03713 | chr8:127047315~127049315 | blood / hematopoietic system | Acute Myeloid Leukemia Cell | Acute Leukemia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03714 | chr8:127047315~127049315 | blood / hematopoietic system | Acute Myeloid Leukemia Cell | Acute Leukemia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03715 | chr8:127047315~127049315 | blood / hematopoietic system | Acute Myeloid Leukemia Cell | Acute Leukemia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03716 | chr8:127047315~127049315 | blood / hematopoietic system | Acute Myeloid Leukemia Cell | Acute Leukemia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03717 | chr8:127047315~127049315 | blood / hematopoietic system | Acute Myeloid Leukemia Cell | Acute Leukemia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_03718 | chr8:128412536~128414073 | colon | colorectal cancer cell lines / primary colorectal tumor material | colorectal carcinoma | Risk-variant enhancer assay; allele-specific TF binding; long-range chromatin interaction |
| E_03719 | chr1:221049243~221051243 | -- | HUVEC | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03720 | chr1:221049243~221051243 | -- | HUVEC | -- | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03721 | chr17:46658000~46660000 | pulmonary artery | HPAE-26 | -- | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_03722 | chr11:8254408~8256408 | sympathetic nervous system | primary neuroblastoma tumors | neuroblastoma | GWAS causal-variant fine-mapping; super-enhancer annotation; allele-specific TF binding and cis-expression |
| E_03723 | chr17:46656000~46658000 | colon | HCT 116 | colorectal cancer | Enhancer activity assay, Functional perturbation assay |
| E_03724 | chr2:180362582~180377003 | -- | myotubes | -- | Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03725 | chr2:180362582~180377003 | -- | myotubes | -- | Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03726 | chr2:180361998~180364335 | -- | myotubes | -- | Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03727 | chr2:180361998~180364335 | -- | myotubes | -- | Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03728 | chr2:180366734~180368371 | -- | myotubes | -- | Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03729 | chr2:180366734~180368371 | -- | myotubes | -- | Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03730 | chr2:180367903~180369540 | -- | myotubes | -- | Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03731 | chr2:180367903~180369540 | -- | myotubes | -- | Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03732 | chr2:180375974~180377844 | -- | myotubes | -- | Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03733 | chr2:180375974~180377844 | -- | myotubes | -- | Chromatin interaction assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03734 | chr5:139970046~139972237 | -- | Peripheral Blood Monocytes | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03735 | chr5:139974521~139975981 | -- | Peripheral Blood Monocytes | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03736 | chr5:139985479~139987671 | -- | Peripheral Blood Monocytes | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03737 | chr5:139987854~139989680 | -- | Peripheral Blood Monocytes | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03738 | chr5:139990822~139992831 | -- | Peripheral Blood Monocytes | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03739 | chr5:140009726~140011735 | -- | Peripheral Blood Monocytes | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03740 | chr2:74208162~74208562 | blood | GM18572 | systemic lupus erythematosus | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_03741 | chr2:74213045~74213445 | blood | GM18572 | systemic lupus erythematosus | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_03742 | chr8:128482317~128483854 | colon | COLO 205 | colorectal cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Allele-specific functional assay; Disease-variant functional analysis |
| E_03743 | chr11:8254408~8256408 | sympathetic nervous system | Neuroblastoma Cell Lines | neuroblastoma | GWAS causal-variant fine-mapping; super-enhancer annotation; allele-specific TF binding and cis-expression |
| E_03744 | chr8:128482317~128483854 | ascitic fluid | COLO 205 | colorectal cancer | Enhancer activity assay; Chromatin interaction assay; Allele-specific regulatory assay; Enhancer chromatin-state assay |
| E_03745 | chr11:8255155~8255707 | -- | SK-N-SH | neuroblastoma | Enhancer activity assay; TF binding assay; Functional variant assay; Genetic association analysis |
| E_03746 | chr2:73956813~73957241 | blood | LCL | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_03747 | chr8:128482317~128483854 | colon | LS174T | colorectal cancer | Enhancer activity assay; TF binding assay; Chromatin interaction assay; Allele-specific regulatory assay |
| E_03748 | chr6:51168034~51174811 | blood / hematopoietic system | Pro-B cell | -- | Endogenous enhancer perturbation; In vivo functional validation |
| E_03749 | chr6:51117747~51120656 | blood / hematopoietic system | Pro-B cell | -- | Endogenous enhancer perturbation |
| E_03750 | chr6:51168147~51170512 | blood / hematopoietic system | Pro-B cell | -- | Endogenous enhancer perturbation |
| E_03751 | chr6:51171474~51173111 | blood / hematopoietic system | Pro-B cell | -- | Endogenous enhancer perturbation |
| E_03752 | chr6:51173363~51175544 | blood / hematopoietic system | Pro-B cell | -- | Endogenous enhancer perturbation |
| E_03753 | chr3:181428000~181429000 | inner cell mass | WA13 | -- | Enhancer activity assay |
| E_03754 | chr7:3199567~3201439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03755 | chr7:3199567~3201439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03756 | chr7:3199567~3201439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03757 | chr7:3199567~3201439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03758 | chr7:3199567~3201439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03759 | chr7:3199567~3201439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03760 | chr7:3199567~3201439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03761 | chr7:3202646~3204360 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03762 | chr7:3202646~3204360 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03763 | chr7:3202646~3204360 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03764 | chr7:3202646~3204360 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03765 | chr7:3202646~3204360 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03766 | chr7:3202646~3204360 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03767 | chr7:3202646~3204360 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03768 | chr7:3205726~3207280 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03769 | chr7:3205726~3207280 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03770 | chr7:3205726~3207280 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03771 | chr7:3205726~3207280 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03772 | chr7:3205726~3207280 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03773 | chr7:3205726~3207280 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03774 | chr7:3205726~3207280 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03775 | chr7:3209567~3211439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03776 | chr7:3209567~3211439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03777 | chr7:3209567~3211439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03778 | chr7:3209567~3211439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03779 | chr7:3209567~3211439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03780 | chr7:3209567~3211439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03781 | chr7:3209567~3211439 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03782 | chr7:3212448~3214558 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03783 | chr7:3212448~3214558 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03784 | chr7:3212448~3214558 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03785 | chr7:3212448~3214558 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03786 | chr7:3212448~3214558 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03787 | chr7:3212448~3214558 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03788 | chr7:3212448~3214558 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03789 | chr7:3216607~3218399 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03790 | chr7:3216607~3218399 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03791 | chr7:3216607~3218399 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03792 | chr7:3216607~3218399 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03793 | chr7:3216607~3218399 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03794 | chr7:3216607~3218399 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03795 | chr7:3216607~3218399 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation |
| E_03796 | chr5:139985479~139987671 | blood | primary classical monocytes | -- | Enhancer landscape assay; Enhancer activity assay; Chromatin-state assay |
| E_03797 | chr5:139987854~139989680 | blood | primary classical monocytes | -- | Enhancer landscape assay; Enhancer activity assay; Chromatin-state assay |
| E_03798 | chr5:139990822~139992831 | blood | primary classical monocytes | -- | Enhancer landscape assay; Enhancer activity assay; Chromatin-state assay |
| E_03799 | chr6:51108708~51130031 | blood / hematopoietic system | Pro-B cell | -- | Endogenous enhancer perturbation; In vivo functional validation |
| E_03800 | chr7:3193003~3218182 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation; In vivo functional validation |
| E_03801 | chr7:3193003~3218182 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation; In vivo functional validation |
| E_03802 | chr7:3193003~3218182 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation; In vivo functional validation |
| E_03803 | chr7:3193003~3218182 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation; In vivo functional validation |
| E_03804 | chr7:3193003~3218182 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation; In vivo functional validation |
| E_03805 | chr7:3193003~3218182 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation; In vivo functional validation |
| E_03806 | chr7:3193003~3218182 | -- | Embryonic Stem Cell | -- | Endogenous enhancer perturbation; In vivo functional validation |
| E_03807 | chr5:140657200~140658500 | blood | Classical monocytes | -- | Enhancer activity assay |
| E_03808 | chr5:140659800~140661200 | blood | Classical monocytes | -- | Enhancer activity assay |
| E_03809 | chr5:140662500~140663800 | blood | Classical monocytes | -- | Enhancer activity assay |
| E_03810 | chr2:223164458~223164688 | skin | Melanoma | Melanoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03811 | chr2:223164846~223165065 | skin | Melanoma | Melanoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03812 | chr2:223164458~223164688 | zone of skin | A-375 | cutaneous melanoma | Enhancer activity assay |
| E_03813 | chr2:223164846~223165065 | zone of skin | SK-MEL-28 | cutaneous melanoma | Enhancer activity assay |
| E_03814 | chr6:45410618~45417584 | -- | B-CPAP,TPC1 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03815 | chr10:43568986~43571244 | blood / hematopoietic system | Neural Crest Cells | Hirschsprung Disease | Enhancer activity assay; Disease-associated enhancer analysis |
| E_03816 | chr10:43568986~43571244 | blood / hematopoietic system | Neural Crest Cells | Hirschsprung Disease | Enhancer activity assay; Disease-associated enhancer analysis |
| E_03817 | chr10:43571244~43572713 | blood / hematopoietic system | Neural Crest Cells | Hirschsprung Disease | Enhancer activity assay; Disease-associated enhancer analysis |
| E_03818 | chr10:43571244~43572713 | blood / hematopoietic system | Neural Crest Cells | Hirschsprung Disease | Enhancer activity assay; Disease-associated enhancer analysis |
| E_03819 | chr17:26531508~26539010 | pancreas | KPC-derived mT3-2D cells | pancreatic ductal adenocarcinoma | TF binding assay; Enhancer chromatin-state assay; Functional perturbation assay; In vivo functional validation |
| E_03820 | chr5:122453050~122453374 | bronchus | Human bronchial smooth muscle cells (HuBrSMCs) | -- | Enhancer activity assay, TF binding assay; Disease-variant functional analysis; In vivo functional validation |
| E_03821 | chr12:9916938~9918379 | lymph node | C1R B cells | -- | Enhancer activity assay, Functional perturbation assay, TF binding assay; Enhancer activity assay; Endogenous enhancer perturbation |
| E_03822 | chr7:149796331~149801250 | striatum | Primary mouse cortical neurons | -- | Functional perturbation assay |
| E_03823 | chr10:5419501~5420500 | breast | MCF-7 | breast carcinoma | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_03824 | chr1:133347574~133364574 | -- | As4.1,Tsukuba hypertensive mice | Hypertension | Enhancer activity assay; TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation; Disease-associated enhancer analysis |
| E_03825 | chr12:9916938~9918379 | blood | Jurkat | -- | Enhancer activity assay, Functional perturbation assay, TF binding assay |
| E_03826 | chr12:113228270~113228366 | spleen | Primary splenic B cells (mature resting and LPS-stimulated) | -- | Functional genetic perturbation assay; Chromatin accessibility assay; Chromatin topology assay; Nuclear positioning assay; Class switch recombination assay |
| E_03827 | chr12:113232344~113232426 | spleen | Primary splenic B cells (mature resting and LPS-stimulated) | -- | Functional genetic perturbation assay; Chromatin accessibility assay; Chromatin topology assay; Nuclear positioning assay; Class switch recombination assay |
| E_03828 | chr12:113244662~113244744 | spleen | Primary splenic B cells (mature resting and LPS-stimulated) | -- | Functional genetic perturbation assay; Chromatin accessibility assay; Chromatin topology assay; Nuclear positioning assay; Class switch recombination assay |
| E_03829 | chr12:113253846~113254040 | spleen | Primary splenic B cells (mature resting and LPS-stimulated) | -- | Functional genetic perturbation assay; Chromatin accessibility assay; Chromatin topology assay; Nuclear positioning assay; Class switch recombination assay |
| E_03830 | chr1:7995001~8260000 | colon | Human colorectal carcinoma cell | -- | Chromatin interaction assay, Functional perturbation assay |
| E_03831 | chr13:28843000~28843500 | blood | primary MLL-AF4 ALL | KMT2A::AFF1-rearranged B-cell acute lymphoblastic leukemia | Fusion-protein occupancy assay; Chromatin interaction assay; Enhancer chromatin-state assay; Functional protein-degradation perturbation |
| E_03832 | chr13:28843000~28843500 | bone marrow | Primary BCP ALL cells | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_03833 | chr9:5459072~5460776 | brain | Brain tumor initiating cells | meningioma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03834 | chr9:5504029~5504679 | brain | Brain tumor initiating cells | meningioma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03835 | chr7:117075400~117076000 | bronchus | 16HBE14o- | -- | Enhancer activity assay; Endogenous enhancer perturbation |
| E_03836 | chr8:141161900~141175436 | brain | Lymphoblastoid Cell Lines | Intellectual Disability | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_03837 | chr7:149796331~149801250 | frontal cortex | striatal neurons | -- | Functional perturbation assay |
| E_03838 | chr11:6639091~6639657 | -- | Mammary | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03839 | chr11:6639091~6639657 | -- | Mammary | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03840 | chr11:6639824~6640424 | -- | Mammary | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03841 | chr11:6639824~6640424 | -- | Mammary | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03842 | chr11:6644257~6644824 | -- | Mammary | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03843 | chr11:6644257~6644824 | -- | Mammary | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03844 | chr11:6639029~6644397 | -- | Mammary | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03845 | chr11:6639029~6644397 | -- | Mammary | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03846 | chr1:23881330~23881475 | blood | primary human monocyte-derived macrophages | -- | Enhancer activity assay; Signaling perturbation assay |
| E_03847 | chr4:124638991~124641160 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03848 | chr4:124638991~124641160 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03849 | chr4:124645999~124647927 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03850 | chr4:124645999~124647927 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03851 | chr5:119677099~119681977 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03852 | chr5:119677099~119681977 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03853 | chr5:119704124~119707831 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03854 | chr5:119704124~119707831 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03855 | chr5:119707931~119710758 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03856 | chr5:119707931~119710758 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03857 | chr5:119710660~119714758 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03858 | chr5:119710660~119714758 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03859 | chr5:98290964~98295647 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03860 | chr5:98290964~98295647 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03861 | chr5:98307793~98312281 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03862 | chr5:98307793~98312281 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03863 | chr5:98310330~98314427 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03864 | chr5:98310330~98314427 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03865 | chr5:98253530~98257713 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03866 | chr5:98253530~98257713 | -- | Mouse Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03867 | chr13:28843000~28843500 | blood | SEM/SEMK2 KMT2A::AFF1 B-ALL cells | KMT2A::AFF1-rearranged B-cell acute lymphoblastic leukemia | Fusion-protein occupancy assay; Chromatin interaction assay; Enhancer chromatin-state assay; Functional protein-degradation perturbation |
| E_03868 | chr13:28843000~28843500 | blood | SEM | KMT2A::AFF1-rearranged B-cell acute lymphoblastic leukemia | Fusion-protein occupancy assay; Chromatin interaction assay; Enhancer chromatin-state assay; Functional protein-degradation perturbation |
| E_03869 | chr13:28843000~28843500 | bone marrow | NALM-6 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_03870 | chr13:28710000~28715000 | bone marrow | NALM-6 | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_03871 | chr8:141161900~141175436 | brain | adult human frontal cortex and cerebellum | -- | Enhancer chromatin-state assay; Chromatin interaction assay; TF/cohesin binding assay; Imprinting assay; Enhancer activity assay; TF binding assay |
| E_03872 | chr8:140900000~140930000 | brain | Adult brain tissue | -- | Chromatin interaction assay, Enhancer activity assay |
| E_03873 | chr12:65260000~66115000 | colon | Human colorectal carcinoma cell | -- | Chromatin interaction assay, Functional perturbation assay |
| E_03874 | chr17:40880001~41560000 | colon | Human colorectal carcinoma cell | -- | Chromatin interaction assay, Functional perturbation assay |
| E_03875 | chr2:181380000~182280000 | colon | Human colorectal carcinoma cell | -- | Chromatin interaction assay, Functional perturbation assay |
| E_03876 | chr8:126650000~129950000 | colon | Human colorectal carcinoma cell | -- | Chromatin interaction assay, Functional perturbation assay |
| E_03877 | chr9:21096000~22491000 | colon | Human colorectal carcinoma cell | -- | Chromatin interaction assay, Functional perturbation assay |
| E_03878 | chr9:5459072~5459797 | brain | Brain tumor initiating cells | meningioma | Enhancer activity assay |
| E_03879 | chr4:101250000~101250600 | embryo | Epiblast-like cells (EpiLC) | -- | Enhancer activity assay |
| E_03880 | chr4:101250000~101250600 | embryo | Epiblast-like cells (EpiLC) | -- | Enhancer activity assay |
| E_03881 | chr1:23888938~23889083 | blood | primary human monocyte-derived macrophages | -- | Enhancer activity and signaling perturbation |
| E_03882 | chr7:117075514~117075933 | -- | Human Bronchial Epithelial Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03883 | chr7:117075514~117075933 | -- | Human Bronchial Epithelial Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03884 | chr1:23884369~23884886 | blood | Primary macrophages | -- | Enhancer activity assay |
| E_03885 | chr1:23892063~23892208 | blood | Primary macrophages | -- | Enhancer activity assay |
| E_03886 | chr4:136148484~136149239 | liver | Hep G2 | -- | Enhancer activity assay |
| E_03887 | chr4:136140654~136141162 | liver | Hep G2 | -- | Enhancer activity assay |
| E_03888 | chr1:23881244~23881761 | -- | Human Monocytes/Macrophages | Cardiometabolic Disorders | Enhancer activity assay; Disease-associated enhancer analysis |
| E_03889 | chr1:23888938~23889083 | -- | Human Monocytes/Macrophages | Cardiometabolic Disorders | Enhancer activity assay; Disease-associated enhancer analysis |
| E_03890 | chr1:110200000~110258000 | blood | NALM-6 | breast cancer | Enhancer activity assay, Functional perturbation assay |
| E_03891 | chr12:98515210~98515289 | skeletal muscle tissue | WS234 (donor 15Vbic) | facioscapulohumeral muscular dystrophy 2 | Enhancer characterization; Chromatin regulator binding assay; Functional perturbation assay; Gene expression assay; Rescue assay |
| E_03892 | chr5:1294000~1297400 | liver | HCC cells | hepatocellular carcinoma | Enhancer activity assay, TF binding assay; TF binding assay; Chromatin interaction assay; Chromatin-state profiling |
| E_03893 | chrX:66800000~67800000 | prostate gland | Human prostate carcinoma cell | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay; In vivo functional validation |
| E_03894 | chr10:81115805~81116305 | blood | THP-1 | inflammatory bowel disease | Enhancer-target functional validation; endogenous perturbation; downstream cellular phenotype; Disease-variant functional analysis |
| E_03895 | chr1:158282456~158282752 | blood | CUTLL1 | T-cell acute lymphoblastic leukemia | TF binding assay; Chromatin interaction assay; Chromatin accessibility profiling; Cancer-specific regulatory-site characterization |
| E_03896 | chr1:199217982~199218479 | blood | CUTLL1 | T-cell acute lymphoblastic leukemia | TF binding assay; Chromatin interaction assay; Chromatin accessibility profiling; Cancer-specific regulatory-site characterization |
| E_03897 | chr7:100772345~100778921 | endometrium | RMS-19 | endometriosis | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03898 | chr1:218299740~218299908 | zone of skin | Primary human dermal fibroblasts | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03899 | chr2:27740600~27741238 | liver | mouse primary hepatocytes | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03900 | chr12:25090158~25090663 | colon | HCT 116,SW480 | colorectal carcinoma | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03901 | chr20:46120155~46120433 | cartilage tissue | SW1353 | chondrosarcoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03902 | chr3:34824938~34837938 | embryo | ES-R1 | -- | CRISPR deletion functional assay |
| E_03903 | chr3:34824938~34837938 | embryo | ES-R1 | -- | CRISPR deletion functional assay |
| E_03904 | chr3:34824938~34837938 | embryo | ES-R1 | -- | CRISPR deletion functional assay |
| E_03905 | chr2:60722150~60722350 | bone marrow | CD34+ hematopoietic stem/progenitor cells | -- | Enhancer activity assay, Functional perturbation assay, TF binding assay; Disease-variant functional analysis; In vivo functional validation |
| E_03906 | chr5:134729406~134737909 | limb | Liebenberg syndrome patient deletion / orthologous mouse model | brachydactyly-elbow wrist dysplasia syndrome | Structural-variant/promoter-insulator perturbation revealing enhancer retargeting; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_03907 | chr11:111343838~111451584 | bone marrow | OCI-Ly1 | diffuse large B-cell lymphoma | Super-enhancer identification; Functional perturbation assay; Drug perturbation assay |
| E_03908 | chr5:147267336~147267640 | islet of Langerhans | INS-1 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_03909 | chr3:2931~3443 | lymph node | CD4+ T | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03910 | chr3:2931~3443 | lymph node | CD4+ T | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03911 | chr5:134729406~134737909 | limb | Liebenberg syndrome patient deletion / orthologous mouse model | brachydactyly-elbow wrist dysplasia syndrome | Structural-variant/promoter-insulator perturbation revealing enhancer retargeting; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_03912 | chr2:60494251~60495546 | blood | CD34+ hematopoietic stem and progenitor cells | sickle cell disease | Functional perturbation assay; enhancer editing assay; Disease-variant functional analysis; In vivo functional validation |
| E_03913 | chr2:60494251~60495546 | blood | CD34+ hematopoietic stem and progenitor cells | beta-thalassemia | Functional perturbation assay; enhancer editing assay; Disease-variant functional analysis; In vivo functional validation |
| E_03914 | chr2:60494251~60495546 | blood | CD34+ hematopoietic stem and progenitor cells | sickle cell disease | Functional perturbation assay; enhancer editing assay; Disease-variant functional analysis; In vivo functional validation |
| E_03915 | chr2:60494251~60495546 | blood | CD34+ hematopoietic stem and progenitor cells | beta-thalassemia | Functional perturbation assay; enhancer editing assay; Disease-variant functional analysis; In vivo functional validation |
| E_03916 | chr13:43362622~43364444 | liver | Hepa 1-6 | -- | Enhancer RNA assay; Coactivator occupancy assay; Functional perturbation assay |
| E_03917 | chr13:69400000~69410000 | limb bud | E11.5 mouse forelimb | brachydactyly-elbow wrist dysplasia syndrome | Structural-variant/promoter-insulator perturbation revealing enhancer retargeting; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_03918 | chr10:77989870~77993100 | liver | Hepa 1-6 | -- | Enhancer RNA assay; Coactivator occupancy assay; Functional perturbation assay |
| E_03919 | chr16:4721118~4724819 | liver | Hepa 1-6 | -- | Enhancer RNA assay; Coactivator occupancy assay; Functional perturbation assay |
| E_03920 | chr2:130280565~130281887 | liver | Hepa 1-6 | -- | Enhancer RNA assay; Coactivator occupancy assay; Functional perturbation assay |
| E_03921 | chr10:79285696~79287696 | blood | THP-1 | inflammatory bowel disease | Functional perturbation assay; enhancer-target validation; Disease-variant functional analysis |
| E_03922 | chr2:6072150~6072450 | bone marrow | CD34+ hematopoietic stem/progenitor cells | -- | Functional perturbation assay, Enhancer activity assay; Disease-variant functional analysis; In vivo functional validation |
| E_03923 | chr11:111284123~111290712 | bone marrow | OCI-Ly1 | diffuse large B-cell lymphoma | Super-enhancer profiling; BET dependency assay; Transcriptional perturbation assay |
| E_03924 | chr3:37229193~37229705 | -- | EL4 | -- | Enhancer activity assay; Functional perturbation assay |
| E_03925 | chr3:37229193~37229705 | -- | EL4 | -- | Enhancer activity assay; Functional perturbation assay |
| E_03926 | chr5:134729406~134737909 | limb | affected family | brachydactyly-elbow wrist dysplasia syndrome | 8.5-kb pathogenic deletion contains H2AFY promoter/first noncoding exon; not an enhancer interval |
| E_03927 | chr11:111357554~111446979 | peritoneal fluid | SU-DHL-6 | diffuse large B-cell lymphoma | Super-enhancer identification; Drug perturbation assay |
| E_03928 | chr5:147267670~147267721 | liver | HIT,Hep G2,INS-1 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03929 | chr5:147267701~147267751 | liver | HIT,Hep G2,INS-1 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03930 | chr3:37225520~37228865 | blood / hematopoietic system | CD4+ T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03931 | chr13:43362622~43364444 | -- | C2C12,MEFs | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03932 | chr2:130280565~130281887 | -- | C2C12,MEFs | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03933 | chr16:4721118~4724819 | -- | C2C12,MEFs | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03934 | chr10:77989870~77993100 | -- | C2C12,MEFs | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03935 | chr5:147267614~147267639 | liver | HIT,Hep G2,INS-1 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03936 | chr13:43362622~43364444 | -- | C2C12,MEFs | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03937 | chr2:130280565~130281887 | -- | C2C12,MEFs | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03938 | chr16:4721118~4724819 | -- | C2C12,MEFs | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03939 | chr10:77989870~77993100 | -- | C2C12,MEFs | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_03940 | chr11:110716521~110832306 | blood / hematopoietic system | B-Cell Lymphoma Cell Lines | diffuse large B-cell lymphoma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03941 | chr3:188892648~189232665 | blood / hematopoietic system | B-Cell Lymphoma Cell Lines | diffuse large B-cell lymphoma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03942 | chr3:37229193~37229705 | -- | HEK293T | -- | Enhancer activity assay; TF-binding-site functional assay |
| E_03943 | chr12:25090158~25096935 | colon | Apoptotic Cell | colorectal carcinoma | Enhancer activity assay; Disease-associated enhancer analysis |
| E_03944 | chr1:178551259~178551689 | bone marrow | Adipose-Derived Mesenchymal Stem Cells-01 | -- | Enhancer activity assay, Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_03945 | chr3:157437977~157438893 | zone of skin | 293T human CD33 | skin squamous cell carcinoma | Chromatin interaction assay, Functional perturbation assay |
| E_03946 | chr14:6760805~6761115 | spinal cord | ependymo-radial glial cell | -- | Enhancer activity assay |
| E_03947 | chr3:128191800~128192300 | bone marrow | Hematopoietic stem/progenitor cells | acute myeloid leukemia | Enhancer activity assay, Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_03948 | chr1:152006173~152012078 | bone marrow | bone marrow-derived macrophages (BMDMs) | -- | Enhancer activity assay, Functional perturbation assay, Chromatin interaction assay |
| E_03949 | chr18:69656860~69683465 | -- | HoxB8-FL cells | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_03950 | chr9:48814346~48815095 | thymus | NKT thymocyte and ILCP | -- | Functional perturbation assay; Endogenous enhancer perturbation; TF binding assay; Chromatin-state profiling; Disease-variant functional analysis; In vivo functional validation |
| E_03951 | chr3:128603821~128604120 | bone marrow | 3) AML cells and primary AML samples | acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) | Endogenous enhancer-hijacking functional validation |
| E_03952 | chr8:128140000~128145000 | colon | HCT 116 | colorectal cancer | Functional enhancer assay; Disease-variant functional analysis |
| E_03953 | chr9:136141944~136147321 | blood / hematopoietic system | K-562,KATO III | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03954 | chr1:204123719~204123725 | -- | Calu-6 | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03955 | chr17:26072592~26074592 | liver | Hep G2 | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_03956 | chr2:202030000~202040000 | nasopharynx | CNE-2 | nasopharyngeal carcinoma | Enhancer activity assay, Functional perturbation assay; In vivo functional validation |
| E_03957 | chr17:45414208~45414987 | breast | 293T human CLDN18.2 | breast cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay; In vivo functional validation |
| E_03958 | chr17:45436112~45436891 | breast | 293T human CLDN18.2 | breast cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay; In vivo functional validation |
| E_03959 | chr7:114541370~114543683 | brain | SK-N-MC | speech and language disorder / childhood apraxia-associated regulatory locus | Endogenous enhancer deletion and target-gene functional characterization |
| E_03960 | chr7:114541370~114543683 | brain | SK-N-MC | speech and language disorder-associated FOXP2 regulatory locus | Endogenous enhancer deletion and target-gene functional characterization |
| E_03961 | chr7:114456873~114463136 | brain | SK-N-MC | speech and language disorder / childhood apraxia-associated regulatory locus | Endogenous enhancer deletion and target-gene functional characterization |
| E_03962 | chr7:114456873~114463136 | brain | SK-N-MC | speech and language disorder-associated FOXP2 regulatory locus | Endogenous enhancer deletion and target-gene functional characterization |
| E_03963 | chr19:61151074~61161722 | -- | Monocytes,Dendritic Cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_03964 | chr19:61158643~61164569 | -- | Monocytes,Dendritic Cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_03965 | chr19:61165425~61172555 | -- | Monocytes,Dendritic Cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_03966 | chr2:144000110~144014615 | -- | Monocytes,Dendritic Cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_03967 | chr2:144014506~144023297 | -- | Monocytes,Dendritic Cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_03968 | chr2:103464661~103471206 | -- | Monocytes,Dendritic Cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_03969 | chr15:63833002~63863200 | colon | HCT 116 | Colon Cancer | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03970 | chr15:63833002~63863200 | colon | HCT 116 | Colon Cancer | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03971 | chr3:127641624~127642545 | brain | Embryonic Stem Cell | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_03972 | chr3:127641624~127642545 | brain | Embryonic Stem Cell | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_03973 | chr3:127641624~127642545 | brain | Embryonic Stem Cell | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_03974 | chr14:77737282~77738405 | kidney | HEK293 | -- | Promoter activity assay; Cis-regulatory mapping assay; Regulatory variant analysis |
| E_03975 | chr1:95952661~95952820 | spleen | Primary splenic CD8 T cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay |
| E_03976 | chr1:95952661~95952820 | spleen | Primary splenic CD8 T cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay |
| E_03977 | chr1:95952661~95952820 | spleen | Primary splenic CD8 T cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay |
| E_03978 | chr10:34385685~34385834 | blood / hematopoietic system | MCT Cells | Skeletal Diseases | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_03979 | chr3:128603821~128604120 | bone marrow | inv(3)/t(3 | acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) | Endogenous enhancer-hijacking functional validation |
| E_03980 | chr1:95932003~95932042 | spleen | Primary splenic CD8 T cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay |
| E_03981 | chr1:95932003~95932042 | spleen | Primary splenic CD8 T cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay |
| E_03982 | chr1:95932003~95932042 | spleen | Primary splenic CD8 T cells | -- | Enhancer activity assay; TF binding assay; Chromatin interaction assay |
| E_03983 | chr14:77264349~77265491 | brain | human temporal cortex samples | Alzheimer disease | Promoter/enhancer deletion mapping and genetic regulatory analysis; Disease-variant functional analysis |
| E_03984 | chr14:77264349~77265491 | brain | reporter cell model | Alzheimer disease | Promoter/enhancer deletion mapping and genetic regulatory analysis; Disease-variant functional analysis |
| E_03985 | chr17:45414208~45414987 | breast | 293T cyno DLL3 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_03986 | chr3:127349185~127349631 | midbrain | mDA progenitors/neurons (E12.5) | -- | Enhancer activity assay, TF binding assay (ChIP-supported); TF binding assay; Chromatin-state profiling |
| E_03987 | chr1:39000000~39645000 | nasopharynx | CNE-2 | nasopharyngeal carcinoma | Enhancer activity assay, Functional perturbation assay; In vivo functional validation |
| E_03988 | chr10:4147~4296 | limb bud | Hypertrophic chondrocytes | -- | Enhancer activity assay, TF binding assay; Enhancer activity assay; TF binding assay |
| E_03989 | chr10:128347441~128347590 | limb bud | Hypertrophic chondrocytes | -- | Enhancer activity assay, TF binding assay; Enhancer activity assay; TF binding assay |
| E_03990 | chr9:133238853~133239354 | blood | K-562 | -- | Enhancer activity assay, TF binding assay; Enhancer activity assay |
| E_03991 | chr19:151500000~152500000 | nasopharynx | CNE-2 | nasopharyngeal carcinoma | Enhancer activity assay, Functional perturbation assay; In vivo functional validation |
| E_03992 | chr14:77264349~77265491 | -- | HEK-293 | Alzheimer's Disease | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_03993 | chr15:63865799~63896492 | colon | HCT 116 | Colon Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03994 | chr15:63865799~63896492 | colon | HCT 116 | Colon Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03995 | chr15:63894512~63932136 | colon | HCT 116 | Colon Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03996 | chr15:63894512~63932136 | colon | HCT 116 | Colon Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_03997 | chr17:26071355~26071455 | kidney | HEK293 | -- | Enhancer activity assay |
| E_03998 | chr22:24114000~24116000 | prostate gland | SM1 (mCRPC cell line) | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay; TF binding assay |
| E_03999 | chr9:128335472~128336978 | blood | Lymphoblastoid cell line | glioma | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_04000 | chr19:45409200~45410200 | breast | MCF-7 | breast carcinoma | Functional perturbation assay |
| E_04001 | chr14:75664000~75664749 | prostate gland | LNCaP | prostate cancer | Functional perturbation assay; In vivo functional validation |
| E_04002 | chr14:76419740~76421740 | prostate gland | LNCaP | prostate cancer | TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation; Disease-associated enhancer analysis |
| E_04003 | chr1:47704791~47705107 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL) | Central Nervous System Leukemia | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_04004 | chr19:15308673~15308842 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL) | Central Nervous System Leukemia | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_04005 | chr2:60447611~60449611 | blood | KG-1 | beta-thalassemia | Enhancer CRISPR perturbation study, Chromatin interaction assay; Endogenous enhancer perturbation |
| E_04006 | chr2:60447611~60449611 | blood | KU812 | beta-thalassemia | Enhancer CRISPR perturbation study, Chromatin interaction assay; Endogenous enhancer perturbation |
| E_04007 | chr11:100674936~100675904 | breast | MCF-7 | breast carcinoma | Enhancer chromatin-state assay; TF binding assay; Functional perturbation assay |
| E_04008 | chr6:86160197~86176777 | skin | Melanoma | Melanoma | TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation; Disease-associated enhancer analysis |
| E_04009 | chr17:26829229~26831311 | heart | Cardiac Progenitor Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_04010 | chr9:128335472~128336978 | brain | U-251MG | glioma | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_04011 | chr6:8120004~8120873 | zone of skin | SK-MEL-28 | cutaneous melanoma | Enhancer activity assay, Functional perturbation assay |
| E_04012 | chr21:40000000~40800000 | heart | Cardiomyocytes | -- | Enhancer activity assay, Chromatin interaction assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_04013 | chr10:72890000~72890392 | retina | developing retina | -- | Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04014 | chr10:72890000~72890392 | retina | developing retina | -- | Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04015 | chr10:72894616~72895600 | retina | developing retina | -- | Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04016 | chrX:7230000~7720000 | embryo | Mouse embryonic stem cells (mESCs) | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_04017 | chr13:56243248~56243833 | -- | P19 | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04018 | chr13:56244114~56244357 | -- | P19 | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04019 | chr13:56245174~56245857 | -- | P19 | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04020 | chr10:72890000~72895600 | retina | Retinal Progenitor Cells | -- | Enhancer deletion assay; In vivo developmental assay; Enhancer activity assay |
| E_04021 | chr10:72890000~72895600 | retina | Retinal Ganglion Cells | -- | Enhancer deletion assay; In vivo developmental assay; Enhancer activity assay |
| E_04022 | chr1:47366207~47368074 | heart | embryonic heart | -- | Enhancer activity assay; Chromatin interaction assay; Chromatin-state profiling |
| E_04023 | chr23:5735883~5736938 | heart | embryonic heart | -- | Enhancer activity assay; Chromatin interaction assay; Chromatin-state profiling |
| E_04024 | chr5:49025012~49026815 | heart | embryonic heart | -- | Enhancer activity assay; Chromatin interaction assay; Chromatin-state profiling |
| E_04025 | chr6:43661350~43663650 | brain | embryonic brain | -- | Enhancer activity assay; Chromatin interaction assay; Chromatin-state profiling |
| E_04026 | chr8:44088636~44090085 | brain | embryonic brain | -- | Enhancer activity assay; Chromatin interaction assay; Chromatin-state profiling |
| E_04027 | chr19:10050000~10650000 | embryo | mouse embryonic stem cells | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_04028 | chr16:95745432~95912361 | heart | Outflow tract cardiac muscle cells | -- | Functional perturbation assay, Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_04029 | chr10:94770000~94776500 | retina | Retinal Progenitor Cells | -- | Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04030 | chr4:147122070~148025142 | embryo | Mouse embryonic stem cells (mESCs) | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_04031 | chr25:17938108~17939563 | kidney | embryonic kidney | -- | Enhancer activity assay |
| E_04032 | chr25:17939264~17940252 | kidney | embryonic kidney | -- | Enhancer activity assay |
| E_04033 | chr5:61665365~61667095 | kidney | embryonic kidney | -- | Enhancer activity assay |
| E_04034 | chr1:7624913~7626890 | skeletal muscle | embryonic myocyte | -- | Enhancer activity assay |
| E_04035 | chr1:19433791~19434807 | skeletal muscle | embryonic myocyte | -- | Enhancer activity assay |
| E_04036 | chr17:46687021~48462216 | embryo | mouse embryonic stem cells | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| E_04037 | chr3:98010000~98160000 | heart | Atrial cardiomyocyte cell line | atrial fibrillation | Functional perturbation assay, Enhancer activity assay |
| E_04038 | chr17:27040383~27042465 | heart | Cardiac progenitor cells | -- | Enhancer activity assay |
| E_04039 | chr5:29314591~29316266 | limb bud | Embryonic limb mesenchyme | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04040 | chr17:62627957~62633457 | -- | Mesencephalon | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_04041 | chr10:63525013~63527013 | blood / hematopoietic system | T-acute lymphoblastic leukemia (T-ALL) | T-cell acute lymphoblastic leukemia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Endogenous enhancer perturbation; Disease-associated enhancer analysis |
| E_04042 | chr2:168744572~168752225 | -- | Induced Pluripotent Stem Cells | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_04043 | chr12:7940709~7941994 | kidney | HEK293 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_04044 | chr5:131406243~131406930 | blood | Jurkat | -- | Enhancer activity assay; TF binding assay; Functional cis-regulatory mapping |
| E_04045 | chr8:89041889~89090124 | -- | Induced Pluripotent Stem Cells | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_04046 | chr10:128906630~128909942 | brain | Primary tumor tissue | glioblastoma | Enhancer activity assay, Functional perturbation assay |
| E_04047 | chr11:98480000~98510000 | mammary gland | Mammary alveolar epithelial cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04048 | chr19:12600000~12650000 | mammary gland | Mammary alveolar epithelial cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04049 | chr14:106328838~106329184 | blood | Human Burkitt lymphoma cell | Burkitt lymphoma | Functional perturbation assay, Enhancer activity assay; Endogenous enhancer perturbation |
| E_04050 | chr16:19007329~19008187 | bone marrow | 103/BCL-2 pre-B cells | -- | Enhancer activity assay; TF binding assay; enhancer-hub / locus-folding analysis |
| E_04051 | chr16:19007329~19008187 | bone marrow | 103/BCL-2 pre-B cells | -- | Enhancer activity assay; TF binding assay; enhancer-hub / locus-folding analysis |
| E_04052 | chr16:19007329~19008187 | bone marrow | 103/BCL-2 pre-B cells | -- | Enhancer activity assay; TF binding assay; enhancer-hub / locus-folding analysis |
| E_04053 | chr16:19007329~19008187 | bone marrow | 103/BCL-2 pre-B cells | -- | Enhancer activity assay; TF binding assay; enhancer-hub / locus-folding analysis |
| E_04054 | chr2:79272263~79272447 | colon | HT-29 | cancer (subtype not defined in abstract) | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04055 | chr2:79272263~79272447 | colon | LIM1215 | cancer (subtype not defined in abstract) | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04056 | chr2:79272263~79272447 | colon | SW480 | cancer (subtype not defined in abstract) | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04057 | chr3:107702615~107714185 | breast | MCF-7 | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04058 | chr3:107842838~107845592 | breast | MCF-7 | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04059 | chr3:107846969~107854683 | breast | MCF-7 | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04060 | chr17:26844119~26844624 | heart | Cardiac progenitor cells from differentiating embryoid bodies | -- | Enhancer activity assay; Chromatin occupancy assay; Functional perturbation assay |
| E_04061 | chr17:26850487~26850997 | heart | Cardiac progenitor cells from differentiating embryoid bodies | -- | Enhancer activity assay; Chromatin occupancy assay; Functional perturbation assay |
| E_04062 | chr8:128413136~128414674 | prostate gland | LNCaP | prostate cancer | Chromatin interaction assay; Enhancer activity assay; Genetic risk regulatory analysis; Disease-variant functional analysis |
| E_04063 | chr7:156583796~156584568 | limb bud | transgenic mouse embryos | preaxial polydactyly II | In vivo enhancer activity assay; disease variant analysis |
| E_04064 | chr2:34963164~34963369 | -- | M12 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; CD40-responsive transcription assay |
| E_04065 | chr2:34954556~34954788 | -- | M12 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay; CD40-responsive transcription assay |
| E_04066 | chr5:86800000~87200000 | mammary gland | Mammary alveolar epithelial cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04067 | chr7:92384001~92385000 | -- | ChiPSC22 | acute myeloid leukemia | Enhancer activity assay; Functional perturbation assay; Genomic engineering assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04068 | chr19:33790000~33792000 | bone marrow | bone marrow mesenchymal stem | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04069 | chr3:12335000~12337000 | bone marrow | bone marrow mesenchymal stem | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04070 | chr3:186560000~186562000 | bone marrow | bone marrow mesenchymal stem | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04071 | chr4:54950000~54952000 | bone marrow | bone marrow mesenchymal stem | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04072 | chr4:54950000~54952000 | bone marrow | bone marrow mesenchymal stem | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04073 | chr6:45300000~45302000 | bone marrow | bone marrow mesenchymal stem | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04074 | chr6:132200000~132202000 | bone marrow | bone marrow mesenchymal stem | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04075 | chr6:132200000~132202000 | bone marrow | bone marrow mesenchymal stem | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04076 | chr11:111150916~111155431 | colon | HCT 116 | colorectal cancer | Regulatory variant functional assay; Enhancer activity assay; TF binding assay |
| E_04077 | chr11:111150916~111155431 | colon | SW480 | colorectal cancer | Regulatory variant functional assay; Enhancer activity assay; TF binding assay |
| E_04078 | chr5:147205131~147212149 | pancreas | Pancreas | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04079 | chr5:147205131~147212149 | pancreas | Pancreas | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04080 | chr5:147263601~147264086 | pancreas | Pancreas | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04081 | chr5:147263601~147264086 | pancreas | Pancreas | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04082 | chr7:92384001~92385000 | -- | ChiPSC22 | acute myeloid leukemia with del(7)(q22q36) | Enhancer activity assay; Functional perturbation assay |
| E_04083 | chr7:92384001~92385000 | blood | Primary del(7q) AML cells (2KFQ | acute myeloid leukemia | Chromatin interaction assay; Enhancer chromatin-state assay; Enhancer hijacking analysis; Target-gene functional validation |
| E_04084 | chr7:92384001~92385000 | bone marrow | Primary del(7q) AML cells (2KFQ | acute myeloid leukemia | Chromatin interaction assay; Enhancer chromatin-state assay; Enhancer hijacking analysis; Target-gene functional validation |
| E_04085 | chr10:127950000~127955000 | mammary gland | Mammary alveolar epithelial cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04086 | chr4:100450000~100455000 | mammary gland | Mammary alveolar epithelial cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04087 | chr3:107662655~107762655 | breast | MCF-7 | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04088 | chr5:147263197~147264197 | pancreas | pancreatic primordium / pancreatic epithelium | -- | Developmental enhancer occupancy; conditional TF knockout; target-gene expression analysis |
| E_04089 | chr5:147263197~147264197 | pancreas | pancreatic primordium / pancreatic epithelium | -- | Developmental enhancer occupancy; conditional TF knockout; target-gene expression analysis |
| E_04090 | chr5:147263567~147264052 | pancreas | E14.5 fetal pancreas | -- | TF binding assay; Developmental functional perturbation assay |
| E_04091 | chr5:147263567~147264052 | pancreas | E14.5 fetal pancreas | -- | TF binding assay; Developmental functional perturbation assay |
| E_04092 | chr11:111152290~111154290 | colon | HCT 116 | colorectal cancer | Enhancer activity assay; Functional variant assay; TF binding assay; Chromatin-state profiling; Disease-variant functional analysis |
| E_04093 | chr11:111152290~111154290 | colon | SW480 | colorectal cancer | Enhancer activity assay; Functional variant assay; TF binding assay; Chromatin-state profiling; Disease-variant functional analysis |
| E_04094 | chr14:106032312~106033352 | blood | Burkitt lymphoma cell line | Burkitt lymphoma | Functional perturbation assay; Endogenous enhancer perturbation |
| E_04095 | chr14:106041116~106041795 | blood | Diffuse large B-cell lymphoma cell line | Burkitt lymphoma | Functional perturbation assay; Endogenous enhancer perturbation |
| E_04096 | chr10:63525013~63527013 | blood | Jurkat E6.1 | T-cell acute lymphoblastic leukemia | Oncogenic TF enhancer mapping; target-gene functional validation |
| E_04097 | chr7:92384001~92385000 | blood | MTM9) and AML-661 PDX | acute myeloid leukemia | Chromatin interaction assay; Enhancer chromatin-state assay; Enhancer hijacking analysis; Target-gene functional validation |
| E_04098 | chr7:92384001~92385000 | bone marrow | MTM9) and AML-661 PDX | acute myeloid leukemia | Chromatin interaction assay; Enhancer chromatin-state assay; Enhancer hijacking analysis; Target-gene functional validation |
| E_04099 | chr7:92384001~92385000 | blood | Primary del(7q) AML cells (2KFQ | acute myeloid leukemia with del(7)(q22q36) | Chromatin interaction assay; Chromatin accessibility assay; Enhancer identification assay |
| E_04100 | chr7:92384001~92385000 | bone marrow | Primary del(7q) AML cells (2KFQ | acute myeloid leukemia with del(7)(q22q36) | Chromatin interaction assay; Chromatin accessibility assay; Enhancer identification assay |
| E_04101 | chr7:107615000~107635000 | bone marrow | bone marrow mesenchymal stem | -- | Enhancer activity assay, Chromatin interaction assay, eQTL validation |
| E_04102 | chr11:111152290~111154290 | colon | HCT 116 | colorectal carcinoma | GWAS fine-mapping; allele-specific enhancer validation; candidate target association |
| E_04103 | chr11:111152290~111154290 | colon | SW480 | colorectal carcinoma | GWAS fine-mapping; allele-specific enhancer validation; candidate target association |
| E_04104 | chr11:111152290~111154290 | colon | HCT 116 | colorectal carcinoma | GWAS fine-mapping; allele-specific enhancer validation; candidate target association |
| E_04105 | chr11:111152290~111154290 | colon | SW480 | colorectal carcinoma | GWAS fine-mapping; allele-specific enhancer validation; candidate target association |
| E_04106 | chr11:111152290~111154290 | colon | HCT 116 | colorectal carcinoma | GWAS fine-mapping; allele-specific enhancer validation; candidate target association |
| E_04107 | chr11:111152290~111154290 | colon | SW480 | colorectal carcinoma | GWAS fine-mapping; allele-specific enhancer validation; candidate target association |
| E_04108 | chr7:92384001~92385000 | blood | MTM9) | acute myeloid leukemia with del(7)(q22q36) | Chromatin interaction assay; Chromatin accessibility assay; Enhancer identification assay |
| E_04109 | chr7:92384001~92385000 | bone marrow | MTM9) | acute myeloid leukemia with del(7)(q22q36) | Chromatin interaction assay; Chromatin accessibility assay; Enhancer identification assay |
| E_04110 | chr2:79165929~79165948 | colon | Primary colorectal-cancer tissues with paired normal colon mucosa | colorectal cancer | clinical-expression association; lncRNA enhancer-complex mechanism; functional perturbation |
| E_04111 | chr8:128412386~128415392 | prostate gland | LNCaP,C4-2B | prostate cancer | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04112 | chr8:128412386~128415392 | prostate gland | LNCaP,C4-2B | prostate cancer | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04113 | chr8:128412386~128415392 | prostate gland | LNCaP,C4-2B | prostate cancer | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04114 | chr7:92384001~92385000 | blood | AML-661 PDX | acute myeloid leukemia with del(7q) | Chromatin interaction assay; Chromatin accessibility assay; Histone modification profiling |
| E_04115 | chr9:19188000~19188100 | blood | M12 B cells | B-cell non-Hodgkin lymphoma | Enhancer activity assay, TF binding assay |
| E_04116 | chr9:19196000~19196100 | blood | M12 B cells | B-cell non-Hodgkin lymphoma | Enhancer activity assay, TF binding assay |
| E_04117 | chr14:106152156~106153203 | blood | BL-41 | Burkitt lymphoma (B-cell non-Hodgkin lymphoma) | IGH 3∩RR core peak 1; dense tiling CRISPRi-defined essential enhancer; eRNA-producing region; causal control of translocated MYC and lymphoma-cell survival |
| E_04118 | chr14:106152156~106153203 | blood | study-wide validation also included DG-75, SUDHL4 and lymphoma samples | Burkitt lymphoma (B-cell non-Hodgkin lymphoma) | IGH 3∩RR core peak 1; dense tiling CRISPRi-defined essential enhancer; eRNA-producing region; causal control of translocated MYC and lymphoma-cell survival |
| E_04119 | chr14:106162681~106163347 | blood | DG-75 | Burkitt lymphoma (B-cell non-Hodgkin lymphoma) | IGH 3∩RR core peak 2; dense tiling CRISPRi-defined essential enhancer; eRNA-producing region; causal control of translocated MYC and lymphoma-cell survival |
| E_04120 | chr14:106162681~106163347 | blood | study-wide validation also included BL-41, SUDHL4 and lymphoma samples | Burkitt lymphoma (B-cell non-Hodgkin lymphoma) | IGH 3∩RR core peak 2; dense tiling CRISPRi-defined essential enhancer; eRNA-producing region; causal control of translocated MYC and lymphoma-cell survival |
| E_04121 | chr1:134714823~134715623 | brain | Primary mouse mesencephalic cells | -- | Enhancer activity assay; TF binding assay |
| E_04122 | chr11:111150916~111155431 | colon | HCT 116,SW480,Colorectal Cancer | colorectal cancer | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04123 | chr5:145320091~145322975 | pancreas | Pancreatic primordium | -- | Enhancer activity assay |
| E_04124 | chr2:79165929~79165948 | colon | HT-29/LIM1215 mechanistic validation | colorectal cancer | clinical-expression association; lncRNA enhancer-complex mechanism; functional perturbation |
| E_04125 | chr3:107705500~107706800 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay |
| E_04126 | chr5:147267297~147268497 | pancreas | Primary pancreatic islets | -- | TF binding assay; Developmental enhancer occupancy assay |
| E_04127 | chr5:147267297~147268497 | pancreas | Primary pancreatic islets | -- | TF binding assay; Developmental enhancer occupancy assay |
| E_04128 | chr17:26829232~26829742 | heart | Cardiac Progenitor Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04129 | chr12:7940709~7941994 | -- | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04130 | chr5:145326114~145328962 | pancreas | Fetal pancreatic | -- | TF binding assay |
| E_04131 | chr10:128568604~128569741 | brain | Primary tumor tissue | glioblastoma | Enhancer activity assay |
| E_04132 | chr10:129033193~129034911 | brain | Primary tumor tissue | glioblastoma | Enhancer activity assay |
| E_04133 | chr7:156583402~156585773 | limb bud | developing limb bud | preaxial polydactyly II | Long-range developmental enhancer discovery; human disease-variant analysis; in vivo enhancer validation |
| E_04134 | chr7:156583796~156584568 | limb | affected families and vertebrate limb reporter models | preaxial polydactyly | Human pathogenic regulatory-variant mapping; long-range developmental enhancer validation |
| E_04135 | chr7:156583796~156584568 | limb | affected families | preaxial polydactyly | Human pathogenic regulatory-variant mapping; long-range developmental enhancer validation |
| E_04136 | chr7:156583796~156584568 | limb | vertebrate limb transgenic models | preaxial polydactyly | Human pathogenic regulatory-variant mapping; long-range developmental enhancer validation |
| E_04137 | chr7:156583402~156585773 | limb bud | transgenic mouse embryo | preaxial polydactyly | In vivo enhancer activity assay; Regulatory variant functional assay |
| E_04138 | chr10:129605804~129607046 | liver | Hepatocyte | -- | Enhancer activity assay |
| E_04139 | chr7:136083275~136084434 | forebrain | Mouse Embryonic Brain Cells | -- | Functional Perturbation Assay, Chromatin Interaction Assay |
| E_04140 | chrY:2792658~2792907 | kidney | HEK293T | 46,XY disorder of sex development | Enhancer activity assay; Functional perturbation assay |
| E_04141 | chr6:135644579~135645062 | bone marrow | DND-41 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay |
| E_04142 | chr16:86178434~86238313 | lung | IMR-90 | -- | Enhancer activity assay; Coactivator binding assay; Functional perturbation assay; DNA methylation assay |
| E_04143 | chr16:1480850~1482378 | intestine | patient-derived intestinal organoids | intractable congenital diarrhoea caused by intestine-critical region deletion | Disease-associated noncoding deletion analysis; transgenic enhancer reporter; endogenous regulatory-region deletion; target-gene rescue; in vivo phenotyping |
| E_04144 | chr9:59048862~59048913 | testis | Round spermatids | -- | Enhancer activity assay, TF binding assay; Enhancer activity assay; In vivo functional validation |
| E_04145 | chr6:4438697~4440197 | blood / hematopoietic system | Mesenchymal-Fibroblast Cells | Fibrotic Disease | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_04146 | chr2:11679389~11680097 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay; Disease-variant functional analysis |
| E_04147 | chr2:234861935~234862442 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay, Functional perturbation assay; Disease-variant functional analysis |
| E_04148 | chr7:142580000~142580293 | skeletal muscle tissue | C3H10T1/2-derived myoblasts | -- | Enhancer activity assay; Functional perturbation assay; TF binding evidence; In vivo functional validation |
| E_04149 | chr15:40397350~40397940 | blood | MEC1 and primary CLL B cells | chronic lymphocytic leukemia | Risk-variant enhancer functional validation |
| E_04150 | chrY:2792658~2792907 | testis | hiPSC-derived Sertoli-like cells | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay; Disease-variant functional analysis |
| E_04151 | chr2:8818311~8820522 | -- | Neuroblastoma Cell Lines | neuroblastoma | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_04152 | chr1:67739940~67741075 | blood | primary CD4-positive T cells | ankylosing spondylitis | Allele-specific enhancer assay; TF-binding assay; phenotype association |
| E_04153 | chr1:67739940~67741075 | blood | primary CD4-positive T cells | ankylosing spondylitis | Enhancer activity assay; TF binding assay; Functional variant assay |
| E_04154 | chr1:98509888~98511451 | -- | Neuroblastoma Cell Lines | Schizophrenia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04155 | chr1:98514701~98515055 | -- | Neuroblastoma Cell Lines | Schizophrenia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04156 | chr1:98516486~98522430 | -- | Neuroblastoma Cell Lines | Schizophrenia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04157 | chr1:98517055~98517909 | -- | Neuroblastoma Cell Lines | Schizophrenia | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04158 | chr11:5246250~5246637 | bone marrow | K-562 | -- | Enhancer activity assay; Endogenous enhancer perturbation |
| E_04159 | chr11:5246250~5246637 | esophagus | KYSE-30 | -- | Enhancer activity assay; Endogenous enhancer perturbation |
| E_04160 | chr16:1480850~1482378 | intestine | Developing gastrointestinal tract | intractable congenital diarrhoea caused by intestine-critical region deletion | Disease-associated noncoding deletion analysis; transgenic enhancer reporter; endogenous regulatory-region deletion; target-gene rescue; in vivo phenotyping |
| E_04161 | chr16:86194740~86195815 | lung | IMR-90 | -- | Functional perturbation assay, TF binding assay |
| E_04162 | chr1:228005620~228006224 | brain | HN4-derived cerebral organoids | Kabuki syndrome | causal disease-enhancer identification and endogenous enhancer deletion; numeric coordinate supplied only by external database harmonization |
| E_04163 | chr1:228005620~228006224 | brain | KMT2D-KO organoids | Kabuki syndrome | causal disease-enhancer identification and endogenous enhancer deletion; numeric coordinate supplied only by external database harmonization |
| E_04164 | chr1:228005620~228006224 | brain | Kabuki patient-derived iPSC organoids | Kabuki syndrome | causal disease-enhancer identification and endogenous enhancer deletion; numeric coordinate supplied only by external database harmonization |
| E_04165 | chr1:228005620~228006224 | diencephalon | HN4-derived cerebral organoids | Kabuki syndrome | causal disease-enhancer identification and endogenous enhancer deletion; numeric coordinate supplied only by external database harmonization |
| E_04166 | chr1:228005620~228006224 | diencephalon | KMT2D-KO organoids | Kabuki syndrome | causal disease-enhancer identification and endogenous enhancer deletion; numeric coordinate supplied only by external database harmonization |
| E_04167 | chr1:228005620~228006224 | diencephalon | Kabuki patient-derived iPSC organoids | Kabuki syndrome | causal disease-enhancer identification and endogenous enhancer deletion; numeric coordinate supplied only by external database harmonization |
| E_04168 | chr1:67739940~67741075 | blood | primary CD4-positive T cells | ankylosing spondylitis | Enhancer activity assay; Functional variant assay |
| E_04169 | chr10:6091181~6091380 | blood | Primary human CD4+ T cells from healthy donors for activation/eQTL mapping | type 1 diabetes mellitus | Activation-dependent autoimmune-risk enhancer; eQTL/GWAS fine-mapping; allele-specific YY1 binding and enhancer activity |
| E_04170 | chr10:6091181~6091380 | blood | Primary human CD4+ T cells from healthy donors for activation/eQTL mapping | multiple sclerosis | Activation-dependent autoimmune-risk enhancer; eQTL/GWAS fine-mapping; allele-specific YY1 binding and enhancer activity |
| E_04171 | chr1:182851627~182852853 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04172 | chr1:182851627~182852853 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04173 | chr1:182851627~182852853 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04174 | chr1:182852133~182854320 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04175 | chr1:182852133~182854320 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04176 | chr1:182852133~182854320 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04177 | chr1:182856227~182857187 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04178 | chr1:182856227~182857187 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04179 | chr1:182856227~182857187 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04180 | chr11:35178343~35180368 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04181 | chr11:35178343~35180368 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04182 | chr11:35178343~35180368 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04183 | chr11:35813868~35814943 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04184 | chr11:35813868~35814943 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04185 | chr11:35813868~35814943 | -- | Tet2-/- | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04186 | chr8:105528423~105529045 | -- | N38 | -- | Enhancer activity assay; In vivo functional validation |
| E_04187 | chr9:110254800~110254851 | testis | Round spermatids | -- | Enhancer activity assay; In vivo functional validation |
| E_04188 | chr16:67520620~67520851 | hypothalamus | N38 | -- | Enhancer activity assay; in vivo enhancer validation |
| E_04189 | chr1:228005620~228006224 | brain | mouse diencephalon | Kabuki syndrome | causal disease-enhancer identification and endogenous enhancer deletion; numeric coordinate supplied only by external database harmonization |
| E_04190 | chr1:228005620~228006224 | diencephalon | mouse diencephalon | Kabuki syndrome | causal disease-enhancer identification and endogenous enhancer deletion; numeric coordinate supplied only by external database harmonization |
| E_04191 | chr10:6091180~6091381 | blood | Jurkat | autoimmune disease | Enhancer activity assay; allele-specific TF binding assay; genetic association assay; Disease-variant functional analysis |
| E_04192 | chr10:6091181~6091380 | blood | Jurkat for mechanistic reporter assays | type 1 diabetes mellitus | Activation-dependent autoimmune-risk enhancer; eQTL/GWAS fine-mapping; allele-specific YY1 binding and enhancer activity |
| E_04193 | chr10:6091181~6091380 | blood | Jurkat for mechanistic reporter assays | multiple sclerosis | Activation-dependent autoimmune-risk enhancer; eQTL/GWAS fine-mapping; allele-specific YY1 binding and enhancer activity |
| E_04194 | chr16:67519201~67519833 | -- | H295R,N38 | -- | Enhancer activity assay; In vivo functional validation |
| E_04195 | chr16:67519609~67519833 | -- | H295R,N38 | -- | Enhancer activity assay; In vivo functional validation |
| E_04196 | chr16:67520417~67521049 | -- | H295R,N38 | -- | Enhancer activity assay; In vivo functional validation |
| E_04197 | chr16:67520417~67520638 | -- | AtT-20,N38 | -- | Enhancer activity assay; In vivo functional validation |
| E_04198 | chr16:67520620~67520851 | -- | H295R | -- | Enhancer activity assay; In vivo functional validation |
| E_04199 | chr1:98515300~98515700 | breast | MCF-7 | Schizophrenia | Enhancer activity assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_04200 | chr1:67739940~67741075 | blood | primary CD4+ T cells/Th1 phenotyping | ankylosing spondylitis | Genetic association/fine-mapping; allele-specific enhancer activity; chromatin-state analysis; allele-specific DNA-binding assay; T-cell phenotyping |
| E_04201 | chr16:67520417~67520638 | hypothalamus | mHypoE-38 | -- | Enhancer activity assay; Tissue-selective enhancer assay |
| E_04202 | chr16:67520620~67520851 | adrenal gland | NCI-H295R | -- | Enhancer activity assay; Tissue-selective enhancer assay |
| E_04203 | chr10:6091181~6091381 | blood | primary activated CD4+ T cells | -- | Activation-specific cis-eQTL fine-mapping; allele-specific enhancer and TF-binding validation; Disease-variant functional analysis |
| E_04204 | chr16:67520417~67520638 | -- | NCI-H295R | -- | Enhancer activity assay |
| E_04205 | chr1:67739940~67741075 | blood | HEK293T reporter assays | ankylosing spondylitis | Genetic association/fine-mapping; allele-specific enhancer activity; chromatin-state analysis; allele-specific DNA-binding assay; T-cell phenotyping |
| E_04206 | chr10:6091181~6091381 | blood | Jurkat | -- | Enhancer activity assay; Allele-specific TF binding assay; Regulatory-variant functional assay; Genetic association/eQTL assay; Disease-variant functional analysis |
| E_04207 | chr10:6091181~6091381 | blood | Jurkat | -- | Enhancer activity assay; Allele-specific TF binding assay; Regulatory-variant functional assay; Genetic association assay; Disease-variant functional analysis |
| E_04208 | chr10:6091181~6091381 | blood | Jurkat reporter validation | -- | Activation-specific cis-eQTL fine-mapping; allele-specific enhancer and TF-binding validation; Disease-variant functional analysis |
| E_04209 | chr10:6064657~6065397 | blood / hematopoietic system | T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_04210 | chr1:67739940~67741075 | blood | primary CD4-positive T cells | ankylosing spondylitis | Candidate regulatory-variant analysis |
| E_04211 | chr4:174441057~174442400 | -- | Neuroblastoma Cell Lines | neuroblastoma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04212 | chr4:174435828~174438057 | -- | Neuroblastoma Cell Lines | neuroblastoma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04213 | chr11:5211019~5213983 | blood / hematopoietic system | K-562 | -- | Enhancer activity assay |
| E_04214 | chr1:67739940~67741075 | blood / hematopoietic system | Lymphoblastoid Cell Lines | ankylosing spondylitis | Enhancer activity assay; Disease-associated enhancer analysis |
| E_04215 | chr16:67520620~67520851 | tongue | Transgenic FVB mouse | -- | In vivo transgenic enhancer activity assay; Nutrient-responsive enhancer assay |
| E_04216 | chr16:67520620~67520851 | tongue | transgenic mouse embryo | -- | In vivo enhancer activity assay |
| E_04217 | chr16:67520417~67520638 | testis | Transgenic FVB mouse | -- | In vivo transgenic enhancer activity assay |
| E_04218 | chr16:67520417~67520851 | testis | transgenic mouse embryo | -- | In vivo enhancer activity assay |
| E_04219 | chr8:127247950~127248600 | pancreas | MIA PaCa-2 | pancreatic ductal adenocarcinoma | Enhancer/eRNA functional validation; Functional perturbation assay; RNA-protein interaction assay; Chromatin occupancy assay |
| E_04220 | chr8:57331591~57335031 | uterus | GD3.5 pregnant mouse uterus / uterine stromal cells | -- | TF binding assay; enhancer chromatin-state mapping; conditional TF perturbation; enhancer orthology/functional validation |
| E_04221 | chr4:74500000~74575000 | liver | Liver sinusoidal endothelial cells (LSEC) | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_04222 | chr6:115566900~115569800 | adipose tissue | C2C12 | -- | Enhancer activity assay; TF binding assay; Functional perturbation assay |
| E_04223 | chr2:150860120~150860367 | brain | Primary Mouse Tissues | -- | Enhancer activity assay, Functional perturbation assay |
| E_04224 | chr2:150860120~150860367 | brain | Primary Mouse Tissues | -- | Enhancer activity assay, Functional perturbation assay |
| E_04225 | chr2:46523219~46568173 | breast | MCF7L-TamR | breast carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_04226 | chr6:52199038~52200503 | lung | Lung,Stomach | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04227 | chr19:11090422~11091028 | liver | Huh-7 | -- | Functional perturbation assay; Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04228 | chr11:5225440~5225500 | bone marrow | CD34+ hematopoietic stem/progenitor cells | beta-thalassemia | Functional perturbation assay, Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04229 | chr2:60722750~60722850 | bone marrow | CD34+ hematopoietic stem/progenitor cells | beta-thalassemia | Functional perturbation assay, Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04230 | chr7:117587146~117589449 | colon | HT-29 | -- | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation |
| E_04231 | chr2:16370000~16380000 | adrenal gland | Kelly | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04232 | chr2:16370000~16380000 | adrenal gland | Kelly | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04233 | chr2:16370000~16380000 | adrenal gland | Kelly | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04234 | chr2:12600000~12649999 | adrenal gland | IMR-5/75 | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04235 | chr2:12600000~12649999 | adrenal gland | IMR-5/75 | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04236 | chr2:12600000~12649999 | adrenal gland | IMR-5/75 | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04237 | chr11:5301983~5302001 | pleural effusion | K-562 | -- | Enhancer activity assay; TF-DNA binding assay; cis-regulatory mutational mapping |
| E_04238 | chr11:5301983~5302001 | pleural effusion | K-562 | -- | Enhancer activity assay; TF-DNA binding assay; cis-regulatory mutational mapping |
| E_04239 | chr4:173516002~173519662 | endometrium | T-HESC immortalized human endometrial stromal cells | -- | Enhancer activation assay; orthologous enhancer functional validation; endogenous target-gene activation |
| E_04240 | chr19:11090150~11090715 | tongue | SCC-25 | -- | Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04241 | chr19:11090550~11090678 | liver | Huh-7 | -- | Enhancer activity assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04242 | chr2:60722238~60722466 | blood | beta-thalassemia patient CD34+ hematopoietic stem/progenitor cells | beta-thalassemia | Endogenous enhancer base-editing functional perturbation |
| E_04243 | chr7:117504671~117505671 | kidney | HEK293T | -- | Functional perturbation assay |
| E_04244 | chr7:127306000~127309000 | skeletal muscle tissue | C2C12 | -- | Enhancer activity assay; TF binding assay |
| E_04245 | chr11:5301983~5302001 | uterine cervix | HeLa | -- | Enhancer activity assay; TF-DNA binding assay; cis-regulatory mutational mapping |
| E_04246 | chr11:5301983~5302001 | uterine cervix | HeLa | -- | Enhancer activity assay; TF-DNA binding assay; cis-regulatory mutational mapping |
| E_04247 | chr11:5288664~5288684 | blood / hematopoietic system | K-562 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04248 | chr11:5288664~5288684 | blood / hematopoietic system | HeLa | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04249 | chr8:127247950~127248600 | pancreas | AsPC-1 | pancreatic ductal adenocarcinoma | Enhancer/eRNA expression validation; RNA-protein interaction assay; Chromatin occupancy assay |
| E_04250 | chr11:5288664~5288684 | blood | K-562 | -- | Enhancer activity assay |
| E_04251 | chr7:117504671~117505671 | lung | UNCCF3T (F508del/F508del human bronchial epithelial cells) | cystic fibrosis | Epigenome editing assay; Functional enhancer perturbation assay |
| E_04252 | chr11:5288664~5288684 | blood | K-562 | -- | Enhancer activity assay; cis-element functional mapping; TF-complex binding assay |
| E_04253 | chr3:38578362~38581496 | heart | isogenic human iPSC-derived cardiomyocytes carrying the RE5 enhancer variant | Brugada syndrome | Regulatory variant enhancer assay; genome editing assay; electrophysiological functional assay; Disease-variant functional analysis |
| E_04254 | chr6:64732005~64901125 | spinal cord | Neurons | -- | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; In vivo functional validation |
| E_04255 | chr2:152735054~152735521 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_04256 | chr2:152735054~152735521 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_04257 | chr12:131949637~131949801 | -- | Normal Human Bronchial Epithelial Cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04258 | chr12:131949637~131949801 | -- | Normal Human Bronchial Epithelial Cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04259 | chr14:47056226~47056692 | -- | LS-8 Cells | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_04260 | chr15:61449862~61451562 | intestine | ApcMin/+ | colorectal cancer | Endogenous enhancer deletion; in vivo tumor-susceptibility assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_04261 | chr15:61449862~61451562 | intestine | Myc-335-null mouse intestinal epithelium | colorectal cancer | Endogenous enhancer deletion; in vivo tumor-susceptibility assay; Endogenous enhancer perturbation; Disease-variant functional analysis; In vivo functional validation |
| E_04262 | chr12:103024800~103025800 | hypothalamus | Mouse primary neurons | obesity | Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04263 | chr17:31670439~31671892 | lens of camera-type eye | embryonic mouse lens/lens-derived cells | -- | Shadow-enhancer activity; promoter-enhancer looping; developmental reporter validation; Chromatin interaction assay |
| E_04264 | chr17:31670439~31671892 | lens of camera-type eye | embryonic mouse lens/lens-derived cells | -- | Shadow-enhancer activity; promoter-enhancer looping; developmental reporter validation; Chromatin interaction assay |
| E_04265 | chr17:31670439~31671892 | lens of camera-type eye | embryonic mouse lens/lens-derived cells | -- | Shadow-enhancer activity; promoter-enhancer looping; developmental reporter validation; Chromatin interaction assay |
| E_04266 | chr17:31670439~31671892 | lens of camera-type eye | embryonic mouse lens/lens-derived cells | -- | Shadow-enhancer activity; promoter-enhancer looping; developmental reporter validation; Chromatin interaction assay |
| E_04267 | chr2:119321593~119322529 | brain | 293T,Progenitor Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_04268 | chr2:119321593~119322529 | brain | 293T,Progenitor Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_04269 | chr2:119321593~119322529 | brain | 293T,Progenitor Cell | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04270 | chr2:119321593~119322529 | brain | 293T,Progenitor Cell | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04271 | chr3:11249688~11250280 | uterine cervix | HeLa | -- | Enhancer chromatin-state assay; Chromatin interaction analysis; Enhancer activity assay; Chromatin interaction assay |
| E_04272 | chr3:128124000~128125500 | bone marrow | AML blasts | acute myeloid leukemia | Functional perturbation assay |
| E_04273 | chr11:5286080~5288080 | blood / hematopoietic system | K-562 | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04274 | chr17:31670439~31671892 | lens of camera-type eye | embryonic mouse lens/lens-derived cells | -- | Shadow-enhancer activity; promoter-enhancer looping; developmental reporter validation |
| E_04275 | chr17:31670439~31671892 | lens of camera-type eye | embryonic mouse lens/lens-derived cells | -- | Shadow-enhancer activity; promoter-enhancer looping; developmental reporter validation |
| E_04276 | chr1:9996966~9997243 | blood | GM12878 | -- | Enhancer chromatin-state assay; Chromatin interaction analysis |
| E_04277 | chr11:5301862~5302715 | blood | K-562 | -- | Enhancer activity assay; chromatin accessibility assay; chromatin modification assay; In vivo functional validation |
| E_04278 | chr15:67301270~67301820 | thyroid gland | TPC-1 | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04279 | chr15:67301270~67301820 | thyroid gland | B-CPAP | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04280 | chr15:67304460~67305010 | thyroid gland | TPC-1 | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04281 | chr15:67304460~67305010 | thyroid gland | B-CPAP | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04282 | chr15:67441595~67443595 | thyroid gland | TPC-1 | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04283 | chr15:67441595~67443595 | thyroid gland | B-CPAP | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04284 | chr15:67442496~67442696 | thyroid gland | TPC-1 | thyroid gland papillary carcinoma | Enhancer activity assay; allele-specific regulatory-variant assay |
| E_04285 | chr15:67442496~67442696 | thyroid gland | B-CPAP | thyroid gland papillary carcinoma | Enhancer activity assay; allele-specific regulatory-variant assay |
| E_04286 | chr15:67457151~67459151 | thyroid gland | TPC-1 | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04287 | chr15:67457151~67459151 | thyroid gland | B-CPAP | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04288 | chr15:67458052~67458252 | thyroid gland | TPC-1 | thyroid gland papillary carcinoma | Enhancer activity assay; allele-specific regulatory-variant assay |
| E_04289 | chr15:67458052~67458252 | thyroid gland | B-CPAP | thyroid gland papillary carcinoma | Enhancer activity assay; allele-specific regulatory-variant assay |
| E_04290 | chr9:14538685~14540685 | breast | MCF-7 | Adenoid Cystic Carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04291 | chr9:14923979~14925979 | breast | MCF-7 | Adenoid Cystic Carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04292 | chr9:15066136~15068136 | breast | MCF-7 | Adenoid Cystic Carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04293 | chr1:92170642~92172642 | breast | MCF-7 | Adenoid Cystic Carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04294 | chr1:92254801~92256801 | breast | MCF-7 | Adenoid Cystic Carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04295 | chr1:92331533~92333533 | breast | MCF-7 | Adenoid Cystic Carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04296 | chr1:92359751~92361751 | breast | MCF-7 | Adenoid Cystic Carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04297 | chr1:92392919~92394919 | breast | MCF-7 | Adenoid Cystic Carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04298 | chr1:92567177~92569177 | breast | MCF-7 | Adenoid Cystic Carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04299 | chr6:70500000~70500100 | blood | Primary B cells | -- | Chromatin interaction assay, TF binding assay; TF binding assay |
| E_04300 | chr12:3941972~3942627 | arcuate nucleus of hypothalamus | arcuate nucleus POMC neurons | obesity | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04301 | chr12:3944600~3944917 | arcuate nucleus of hypothalamus | arcuate nucleus POMC neurons | obesity | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04302 | chr6:70500000~70500100 | blood | 293T mouse CLDN18.2 | plasmacytoma | Chromatin interaction assay, TF binding assay |
| E_04303 | chr6:70522000~70522100 | blood | 293T mouse CLDN18.2 | plasmacytoma | Chromatin interaction assay, TF binding assay |
| E_04304 | chr6:70546000~70546100 | blood | 293T mouse CLDN18.2 | plasmacytoma | Chromatin interaction assay, TF binding assay |
| E_04305 | chr1:9996966~9997243 | blood / hematopoietic system | GM12878,CD4+ T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04306 | chr3:11249688~11250280 | blood / hematopoietic system | GM12878,CD4+ T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04307 | chr6:70712244~70713044 | blood | MPC-11 | -- | Chromatin interaction assay; TF binding assay |
| E_04308 | chr6:70712244~70713044 | blood | MPC-11 | -- | Chromatin interaction assay; TF binding assay |
| E_04309 | chr6:70720691~70721851 | blood | MPC-11 | -- | Chromatin interaction assay; TF binding assay |
| E_04310 | chr6:70720691~70721851 | blood | MPC-11 | -- | Chromatin interaction assay; TF binding assay |
| E_04311 | chr6:70685249~70686058 | blood | MPC-11 | -- | Chromatin interaction assay; TF binding assay |
| E_04312 | chr6:70693703~70694944 | blood | MPC-11 | -- | Chromatin interaction assay; TF binding assay |
| E_04313 | chr6:67556736~67558736 | blood / hematopoietic system | B Cell,T Cell,MPC-11 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_04314 | chr6:67556736~67558736 | blood / hematopoietic system | B Cell,T Cell,MPC-11 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_04315 | chr6:67556736~67558736 | blood / hematopoietic system | B Cell,T Cell,MPC-11 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_04316 | chr6:67561736~67563736 | blood / hematopoietic system | B Cell,T Cell,MPC-11 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_04317 | chr6:67561736~67563736 | blood / hematopoietic system | B Cell,T Cell,MPC-11 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_04318 | chr6:67561736~67563736 | blood / hematopoietic system | B Cell,T Cell,MPC-11 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_04319 | chr6:67560136~67562136 | blood / hematopoietic system | B Cell,T Cell,MPC-11 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_04320 | chr6:67560136~67562136 | blood / hematopoietic system | B Cell,T Cell,MPC-11 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_04321 | chr6:67560136~67562136 | blood / hematopoietic system | B Cell,T Cell,MPC-11 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_04322 | chr15:67442496~67442696 | thyroid gland | TPC-1 | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04323 | chr15:67458052~67458252 | thyroid gland | TPC-1 | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04324 | chr3:128603821~128604120 | bone marrow | inv(3) AML and G2DHE BAC-transgenic hematopoietic models | acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2) | Genetic enhancer-hijacking validation |
| E_04325 | chr15:67442496~67442696 | thyroid gland | B-CPAP | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04326 | chr15:67458052~67458252 | thyroid gland | B-CPAP | thyroid gland papillary carcinoma | Enhancer activity assay; Allele-specific regulatory variant assay |
| E_04327 | chr6:70712244~70713044 | spleen | Primary splenic B cells | -- | Chromatin interaction assay |
| E_04328 | chr6:70720691~70721851 | spleen | Primary splenic B cells | -- | Chromatin interaction assay |
| E_04329 | chr6:70675569~70676084 | spleen | Primary splenic B cells | -- | Chromatin interaction assay |
| E_04330 | chr11:5286080~5288080 | blood | K-562 | -- | Enhancer activity assay; chromatin regulatory assay |
| E_04331 | chr3:128124000~128125500 | bone marrow | HSPCs | -- | Enhancer activity assay |
| E_04332 | chr3:70961242~70974816 | umbilical vein | HUVEC-C | -- | dCas9-KRAB CRISPRi loss-of-function, dual-luciferase reporter assay |
| E_04333 | chr12:114640000~114670000 | blood / hematopoietic system | B Cell | Autoimmune Diseases | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_04334 | chr12:114460000~114490000 | blood / hematopoietic system | B Cell | Autoimmune Diseases | TF-binding/chromatin assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_04335 | chr6:122652222~122653558 | embryo | Primary MEFs from 129 and 129/C57BL/6 E12.5-E13.5 embryos | -- | TF binding assay; Enhancer activity assay; Chromatin accessibility assay; Nucleosome positioning assay; Chromatin topology assay; Cellular reprogramming assay |
| E_04336 | chr6:122652222~122653558 | embryo | Primary MEFs from 129 and 129/C57BL/6 E12.5-E13.5 embryos | -- | TF binding assay; Enhancer activity assay; Chromatin accessibility assay; Nucleosome positioning assay; Chromatin topology assay; Cellular reprogramming assay |
| E_04337 | chr6:122652222~122653558 | embryo | Primary MEFs from 129 and 129/C57BL/6 E12.5-E13.5 embryos | -- | TF binding assay; Enhancer activity assay; Chromatin accessibility assay; Nucleosome positioning assay; Chromatin topology assay; Cellular reprogramming assay |
| E_04338 | chr18:61533339~61545796 | blood / hematopoietic system | MonoMac6,K-562 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04339 | chr18:61533339~61545796 | blood / hematopoietic system | MonoMac6,K-562 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04340 | chr14:92450000~92451800 | bone element | A-673 | Ewing sarcoma | Functional perturbation assay |
| E_04341 | chr1:181104024~181104549 | breast | MCF-7 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04342 | chr9:118706130~118707280 | breast | MCF-7 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04343 | chr6:122652222~122653558 | embryo | mouse embryonic stem cells | -- | TF binding assay; Enhancer reporter assay; Chromatin accessibility assay; Nucleosome positioning assay; Chromatin topology assay |
| E_04344 | chr6:122652222~122653558 | embryo | mouse embryonic stem cells | -- | TF binding assay; Enhancer reporter assay; Chromatin accessibility assay; Nucleosome positioning assay; Chromatin topology assay |
| E_04345 | chr6:122652222~122653558 | embryo | mouse embryonic stem cells | -- | TF binding assay; Enhancer reporter assay; Chromatin accessibility assay; Nucleosome positioning assay; Chromatin topology assay |
| E_04346 | chr18:61274230~61274810 | blood | K-562 | -- | Enhancer reporter assay; eRNA-associated regulatory-element assay |
| E_04347 | chr1:117752000~117754000 | breast | MCF-7 | -- | Enhancer activity assay |
| E_04348 | chr1:179369000~179374000 | prostate gland | LNCaP | -- | Enhancer activity assay |
| E_04349 | chr20:21452815~21462458 | -- | HeLa | Ewing Sarcoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04350 | chr20:21452815~21462458 | -- | 293T | Ewing Sarcoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04351 | chr18:61274230~61274810 | blood | Mono-Mac-6 | -- | Enhancer/eRNA functional assay; TF recruitment assay; Transcriptional pause-release assay |
| E_04352 | chr14:97410723~97443618 | -- | HeLa | Ewing Sarcoma | Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04353 | chr14:97410723~97443618 | -- | 293T | Ewing Sarcoma | Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04354 | chr3:103180000~103230000 | adipose tissue | C3H/10T1/2 clone 8 | -- | Regulatory element functional validation, 3D chromatin architecture analysis, epigenomic profiling |
| E_04355 | chr3:103470000~103520000 | adipose tissue | C3H/10T1/2 clone 8 | -- | Regulatory element functional validation, 3D chromatin architecture analysis, epigenomic profiling |
| E_04356 | chr12:117170000~117198000 | spleen | CH12F3-2A | -- | Regulatory element functional validation, super-enhancer activation analysis |
| E_04357 | chr6:6058554~6059028 | embryo | Embryonic whole mount | -- | Enhancer activity assay |
| E_04358 | chr6:6163229~6163674 | embryo | Embryonic whole mount | -- | Enhancer activity assay |
| E_04359 | chr3:108015219~108015290 | -- | 293T | -- | Enhancer activity assay; Endogenous enhancer perturbation |
| E_04360 | chr6:60769316~60772093 | brain | Primary midbrain dopaminergic neurons | -- | Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04361 | chr2:27480000~27480400 | embryo | mouse embryonic stem cells | -- | CRISPR enhancer knockout assay |
| E_04362 | chr4:44520195~44520234 | blood / hematopoietic system | Lymphopoiesis B Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_04363 | chr4:44520195~44520234 | blood / hematopoietic system | Lymphopoiesis B Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_04364 | chr4:44520195~44520234 | blood / hematopoietic system | Lymphopoiesis B Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_04365 | chr4:44520195~44520234 | blood / hematopoietic system | Lymphopoiesis B Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; In vivo functional validation |
| E_04366 | chr11:5225400~5225774 | bone marrow | K-562 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04367 | chr14:48579937~48581029 | retina | Primary Mouse Embryonic Retinal Explant Cells | -- | Enhancer activity assay |
| E_04368 | chr14:48584564~48585012 | retina | Primary Mouse Embryonic Retinal Explant Cells | -- | Enhancer activity assay |
| E_04369 | chr14:48606973~48608016 | retina | Primary Mouse Embryonic Retinal Explant Cells | -- | Enhancer activity assay |
| E_04370 | chr14:48608144~48609697 | retina | Primary Mouse Embryonic Retinal Explant Cells | -- | Enhancer activity assay |
| E_04371 | chr14:48616314~48617497 | retina | Primary Mouse Embryonic Retinal Explant Cells | -- | Enhancer activity assay |
| E_04372 | chr14:48624486~48626389 | retina | Primary Mouse Embryonic Retinal Explant Cells | -- | Enhancer activity assay |
| E_04373 | chr14:48662841~48663211 | retina | Primary Mouse Embryonic Retinal Explant Cells | -- | Enhancer activity assay |
| E_04374 | chr6:1614904~1616335 | embryo | E11.5 transgenic mouse embryo | -- | Enhancer activity assay; Motif perturbation assay |
| E_04375 | chr6:1614904~1616335 | embryo | E11.5 transgenic mouse embryo | -- | Enhancer activity assay; Motif perturbation assay |
| E_04376 | chr6:1616341~1617336 | embryo | E11.5 transgenic mouse embryo | -- | Enhancer activity assay; Motif perturbation assay |
| E_04377 | chr6:1616341~1617336 | embryo | E11.5 transgenic mouse embryo | -- | Enhancer activity assay; Motif perturbation assay |
| E_04378 | chr6:1619847~1620844 | embryo | E11.5 transgenic mouse embryo | -- | Enhancer activity assay; Motif perturbation assay |
| E_04379 | chr6:1619847~1620844 | embryo | E11.5 transgenic mouse embryo | -- | Enhancer activity assay; Motif perturbation assay |
| E_04380 | chr6:1702408~1703763 | embryo | E11.5 transgenic mouse embryo | -- | Enhancer activity assay |
| E_04381 | chr6:1702408~1703763 | embryo | E11.5 transgenic mouse embryo | -- | Enhancer activity assay |
| E_04382 | chr11:5301862~5302715 | blood | K-562 | -- | Enhancer-blocking assay; chromatin modification assay; functional perturbation assay |
| E_04383 | chr14:48593170~48594188 | retina | Primary Mouse Embryonic Retinal Explant Cells | -- | Enhancer activity assay |
| E_04384 | chr4:118656335~118661035 | bone marrow | Primary B cell progenitors | -- | Enhancer activity assay, TF binding assay |
| E_04385 | chr6:60769316~60772093 | substantia nigra | Genetically engineered C57BL/6J mice | Parkinson disease | In vivo causal neuronal enhancer disruption in a Parkinson disease mouse model |
| E_04386 | chr6:60769316~60772093 | substantia nigra | midbrain dopaminergic neurons | Parkinson disease | In vivo causal neuronal enhancer disruption in a Parkinson disease mouse model |
| E_04387 | chr11:5271421~5273421 | blood / hematopoietic system | K-562 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04388 | chr2:103887795~103888195 | -- | Embryo | -- | TF-binding/chromatin assay |
| E_04389 | chr2:103886995~103888995 | -- | Embryo | -- | TF-binding/chromatin assay |
| E_04390 | chr6:1614188~1617051 | brain | Embryonic Stem Cell | -- | Experimentally supported enhancer study |
| E_04391 | chr6:1614188~1617051 | brain | Embryonic Stem Cell | -- | Experimentally supported enhancer study |
| E_04392 | chr6:1615843~1617834 | brain | Embryonic Stem Cell | -- | Experimentally supported enhancer study |
| E_04393 | chr6:1615843~1617834 | brain | Embryonic Stem Cell | -- | Experimentally supported enhancer study |
| E_04394 | chr6:1619348~1621343 | brain | Embryonic Stem Cell | -- | Experimentally supported enhancer study |
| E_04395 | chr6:1619348~1621343 | brain | Embryonic Stem Cell | -- | Experimentally supported enhancer study |
| E_04396 | chr6:1701730~1704441 | brain | Embryonic Stem Cell | -- | Experimentally supported enhancer study |
| E_04397 | chr6:1701730~1704441 | brain | Embryonic Stem Cell | -- | Experimentally supported enhancer study |
| E_04398 | chr4:156021490~156022916 | spleen | Primary mouse regulatory T cells | -- | Functional perturbation assay, Enhancer activity assay; Endogenous enhancer perturbation |
| E_04399 | chr17:47950000~47955000 | adrenal gland | SK-N-BE(2) | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04400 | chr17:47950000~47955000 | adrenal gland | SK-N-BE(2) | neuroblastoma | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04401 | chr10:87376120~87376374 | central nervous system | Embryonic neuroprogenitor cells | -- | Functional perturbation assay, Enhancer activity assay; Enhancer activity assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04402 | chr4:84277627~84281723 | -- | AGS | gastric cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04403 | chr6:71341692~71345212 | blood / hematopoietic system | CD4+ T Cell | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04404 | chr6:71341692~71345212 | blood / hematopoietic system | CD4+ T Cell | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04405 | chr6:122563494~122564540 | lymph node | Germinal center B cells | -- | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; In vivo functional validation |
| E_04406 | chr6:122573553~122574125 | lymph node | Germinal center B cells | -- | Enhancer activity assay, Functional perturbation assay; Enhancer activity assay; In vivo functional validation |
| E_04407 | chr3:34756748~34761748 | embryo | murine embryonic stem cells (mESCs) | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04408 | chr6:122612768~122617768 | embryo | murine embryonic stem cells (mESCs) | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04409 | chr6:122652768~122657768 | embryo | murine embryonic stem cells (mESCs) | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04410 | chr6:122717768~122722768 | embryo | murine embryonic stem cells (mESCs) | -- | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04411 | chr17:69541883~69542989 | -- | TM4 | -- | Enhancer activity assay; In vivo functional validation |
| E_04412 | chr3:46988756~46990332 | bone marrow | primary human megakaryocytes | -- | Enhancer activity; direct TF occupancy; enhancer-target linkage |
| E_04413 | chr17:69487560~69491400 | -- | HEK-293 | Disorders Of Sexual Development | Enhancer activity assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_04414 | chr17:69487560~69491400 | -- | HEK-293 | Disorders Of Sexual Development | Enhancer activity assay; In vivo functional validation; Disease-associated enhancer analysis |
| E_04415 | chr1:165827290~165830012 | limb bud | E11.5 embryonic limb bud | -- | Enhancer activity assay; In vivo enhancer deletion assay; Developmental enhancer assay; Candidate target expression analysis; Endogenous enhancer perturbation; In vivo functional validation |
| E_04416 | chr1:165827290~165830012 | limb bud | E11.5 mouse limb bud | -- | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04417 | chr4:117063735~117065404 | limb bud | E11.5 embryonic limb bud | -- | Enhancer activity assay; In vivo enhancer deletion assay; Developmental enhancer assay; Candidate target expression analysis; Endogenous enhancer perturbation; In vivo functional validation |
| E_04418 | chr4:117063735~117065404 | limb bud | E11.5 mouse limb bud | -- | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04419 | chr14:90847327~90849327 | blood / hematopoietic system | MCF-7 | Congenital Limb Deformity | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04420 | chr14:90847327~90849327 | blood / hematopoietic system | HeLa | Congenital Limb Deformity | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04421 | chr14:90847327~90849327 | blood / hematopoietic system | HCT 116 | Congenital Limb Deformity | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04422 | chr2:136608729~136608757 | colon | Caco-2 | -- | Enhancer activity assay; TF binding assay |
| E_04423 | chr2:136608729~136608757 | colon | Caco-2 | -- | Enhancer activity assay; TF binding assay; Allele-specific functional assay |
| E_04424 | chr11:5191975~5193451 | blood | transgenic mouse erythroid cells | hereditary persistence of fetal hemoglobin | In vivo enhancer activity assay; disease breakpoint analysis |
| E_04425 | chr11:5191975~5193451 | blood | transgenic mouse erythroid cells | hereditary persistence of fetal hemoglobin | In vivo enhancer activity assay; disease breakpoint analysis |
| E_04426 | chr11:5214864~5215676 | blood | transgenic mouse erythroid cells | hereditary persistence of fetal hemoglobin | In vivo enhancer activity assay; disease breakpoint analysis |
| E_04427 | chr11:5214864~5215676 | blood | transgenic mouse erythroid cells | hereditary persistence of fetal hemoglobin | In vivo enhancer activity assay; disease breakpoint analysis |
| E_04428 | chr11:5168384~5181696 | blood | transgenic mouse erythroid cells | hereditary persistence of fetal hemoglobin | In vivo enhancer activity assay; disease breakpoint analysis |
| E_04429 | chr11:5168384~5181696 | blood | transgenic mouse erythroid cells | hereditary persistence of fetal hemoglobin | In vivo enhancer activity assay; disease breakpoint analysis |
| E_04430 | chr14:90847327~90849327 | blood / hematopoietic system | K-562 | Congenital Limb Deformity | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04431 | chr14:90847327~90849327 | blood / hematopoietic system | Nb4 | Congenital Limb Deformity | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04432 | chr14:61103201~61105984 | kidney | 16-17 week human fetal nephron progenitors | -- | Enhancer activity assay; TF binding assay; Chromatin-state profiling |
| E_04433 | chr14:61103201~61105984 | kidney | 16-17 week human fetal nephron progenitors | -- | Enhancer activity assay; TF binding assay; Gene expression assay; Chromatin-state profiling |
| E_04434 | chr14:61119031~61119800 | kidney | 16-17 week human fetal nephron progenitors | -- | Enhancer activity assay; TF binding assay; Chromatin-state profiling |
| E_04435 | chr14:61119031~61119800 | kidney | 16-17 week human fetal nephron progenitors | -- | Enhancer activity assay; TF binding assay; Gene expression assay; Chromatin-state profiling |
| E_04436 | chr3:46988756~46990332 | bone marrow | K-562 functional reporter model | -- | Enhancer activity; direct TF occupancy; enhancer-target linkage |
| E_04437 | chr11:5191975~5193451 | blood | transgenic mouse erythroid cells | hereditary persistence of fetal hemoglobin | In vivo enhancer activity assay; Breakpoint-associated enhancer assay |
| E_04438 | chr14:61101000~61104000 | kidney | 16-17 week human fetal nephron progenitor | -- | Enhancer activity assay, TF binding assay, Gene expression assay |
| E_04439 | chr14:61113500~61116500 | kidney | 16-17 week human fetal nephron progenitor | -- | Enhancer activity assay, TF binding assay, Gene expression assay |
| E_04440 | chr14:61101000~61102000 | kidney | Nephron Progenitor | -- | Enhancer activity assay, TF binding assay |
| E_04441 | chr14:61101000~61102000 | kidney | Nephron Progenitor | -- | Enhancer activity assay, TF binding assay |
| E_04442 | chr14:61116934~61117934 | kidney | Nephron Progenitor | -- | Enhancer activity assay, TF binding assay |
| E_04443 | chr14:61116934~61117934 | kidney | Nephron Progenitor | -- | Enhancer activity assay, TF binding assay |
| E_04444 | chr3:46988575~46990242 | blood / hematopoietic system | K-562 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04445 | chr2:136531405~136531505 | -- | Caco-2 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04446 | chr2:136531405~136531505 | -- | Caco-2 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04447 | chr14:61121917~61123917 | -- | Nephron Progenitors | -- | TF-binding/chromatin assay |
| E_04448 | chr14:61106417~61108417 | -- | Nephron Progenitors | -- | TF-binding/chromatin assay |
| E_04449 | chr17:69541883~69542989 | mesonephric mesenchyme | patient DNA | hypospadias | Enhancer-variant functional assay |
| E_04450 | chr17:69498800~69500700 | testis | TM4 | -- | Enhancer activity assay |
| E_04451 | chr17:69541883~69542989 | mesonephric mesenchyme | genital-tubercle/developmental enhancer reporter models | hypospadias | Enhancer-variant functional assay |
| E_04452 | chr2:46578867~46579857 | thoracic aorta | TeloHAEC | -- | Enhancer activity assay; Functional perturbation assay |
| E_04453 | chr14:98541905~98544383 | bone marrow | Primary lineage-ambiguous leukemia cells | acute leukemia of ambiguous lineage | Enhancer hijacking assay; Chromatin interaction assay; Structural-variant regulatory assay |
| E_04454 | chr2:44123800~44124118 | internal ear | mESC differentiated hair cell | -- | Enhancer activity assay, Functional perturbation assay |
| E_04455 | chr11:75928700~75928930 | lung | NCI-H920 | small cell lung carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04456 | chr14:22758000~22759600 | liver | Hep-G2 | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay, eRNA functional assay; Chromatin interaction assay |
| E_04457 | chr14:24435744~24437744 | liver | Hep G2,HL-7702 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04458 | chr13:94663320~94664200 | adrenal gland | NCI-H295R | esophageal squamous cell carcinoma | Enhancer activity assay, CNV functional assay; Disease-variant functional analysis |
| E_04459 | chr9:21816751~21818751 | blood / hematopoietic system | Human 2BS Diploid Fibroblast Cells | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04460 | chr11:69470000~69470500 | lymphoid tissue | DLBCL cells | diffuse large B-cell lymphoma | Chromatin interaction assay; Disease-variant functional analysis |
| E_04461 | chr3:34645597~34646134 | brain | Mouse Embryos | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04462 | chr11:5293686~5294250 | blood / hematopoietic system | K-562 | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04463 | chr9:22117000~22118500 | lung | NTERA-2 | -- | Enhancer activity assay, Chromatin interaction assay |
| E_04464 | chr7:103771431~103772043 | -- | Pleen Cells,MEL cells | -- | TF-binding/chromatin assay; In vivo functional validation |
| E_04465 | chr12:132285987~132290767 | -- | Ishikawa Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_04466 | chr12:132281970~132287430 | -- | Ishikawa Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_04467 | chr12:132342570~132347690 | -- | Ishikawa Cell | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation |
| E_04468 | chr6:37997692~38001538 | breast | T-47D | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04469 | chr6:38010769~38019538 | breast | T-47D | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04470 | chr6:38032307~38035230 | breast | T-47D | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04471 | chr11:45868494~45868510 | -- | U2OS | -- | Enhancer activity assay; TF binding assay; Circadian regulatory-element dissection assay |
| E_04472 | chr7:117342000~117345000 | zone of skin | COLO 829 | cutaneous melanoma | Chromatin interaction assay |
| E_04473 | chr19:2482923~2484923 | -- | HEK-293 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04474 | chr19:2482923~2484923 | -- | HEK-293 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04475 | chr19:2482923~2484923 | -- | HEK-293 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04476 | chr14:22420000~22422000 | blood | Leukemic B Lymphoblasts | B-cell acute lymphoblastic leukemia | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_04477 | chr7:117074000~117077000 | nasal cavity epithelium | HNECs | -- | Chromatin interaction assay |
| E_04478 | chr20:30244800~30316534 | breast | MDA-MB-231 | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04479 | chr16:92629000~92629500 | bone marrow | Mouse hematopoietic progenitor cell | -- | Enhancer activity assay |
| E_04480 | chr16:92632000~92632500 | bone marrow | Mouse hematopoietic progenitor cell | -- | Enhancer activity assay |
| E_04481 | chr16:92679000~92679500 | bone marrow | Mouse hematopoietic progenitor cell | -- | Enhancer activity assay |
| E_04482 | chr16:92697000~92697500 | bone marrow | Mouse hematopoietic progenitor cell | -- | Enhancer activity assay |
| E_04483 | chr14:22420000~22422000 | thymus | T Lymphocyte Progenitors | -- | Enhancer activity assay, Chromatin interaction assay, Functional perturbation assay |
| E_04484 | chr6:151917241~152028736 | breast | T-47D | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04485 | chr16:92300180~92300670 | blastocyst | HPC-7 | -- | Runx1 -327 candidate enhancer; Chromatin interaction assay; Negative enhancer activity assay |
| E_04486 | chr16:92412100~92412620 | blastocyst | HPC-7 | -- | Runx1 -58 enhancer; Chromatin interaction assay; In vivo enhancer activity assay |
| E_04487 | chr16:92663850~92664380 | blastocyst | HPC-7 | -- | Runx1 +24 enhancer; Chromatin interaction assay; In vivo enhancer activity assay |
| E_04488 | chr16:92706240~92706730 | blastocyst | HPC-7 | -- | Runx1 +110 enhancer; Chromatin interaction assay; In vivo enhancer activity assay |
| E_04489 | chr16:92261320~92261830 | blastocyst | HPC-7 | -- | Runx1 -371 enhancer; Chromatin interaction assay; In vivo enhancer activity assay |
| E_04490 | chr16:92274840~92275330 | blastocyst | HPC-7 | -- | Runx1 -368 enhancer; Chromatin interaction assay; In vivo enhancer activity assay |
| E_04491 | chr16:92288710~92289240 | blastocyst | HPC-7 | -- | Runx1 -354 enhancer; Chromatin interaction assay; In vivo enhancer activity assay |
| E_04492 | chr16:92303420~92303910 | blastocyst | HPC-7 | -- | Runx1 -321 enhancer; Chromatin interaction assay; In vivo enhancer activity assay |
| E_04493 | chr16:92314760~92315270 | blastocyst | HPC-7 | -- | Runx1 -303 enhancer; Chromatin interaction assay; In vivo enhancer activity assay |
| E_04494 | chr16:92431630~92432140 | blastocyst | HPC-7 | -- | Runx1 -48 enhancer; Chromatin interaction assay; In vivo enhancer activity assay |
| E_04495 | chr11:69468873~69470873 | breast | MCF-7 | Breast Tumor | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04496 | chr16:92625802~92627802 | -- | HPC-7 | Leukaemia | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04497 | chr7:117011495~117063767 | skin | Human Nasal Epithelial Cell,Skin Fibroblasts Cell | Cystic Fibrosis | Enhancer activity assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04498 | chr7:117282955~117335227 | skin | Human Nasal Epithelial Cell,Skin Fibroblasts Cell | Epithelial Cancer | Enhancer activity assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04499 | chr14:22420000~22422000 | zone of skin | Primary human epidermal keratinocytes (HEKa) | -- | Enhancer activity assay, Chromatin interaction assay |
| E_04500 | chr11:45846943~45846959 | -- | U-2 OS | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04501 | chr11:45846943~45846959 | -- | U-2 OS | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04502 | chr2:46578867~46579857 | kidney | HEK293T | -- | Enhancer activity assay; Allele-specific functional assay |
| E_04503 | chr7:117323000~117324600 | colon | Caco-2 | colorectal adenocarcinoma | Enhancer activity assay |
| E_04504 | chr13:95865319~95866199 | -- | Umbilical Vein Endothelial Cell,ESCC | esophageal squamous cell carcinoma | Enhancer activity assay; Disease-associated enhancer analysis |
| E_04505 | chr11:45846943~45846959 | breast | MCF-7 | -- | Enhancer activity assay |
| E_04506 | chr6:88180000~88180500 | bone marrow | Hematopoietic stem cells, HSPCs | -- | Regulatory element functional validation, in vivo mouse model validation; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04507 | chr11:100854851~100856851 | -- | Mammary | -- | TF-binding/chromatin assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04508 | chr2:122651534~122668846 | -- | Macrophage | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04509 | chr2:122651534~122668846 | -- | Macrophage | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04510 | chr8:81286250~81293977 | -- | Lymphoblastoid Cell Lines | National Institute of Allergy and Infectious Diseases | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04511 | chr11:5278952~5279402 | bone marrow | K-562 | -- | CRISPRi-based single-cell enhancer perturbation |
| E_04512 | chr8:130180217~130180629 | blood | human and mouse T-ALL models | T-cell acute lymphoblastic leukemia | TF requirement for oncogenic enhancer activity and accessibility |
| E_04513 | chr8:130180217~130180629 | bone marrow | human and mouse T-ALL models | T-cell acute lymphoblastic leukemia | TF requirement for oncogenic enhancer activity and accessibility |
| E_04514 | chr14:78351421~78354313 | blood / hematopoietic system | T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04515 | chr14:78351421~78354313 | blood / hematopoietic system | T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04516 | chr6:70725951~70726429 | -- | S194/5.XXO.BU.1 | -- | Enhancer activity assay; Functional perturbation assay; Chromatin accessibility assay; Chromatin structure assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04517 | chr6:70735260~70736060 | -- | S194/5.XXO.BU.1 | -- | Enhancer activity assay; Functional perturbation assay; Chromatin accessibility assay; Chromatin structure assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04518 | chr11:5258353~5258721 | pleural effusion | K-562 | -- | CRISPRi-based single-cell endogenous enhancer perturbation |
| E_04519 | chr6:37151046~37151259 | blood | K-562 | -- | Multiplex endogenous enhancer perturbation with single-cell transcriptomic readout |
| E_04520 | chr8:130180065~130180972 | blood | T-ALL cell lines and primary T-ALL | T-cell acute lymphoblastic leukemia | TF dependency of oncogenic enhancer activity |
| E_04521 | chr14:78384835~78446843 | blood / hematopoietic system | T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04522 | chr14:78384835~78446843 | blood / hematopoietic system | T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04523 | chr8:81274400~81275960 | blood | K-562 | chronic myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; Disease-variant functional analysis |
| E_04524 | chr6:70989543~70989643 | blood | LPRB3 112 | plasmacytoma | Functional perturbation assay |
| E_04525 | chr6:70999043~70999143 | blood | LPRB3 112 | plasmacytoma | Functional perturbation assay |
| E_04526 | chr8:130180065~130180972 | bone marrow | human T-ALL cells | T-cell acute lymphoblastic leukemia | TF requirement for oncogenic enhancer activity |
| E_04527 | chr8:130180065~130180972 | bone marrow | NOTCH1/TAL1 leukemia models | T-cell acute lymphoblastic leukemia | TF requirement for oncogenic enhancer activity |
| E_04528 | chr8:130180065~130180972 | blood | human T-ALL cells | T-cell acute lymphoblastic leukemia | TF requirement for oncogenic enhancer activity |
| E_04529 | chr8:130180065~130180972 | blood | NOTCH1/TAL1 leukemia models | T-cell acute lymphoblastic leukemia | TF requirement for oncogenic enhancer activity |
| E_04530 | chr22:43901526~43904612 | blood | K-562 | chronic myeloid leukemia | Super-enhancer activity assay, Functional perturbation assay |
| E_04531 | chr14:22556439~22556536 | blood | Primary human peripheral blood CD3+ T cells | -- | Functional enhancer perturbation assay; Endogenous cis-regulatory element validation |
| E_04532 | chr14:101283029~101284356 | liver | HuH-6 | hepatoblastoma | Enhancer activity assay; Functional perturbation assay; Tumorigenicity assay; Endogenous enhancer perturbation |
| E_04533 | chr15:69452739~69453134 | cervix-derived cell culture | HeLa | -- | Motif-defined enhancer discovery; Golgi-stress response assay; reporter/mutagenesis analysis |
| E_04534 | chr7:156791087~156791875 | limb bud | E11.5 transgenic and targeted-replacement mouse embryos carrying the human ZRS ortholog | -- | In vivo enhancer sufficiency assay; ortholog replacement assay; TF-motif functional rescue; developmental phenotype assay |
| E_04535 | chr8:83287756~83287955 | embryo | Mouse Embryonic Fibroblasts | -- | Enhancer recruitment assay; TF/cofactor binding assay; Functional perturbation assay; In vitro transcription assay |
| E_04536 | chr14:67742375~67743103 | gonad | Epithelial Cell,Granulosa Cells,GT1-7,GN11,Embryonic Stem Cell | -- | Enhancer activity assay; In vivo functional validation |
| E_04537 | chr14:67742375~67743103 | gonad | Epithelial Cell,Granulosa Cells,GT1-7,GN11,Embryonic Stem Cell | -- | Enhancer activity assay; In vivo functional validation |
| E_04538 | chrX:7954360~7956360 | heart | Embryonic Stem Cell | -- | Enhancer activity assay; In vivo functional validation |
| E_04539 | chr11:5224750~5226210 | urinary bladder | T24 | -- | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04540 | chr5:28563148~28563921 | neural tube | ES-E14 | -- | Synthetic enhancer activation assay; Cohesin functional perturbation assay; Chromatin conformation analysis |
| E_04541 | chr5:28875380~28876679 | diencephalon | ES-E14 | -- | Synthetic enhancer activation assay; Cohesin/CTCF functional perturbation assay; Chromatin conformation analysis |
| E_04542 | chr5:29314497~29315862 | limb bud | ES-E14 | -- | Synthetic enhancer activation assay; Cohesin/CTCF functional perturbation assay; Chromatin conformation analysis |
| E_04543 | chr17:37912040~37913027 | blood | MP1 mature B-cell line | autoimmune disease susceptibility at 17q12-21 | Disease-variant enhancer reporter assay; GWAS/epigenomic prioritization; site-directed allelic comparison |
| E_04544 | chr17:38050770~38051866 | blood | MT-2 | autoimmune disease susceptibility at 17q12-21 | Disease-variant enhancer reporter assay; GWAS/epigenomic prioritization; site-directed allelic comparison |
| E_04545 | chr3:186938165~186940165 | blood / hematopoietic system | Lymphoma Cell | B-Cell Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04546 | chr8:128588859~128589357 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay; Enhancer activity assay; Disease-variant functional analysis |
| E_04547 | chr8:128600697~128601159 | uterine cervix | HeLa | prostate cancer | Enhancer activity assay, TF binding assay; Enhancer activity assay; Disease-variant functional analysis |
| E_04548 | chr8:128600697~128601159 | uterine cervix | HeLa | prostate cancer | Enhancer activity assay, TF binding assay; Enhancer activity assay; Disease-variant functional analysis |
| E_04549 | chr14:22556439~22556536 | blood | Jurkat E6.1 | -- | CRISPR-based enhancer screening assay; Functional enhancer perturbation assay |
| E_04550 | chr17:37912040~37913027 | blood | Activated U-937 | autoimmune disease susceptibility at 17q12-21 | Disease-variant enhancer reporter assay; GWAS/epigenomic prioritization; site-directed allelic comparison |
| E_04551 | chr17:37912040~37913027 | blood | NALM-6 | autoimmune disease susceptibility at 17q12-21 | Disease-variant enhancer reporter assay; GWAS/epigenomic prioritization; site-directed allelic comparison |
| E_04552 | chr17:38026822~38029614 | blood | Activated U-937 | autoimmune disease susceptibility at 17q12-21 | Disease-variant enhancer reporter assay; GWAS/epigenomic prioritization; site-directed allelic comparison |
| E_04553 | chr3:187559165~187589165 | blood / hematopoietic system | Lymphoma Cell | B-Cell Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04554 | chr8:128588859~128589357 | left supraclavicular lymph node | LNCaP | prostate cancer | Enhancer activity assay; TF binding assay; Androgen-responsive enhancer assay; Disease-variant functional analysis |
| E_04555 | chr8:128588859~128589357 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF binding assay; Epigenomic profiling; Disease-variant functional analysis |
| E_04556 | chr8:128600697~128601159 | left supraclavicular lymph node | LNCaP | prostate cancer | Enhancer activity assay; TF binding assay; Androgen-responsive enhancer assay; Risk-variant functional assay; Disease-variant functional analysis |
| E_04557 | chr8:128600697~128601159 | left supraclavicular lymph node | LNCaP | prostate cancer | Enhancer activity assay; TF binding assay; Risk-variant functional assay; Disease-variant functional analysis |
| E_04558 | chr3:187088165~187909165 | blood / hematopoietic system | Lymphoma Cell | B-Cell Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04559 | chrX:7826505~7830405 | bone marrow | ES | -- | Enhancer activity assay, TF binding assay |
| E_04560 | chr8:83287848~83288068 | blood / hematopoietic system | Brown Fat Cell | -- | TF-binding/chromatin assay |
| E_04561 | chr11:5264845~5266345 | blood / hematopoietic system | K-562 | -- | TF-binding/chromatin assay |
| E_04562 | chr8:120880096~120882492 | lung | Embryonic lung tissue | -- | Functional perturbation assay |
| E_04563 | chr5:110175120~110177136 | heart | Blood | Heart Failure | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04564 | chr4:101576220~101578659 | -- | Endothelial Cells (ECs) | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04565 | chr1:133275546~133275787 | kidney | As4.1 | -- | Enhancer activity assay; cis-element functional mapping; TF binding assay |
| E_04566 | chr11:5270500~5271500 | blood | K-562 | -- | Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04567 | chr11:5301862~5302715 | blood | K-562 | -- | Enhancer activity assay; Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04568 | chr8:128910869~128911521 | blood | K-562 | -- | Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04569 | chr8:128972341~128973219 | blood | K-562 | -- | Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04570 | chr8:129057272~129057795 | blood | K-562 | -- | Functional perturbation assay; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04571 | chr12:48369059~48369213 | -- | SW 1353 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04572 | chr8:128747315~128748315 | colon | HCT 116 | colorectal cancer | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04573 | chr8:128749415~128750415 | colon | HCT 116 | colorectal cancer | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04574 | chr12:48369059~48369213 | cartilage tissue | SW1353 | -- | Enhancer occupancy assay; functional response assay; Enhancer activity assay; TF binding assay |
| E_04575 | chr8:128346390~128347994 | -- | HEK-293 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04576 | chr8:128327941~128330615 | -- | HEK-293 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04577 | chr8:128299198~128301336 | -- | HEK-293 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04578 | chr8:128296257~128297326 | -- | HEK-293 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04579 | chr12:48355000~48355154 | cartilage tissue | Human chondrosarcoma cell | chondrosarcoma | Enhancer activity assay |
| E_04580 | chr5:110175800~110176600 | heart | 293T | Heart Failure | Enhancer activity assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04581 | chr1:152019738~152021345 | liver | Huh-7 | hepatocellular carcinoma | Enhancer activity assay; TF binding assay; Chromatin-state profiling |
| E_04582 | chr2:16000000~16002000 | lung | H446 cells | small cell lung carcinoma | Super-enhancer activity assay |
| E_04583 | chr20:5921142~6004055 | brain | Glioma stem cell | glioblastoma | Enhancer activity assay, TF binding assay, Functional perturbation assay |
| E_04584 | chr4:73725619~73726851 | skeletal muscle tissue | Human Skeletal Myotubes | -- | Enhancer activity assay, Chromatin interaction assay |
| E_04585 | chr7:95608432~95609655 | skeletal muscle tissue | Human Skeletal Myotubes | -- | Enhancer activity assay, Chromatin interaction assay |
| E_04586 | chr2:75208104~75210328 | limb | E10.5-E12.5 limb bud cells | -- | Enhancer activity assay; Chromatin interaction assay; Developmental gene-regulation assay |
| E_04587 | chr2:75208104~75210328 | limb | E10.5-E12.5 limb bud cells | -- | Enhancer activity assay; Chromatin interaction assay; Developmental gene-regulation assay |
| E_04588 | chr1:181117806~181122451 | colon | HCT 116 | cervical cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04589 | chrX:135959959~135963959 | pituitary gland | GH3 | X-linked acrogigantism | Enhancer activity assay; Chromatin interaction assay |
| E_04590 | chr2:535659~535798 | embryo | embryonic cell | -- | Functional perturbation assay |
| E_04591 | chr2:577491~577557 | embryo | embryonic cell | -- | Functional perturbation assay |
| E_04592 | chr2:684320~684414 | embryo | embryonic cell | -- | Functional perturbation assay |
| E_04593 | chr2:716946~717020 | embryo | Whole zebrafish embryos | -- | Functional perturbation assay; Gene expression analysis; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04594 | chr2:716946~717020 | embryo | embryonic cell | -- | Functional perturbation assay |
| E_04595 | chr20:26689284~26689441 | embryo | Whole zebrafish embryos | -- | Functional perturbation assay; Gene expression analysis; Endogenous enhancer perturbation; Disease-variant functional analysis |
| E_04596 | chr20:26689284~26689441 | embryo | embryonic cell | -- | Functional perturbation assay |
| E_04597 | chr3:181433217~181434197 | breast | breast tumor mammosphere-forming cells | breast carcinoma | Enhancer activity assay; functional perturbation assay |
| E_04598 | chr5:131406243~131406930 | blood | Jurkat | -- | Review-supported enhancer activity assay; TF binding assay; chromatin accessibility assay |
| E_04599 | chr5:131406243~131406930 | blood | Jurkat | -- | Review-supported enhancer activity assay; TF binding assay; chromatin accessibility assay |
| E_04600 | chrX:135577559~135581959 | blood | PBMCs | -- | Chromatin interaction assay; Disease-variant functional analysis |
| E_04601 | chrX:135656769~135660247 | blood | PBMCs | -- | Chromatin interaction assay; Disease-variant functional analysis |
| E_04602 | chrX:135846959~135851769 | blood | PBMCs | -- | Chromatin interaction assay; Disease-variant functional analysis |
| E_04603 | chrX:135990759~135994160 | blood | PBMCs | -- | Chromatin interaction assay; Disease-variant functional analysis |
| E_04604 | chrX:135625877~135641072 | blood | PBMCs | -- | Chromatin interaction assay; Disease-variant functional analysis |
| E_04605 | chr5:132002000~132008000 | bone element | MG-63 | osteosarcoma | Enhancer activity assay |
| E_04606 | chr1:51429600~51450093 | brain | Glioma stem cell | glioma | Enhancer activity assay |
| E_04607 | chr3:181425707~181426096 | breast | MCF-7 | breast carcinoma | Enhancer activity assay |
| E_04608 | chr3:34646162~34646551 | breast | MCF-7 | breast cancer | Enhancer activity assay; Disease-associated enhancer analysis |
| E_04609 | chr11:53495000~53501000 | blood | Murine T Lymphocytes | -- | Enhancer activity assay |
| E_04610 | chr6:135194929~135196024 | bone marrow | PDX#2263 | acute myeloid leukemia | Enhancer essentiality screen; Functional cis-regulatory-element perturbation assay |
| E_04611 | chr8:128041672~128043891 | bone marrow | CD34+ cells | beta-thalassemia | Functional perturbation assay |
| E_04612 | chr10:131265950~131266000 | brain | KYSE-410 | glioblastoma | Functional perturbation assay, Enhancer activity assay |
| E_04613 | chr5:134350424~134352424 | breast | MCF-7 | breast cancer | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04614 | chr12:103439326~103439476 | hypothalamus | POMC Arcuate Neuron | -- | Enhancer activity assay |
| E_04615 | chr12:113220000~113233375 | plasma-cell tumor / hematopoietic tumor context | primary mouse plasmacytoma cells | plasmacytoma | Genetic enhancer deletion; tumorigenesis/translocation analysis; Myc-expression assessment |
| E_04616 | chr21:43770915~43772915 | breast | MCF-7 | breast cancer | Enhancer chromatin-state assay; Enhancer occupancy assay; Transcriptional regulation assay |
| E_04617 | chr21:43795658~43798708 | breast | MCF-7 | breast cancer | Enhancer-associated chromatin-state assay; Signaling perturbation assay |
| E_04618 | chr21:43796920~43797320 | breast | MCF-7 | breast cancer | Enhancer chromatin-state assay; Chromatin co-occupancy assay; Functional signaling perturbation assay |
| E_04619 | chr21:43796920~43797320 | breast | MCF-7 | breast cancer | Enhancer-associated chromatin-state assay; signaling perturbation assay |
| E_04620 | chr19:57566145~57571006 | -- | HeLa | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_04621 | chr7:6502892~6504892 | -- | HeLa | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04622 | chr8:128173203~128174158 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04623 | chr8:128423748~128424352 | breast | MCF-7 | breast carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04624 | chr8:128482486~128483650 | colon | LS174T | colorectal carcinoma | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04625 | chr8:128589642~128590670 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04626 | chr19:57566145~57571006 | -- | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_04627 | chr7:6502892~6504892 | -- | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04628 | chr12:113220000~113233375 | plasma-cell tumor / hematopoietic tumor context | established T(12 | plasmacytoma | Genetic enhancer deletion; tumorigenesis/translocation analysis; Myc-expression assessment |
| E_04629 | chr12:113220000~113233375 | plasma-cell tumor / hematopoietic tumor context | 15)+ plasmacytoma cells | plasmacytoma | Genetic enhancer deletion; tumorigenesis/translocation analysis; Myc-expression assessment |
| E_04630 | chr8:128482317~128483854 | prostate gland | LNCaP | prostate cancer | Enhancer-associated chromatin assay; Chromatin interaction assay |
| E_04631 | chr12:113220000~113255414 | plasma-cell tumor / hematopoietic tumor context | T(12 | plasmacytoma | Enhancer-cluster deletion; tumor-cell functional perturbation; Myc-expression analysis |
| E_04632 | chr12:113220000~113255414 | plasma-cell tumor / hematopoietic tumor context | 15)+ plasmacytoma cells | plasmacytoma | Enhancer-cluster deletion; tumor-cell functional perturbation; Myc-expression analysis |
| E_04633 | chr21:43770915~43772915 | breast | MCF-7 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04634 | chr21:43770915~43772915 | breast | MCF-7 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04635 | chr2:239866844~239871938 | lung | NCI-H460 | chronic obstructive pulmonary disease | Enhancer activity assay; Functional perturbation assay |
| E_04636 | chr2:239884251~239900294 | lung | NCI-H460 | chronic obstructive pulmonary disease | Enhancer activity assay; Functional perturbation assay |
| E_04637 | chr2:20628003~20667995 | liver | Huh-7 | hepatocellular carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_04638 | chr2:172661000~172662500 | prostate gland | VCaP | prostate cancer | Enhancer activity assay, TF binding assay, Chromatin interaction assay |
| E_04639 | chr7:155845627~155847652 | limb | Caco-2 | preaxial polydactyly-hypertrichosis | Silencer activity assay; Disease-associated structural-variant assay |
| E_04640 | chr8:29203575~29214287 | breast | MCF-7,MDA-MB-231 | Breast Cancer | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04641 | chr11:69470000~69470500 | lymph node | Raji | breast cancer | Chromatin interaction assay |
| E_04642 | chr2:11600000~11700000 | breast | MCF-7 | breast cancer | Genome-wide enhancer-promoter interaction mapping; TF binding assay; chromatin-loop validation; TF-dependence validation |
| E_04643 | chr21:42300000~42500000 | breast | MCF-7 | breast cancer | Genome-wide enhancer-promoter interaction mapping; TF binding assay; chromatin-loop validation; TF-dependence validation |
| E_04644 | chr14:97720000~97780000 | blood | Peer | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_04645 | chr11:47394824~47395023 | bone marrow | myeloid progenitor cells and leukemia-relevant myeloid models | acute myeloid leukemia-associated myeloid differentiation | Direct TF-enhancer functional validation |
| E_04646 | chr14:54227135~54228033 | -- | P5424 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04647 | chr14:54227135~54228033 | -- | P5424 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04648 | chr14:54227135~54228033 | -- | P5424 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04649 | chr6:71321750~71323696 | -- | P5424 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04650 | chr6:71321750~71323696 | -- | P5424 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04651 | chr6:71321750~71323696 | -- | P5424 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04652 | chr3:112045517~112046117 | -- | HUVEC | Graft Rejection,Autoimmune Diseases,Spontaneous Abortion | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04653 | chr3:112045517~112046117 | -- | HUVEC | Graft Rejection,Autoimmune Diseases,Spontaneous Abortion | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04654 | chr3:112045517~112046117 | -- | HUVEC | Graft Rejection,Autoimmune Diseases,Spontaneous Abortion | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04655 | chr8:48025841~48796048 | liver | Huh-7 | hepatocellular carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; TF binding assay |
| E_04656 | chr11:69468761~69470761 | -- | MDA-MB-23,MDA-MB-436 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04657 | chr5:172196326~172199378 | breast | MCF-7,MDA-MB-231 | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04658 | chr3:112045517~112046117 | liver | Liver sinusoidal endothelial cell | -- | Enhancer activity assay |
| E_04659 | chr7:155845627~155847652 | -- | Caco-2 | -- | Enhancer activity assay |
| E_04660 | chr1:28883749~28884318 | bone marrow | K-562 | -- | Functional perturbation assay; Endogenous enhancer perturbation |
| E_04661 | chr3:93993657~93995818 | small intestine | ILC3s | -- | Functional perturbation assay |
| E_04662 | chr19:3441054~3441445 | amygdala | primary amygdala neurons | -- | Enhancer activity assay; Epigenetic modulation assay; Functional perturbation assay; DNA methylation profiling |
| E_04663 | chr19:3441054~3441445 | hypothalamus | primary hypothalamic neurons | -- | Enhancer activity assay; Epigenetic modulation assay; Functional perturbation assay; DNA methylation profiling |
| E_04664 | chr17:72118256~72120256 | bone element | MEF GFP-LC3-RFP-LC3deltaG | osteosarcoma | Enhancer activity assay, TF binding assay |
| E_04665 | chr21:42880000~42880500 | brain | HD-MB03 | Medulloblastoma | Chromatin interaction assay |
| E_04666 | chr1:133347808~133348049 | kidney | juxtaglomerular cells | -- | Enhancer activity assay; Functional perturbation assay; In vivo physiological assay; Endogenous enhancer perturbation; In vivo functional validation |
| E_04667 | chr19:51353370~51354238 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; Functional signaling perturbation assay |
| E_04668 | chr11:47394824~47395023 | bone marrow | primary AML samples and human myeloid cells | acute myeloid leukemia | TF-site and disease-variant enhancer validation |
| E_04669 | chrX:135656769~135660247 | blood | PBMCs | -- | Chromatin interaction assay; Disease-variant functional analysis |
| E_04670 | chrX:135846959~135851769 | blood | PBMCs | -- | Chromatin interaction assay; Disease-variant functional analysis |
| E_04671 | chrX:135959959~135963959 | blood | PBMCs | -- | Chromatin interaction assay; Disease-variant functional analysis |
| E_04672 | chrX:135990759~135994160 | blood | PBMCs | -- | Chromatin interaction assay; Disease-variant functional analysis |
| E_04673 | chr11:45582000~45582499 | thymus | double-negative thymocyte | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay; Enhancer activity assay |
| E_04674 | chr11:45586000~45586499 | thymus | double-negative thymocyte | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay; Enhancer activity assay |
| E_04675 | chr2:202120390~202125986 | blood / hematopoietic system | Human Mammary Epithelial Normal Breast Cell Line | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04676 | chr2:202120390~202125986 | blood / hematopoietic system | Human Mammary Epithelial Normal Breast Cell Line | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04677 | chr2:202120390~202125986 | blood / hematopoietic system | Human Mammary Epithelial Normal Breast Cell Line | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04678 | chr21:42668000~42671000 | breast | Breast Cancer Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04679 | chr20:43210000~43212000 | liver | Hep-G2 | hepatocellular carcinoma | Enhancer activity assay; TF binding assay |
| E_04680 | chr3:184276287~184278287 | colon | colorectal tumor specimens | colorectal cancer | Enhancer activity assay; TF/chromatin occupancy; chromatin accessibility analysis; pathway-dependent enhancer reactivation; disease-associated enhancer decommissioning |
| E_04681 | chr11:45582000~45582499 | thymus | double-positive thymocyte | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04682 | chr11:45582000~45582499 | thymus | naive CD4-positive T cell | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04683 | chr11:45586000~45586499 | thymus | double-positive thymocyte | -- | Enhancer activity assay, Chromatin interaction assay, TF binding assay |
| E_04684 | chr2:202204362~202205119 | breast | T-47D | breast carcinoma | Enhancer activity assay, TF binding assay |
| E_04685 | chrX:135632564~135633920 | blood | X-LAG patient-derived PBMCs | X-linked acrogigantism | Chromatin interaction assay; Structural variant functional assessment |
| E_04686 | chr1:133347808~133348049 | kidney | Kidney | -- | In vivo functional validation |
| E_04687 | chr11:5280741~5280786 | blood | K-562 | -- | Enhancer transcriptional regulation assay, Activity validation |
| E_04688 | chr6:88202011~88204330 | liver | Hepatocyte | -- | Enhancer activity assay, TF binding assay; Chromatin-state profiling |
| E_04689 | chr11:32145270~32146411 | blood vessel | Endothelial cells | -- | Enhancer activity assay; Chromatin-state profiling |
| E_04690 | chr13:28809515~28811310 | blood vessel | Endothelial cells | -- | Enhancer activity assay; Chromatin-state profiling |
| E_04691 | chr17:12982583~12985936 | blood vessel | Endothelial cells | -- | Enhancer activity assay; Chromatin-state profiling |
| E_04692 | chr3:87786601~87790798 | blood vessel | Endothelial cells | -- | Enhancer activity assay; Chromatin-state profiling |
| E_04693 | chr5:93426293~93427320 | blood vessel | Endothelial cells | -- | Enhancer activity assay; Chromatin-state profiling |
| E_04694 | chr7:116256647~116260817 | heart | Cardiomyocytes | -- | Enhancer activity assay; Chromatin-state profiling |
| E_04695 | chr8:28216799~28218903 | blood vessel | Endothelial cells | -- | Enhancer activity assay; Chromatin-state profiling |
| E_04696 | chr8:28216817~28218896 | blood vessel | Endothelial cells | -- | Enhancer activity assay; Chromatin-state profiling |
| E_04697 | chr4:114743698~114748936 | blood vessel | Endothelial cells | -- | Enhancer activity assay; Chromatin-state profiling |
| E_04698 | chr5:29641240~29642424 | limb bud | E11.5 posterior limb bud/ZPA | -- | Enhancer activity assay; Chromatin interaction assay; Functional genomic rearrangement assay |
| E_04699 | chr3:184276287~184278287 | colon | HT-29 | colorectal cancer | Enhancer activity assay; TF/chromatin occupancy; chromatin accessibility analysis; pathway-dependent enhancer reactivation; disease-associated enhancer decommissioning |
| E_04700 | chr3:184276287~184278287 | colon | LS174T and other colorectal carcinoma cell lines | colorectal cancer | Enhancer activity assay; TF/chromatin occupancy; chromatin accessibility analysis; pathway-dependent enhancer reactivation; disease-associated enhancer decommissioning |
| E_04701 | chr20:42977441~42978040 | liver | Hep G2 | hepatocellular carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04702 | chr20:42977441~42978040 | liver | Hep G2 | hepatocellular carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04703 | chr20:42977441~42978040 | liver | Hep G2 | hepatocellular carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04704 | chr2:202122500~202124030 | breast | MCF-10A | breast cancer susceptibility | Enhancer activity assay; Functional variant assay; Genetic association study; eQTL analysis |
| E_04705 | chr2:202122500~202124030 | breast | T-47D | breast cancer susceptibility | Enhancer activity assay; Functional variant assay; Genetic association study; eQTL analysis |
| E_04706 | chr6:88202011~88204330 | -- | Embryonic Endothelial Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04707 | chr14:97485490~97486674 | limb bud | E11.5 Z2D engineered embryonic limb bud | -- | Heterologous enhancer replacement assay; Functional genomic rearrangement assay; Chromatin interaction assay |
| E_04708 | chr5:29641240~29642424 | limb bud | E11.5 mouse limb bud | -- | Long-range enhancer-promoter interaction; structural perturbation |
| E_04709 | chr5:29641240~29642424 | limb bud | E11.5 mouse limb bud | -- | Structural rescue assay |
| E_04710 | chr5:29641240~29642424 | limb bud | E11.5 mouse limb bud | -- | Enhancer-distance functional test |
| E_04711 | chr5:29641240~29642424 | limb bud | E11.5 mouse limb bud | -- | TAD architecture perturbation |
| E_04712 | chr19:50850114~50850982 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; Disease-associated enhancer analysis |
| E_04713 | chr1:42958018~42958389 | blood | K-562 | -- | Enhancer discovery; Nascent-transcription regulation assay; Reporter-validation panel |
| E_04714 | chr1:244970941~244971645 | blood | K-562 | -- | Enhancer discovery; Nascent-transcription regulation assay; Reporter-validation panel |
| E_04715 | chr17:51121344~51122474 | blood | K-562 | -- | Enhancer discovery; Nascent-transcription regulation assay; Reporter-validation panel |
| E_04716 | chr17:74875718~74876890 | blood | K-562 | -- | Enhancer discovery; Nascent-transcription regulation assay; Reporter-validation panel |
| E_04717 | chr19:40464709~40464990 | blood | K-562 | -- | Enhancer discovery; Nascent-transcription regulation assay; Reporter-validation panel |
| E_04718 | chr19:43754969~43756655 | blood | K-562 | -- | Enhancer discovery; Nascent-transcription regulation assay; Reporter-validation panel |
| E_04719 | chr19:46786236~46786920 | blood | K-562 | -- | Enhancer discovery; Nascent-transcription regulation assay; Reporter-validation panel |
| E_04720 | chr19:48872999~48873182 | blood | K-562 | -- | Enhancer discovery; Nascent-transcription regulation assay; Reporter-validation panel |
| E_04721 | chr21:46325282~46325509 | blood | K-562 | -- | Enhancer discovery; Nascent-transcription regulation assay; Reporter-validation panel |
| E_04722 | chr6:28895115~28896348 | blood | K-562 | -- | Enhancer discovery; Nascent-transcription regulation assay; Reporter-validation panel |
| E_04723 | chr14:97485490~97486674 | embryo | E14 mouse embryonic stem cells | -- | Genome-engineering assay; Heterologous enhancer replacement construct generation |
| E_04724 | chr5:29641240~29642424 | embryo | E14 mouse embryonic stem cells | -- | Genome-engineering assay for a known enhancer locus |
| E_04725 | chr14:56793806~56795906 | blood | Lymphoblastoid | -- | Super-enhancer activity assay, Functional perturbation assay |
| E_04726 | chr11:111250000~111350000 | lymph node | BE10 | diffuse large B-cell lymphoma | Enhancer activity assay, Functional perturbation assay |
| E_04727 | chr2:60495216~60495315 | bone marrow | CD34+ hematopoietic stem cells | -- | Functional perturbation assay |
| E_04728 | chr2R:5208000~5208523 | embryo | nc14 embryo | -- | Enhancer activity assay; Functional perturbation assay |
| E_04729 | chr3R:26880000~26880523 | embryo | Embryo | -- | Enhancer activity assay; Functional perturbation assay |
| E_04730 | chr17:44026548~44026648 | prostate gland | LNCaP | Parkinsonian disorders | Enhancer activity assay, TF binding assay; Disease-variant functional analysis |
| E_04731 | chr17:30249928~30278499 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04732 | chr17:30249928~30278499 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04733 | chr6:98336842~98365566 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04734 | chr6:98336842~98365566 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04735 | chr10:64737032~64737909 | bone tissue | A-673 and additional Ewing sarcoma models | Ewing sarcoma | Enhancer activity; fusion-TF occupancy; susceptibility-variant functional assay |
| E_04736 | chr10:23502416~23510031 | pancreas | Embryonic Stem Cell | Pancreatic Agenesis | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04737 | chr10:23502416~23510031 | pancreas | Embryonic Stem Cell | Pancreatic Agenesis | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04738 | chr12:98559923~98563615 | -- | Induced Pluripotent Stem Cells | Schizophrenia | Enhancer activity assay; Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04739 | chr10:64737032~64737909 | -- | Mouse Embryonic Stem Cell | Ewing Sarcoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04740 | chr1:24520000~24525000 | breast | MCF-10A | -- | Enhancer activity assay |
| E_04741 | chr1:24601612~24626812 | blood / hematopoietic system | Raji lymphoblastic B cells | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04742 | chr3:189630000~189680000 | prostate gland | VCaP | -- | Enhancer activity assay |
| E_04743 | chr1:24601612~24626812 | blood / hematopoietic system | Raji lymphoblastic B cells | Breast Cancer | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04744 | chr12:98562692~98566384 | -- | Induced Pluripotent Stem Cells | Schizophrenia | Chromatin interaction assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04745 | chr1:24589812~24645812 | breast | Mammary Epithelial Cell MCF10A and MCF12A | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04746 | chr12:2350700~2350812 | brain | SH-SY5Y | neuroblastoma | Enhancer activity assay |
| E_04747 | chr3:189109942~189219942 | breast | Mammary Epithelial Cell MCF10A and MCF12A | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04748 | chr3:189203942~189313942 | breast | Mammary Epithelial Cell MCF10A and MCF12A | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04749 | chr1:24589812~24645812 | breast | Mammary Epithelial Cell MCF10A and MCF12A | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04750 | chr10:23508149~23508510 | pancreas | hESC-derived progenitors | -- | TF binding assay; Disease-variant functional analysis |
| E_04751 | chr3:189109942~189219942 | breast | Mammary Epithelial Cell MCF10A and MCF12A | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04752 | chr3:189203942~189313942 | breast | Mammary Epithelial Cell MCF10A and MCF12A | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04753 | chr10:64739850~64739980 | bone element | A-673 | Ewing sarcoma | Enhancer activity assay |
| E_04754 | chr1:47220000~47260000 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_04755 | chr1:47220000~47260000 | bone marrow | MOLT-3 | T-cell acute lymphoblastic leukemia | Enhancer activity assay, Functional perturbation assay |
| E_04756 | chr17:38082607~38083007 | blood | Primary human CD4+ T cells | asthma | Endogenous disease-variant base editing; enhancer-context functional validation; TF binding assay; target-gene expression assay |
| E_04757 | chr4:77558000~77558500 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay; TF binding assay; Chromatin-state profiling |
| E_04758 | chr3:180728712~180730712 | brain | Neural Stem Cells | Low-grade astrocytomas | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04759 | chr19:34845032~34847032 | prostate gland | Prostate Cancer Cell Lines | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04760 | chr11:72897942~72912333 | breast | MCF-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04761 | chr19:102157620~102158432 | spinal cord | Primary oligodendrocytes | -- | Enhancer activity assay, TF binding assay |
| E_04762 | chr9:107683970~107684232 | pancreas | Islet | -- | Enhancer activity assay, TF binding assay |
| E_04763 | chr5:22013999~22070602 | cochlea | Mouse cochlear outer hair cells | hereditary sensorineural hearing loss | Slc26a5 intronic E1 element within experimentally dissected Slc26a5 regulatory locus; endogenous knockout and OHC-specific reporter validation |
| E_04764 | chr5:22013999~22070602 | cochlea | Slc26a5 enhancer-knockout and Slc26a5-mutant therapeutic models | hereditary sensorineural hearing loss | Slc26a5 intronic E1 element within experimentally dissected Slc26a5 regulatory locus; endogenous knockout and OHC-specific reporter validation |
| E_04765 | chr5:22013999~22070602 | cochlea | Mouse cochlear outer hair cells | hereditary sensorineural hearing loss | Slc26a5 intronic E2 element within experimentally dissected Slc26a5 regulatory locus; cooperative endogenous knockout and OHC-specific reporter validation |
| E_04766 | chr5:22013999~22070602 | cochlea | Slc26a5 E1/E2 enhancer-double-knockout and therapeutic models | hereditary sensorineural hearing loss | Slc26a5 intronic E2 element within experimentally dissected Slc26a5 regulatory locus; cooperative endogenous knockout and OHC-specific reporter validation |
| E_04767 | chr6:142706180~142706230 | urinary bladder | 5637 | urinary bladder carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_04768 | chr6:142706180~142706230 | urinary bladder | SW780 | urinary bladder carcinoma | Enhancer activity assay, Functional perturbation assay |
| E_04769 | chr17:42078767~42079095 | liver | Hep-G2 | -- | Enhancer activity assay;TF binding assay |
| E_04770 | chr17:42078767~42079095 | liver | Hep-G2 | -- | Enhancer activity assay;TF binding assay |
| E_04771 | chr4:100078375~100078940 | liver | HepG2 | -- | Reporter-based enhancer mapping; TF-binding and site-mutation validation |
| E_04772 | chr4:100078375~100078940 | liver | H1299 negative-control cell line | -- | Reporter-based enhancer mapping; TF-binding and site-mutation validation |
| E_04773 | chr4:100078375~100078940 | liver | HepG2 | -- | Reporter-based enhancer mapping; TF-binding and site-mutation validation |
| E_04774 | chr4:100078375~100078940 | liver | H1299 negative-control cell line | -- | Reporter-based enhancer mapping; TF-binding and site-mutation validation |
| E_04775 | chr17:38082607~38083007 | blood | Jurkat | asthma | Endogenous disease-variant base editing; enhancer-context functional validation; TF binding assay; target-gene expression assay |
| E_04776 | chr4:77511788~77605824 | prostate gland | LNCaP,CWR22Rv1 | prostate cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04777 | chr17:42059156~42059522 | liver | Hep-G2 | -- | Enhancer activity assay, TF binding assay; Enhancer activity assay; TF binding assay |
| E_04778 | chr17:42078865~42079198 | liver | Hep G2 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04779 | chr17:42078865~42079198 | liver | Hep G2 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04780 | chr17:42078865~42079198 | liver | Hep G2 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04781 | chr6:142706180~142706230 | umbilical vein | HUVEC-C | -- | Enhancer activity assay, Functional perturbation assay |
| E_04782 | chr6:142706180~142706230 | brain | Neuro-2a | -- | Enhancer activity assay, Functional perturbation assay |
| E_04783 | chr19:10215891~10216703 | -- | Oligodendroglial Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04784 | chr3:51508734~51512187 | pancreas | 汕TC-3,INS-1,汐TC1.6,NIH3T3 | Insulin Deficiency | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04785 | chr17:42078767~42079095 | liver | Hep-G2 | -- | Enhancer activity assay |
| E_04786 | chr4:94419116~94437803 | blood / hematopoietic system | 231/ER汐Wt Cells,231/ER汐LQ Cells | Breast Cancer | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04787 | chr2:98362566~98364423 | -- | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay; Chromatin interaction assay |
| E_04788 | chr2:115794340~115800495 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04789 | chr12:79240000~79242000 | brain | Primary cortical neurons | -- | Enhancer activity assay, TF binding assay |
| E_04790 | chr15:93680000~93682000 | brain | Primary cortical neurons | -- | Enhancer activity assay |
| E_04791 | chr2:74292472~74294212 | cerebellum | embryonic cerebellar cells / transgenic reporter embryos | -- | Transcribed-enhancer discovery; In vivo enhancer reporter assay |
| E_04792 | chr2:9881939~9882773 | lens of camera-type eye | Lens epithelial cells | -- | Enhancer activity assay |
| E_04793 | chr2:9895741~9896397 | lens of camera-type eye | Lens epithelial cells | -- | Enhancer activity assay |
| E_04794 | chr2:9895741~9898314 | lens of camera-type eye | Lens epithelial cells | -- | Enhancer activity assay |
| E_04795 | chr2:9897700~9898314 | lens of camera-type eye | Lens epithelial cells | -- | Enhancer activity assay |
| E_04796 | chr1:230294600~230294900 | liver | Hep-G2 | -- | GWAS-linked HDL-C regulatory variant; allele-specific enhancer activity and TF binding |
| E_04797 | chr1:230294600~230294900 | liver | Hep-G2 | -- | GWAS-linked HDL-C regulatory variant; allele-specific enhancer activity and TF binding |
| E_04798 | chr1:230294600~230294900 | liver | Hep-G2 | -- | GWAS-linked HDL-C regulatory variant; allele-specific enhancer activity and TF binding |
| E_04799 | chr1:230294600~230294900 | liver | Hep-G2 | -- | GWAS-linked HDL-C regulatory variant; allele-specific enhancer activity and TF binding |
| E_04800 | chr9:133601400~133601900 | zone of skin | BJ [Human fibroblast] | -- | Enhancer activity assay; TF binding assay |
| E_04801 | chr18:60786011~60788011 | -- | Jurkat | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04802 | chr18:60786011~60788011 | -- | Jurkat | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04803 | chr18:60786011~60788011 | -- | Jurkat | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04804 | chr3:37126710~37127250 | spleen | Primary splenic T cells | -- | Enhancer activity assay; TF binding assay; ligand-responsive endogenous target validation; genetic TF-dependence validation |
| E_04805 | chr3:37126710~37127250 | thymus | Primary thymocytes | -- | Enhancer activity assay; TF binding assay; ligand-responsive endogenous target validation; genetic TF-dependence validation |
| E_04806 | chr11:5196000~5197000 | blood | K-562 | -- | Enhancer activity assay |
| E_04807 | chr1:230294600~230294900 | liver | Hep-G2 | -- | GWAS-linked HDL-C regulatory variant; allele-specific enhancer activity and TF binding |
| E_04808 | chr1:230293530~230305966 | liver | Hep G2 | -- | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_04809 | chr3:37126710~37127250 | thymus | ET | -- | Enhancer activity assay; TF binding assay; ligand-responsive endogenous target validation; genetic TF-dependence validation |
| E_04810 | chr3:37126710~37127250 | liver | Hepa-1c1c7 | -- | Enhancer activity assay; TF binding assay; ligand-responsive endogenous target validation; genetic TF-dependence validation |
| E_04811 | chr3:37126710~37127250 | liver | Hepa-1c1c7 | -- | Enhancer activity assay; TF binding assay; ligand-responsive endogenous target validation; genetic TF-dependence validation |
| E_04812 | chr4:81212120~81212422 | cerebellum | Cerebellar granule cells | -- | TF binding assay |
| E_04813 | chr15:37116298~37122452 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_04814 | chr9:132491985~132492534 | lung | HFL-1 | Lung Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04815 | chr9:132491985~132492534 | lung | HFL-1 | Lung Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04816 | chr4:81219772~81219968 | cerebellum | Cerebellar granule cells | -- | TF binding assay, Enhancer activity assay |
| E_04817 | chr4:82235567~82235814 | cerebellum | Cerebellar granule cells | -- | TF binding assay, Enhancer activity assay |
| E_04818 | chr4:82185096~82185615 | cerebellum | Cerebellar granule cells | -- | TF binding assay, Enhancer activity assay |
| E_04819 | chr3:108296550~108297750 | blood / hematopoietic system | K-562 | -- | Enhancer activity assay |
| E_04820 | chr2:9838078~9840078 | -- | Mouse Embryos | -- | Enhancer activity assay |
| E_04821 | chr11:5314490~5316194 | pleural effusion | K-562 | -- | Enhancer activity assay; LTR promoter/enhancer activity assay; Endogenous transcription assay |
| E_04822 | chr2:219988763~219991870 | lung | Primary human LUSC tumor cells | squamous cell lung carcinoma | Enhancer activity assay; Disease-variant functional analysis |
| E_04823 | chr21:36180372~36181392 | bone marrow | K-562 | acute myeloid leukemia | Enhancer activity assay; Disease-variant functional analysis |
| E_04824 | chr21:36180372~36181392 | blood / hematopoietic system | Leukemia Cell Lines,K-562 | acute myeloid leukemia | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04825 | chr19:33299481~33300688 | breast | Breast Cancer Cell | colorectal cancer | TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04826 | chr20:3508597~3508795 | brain | Neural progenitor | -- | Enhancer activity assay, TF binding assay; TF binding assay; Chromatin-state profiling |
| E_04827 | chr4:29119847~29120047 | -- | Embryo | -- | Enhancer activity assay; In vivo functional validation |
| E_04828 | chr1:226065482~226067482 | -- | Perinodal Cells | -- | In vivo functional validation |
| E_04829 | chr20:54937784~54938182 | blood / hematopoietic system | G1E-ER4 Cells | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04830 | chr4:29115647~29140947 | -- | Embryo | -- | Enhancer activity assay; In vivo functional validation |
| E_04831 | chr3:150450617~150456921 | breast | MCF-7 | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04832 | chr3:150450617~150456921 | breast | MCF-7 | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04833 | chr6:1679010~1683521 | breast | MCF-7 | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04834 | chr6:1679010~1683521 | breast | MCF-7 | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04835 | chr17:85527960~85530660 | brain | The Subventricular Zone Of Lateral Ganglionic Eminence??LGE SVZ?? | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04836 | chr17:85463916~85466386 | brain | The Subventricular Zone Of Lateral Ganglionic Eminence??LGE SVZ?? | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04837 | chr17:85392908~85395234 | brain | The Subventricular Zone Of Lateral Ganglionic Eminence??LGE SVZ?? | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04838 | chr10:21410566~21412861 | -- | Primary Mouse Embryonic Fibroblasts | -- | TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_04839 | chr11:19833945~19851027 | -- | Primary Mouse Embryonic Fibroblasts | -- | TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_04840 | chr17:45790442~45800636 | -- | Primary Mouse Embryonic Fibroblasts | -- | TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_04841 | chr22:43012000~43013000 | umbilical vein | HUVEC-C | -- | Enhancer activity assay |
| E_04842 | chr15:98129939~98130247 | cartilage tissue | -- | -- | Enhancer activity assay, TF binding assay; Enhancer activity assay |
| E_04843 | chr14:75355295~75355954 | blood | -- | -- | Enhancer activity assay, TF binding assay; TF binding assay |
| E_04844 | chr14:75355955~75357027 | blood | -- | -- | Enhancer activity assay, TF binding assay; TF binding assay |
| E_04845 | chr14:75363000~75363900 | blood | -- | -- | Enhancer activity assay, TF binding assay; TF binding assay |
| E_04846 | chr14:75371600~75372700 | blood | -- | -- | Enhancer activity assay, TF binding assay; TF binding assay |
| E_04847 | chr14:75408900~75410500 | blood | -- | -- | Enhancer activity assay, TF binding assay; TF binding assay |
| E_04848 | chr14:75415600~75416800 | blood | -- | -- | Enhancer activity assay, TF binding assay; TF binding assay |
| E_04849 | chr7:46352720~46353957 | -- | C2C12 | -- | TF-binding/chromatin assay |
| E_04850 | chr7:46352720~46353957 | -- | C2C12 | -- | TF-binding/chromatin assay |
| E_04851 | chr7:46352720~46353957 | -- | C2C12 | -- | TF-binding/chromatin assay |
| E_04852 | chr7:46352720~46353957 | -- | C2C12 | -- | TF-binding/chromatin assay |
| E_04853 | chr7:46370375~46374302 | -- | C2C12 | -- | TF-binding/chromatin assay |
| E_04854 | chr7:46370375~46374302 | -- | C2C12 | -- | TF-binding/chromatin assay |
| E_04855 | chr7:46370375~46374302 | -- | C2C12 | -- | TF-binding/chromatin assay |
| E_04856 | chr7:46370375~46374302 | -- | C2C12 | -- | TF-binding/chromatin assay |
| E_04857 | chr15:98750000~98750480 | cartilage tissue | SW1353 | chondrosarcoma | Enhancer activity assay, TF binding assay |
| E_04858 | chr15:97977739~97977942 | -- | HeLa | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04859 | chr22:35686840~35687280 | -- | Vascular Endothelial Cell | -- | TF-binding/chromatin assay |
| E_04860 | chr13:41947040~41947582 | bone marrow | St-2 | -- | Enhancer activity assay |
| E_04861 | chr22:35736840~35737280 | -- | Endothelial Cells (ECs) | -- | TF-binding/chromatin assay |
| E_04862 | chr16:95721049~95979933 | heart | cardiac endothelial cells | -- | Super-enhancer functional perturbation assay; EndoMT assay; In vivo ageing phenotype assay |
| E_04863 | chr16:95721049~95979933 | heart | aortic endothelial cells | -- | Super-enhancer functional perturbation assay; EndoMT assay; In vivo ageing phenotype assay |
| E_04864 | chr7:97700267~97768731 | cochlea | Mouse cochlear outer and inner hair cells | -- | Intronic EnhancerA within Myo7a locus; approximately 400-bp endogenous deletion; isoform-specific tonotopic regulation and auditory phenotyping |
| E_04865 | chr7:97700267~97768731 | cochlea | EnhancerA-deletion mice | -- | Intronic EnhancerA within Myo7a locus; approximately 400-bp endogenous deletion; isoform-specific tonotopic regulation and auditory phenotyping |
| E_04866 | chr2:105444500~105457500 | islet of Langerhans | Beta-TC-3 | -- | Chromatin interaction/dynamics assay using previously characterized enhancers |
| E_04867 | chr2:105629500~105640500 | islet of Langerhans | Beta-TC-3 | -- | Chromatin interaction/dynamics assay using previously characterized enhancers |
| E_04868 | chr15:56550000~56550573 | colon | LS180 | colorectal carcinoma | Enhancer activity assay, TF binding assay |
| E_04869 | chr3:180986412~180988412 | pancreas | CD8+ T cell | type 1 diabetes mellitus | Enhancer activity assay |
| E_04870 | chr2:234665349~234665739 | liver | Hep G2 | hepatocellular carcinoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04871 | chr4:34888479~34889907 | gonad | 汐T3-1 Cells | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04872 | chr19:51353600~51354200 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay; TF binding assay |
| E_04873 | chr19:44905642~44906512 | prostate gland | LNCaP | prostate cancer | Enhancer activity assay, TF binding assay |
| E_04874 | chr6:43769226~43769421 | pulmonary artery | bovine pulmonary artery endothelial cells | -- | Hypoxia-responsive enhancer activity assay; cis-element functional mapping |
| E_04875 | chr6:84520000~84524600 | pituitary gland | AlphaT3-1 | -- | Enhancer activity assay, Chromatin interaction assay |
| E_04876 | chr16:155136~155210 | blood | CD71+ erythroid cells from peripheral blood of the MCS-duplication carrier | hemoglobin H disease | Chromatin accessibility assay; structural variant analysis |
| E_04877 | chr16:155136~155210 | blood | CD71+ erythroid cells from peripheral blood of the MCS-duplication carrier | hemoglobin H disease | Chromatin accessibility assay; structural variant analysis |
| E_04878 | chr16:164235~164590 | pleural effusion | K-562 | hemoglobin H disease | Enhancer activity assay; structural variant functional analysis |
| E_04879 | chr16:170166~170655 | blood | CD71+ erythroid cells from peripheral blood of the MCS-duplication carrier | hemoglobin H disease | Chromatin accessibility assay; structural variant analysis |
| E_04880 | chr16:170166~170655 | blood | CD71+ erythroid cells from peripheral blood of the MCS-duplication carrier | hemoglobin H disease | Chromatin accessibility assay; structural variant analysis |
| E_04881 | chr16:193013~193087 | blood | CD71+ erythroid cells from peripheral blood of the MCS-duplication carrier | hemoglobin H disease | Chromatin accessibility assay; structural variant analysis |
| E_04882 | chr16:193013~193087 | blood | CD71+ erythroid cells from peripheral blood of the MCS-duplication carrier | hemoglobin H disease | Chromatin accessibility assay; structural variant analysis |
| E_04883 | chr17:60983452~60984775 | colon | HEK293FT,FLP-IN T-REX 293 CELLS | colorectal cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04884 | chr17:60986269~60989232 | colon | HEK293FT,FLP-IN T-REX 293 CELLS | colorectal cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04885 | chr8:128816178~128817335 | colon | HEK293FT,FLP-IN T-REX 293 CELLS | colorectal cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04886 | chr14:67745496~67746000 | -- | GT1-1 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04887 | chr14:67745496~67746000 | -- | GT1-1 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04888 | chr14:67745496~67746000 | -- | GT1-1 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04889 | chr14:67745323~67746327 | -- | GT1-1 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04890 | chr8:118163800~118164175 | islet of Langerhans | Beta-TC-3 | -- | Enhancer activity assay; Functional variant assay |
| E_04891 | chr2:234665349~234665739 | liver | HepaRG | -- | Nuclear-receptor enhancer assay; coactivator perturbation; TF/cofactor occupancy |
| E_04892 | chr2:46315253~46315668 | blood vessel | Endothelial cells | -- | Enhancer activity assay |
| E_04893 | chr10:116270311~116271768 | blood vessel | Endothelial cells | -- | Enhancer activity assay |
| E_04894 | chr16:18703897~18705643 | blood vessel | Endothelial cells | -- | Enhancer activity assay |
| E_04895 | chr17:31905602~31906289 | blood vessel | Endothelial cells | -- | Enhancer activity assay |
| E_04896 | chr2:26575785~26576489 | blood vessel | Endothelial cells | -- | Enhancer activity assay |
| E_04897 | chr4:55670153~55670693 | blood vessel | Endothelial cells | -- | Enhancer activity assay |
| E_04898 | chr4:118489677~118490197 | blood vessel | Endothelial cells | -- | Enhancer activity assay |
| E_04899 | chr9:37400589~37400968 | blood vessel | Endothelial cells | -- | Enhancer activity assay |
| E_04900 | chr9:37401768~37402146 | blood vessel | Endothelial cells | -- | Enhancer activity assay |
| E_04901 | chr1:20173000~20175000 | inner cell mass | H1 human embryonic stem | -- | Enhancer activity assay |
| E_04902 | chr6:161119825~161121825 | liver | Hep G2 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04903 | chr6:161119825~161121825 | liver | MCF-7 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04904 | chr6:161110725~161112725 | liver | Hep G2 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04905 | chr6:161110725~161112725 | liver | MCF-7 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04906 | chr5:104397936~104398396 | blood vessel | Vascular smooth muscle cells | -- | Enhancer activity assay |
| E_04907 | chr8:62860000~62865000 | forebrain | Mouse embryonic day 11.5 forebrain tissue | -- | Enhancer activity assay |
| E_04908 | chr13:40839693~40853195 | blood / hematopoietic system | CD4+ T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04909 | chr9:4600913~4608373 | blood / hematopoietic system | CD4+ T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04910 | chr17:63168191~63175262 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04911 | chr2:86750000~86800000 | forebrain | Mouse embryonic day 11.5 forebrain tissue | -- | Enhancer activity assay |
| E_04912 | chr8:57069398~57069482 | prostate gland | LNCaP | -- | TF-binding/chromatin assay |
| E_04913 | chr10:87283358~87312833 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04914 | chr6:161085524~161086263 | liver | Hep-G2 | -- | Enhancer activity assay |
| E_04915 | chr6:161092630~161095030 | liver | Hep-G2 | -- | Enhancer activity assay |
| E_04916 | chr13:40839693~40853195 | -- | -- | -- | -- |
| E_04917 | chr9:4600913~4608373 | -- | -- | -- | -- |
| E_04918 | chr13:39700000~39750000 | colon | HCT 116 | -- | Enhancer activity assay |
| E_04919 | chr6:161110725~161112725 | breast | MCF-7 | -- | Enhancer activity assay; Hormone-response assay |
| E_04920 | chr6:161110725~161112725 | liver | hepatic reporter cell models | -- | Estrogen-responsive enhancer/promoter regulatory assay; Enhancer activity assay |
| E_04921 | chr6:161119825~161121825 | liver | hepatic reporter cell models | -- | Estrogen-responsive enhancer/promoter regulatory assay; Enhancer activity assay |
| E_04922 | chr15:52315678~52316298 | islet of Langerhans | Beta-TC-3 | -- | Enhancer activity assay; cell-type-specific reporter assay |
| E_04923 | chr6:161110725~161112725 | liver | Hep-G2 | -- | Enhancer activity assay; Hormone-response assay |
| E_04924 | chr6:161110725~161112725 | breast | MCF-7 | -- | Enhancer activity assay; Hormone-response assay |
| E_04925 | chr8:117978845~117979466 | -- | 汕TC-3,汐TC-6 | Type 2 Diabetes Mellitus | Enhancer activity assay; Disease-associated enhancer analysis |
| E_04926 | chr15:52315678~52316298 | -- | 汕TC-3,汐TC-6 | Type 2 Diabetes Mellitus | Enhancer activity assay; Disease-associated enhancer analysis |
| E_04927 | chr6:161110725~161112725 | liver | Hep-G2 | -- | Enhancer activity assay; Hormone-response assay |
| E_04928 | chr15:5249678~5250298 | -- | 汕TC-3 | -- | Enhancer activity assay |
| E_04929 | chr14:72448647~72451627 | -- | SK-N-SH | Schizophrenia | Enhancer RNA functional perturbation assay; Transcriptome assay; Neuronal differentiation assay |
| E_04930 | chr16:49740654~49742654 | -- | G1E Cells | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04931 | chr2:191800000~191801000 | zone of skin | Melanoma cells | cutaneous melanoma | Enhancer activity assay, TF binding assay |
| E_04932 | chr1:133275546~133275787 | kidney | As4.1 | -- | Enhancer activity assay; Cross-species cis-regulatory functional analysis |
| E_04933 | chr12:113427251~113427729 | -- | P3X63Ag8 | -- | Enhancer activity assay; Cell-type specificity assay; Functional deletion mapping |
| E_04934 | chr14:99770698~99782638 | -- | A673/TR/shEF1 Cells | Ewing Sarcoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04935 | chr1:116896120~116904325 | -- | A673/TR/shEF1 Cells | Ewing Sarcoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04936 | chr16:74568579~74583481 | -- | A673/TR/shEF1 Cells | Ewing Sarcoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04937 | chr22:35767400~35768600 | uterine cervix | HeLa | breast cancer | TF binding assay; Enhancer occupancy assay; Transcriptional coactivator assay |
| E_04938 | chr22:35772400~35773600 | uterine cervix | HeLa | breast cancer | TF binding assay; Enhancer occupancy assay; Transcriptional coactivator assay |
| E_04939 | chr1:1092486~1093650 | breast | HMLE | -- | Enhancer activity assay; Chromatin state assay; eRNA analysis |
| E_04940 | chr1:1092486~1093650 | breast | HMLE | -- | Enhancer activity assay; Chromatin state assay; eRNA analysis |
| E_04941 | chr1:1092486~1093650 | breast | HMLE | -- | Enhancer activity assay; Chromatin state assay; eRNA analysis |
| E_04942 | chr1:1083900~1085900 | breast | HMLE | breast cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04943 | chr6:52296135~52334522 | blood / hematopoietic system | Limb Cells | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04944 | chr6:52585919~52613016 | blood / hematopoietic system | Limb Cells | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04945 | chr9:21206044~21206127 | blood | U-937 | histiocytic lymphoma | Enhancer activity assay, TF binding assay |
| E_04946 | chr14:72448647~72451627 | dorsolateral prefrontal cortex | BrainSeq Phase 1 postmortem dorsolateral prefrontal cortex | Schizophrenia | Enhancer activity-associated transcription analysis; Genetic association analysis; eQTL analysis; Mendelian randomization analysis; Disease-variant functional analysis |
| E_04947 | chr6:52527210~52556565 | -- | Limb,Head | Limb malformation | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04948 | chr6:52407532~52459468 | -- | Limb,Head | Limb malformation | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_04949 | chr6:52765812~52891511 | blood / hematopoietic system | Limb Cells | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04950 | chr6:52908070~53037532 | blood / hematopoietic system | Limb Cells | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_04951 | chr22:35766960~35768960 | breast | HeLa | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04952 | chr12:114666216~114667377 | lymphoid tissue | ROV-S | plasmacytoma | Enhancer activity assay, TF binding assay |
| E_04953 | chr2:191834162~191834795 | skin | Mm96 | melanoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04954 | chr22:35767789~35768189 | uterine cervix | HeLa | breast cancer | TF binding assay; Transcriptional coactivator assay |
| E_04955 | chr22:35772789~35773189 | uterine cervix | HeLa | breast cancer | TF binding assay; Transcriptional coactivator assay |
| E_04956 | chr9:21077976~21078020 | pleural effusion | U-937 | -- | TF-DNA binding assay; Endogenous gene expression assay; Cis-regulatory element mapping |
| E_04957 | chr9:21077976~21078020 | kidney | HEK293 | -- | Enhancer activity assay; Functional cis-regulatory assay |
| E_04958 | chr9:21077976~21078020 | blood | Jurkat | -- | Enhancer activity assay; Functional cis-regulatory assay |
| E_04959 | chr4:150577837~150588968 | bone marrow | SK-N-BE(2) | neuroblastoma | Super-enhancer identification; Functional perturbation assay; Transcriptomic analysis; Tumor growth and migration assay |
| E_04960 | chr2:16200000~16205000 | blood | Monocyte | -- | Super enhancer activity assay |
| E_04961 | chr8:47323116~47325387 | embryo | mouse embryonic stem cells | -- | Enhancer activity assay; TF binding assay; developmental regulatory assay |
| E_04962 | chr8:47323116~47325387 | embryo | mouse embryonic stem cells | -- | Enhancer activity assay; TF binding assay; developmental regulatory assay |
| E_04963 | chr11:103459000~103463000 | mammary gland | Mammary epithelial cell | -- | Enhancer activity assay, TF binding assay |
| E_04964 | chr6:88093936~88094192 | liver | E13.5 fetal liver myeloid progenitors | anemia | Functional perturbation assay; Gene expression assay; Hematopoietic differentiation assay |
| E_04965 | chr2:25423079~25423874 | blood / hematopoietic system | Th1 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04966 | chr6:88180138~88180212 | liver | E13.5 fetal liver hematopoietic stem/progenitor cells | GATA2 deficiency syndrome | Functional perturbation assay; Gene expression assay; In vivo developmental assay |
| E_04967 | chr1:101402363~101412724 | -- | HUVEC | Atherosclerosis | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04968 | chr20:62593247~62595247 | liver | SK-N-AS,Hep G2 | Amyotrophic Lateral Sclerosis | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_04969 | chr11:5198400~5198625 | blood | K-562 | -- | TF binding assay, Enhancer activity assay; TF binding assay |
| E_04970 | chr17:6565038~6567038 | liver | Human Liver Cell | Fatty Liver Disease | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04971 | chr11:5255062~5258441 | blood / hematopoietic system | K-562 | Erythrocytic Leukemia | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04972 | chr1:33353796~33354196 | -- | HC11 Mammary Epithelium | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04973 | chr1:33353796~33354196 | -- | HC11 Mammary Epithelium | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04974 | chr1:33353796~33354196 | -- | HC11 Mammary Epithelium | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04975 | chr1:33353796~33354196 | -- | HC11 Mammary Epithelium | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04976 | chr1:33353796~33354196 | -- | HC11 Mammary Epithelium | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04977 | chr1:33353796~33354196 | -- | HC11 Mammary Epithelium | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04978 | chr17:2261913~2262186 | liver | Hep-G2 | -- | Enhancer activity assay |
| E_04979 | chr2:25423970~25424765 | blood | primary CD4+ Th1 cells | -- | Enhancer activity assay; Cis-regulatory interaction assay |
| E_04980 | chr5:87705429~87705829 | mammary gland | HC11 | -- | Enhancer occupancy assay; Chromatin modification assay; Functional hormone-response assay |
| E_04981 | chr5:87705429~87705829 | mammary gland | HC11 | -- | Enhancer occupancy assay; Chromatin modification assay; Functional hormone-response assay |
| E_04982 | chr5:87705429~87705829 | mammary gland | HC11 | -- | Enhancer occupancy assay; Chromatin modification assay; Functional hormone-response assay |
| E_04983 | chr5:87705429~87705829 | mammary gland | HC11 | -- | Enhancer occupancy assay; Chromatin modification assay; Functional hormone-response assay |
| E_04984 | chr17:6285838~6586838 | liver | Human Liver Cell | Steatosis | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04985 | chr18:28988494~35919423 | lung | NCI-H1963 | small cell lung carcinoma | Enhancer activity assay, TF binding assay, Functional perturbation assay; Chromatin-state profiling |
| E_04986 | chr3:12311574~12312573 | kidney | HEK293T | -- | Enhancer activity assay, TF binding assay |
| E_04987 | chr7:143459000~143459700 | embryo | E11.5 primary maxillary arch cells | -- | Enhancer activity assay; TF binding assay; developmental regulatory assay |
| E_04988 | chr17:73746447~73746564 | islet of Langerhans | Islet | -- | Enhancer activity assay |
| E_04989 | chr16:59471850~59472124 | lung | EL4 | Pulmonary Inflammation | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04990 | chr16:59471850~59472124 | lung | EL4 | Pulmonary Inflammation | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04991 | chr6:124835092~124835618 | thymus | CD4-positive, CD8-positive thymocyte | -- | Genome-wide regulatory element profiling |
| E_04992 | chr2:176760000~176800000 | limb | embryonic limb tissue | -- | In vivo enhancer activity assay; functional perturbation assay |
| E_04993 | chr2:74460000~74500000 | limb | embryonic limb tissue | -- | In vivo enhancer activity assay; functional perturbation assay |
| E_04994 | chr17:72860066~72860183 | -- | HeLa,H295R,KGN | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_04995 | chr3:34757100~34758037 | embryoid body | Pluripotent cells from 21-day mouse embryoid bodies | -- | Enhancer activity assay; Disease-variant functional analysis |
| E_04996 | chr3:34761100~34762000 | embryoid body | Pluripotent cells from 21-day mouse embryoid bodies | -- | Enhancer activity assay; Disease-variant functional analysis |
| E_04997 | chr10:33492690~33519530 | -- | Normal Epidermal Cell | EEC syndrome | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04998 | chr10:33492690~33519530 | -- | Normal Epidermal Cell | EEC syndrome | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_04999 | chr10:33512793~33539633 | -- | Normal Epidermal Cell | EEC syndrome | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05000 | chr10:33512793~33539633 | -- | Normal Epidermal Cell | EEC syndrome | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05001 | chr10:33637535~33664375 | -- | Normal Epidermal Cell | EEC syndrome | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05002 | chr10:33637535~33664375 | -- | Normal Epidermal Cell | EEC syndrome | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05003 | chr8:128413174~128414429 | colon | colorectal cancer cell lines | colorectal carcinoma | Cancer-risk enhancer variant functional characterization; allele-specific TF binding |
| E_05004 | chr8:128413174~128414429 | colon | heterozygous enhancer models | colorectal carcinoma | Cancer-risk enhancer variant functional characterization; allele-specific TF binding |
| E_05005 | chr8:128413174~128414429 | colon | colorectal cancer cell lines | colorectal carcinoma | Cancer-risk enhancer variant functional characterization; allele-specific TF binding |
| E_05006 | chr8:128413174~128414429 | colon | heterozygous enhancer models | colorectal carcinoma | Cancer-risk enhancer variant functional characterization; allele-specific TF binding |
| E_05007 | chr8:128413174~128414429 | colon | colorectal cancer cell lines | colorectal carcinoma | Cancer-risk enhancer variant functional characterization; allele-specific TF binding |
| E_05008 | chr8:128413174~128414429 | colon | heterozygous enhancer models | colorectal carcinoma | Cancer-risk enhancer variant functional characterization; allele-specific TF binding |
| E_05009 | chr6:36640937~36642937 | breast | MCF-7 | Tumour | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05010 | chr6:36640937~36642937 | breast | A549 | Tumour | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05011 | chr6:36640937~36642937 | breast | HeLa | Tumour | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05012 | chr6:36647237~36649237 | breast | MCF-7 | Tumour | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05013 | chr6:36647237~36649237 | breast | A549 | Tumour | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05014 | chr6:36647237~36649237 | breast | HeLa | Tumour | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05015 | chr6:36640937~36642937 | breast | 293T | Tumour | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05016 | chr6:36647237~36649237 | breast | 293T | Tumour | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05017 | chr3:34757100~34758037 | -- | ES-C57BL/6 | -- | Enhancer activity assay; Singleton reporter validation; Disease-variant functional analysis |
| E_05018 | chr3:34761100~34762000 | -- | ES-C57BL/6 | -- | Enhancer activity assay; Singleton reporter validation; Disease-variant functional analysis |
| E_05019 | chr2:218000000~218700000 | breast | Breast Adipose Fibroblasts (BAFs) | -- | Enhancer activity assay, Chromatin interaction assay |
| E_05020 | chrX:92353371~92355054 | forebrain | mouse embryonic forebrain | -- | Endogenous enhancer knockout; single and combinatorial enhancer deletion; neurodevelopmental phenotyping |
| E_05021 | chr11:94903148~94903180 | spleen | splenic stress erythroid progenitors | anemia | Functional perturbation assay; Gene expression assay; Stress erythropoiesis assay |
| E_05022 | chr2:75120051~75165771 | -- | Murine Limb Bud Cells | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_05023 | chr2:75413472~75451553 | -- | Murine Limb Bud Cells | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_05024 | chr11:102006458~102008458 | -- | Osteocyte Cell Lines | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05025 | chr5:56028968~56031097 | breast epithelium | Bre-80 | breast carcinoma | Enhancer activity assay; Chromatin interaction assay |
| E_05026 | chr1:38469166~38512500 | blood / hematopoietic system | BM Cell | Acute Leukemia | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05027 | chr1:38469166~38512500 | blood / hematopoietic system | BM Cell | Acute Leukemia | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05028 | chr14:105051517~105351516 | blood / hematopoietic system | DHL-4,DHL-9 | Lymphoma | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_05029 | chr11:101892458~101969015 | bone element | 1390G3 | -- | Enhancer activity assay |
| E_05030 | chr14:105860000~105860500 | heart | H9c2(2-1) | -- | Chromatin interaction assay |
| E_05031 | chr21:40003867~40015913 | blood / hematopoietic system | HEL | Leukemia | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05032 | chr21:40003867~40015913 | blood / hematopoietic system | HEL | Leukemia | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05033 | chr21:40003867~40015913 | blood / hematopoietic system | HEL | Leukemia | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05034 | chr17:61927353~61928827 | testis | HEK293 | -- | Dual promoter-enhancer reporter characterization; evolutionary regulatory comparison |
| E_05035 | chr5:125345378~125345495 | -- | HIT DH5A cells (RBC) | -- | Enhancer activity assay; Chromatin interaction assay |
| E_05036 | chr5:125995862~125995972 | -- | HIT DH5A cells (RBC) | -- | Enhancer activity assay; Chromatin interaction assay |
| E_05037 | chr11:119715961~119716245 | brain | Neuro-2a | -- | Enhancer activity assay |
| E_05038 | chr6:122726952~122727236 | -- | N2a | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05039 | chr6:122726952~122727236 | -- | N2a | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05040 | chr12:8217947~8219702 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05041 | chr12:8217947~8219702 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05042 | chr12:8217947~8219702 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05043 | chr12:8217947~8219702 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05044 | chr12:8217947~8219702 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05045 | chr12:8217947~8219702 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05046 | chr12:54757502~54758950 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05047 | chr12:54757502~54758950 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05048 | chr12:54757502~54758950 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05049 | chr12:54757502~54758950 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05050 | chr12:54757502~54758950 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05051 | chr12:54757502~54758950 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05052 | chr17:34411749~34415000 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05053 | chr17:34411749~34415000 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05054 | chr17:34411749~34415000 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05055 | chr17:34411749~34415000 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05056 | chr17:34411749~34415000 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05057 | chr17:34411749~34415000 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05058 | chr17:34416207~34419359 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05059 | chr17:34416207~34419359 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05060 | chr17:34416207~34419359 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05061 | chr17:34416207~34419359 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05062 | chr17:34416207~34419359 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05063 | chr17:34416207~34419359 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05064 | chr17:34429460~34432613 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05065 | chr17:34429460~34432613 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05066 | chr17:34429460~34432613 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05067 | chr17:34429460~34432613 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05068 | chr17:34429460~34432613 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05069 | chr17:34429460~34432613 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05070 | chr2:113595983~113598617 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05071 | chr2:113595983~113598617 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05072 | chr2:113595983~113598617 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05073 | chr2:113595983~113598617 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05074 | chr2:113595983~113598617 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05075 | chr2:113595983~113598617 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05076 | chr2:113597789~113600339 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05077 | chr2:113597789~113600339 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05078 | chr2:113597789~113600339 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05079 | chr2:113597789~113600339 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05080 | chr2:113597789~113600339 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05081 | chr2:113597789~113600339 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05082 | chr5:158755252~158761634 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05083 | chr5:158755252~158761634 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05084 | chr5:158755252~158761634 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05085 | chr5:158755252~158761634 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05086 | chr5:158755252~158761634 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05087 | chr5:158755252~158761634 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05088 | chr5:158783552~158790360 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05089 | chr5:158783552~158790360 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05090 | chr5:158783552~158790360 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05091 | chr5:158783552~158790360 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05092 | chr5:158783552~158790360 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05093 | chr5:158783552~158790360 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05094 | chr5:158787331~158794352 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05095 | chr5:158787331~158794352 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05096 | chr5:158787331~158794352 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05097 | chr5:158787331~158794352 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05098 | chr5:158787331~158794352 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05099 | chr5:158787331~158794352 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05100 | chr1:203273730~203275395 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05101 | chr1:203273730~203275395 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05102 | chr1:203273730~203275395 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05103 | chr1:203273730~203275395 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05104 | chr1:203273730~203275395 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05105 | chr1:203273730~203275395 | -- | THP-1 | -- | TF-binding/chromatin assay |
| E_05106 | chr11:5250264~5250295 | blood / hematopoietic system | K-562,HEL | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05107 | chr11:5250264~5250295 | blood / hematopoietic system | K-562,HEL | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05108 | chr11:5250535~5250560 | blood / hematopoietic system | K-562,HEL | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05109 | chr11:5250535~5250560 | blood / hematopoietic system | K-562,HEL | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05110 | chr11:5248027~5248047 | blood / hematopoietic system | K-562,HEL | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05111 | chr11:5248027~5248047 | blood / hematopoietic system | K-562,HEL | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05112 | chr11:5250751~5250777 | blood / hematopoietic system | K-562,HEL | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05113 | chr11:5250751~5250777 | blood / hematopoietic system | K-562,HEL | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05114 | chr11:5250704~5250719 | blood / hematopoietic system | K-562,HEL | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05115 | chr11:5250704~5250719 | blood / hematopoietic system | K-562,HEL | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05116 | chr6:122727606~122727632 | -- | N2a | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05117 | chr6:122727606~122727632 | -- | N2a | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05118 | chr17:61927353~61928827 | testis | HEK293T | -- | Dual promoter-enhancer activity assay; Transcript characterization assay |
| E_05119 | chr5:125344507~125346243 | kidney | Human embryonic kidney cell | -- | Enhancer activity assay |
| E_05120 | chr5:125995897~125996243 | kidney | Human embryonic kidney cell | -- | Enhancer activity assay |
| E_05121 | chr17:61927353~61928827 | -- | GC-spd(ts),Hepa 1-6,293T | -- | Enhancer activity assay |
| E_05122 | chr19:44910240~44910647 | brain | HMC3 | -- | Enhancer activity assay, TF binding assay |
| E_05123 | chr4:88070000~88070500 | bone marrow | RAW 264.7 | -- | TF binding assay, Enhancer activity assay; Disease-variant functional analysis |
| E_05124 | chr21:36200000~36210000 | breast | MCF-7 | breast cancer | Enhancer activity assay |
| E_05125 | chr11:72905735~72906735 | breast | MCF-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_05126 | chr6:1636681~1642781 | breast | MCF-7 | -- | TF-binding/chromatin assay; Chromatin interaction assay |
| E_05127 | chr8:36785613~36985613 | brain | Brain | Schizophrenia | TF-binding/chromatin assay; Chromatin interaction assay; Disease-associated enhancer analysis |
| E_05128 | chr11:82630000~82650000 | blood | Jurkat | T-cell acute lymphoblastic leukemia | Chromatin interaction assay |
| E_05129 | chr5:17483518~17484083 | heart | HEK293 | ventricular septal defect | Enhancer activity assay |
| E_05130 | chr1:23881789~23881796 | gonad | Immortalized Murine Gonadotrope L汕T2 Cell,Ovarian Cancer Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05131 | chr12:100693355~100695355 | breast | MCF-7 | -- | TF-binding/chromatin assay |
| E_05132 | chr12:100731355~100733355 | breast | MCF-7 | -- | TF-binding/chromatin assay |
| E_05133 | chr13:43111372~43112072 | bone element | MG-63 | osteosarcoma | TF binding assay |
| E_05134 | chr4:136140539~136140546 | gonad | Immortalized Murine Gonadotrope L??T2 Cell,Ovarian Cancer Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05135 | chr11:82608774~82612886 | -- | IMR-90 | -- | Chromatin interaction assay |
| E_05136 | chr13:43111372~43112072 | -- | MG-63 | -- | TF-binding/chromatin assay |
| E_05137 | chr2L:20040500~20041072 | brain | -- | -- | in vivo reporter assay |
| E_05138 | chr2R:16905793~16906591 | brain | -- | -- | in vivo reporter assay |
| E_05139 | chr2R:19127550~19127921 | brain | -- | -- | in vivo reporter assay |
| E_05140 | chr3R:16286178~16286811 | brain | -- | -- | in vivo reporter assay |
| E_05141 | chrX:534837~535834 | brain | -- | -- | in vivo reporter assay |
| E_05142 | chrX:18554916~18555296 | brain | -- | -- | in vivo reporter assay |
| E_05143 | chr2L:20040500~20041072 | brain | -- | -- | in vivo reporter assay |
| E_05144 | chr2L:20040500~20041072 | brain | -- | -- | in vivo reporter assay |
| E_05145 | chr2L:20040500~20041072 | brain | -- | -- | in vivo reporter assay |
| E_05146 | chr2R:16905793~16906591 | brain | -- | -- | in vivo reporter assay |
| E_05147 | chr2R:16905793~16906591 | brain | -- | -- | in vivo reporter assay |
| E_05148 | chr2R:19127550~19127921 | brain | -- | -- | in vivo reporter assay |
| E_05149 | chr2R:19127550~19127921 | brain | -- | -- | in vivo reporter assay |
| E_05150 | chr3R:16286178~16286811 | brain | -- | -- | in vivo reporter assay |
| E_05151 | chr3R:16286178~16286811 | brain | -- | -- | in vivo reporter assay |
| E_05152 | chrX:534837~535834 | brain | -- | -- | in vivo reporter assay |
| E_05153 | chrX:534837~535834 | brain | -- | -- | in vivo reporter assay |
| E_05154 | chrX:18554916~18555296 | brain | -- | -- | in vivo reporter assay |
| E_05155 | chrX:18554916~18555296 | brain | -- | -- | in vivo reporter assay |
| E_05156 | chrX:18554916~18555296 | brain | -- | -- | in vivo reporter assay |
| E_05157 | chrX:18554916~18555296 | brain | -- | -- | in vivo reporter assay |
| E_05158 | chrX:18554916~18555296 | brain | -- | -- | in vivo reporter assay |
| E_05159 | chr14:78383543~78384543 | bone tissue | mouse osteoblast-lineage / reporter-cell context | -- | Vitamin-D-responsive enhancer mapping; nuclear-receptor binding; histone-acetylation analysis |
| E_05160 | chr14:78383543~78384543 | bone tissue | mouse osteoblast-lineage / reporter-cell context | -- | Vitamin-D-responsive enhancer mapping; nuclear-receptor binding; histone-acetylation analysis |
| E_05161 | chr3L:9193218~9194041 | brain | -- | -- | in vivo reporter assay |
| E_05162 | chr3L:9193218~9194041 | brain | -- | -- | in vivo reporter assay |
| E_05163 | chr5:172648612~172649177 | heart | Leukocytes | Congenital Heart Disease | Enhancer activity assay; Disease-associated enhancer analysis |
| E_05164 | chr6:396135~396636 | zone of skin | Human melanoma cells | cutaneous melanoma | Enhancer activity assay |
| E_05165 | chr4:4756237~4758006 | cerebellum | Human NSCLP proband blood DNA | nonsyndromic cleft lip with or without cleft palate | Enhancer variant association study; Functional enhancer validation |
| E_05166 | chr4:4756237~4758006 | cerebellum | Human NSCLP proband blood DNA | nonsyndromic cleft lip with or without cleft palate | Enhancer variant association study; Functional enhancer validation |
| E_05167 | chr4:124383428~124386454 | cerebellum | Human NSCLP proband blood DNA | nonsyndromic cleft lip with or without cleft palate | Enhancer variant association study; Functional enhancer validation |
| E_05168 | chrX:30331500~30332000 | adrenal gland | human congenital adrenal-hypoplasia family / reporter model | X-linked adrenal hypoplasia congenita with hypogonadotropic hypogonadism | Human structural-variant regulatory genetics; conserved-element reporter assay; TF-response assay |
| E_05169 | chrX:30331500~30332000 | testis | human congenital adrenal-hypoplasia/hypogonadotropic-hypogonadism family / reporter model | X-linked adrenal hypoplasia congenita with hypogonadotropic hypogonadism | Human structural-variant regulatory genetics; conserved-element reporter assay; TF-response assay |
| E_05170 | chrX:30331500~30332000 | adrenal gland | source duplicate retained: inversion-breakpoint regulatory context | X-linked adrenal hypoplasia congenita with hypogonadotropic hypogonadism | Human structural-variant regulatory genetics; conserved-element reporter assay; TF-response assay |
| E_05171 | chrX:30317939~30318739 | kidney | HEK-293 | X-Linked Congenital Adrenal Hypoplasia | Enhancer activity assay; Disease-associated enhancer analysis |
| E_05172 | chr3:69863244~70187654 | skin | Melanoma | Melanoma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05173 | chr1:183149939~183150336 | colon | Human normal colon epithelial cell | -- | Enhancer activity assay, TF binding assay; TF binding assay |
| E_05174 | chr11:118767466~118769582 | breast | MCF-7 | breast cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05175 | chr15:90288698~90290698 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05176 | chr10:127874742~127875307 | embryo | NIH 3T3 | -- | Enhancer activity assay; TF binding assay; Gene-expression assay |
| E_05177 | chr11:105000000~105000100 | blood | EL4 | -- | Enhancer activity assay, TF binding assay |
| E_05178 | chr14:54000000~54000100 | blood | EL4 | -- | Enhancer activity assay, TF binding assay |
| E_05179 | chr1:183149939~183150336 | small intestine | Intestinal Epithelial Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05180 | chr14:106327635~106328903 | -- | GM12878 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05181 | chr9:126900000~126900625 | -- | GM12878 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05182 | chr9:126964375~126965000 | -- | GM12878 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05183 | chr9:126980625~126981125 | -- | GM12878 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05184 | chr9:127001250~127001875 | -- | GM12878 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05185 | chr9:127047500~127048375 | -- | GM12878 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05186 | chr1:226085596~226087967 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05187 | chr1:226085596~226087967 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05188 | chr1:226085596~226087967 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05189 | chr1:64083756~64083861 | -- | SK-N-MC | Insomnia | TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_05190 | chr1:64087305~64087660 | -- | SK-N-MC | Insomnia | TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_05191 | chr20:8684437~8686556 | -- | SK-N-MC | Insomnia | TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_05192 | chr20:8687417~8688741 | -- | SK-N-MC | Insomnia | TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_05193 | chr20:8718344~8719933 | -- | SK-N-MC | Insomnia | TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_05194 | chr21:34091200~34091900 | uterine cervix | HeLa | -- | TF binding assay; enhancer activity assay; chromatin-signature enhancer validation |
| E_05195 | chr5:131790596~131791596 | uterine cervix | HeLa | -- | TF binding assay; enhancer activity assay; chromatin-signature enhancer validation |
| E_05196 | chr7:115940408~115941408 | uterine cervix | HeLa | -- | TF binding assay; enhancer activity assay; chromatin-signature enhancer validation |
| E_05197 | chr9:129175952~129176952 | uterine cervix | HeLa | -- | TF binding assay; enhancer activity assay; chromatin-signature enhancer validation |
| E_05198 | chr5:131784000~131784700 | uterine cervix | HeLa | -- | Enhancer activity assay |
| E_05199 | chr5:130999000~131001000 | uterine cervix | HeLa | -- | Enhancer activity assay |
| E_05200 | chr11:118813865~118815965 | breast | MCF-7 | breast carcinoma | Enhancer activity assay |
| E_05201 | chr7:95210132~95260132 | kidney | ccRCC Cells | Clear Cell Renal Cell Carcinoma | TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_05202 | chr4:26075179~26135897 | blood / hematopoietic system | CD4+ T Cell | rheumatoid arthritis | TF-binding/chromatin assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_05203 | chr11:95817801~95818824 | breast | MCF10CA1h,MCF10CA1a | Breast Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05204 | chr22:20224442~20228467 | brain | NT2/D1 | -- | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_05205 | chr14:67741735~67744661 | gonad | GT1-7 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05206 | chr6:135459326~135461326 | blood / hematopoietic system | K-562 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05207 | chr6:135459326~135461326 | blood / hematopoietic system | K-562 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05208 | chr22:20224442~20228467 | brain | Neuronal | -- | Enhancer activity assay |
| E_05209 | chr10:62893206~62923461 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05210 | chr10:62893206~62923461 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05211 | chr3:133531418~133563926 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05212 | chr3:133531418~133563926 | -- | Embryonic Stem Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05213 | chr12:35939690~35990427 | -- | ST2 | -- | TF-binding/chromatin assay |
| E_05214 | chr12:35939690~35990427 | -- | ST2 | -- | TF-binding/chromatin assay |
| E_05215 | chr12:35841201~35921783 | -- | ST2 | -- | TF-binding/chromatin assay |
| E_05216 | chr12:35841201~35921783 | -- | ST2 | -- | TF-binding/chromatin assay |
| E_05217 | chr12:35769572~35823293 | -- | ST2 | -- | TF-binding/chromatin assay |
| E_05218 | chr12:35769572~35823293 | -- | ST2 | -- | TF-binding/chromatin assay |
| E_05219 | chr12:35690979~35768472 | -- | ST2 | -- | TF-binding/chromatin assay |
| E_05220 | chr12:35690979~35768472 | -- | ST2 | -- | TF-binding/chromatin assay |
| E_05221 | chr4:55565908~55608014 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05222 | chr6:122696853~122708211 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05223 | chr6:122696853~122708211 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05224 | chr6:122696853~122708211 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05225 | chr6:122696853~122708211 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05226 | chr6:122696853~122708211 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05227 | chr6:122653828~122675804 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05228 | chr6:122653828~122675804 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05229 | chr6:122653828~122675804 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05230 | chr6:122653828~122675804 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05231 | chr6:122653828~122675804 | -- | Mouse Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05232 | chr7:129854050~129895632 | -- | Adipose Progenitor Cell | -- | TF-binding/chromatin assay; Chromatin interaction assay; Genetic-variant functional analysis |
| E_05233 | chr22:18897006~18899006 | blood / hematopoietic system | DLBCL Cells | diffuse large B-cell lymphoma | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05234 | chr11:47363009~47364009 | blood / hematopoietic system | Human Myeloid Cells | acute myeloid leukemia | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05235 | chr11:44390063~44390123 | -- | HEK-293 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05236 | chr7:100474191~100474841 | -- | Platinum E cells | -- | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_05237 | chr7:100474191~100474841 | -- | Platinum E cells | -- | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_05238 | chr10:62128342~62130342 | -- | Germ Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05239 | chr4:115100426~115102426 | -- | 416B | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05240 | chr4:115074426~115076426 | blood / hematopoietic system | Hematopoietic Stem Cell,Progenitor Cell | Acute Leukemia | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05241 | chr4:115074426~115076426 | blood / hematopoietic system | Hematopoietic Stem Cell,Progenitor Cell | Acute Leukemia | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05242 | chr2:136582836~136583741 | -- | Caco-2,Cheek Cell | -- | Enhancer activity assay; TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_05243 | chrX:92353371~92355054 | forebrain | mouse embryo | -- | Endogenous ultraconserved enhancer deletion; in vivo phenotyping |
| E_05244 | chr6:4488518~4490518 | skin of body | Primary dermal fibroblasts from Tsk1/+ mice | systemic sclerosis | Enhancer activity assay; Transgenic reporter assay; Disease-model enhancer activation assay; Cytokine-responsive enhancer assay |
| E_05245 | chr6:4486118~4492118 | skin of body | Primary dermal fibroblasts from Tsk1/+ mice | systemic sclerosis | Enhancer activity assay; Transgenic reporter assay; Disease-model enhancer activation assay; Fibroblast-lineage enhancer assay |
| E_05246 | chr6:122481665~122483665 | zone of skin | Dermal Fibroblast | scleroderma | Enhancer activity assay |
| E_05247 | chr6:122479265~122485265 | zone of skin | Dermal Fibroblast | scleroderma | Enhancer activity assay |
| E_05248 | chr6:4486118~4492118 | skin of body | Tsk1/+ mouse dermal fibroblasts | systemic sclerosis-like fibrosis (tight-skin mouse model) | In vivo fibroblast-specific enhancer assay; fibrosis-model comparison |
| E_05249 | chr8:129546728~129712179 | blood | SEM B-ALL cells | B-cell acute lymphoblastic leukemia | Acute architectural-factor depletion; enhancer-promoter interaction analysis; target-gene response |
| E_05250 | chr17:61449600~61451600 | lung | Lung fibroblasts | -- | Super-enhancer functional study, Chromatin interaction assay |
| E_05251 | chr3:181572712~181574712 | breast | MCF-7 | breast cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05252 | chr7:114541370~114542201 | blood | K-562 | -- | Enhancer activity assay |
| E_05253 | chr13:83661050~83662862 | heart | Embryonic Stem Cell | -- | Chromatin interaction assay |
| E_05254 | chr8:59795280~59797080 | heart | Embryonic Stem Cell | -- | Chromatin interaction assay |
| E_05255 | chr12:56728500~56735000 | blood / monocyte-macrophage system | THP-1 macrophage-like cells | tuberculosis / Mycobacterium tuberculosis infection | Macrophage enhancer chromatin profiling; direct AHR enhancer binding; infection-responsive transcriptional regulation; AHR perturbation |
| E_05256 | chr12:56728500~56735000 | blood / monocyte-macrophage system | human and mouse macrophage validation | tuberculosis / Mycobacterium tuberculosis infection | Macrophage enhancer chromatin profiling; direct AHR enhancer binding; infection-responsive transcriptional regulation; AHR perturbation |
| E_05257 | chr6:36632237~36634237 | blood / hematopoietic system | Human Diploid BJ Fibroblast Cell Lines | -- | TF-binding/chromatin assay |
| E_05258 | chr8:143896217~143898217 | blood / hematopoietic system | Human Diploid BJ Fibroblast Cell Lines | -- | TF-binding/chromatin assay |
| E_05259 | chr1:60908875~60908895 | blood / hematopoietic system | T Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05260 | chr7:114541370~114542201 | -- | HEK-293,SK-N-MC | -- | Enhancer activity assay |
| E_05261 | chr1:92921568~92937818 | blood / hematopoietic system | HEL | Leukemia | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05262 | chr4:74586223~74591223 | heart | AC16 | Heart Disease | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05263 | chr19:51354804~51355203 | prostate gland | LNCaP | -- | TF-binding/chromatin assay |
| E_05264 | chr21:42822120~42822800 | prostate gland | LNCaP | -- | TF-binding/chromatin assay |
| E_05265 | chr1:109816874~109818905 | liver | primary human hepatocytes | myocardial infarction susceptibility / LDL-cholesterol trait | Disease-variant functional analysis; enhancer activity; TF-binding mechanism; in vivo target-gene perturbation |
| E_05266 | chr12:113302447~113305102 | -- | Blood | -- | TF-binding/chromatin assay |
| E_05267 | chr12:113305522~113308796 | -- | Blood | -- | TF-binding/chromatin assay |
| E_05268 | chr12:113314217~113314925 | -- | Blood | -- | TF-binding/chromatin assay |
| E_05269 | chr12:68546200~68546440 | blood | Primary T cells | -- | Enhancer activity assay |
| E_05270 | chr6:115409226~115436116 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05271 | chr6:115409226~115436116 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05272 | chr6:115409226~115436116 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05273 | chr6:115507545~115533315 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05274 | chr6:115507545~115533315 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05275 | chr6:115507545~115533315 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05276 | chr6:31130679~31130761 | -- | NT2 | -- | TF-binding/chromatin assay |
| E_05277 | chr6:31130445~31130606 | -- | NT2 | -- | TF-binding/chromatin assay |
| E_05278 | chr6:31129568~31129735 | -- | NT2 | -- | TF-binding/chromatin assay |
| E_05279 | chr12:21439733~21439973 | -- | HeLa | -- | Enhancer activity assay |
| E_05280 | chr12:68549287~68549545 | -- | HeLa | -- | Enhancer activity assay |
| E_05281 | chr12:68549796~68550055 | -- | HeLa | -- | Enhancer activity assay |
| E_05282 | chr12:68553503~68553754 | -- | HeLa | -- | Enhancer activity assay |
| E_05283 | chr12:68553762~68554012 | -- | HeLa | -- | Enhancer activity assay |
| E_05284 | chr12:68544280~68544520 | uterine cervix | HeLa | -- | Enhancer activity assay |
| E_05285 | chr6:135096362~135097644 | blood | HUDEP-2 and primary CD34+-derived erythroblasts | -- | Enhancer-associated lncRNA functional assay; Regulatory-locus perturbation assay |
| E_05286 | chr5:372500~376000 | -- | Circulating Monocytes Cell | Cardiovascular Cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05287 | chr12:56330413~56330909 | -- | A9 | Fibrotic Disease | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05288 | chr7:53527011~53528648 | -- | C2C12 | -- | TF-binding/chromatin assay |
| E_05289 | chr14:50787449~50787634 | -- | Mitotic Cell | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05290 | chrX:140806807~140808327 | -- | F9 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05291 | chr10:131265598~131265656 | lung | Human Bronchial Epithelial Cell,Lung cancer-derived Cell Lines,Glioblastoma Cell Lines | lung adenocarcinoma | Enhancer activity assay; Genetic-variant functional analysis; Disease-associated enhancer analysis |
| E_05292 | chr12:48368959~48369159 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05293 | chr12:48368959~48369159 | -- | HeLa | -- | TF-binding/chromatin assay |
| E_05294 | chr3:32993199~32996133 | blood / hematopoietic system | T Cell | asthma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05295 | chr3:33000399~33003599 | blood / hematopoietic system | T Cell | asthma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05296 | chr3:34181595~34184395 | blood / hematopoietic system | T Cell | asthma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05297 | chr3:34201595~34204662 | blood / hematopoietic system | T Cell | asthma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05298 | chr12:48368959~48369159 | -- | HEK-293 | -- | TF-binding/chromatin assay |
| E_05299 | chr12:48368959~48369159 | -- | HEK-293 | -- | TF-binding/chromatin assay |
| E_05300 | chr17:42409879~42412035 | pancreas | PANC-1 | pancreatic ductal adenocarcinoma | Enhancer activity assay |
| E_05301 | chr6:33548076~33548616 | kidney | HEK293T | intracranial germ cell tumor | Disease-associated enhancer activity assay; Allele-specific enhancer activity assay; Functional variant validation |
| E_05302 | chr16:86238601~86253509 | lung | ACDMPV patient genomic DNA/lung tissue | alveolar capillary dysplasia with misalignment of pulmonary veins | Pathogenic CNV overlap mapping; enhancer-core narrowing; lung chromatin-state integration; allele-specific methylation analysis |
| E_05303 | chr20:44639323~44641625 | liver | HCCLM3 | hepatocellular carcinoma | Enhancer activity assay |
| E_05304 | chr20:44637014~44637468 | -- | Hepatocellular Carcinoma | hepatocellular carcinoma | Enhancer activity assay; Disease-associated enhancer analysis |
| E_05305 | chr10:61403948~61408233 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05306 | chr10:61403948~61408233 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05307 | chr10:61402781~61405448 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05308 | chr10:61402781~61405448 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05309 | chr7:110936000~111070000 | liver | mouse fetal liver erythroid cells | -- | Chromatin interaction assay |
| E_05310 | chr7:110936000~111070000 | liver | mouse fetal liver erythroid cells | -- | Chromatin interaction assay |
| E_05311 | chr7:110936000~111070000 | liver | mouse fetal liver erythroid cells | -- | Chromatin interaction assay |
| E_05312 | chr7:110936000~111070000 | liver | mouse fetal liver erythroid cells | -- | Chromatin interaction assay |
| E_05313 | chr7:110936000~111070000 | liver | mouse fetal liver erythroid cells | -- | Chromatin interaction assay |
| E_05314 | chr7:110936000~111070000 | liver | mouse fetal liver erythroid cells | -- | Chromatin interaction assay |
| E_05315 | chr16:86238601~86253509 | lung | human lung fibroblast ENCODE regulatory context | alveolar capillary dysplasia with misalignment of pulmonary veins | Pathogenic CNV overlap mapping; enhancer-core narrowing; lung chromatin-state integration; allele-specific methylation analysis |
| E_05316 | chr6:70675569~70676084 | blood | MPC-11 | -- | Enhancer activity assay |
| E_05317 | chr6:70685249~70686058 | blood | MPC-11 | -- | Enhancer activity assay |
| E_05318 | chr6:70693703~70694944 | blood | MPC-11 | -- | Enhancer activity assay |
| E_05319 | chr6:70713757~70715084 | blood | MPC-11 | -- | Enhancer co-activator assay; DNase I hypersensitivity assay |
| E_05320 | chr6:70685249~70686058 | blood | MPC-11 | -- | Enhancer activity assay |
| E_05321 | chr6:70693703~70694944 | blood | MPC-11 | -- | Enhancer activity assay |
| E_05322 | chr6:70675569~70676084 | blood | MPC-11 | -- | Enhancer activity assay |
| E_05323 | chr6:70713757~70715084 | blood | MPC-11 | -- | Enhancer co-activator assay;DNase I hypersensitivity assay |
| E_05324 | chr6:70763764~70765090 | -- | S194,MPC-11 | -- | Enhancer activity assay |
| E_05325 | chr6:70725576~70726090 | -- | S194,MPC-11 | -- | Enhancer activity assay |
| E_05326 | chr6:70743710~70744950 | -- | S194,MPC-11 | -- | Enhancer activity assay |
| E_05327 | chr6:70735256~70736064 | -- | S194,MPC-11 | -- | Enhancer activity assay |
| E_05328 | chr12:109986000~109986710 | -- | WT Mouse Embryonic Fibroblasts | -- | TF-binding/chromatin assay |
| E_05329 | chr8:140657900~141002079 | -- | 5637 | Bladder Cancer | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05330 | chr2:129350852~129356319 | -- | Macrophage | -- | TF-binding/chromatin assay |
| E_05331 | chr9:124638991~124641160 | skin | LP89 | -- | TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_05332 | chr17:40206839~40206900 | gonad | Somatic Spleen Cells,Spermatogenic Germ Cells | -- | TF-binding/chromatin assay |
| E_05333 | chr11:32403489~32405489 | -- | Human Podocyte Cell Line AB8/13 | -- | Enhancer activity assay |
| E_05334 | chr9:16857980~16858579 | brain | Primary neurons | -- | Enhancer activity assay; Disease-variant functional analysis |
| E_05335 | chr17:85795937~85796217 | -- | Metanephric Mesenchymal (MM) cells | -- | TF-binding/chromatin assay |
| E_05336 | chr17:85797325~85797927 | -- | Metanephric Mesenchymal (MM) cells | -- | TF-binding/chromatin assay |
| E_05337 | chr7:46371356~46373481 | -- | C2C12 | -- | Enhancer activity assay; TF-binding/chromatin assay |
| E_05338 | chr9:133267998~133270594 | blood | Bm-derived and control CD34+ erythroid cultures | -- | Human genotype-to-enhancer functional validation; direct TF occupancy; TF binding assay |
| E_05339 | chr9:133267998~133270594 | blood | Bm-derived and control CD34+ erythroid cultures | -- | Human genotype-to-enhancer functional validation; direct TF occupancy; TF binding assay |
| E_05340 | chr16:23143036~23145036 | -- | Offspring Adipocytes | Sleep Fragmentation | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05341 | chr7:24461573~24462573 | colon | Colon Cancer Cell | -- | TF-binding/chromatin assay |
| E_05342 | chr2R:212338~212586 | embryo | Schneider 2 | -- | Enhancer activity assay; Enhancer-enhancer cooperativity assay; Housekeeping core-promoter activity assay |
| E_05343 | chr2R:13743428~13743676 | embryo | Schneider 2 | -- | Enhancer activity assay; Enhancer-enhancer cooperativity assay; Developmental core-promoter activity assay |
| E_05344 | chr3R:18457294~18457542 | embryo | Schneider 2 | -- | Enhancer activity assay; Enhancer-enhancer cooperativity assay; Developmental core-promoter activity assay |
| E_05345 | chrX:1374546~1374794 | embryo | Schneider 2 | -- | Enhancer activity assay; Enhancer-enhancer cooperativity assay; Developmental core-promoter activity assay |
| E_05346 | chrX:18546964~18547212 | embryo | Schneider 2 | -- | Enhancer activity assay; Enhancer-enhancer cooperativity assay; Housekeeping core-promoter activity assay |
| E_05347 | chr4:23811733~23994829 | skin | CHL-1 | Melanoma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05348 | chr11:44386118~44393090 | -- | Macrophage | Inflammatory Disease | Enhancer activity assay; TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05349 | chr4:115095426~115097426 | blood / hematopoietic system | Embryonic Stem Cell | -- | TF-binding/chromatin assay |
| E_05350 | chr8:128748315~128750245 | dermis | Primary Dermal Lymphatic Endothelial Cells (hLECs) | -- | Enhancer activity assay |
| E_05351 | chr11:5248824~5249485 | -- | Embryonic Blood Cells | -- | Experimentally supported enhancer study |
| E_05352 | chr11:5248824~5249485 | -- | Embryonic Blood Cells | -- | Experimentally supported enhancer study |
| E_05353 | chr12:103852772~103852898 | -- | Hepatoma Cells | -- | TF-binding/chromatin assay |
| E_05354 | chr12:103852898~103853032 | -- | Hepatoma Cells | -- | TF-binding/chromatin assay |
| E_05355 | chr12:103853032~103853127 | -- | Hepatoma Cells | -- | TF-binding/chromatin assay |
| E_05356 | chr9:97396388~97401553 | -- | Hepatocellular Carcinoma | hepatocellular carcinoma | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05357 | chr12:109528035~109532509 | -- | Embryonic Stem Cell | -- | TF-binding/chromatin assay; Genetic-variant functional analysis |
| E_05358 | chr11:5268575~5268621 | blood / hematopoietic system | K-562 | -- | Experimentally supported enhancer study |
| E_05359 | chr9:88325101~88326201 | -- | Hepatic Myofibroblasts | Hepatic Fibrosis | Enhancer activity assay; Disease-associated enhancer analysis |
| E_05360 | chr8:130386715~130591515 | blood / hematopoietic system | Acute Myeloid Leukemia Cell | -- | TF-binding/chromatin assay |
| E_05361 | chr19:18373265~18374622 | adrenal gland | SK-N-BE(2) | neuroblastoma | Enhancer activity assay |
| E_05362 | chr15:97898854~97902854 | colon | YAMC Cell | Colon Cancer | Enhancer activity assay; Disease-associated enhancer analysis |
| E_05363 | chr15:97911426~97915997 | colon | YAMC Cell | Colon Cancer | Enhancer activity assay; Disease-associated enhancer analysis |
| E_05364 | chr17:48258757~48260757 | -- | C2C12 | -- | Enhancer activity assay |
| E_05365 | chr3:48598405~48598558 | -- | TE-671 | Myocardial Ischemia | Enhancer activity assay; Disease-associated enhancer analysis |
| E_05366 | chr3:48598405~48598558 | umbilical vein | HUVEC-C | -- | Enhancer activity assay |
| E_05367 | chr17:32579684~32579693 | -- | HEK-293,HEK-MOR Cells | -- | TF-binding/chromatin assay |
| E_05368 | chr17:48105016~48105270 | lung cell culture | A-549 | -- | Single-cell enhancer-transcription assay; target-gene causality not established |
| E_05369 | chr20:56293544~56293843 | lung cell culture | A-549 | -- | Single-cell enhancer-transcription assay; target-gene causality not established |
| E_05370 | chr10:3929991~3930887 | lung cell culture | A-549 | -- | Single-cell enhancer-transcription assay; target-gene causality not established |
| E_05371 | chr12:85515101~85543901 | -- | Macrophage | -- | TF-binding/chromatin assay |
| E_05372 | chr4:56895793~56962351 | kidney | Human embryonic kidney cell | -- | TF-binding/chromatin assay |
| E_05373 | chr21:35982223~35983306 | -- | Acute T-Cell Leukaemia Cell | -- | Enhancer activity assay |
| E_05374 | chr21:36141738~36142821 | -- | Acute T-Cell Leukaemia Cell | -- | Enhancer activity assay |
| E_05375 | chr11:111456657~111460228 | developing craniofacial mesenchyme / jaw | Human/Neanderthal EC1.45 sequences functionally tested in transgenic zebrafish | -- | EC1.45 evolutionary enhancer-variant functional assay; orthologous canonical enhancer interval; dual reporter; lineage tracing; SOX9 phenocopy |
| E_05376 | chr11:111456657~111460228 | developing craniofacial mesenchyme / jaw | canonical orthologous EC1.45 interval represented by mouse Rr80 | -- | EC1.45 evolutionary enhancer-variant functional assay; orthologous canonical enhancer interval; dual reporter; lineage tracing; SOX9 phenocopy |
| E_05377 | chr4:10157134~10395586 | limb | E14.5 transgenic mouse embryo | -- | Enhancer activity assay (DJE2; BAC-defined distal joint enhancer region) |
| E_05378 | chr4:10329803~10537032 | limb | E14.5 transgenic mouse embryo | -- | Enhancer activity assay (DJE1; BAC-defined distal joint enhancer region) |
| E_05379 | chr4:97123309~97712957 | -- | Embryonic Fibroblast | Malignancies | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05380 | chr1:153628434~153632039 | -- | HEKa | -- | Experimentally supported enhancer study |
| E_05381 | chr3:78597238~79767998 | breast | Colorectal Cancer,Breast Cancer Cell | colorectal cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05382 | chr3:78597238~79767998 | breast | Colorectal Cancer,Breast Cancer Cell | breast cancer | TF-binding/chromatin assay; Disease-associated enhancer analysis |
| E_05383 | chr6:135468624~135469679 | -- | K-562 | myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; TF occupancy assay; TF functional perturbation assay; Epigenome editing assay |
| E_05384 | chr6:135414242~135415630 | -- | K-562 | myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; TF occupancy assay; Epigenome editing assay |
| E_05385 | chr6:135467317~135468351 | -- | K-562 | myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; Histone-mark validation |
| E_05386 | chr6:135467317~135468351 | -- | HEK293T | myeloid leukemia | Enhancer activity assay; TF functional perturbation assay |
| E_05387 | chr6:135468624~135469679 | -- | K-562 | myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; TF occupancy assay; Epigenome editing assay |
| E_05388 | chr6:135468624~135469679 | -- | K-562 | myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; TF occupancy assay |
| E_05389 | chr6:135414242~135415630 | -- | K-562 | myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; TF occupancy assay |
| E_05390 | chr6:135468624~135469679 | -- | K-562 | myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; TF occupancy assay |
| E_05391 | chr6:135468624~135469679 | -- | K-562 | myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; TF occupancy assay |
| E_05392 | chr6:135414242~135415630 | -- | K-562 | myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; TF occupancy assay |
| E_05393 | chr6:135414242~135415630 | -- | K-562 | myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; TF occupancy assay |
| E_05394 | chr6:135414242~135415630 | -- | K-562 | myeloid leukemia | Enhancer activity assay; Chromatin interaction assay; TF occupancy assay |
| E_05395 | chr6:135468624~135469679 | -- | HEK293T | myeloid leukemia | Enhancer activity assay; TF functional perturbation assay |
| E_05396 | chr6:135468624~135469679 | -- | U-937 | myeloid leukemia | Chromatin interaction assay; Differentiation-associated enhancer-promoter dynamics |
| E_05397 | chr6:135414242~135415630 | -- | U-937 | myeloid leukemia | Chromatin interaction assay; Differentiation-associated enhancer-promoter dynamics |
| E_05398 | chr6:135468624~135469679 | -- | HL-60 | myeloid leukemia | Chromatin interaction assay; Differentiation-associated enhancer-promoter dynamics |
| E_05399 | chr6:135414242~135415630 | -- | HL-60 | myeloid leukemia | Chromatin interaction assay; Differentiation-associated enhancer-promoter dynamics |
| E_05400 | chr6:135467317~135468351 | -- | HeLa | myeloid leukemia | Enhancer activity assay; Heterologous reporter validation |
| E_05401 | chr6:135468624~135469679 | -- | HeLa | myeloid leukemia | Enhancer activity assay; Heterologous reporter validation |
| E_05402 | chr6:135414242~135415630 | -- | HeLa | myeloid leukemia | Enhancer activity assay; Heterologous reporter validation |